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ABSTRACT 
Sphingolipids are a large family of ubiquitous molecules involved in many 
cellular events such as proliferation, differentiation and apoptosis. In all organisms 
the first and rate-limiting step of the sphingolipid biosynthetic pathway is catalysed 
by the pyridoxal 5'-phosphate (PLP)-dependent enzyme Serine Palmitoyltransferase 
(SPT). Many human diseases are caused by abnormalities in sphingolipid catabolism, 
and it was discovered that the human neurologic disease Hereditary Sensory and 
Autonomic Neuropathy type 1 (HSAN1) is caused by mutations of SPT. 
In this study recombinant SPT from the sphingolipid-producing bacterium 
Sphingomonas paucimobilis was used as a model for the human enzyme in order to 
provide an insight into the effects of HSANI mutations on the structure and 
mechanism of the human isoform. A second Sphingomonas strain (S. wittichii) has 
been used to begin a study of the bacterial glycosphingolipid pathway since its whole 
genome sequence is available. 
Three bacterial SPT HSAN1 mimic mutants N100W, N100Y and N100C 
have been successfully cloned, expressed and purified. Their ability to produce 3-
ketodihydrosphingosine (KDS) was measured by radiochemical assay and a full 
kinetic evaluation carried out using a new spectrophotometric assay. Characteristic 
spectroscopic properties displayed by SPT provided useful information on substrate 
binding, specificity and on the formation of intermediates during the catalytic cycle. 
All three HSANI mutants were successfully crystallised in the holo-(PLP bound) 
form. Four high-resolution structures were solved in total including three in the holo-
form (NIOOC: 1.25A, NIOOW: 1.43A and N100Y: 1.5A) as well as the PLP: L-serine 
external aldimine complex of SPT N100Y (2.15A), which was trapped by soaking 
the crystal with the L-serine substrate. 
A putative SPT homologue was identified in S. wittichii and a recombinant 
form of the enzyme was cloned and characterised. After further analysis of the S. 
wittichii genome, a small ORF encoding a putative acyl carrier protein (ACP) of'-8.8 
kDa was identified upstream of the SPT gene. A plausible hypothesis is that this 
ACP could be the acyl donor for its SPT partner, together forming a novel link 
between sphingolipid and fatty acid biosynthesis. The ACP and SPT genes were 
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successfully cloned and co-expressed in E. coli. Recombinant SPT S. wittichii was 
purified and shown to be enzymatically active. Crystals that diffracted to 2.1 A were 
prepared and the S. wittichii SPT structure was solved by molecular replacement. 
Recombinant ACP was expressed in its apo-form form that required further in vitro 
modification to its active holo-form using a phosphopantetheinyl transferase 
(PPTase). An S. wittichii acyl carrier protein synthase (ACPS) gene was identified, 
the corresponding clone was designed and the protein successfully expressed and 
purified. ACPS S. wittichii was active and converted the apo-ACP into its holo-form. 
Transfer of acyl chains of increasing length (C 10, C12, C14 and C16) onto ACP was 
investigated using several PPTases (ACPS S. coelicolor, Sfp B. subtilis and Svp S. 
verticillus). The holo-ACP was formed with two of the PPTs tested, Sfp and Svp. 
Only Sfp successfully transferred short acyl-chains onto ACP. 
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CHAPTER I: INTRODUCTION 
1.1 INTRODUCTION TO SPHINGOLIPIDS 
1.1.1 Structure, Function, Pathways 
It is now 125 years since the concept of sphingolipid-like molecules and their 
role in brain metabolism was first introduced by Johann Thudichum'. Intrigued by 
their structures and biological functions. he described them as Sphinx-like* 
molecules, as these new compounds reminded him of the Sphinx riddles. A half—
century later, Herbert Carter" determined the chemical structure of the family and 
named them sphingolipids. All sphingolipids contain a common sphingosin& 
component comprised of an unsaturated hydrocarbon chain and a polar head group 
arising from serine (Figure I-i). Diversity in the sphingolipid family arises from 
derivatisation of the sphingosine skeleton via acylation of the amino group with 
various fatty acids to form ceramides (Figure 1-2). The addition of diverse polar 
head-groups on the ceramide hydroxyl leads to either sphingornyelins or 
glycosphingolipids (Figure 1-2). 
OH 
NH 
Figure I—I General structure of the sphingolipids. Representation of their 3 distinctive parts, 
the sphingosine skeleton is coloured blue, the fatty acid group is black and the variable polar 
head group is red. 
Sphingolipids are ubiquitous constituents of eukaryotic membranes and are also 
found in some prokaryotic organisms. Sphingolipids are known to be highly 
bioactive molecules and they are involved in many important functions in the body. 
Their metabolites act as second messengers which are involved in proliferation, 
differentiation and apoptosis3 . In association with cholesterol, they form lipid-rafts 
which are implicated in signal transduction and membrane trafficking 5 . Furthermore, 
sphingolipid metabolites play crucial roles in some pathological processes 6 . In 
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addition, malfunction of enzymes within the sphingolipid biosynthetic pathway can 
also lead to severe disease. For example the human neurological disease Hereditary 
Sensory and Neuropathy Type 1 (HSANI) is caused by mutation of serine 
palmitoyltanserase 7 (SPT), the first enzyme in the pathway. 
0 	 CO2H 
H2NCH2OH 
SPT 
Patmitoyl-CoA 	 + 	L-serine 
0H 
3-ketodihydrosphingosine (KDS) 	 NI-12 
OH 
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Dihydrosphingosine (DHS) 	 NI-12 
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Figure 1-2 Abbreviated sphingolipid biosynthetic pathway showing the early steps. 
Sphingolipids (SLs) are found in a wide variety of species and some have their own 
sphingolipid biosynthetic pathways (Figure 1-2). Eukaryotic SL pathways from 
organisms such as mammals, plants and fungi have been extensively studied and 
most of the intermediates and enzymes have been identified and characterised. 
Comprehensive reviews of the yeast and plant pathways were recently published" ' . 
The first steps of SL biosynthesis, namely Claisen-condensation and ketone 
reduction are highly conserved. SLs and glycosphingolipids (GSLs) diversity occurs 
throughout the organisms with the attachment of various N-acyl chains, 
hydroxylation at specific carbons and addition of complex sugars. Interest about the 
bacterial SL pathway arose with the discovery of an atypical family of Gram-
negative bacteria that have a membrane composed of GSLs (Figure 1-3) instead of 
the usual lipopolysacchandes (LPS). These bacteria nammed "Sphingomonads" 
include organisms such as Sphingomonas paucimobilis, Sphingobacterium 
multivorum, Sphingobium yanoikuyae and Sphingomonas wittichii' 0 . Since bacterial 
GSLs have similar core structures to their eukaryotic homologs it was assumed that 
the pathway would begin with the production of the common intermediate, 3-
ketodihydrosphingosine (KDS) from L-senne and palmitoyl-CoA. This reaction is 
catalysed by the enzyme serine palmitoyltransferase (SPT; EC2.3.1.50). Indeed, 
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Figure 1-3 Chemical structure of GSL-4A, GSL-1 and GSL-1' isolated from S.paucimobilis 
and S. wittichii. 
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1.1.2 Bacterial Glycosphingolipids 
The structure and composition of GSLs isolated from "Sphingomonads" and 
in particular S. paucimobilis and S. wittichii has been extensively studied by Kawara 
et al. 13 ' 7 . All bacterial GSLs have a similar fatty acid composition but the 
saccharidic moiety differs with species (Figure 1-3). The GSLs of S. paucimobilis 
were shown to contain the three following dihydrosphingosines; erythro-1,3-
dihydroxy-2-amino-octadecane (DS 18:0), erythro- 1,3 -dihydroxy-2-amino-cis 13,14-
methylene-eicosane (DS2 1 cycl) in comparable amounts and erythro- 1,3 -dihydroxy-
2-amino-cisl3,14-eicosene (DS20:1) as a minor component (Figure 1-3 R, a,b,c). 
The fatty acid was shown to be 2-hydroxymyristic acid (2-011-C114:0) (Figure 1-3 R 2 
d). They are also composed of two types of saccharide moiety, GSL-1 (Figure 1-3) 
which contains only glucuronic acid (GlcA) and GSL-4A (Figure 1-3) which is 
composed of mannose (Man), galactose (Gal), glucosamine (G1cN) and glucuronic 
acid (GIcA). S. wittichii GSLs contain only two dihydrosphingosine chains, 1,3-
dihydroxy-2-amino-octadecane (DS 18:0) and 1 ,3-dihydroxy-2-amino-cisl 3,14-
methylene-eicosane (DS2lcycl)(Figure 1-3 R, a,b). The ceramide portion is 
composed of myristic acid (C14:0) or 2-hydroxy-myristic acid (2-011-C14:0) (Figure 
1-3 R2  d, e). One of the GSLs is GSL-1 present in S. paucimobilis and common to all 
Sphingomonas spp and the other is GSL- 1' which contains a galacturonic acid (GalA) 
instead of the G1eA present in GSL-1. A first study on the configuration of the sugar-
lipid linkage reports that the Galacto-ceramide of S. yanoikuyae was 13 18 After 
repeating these experiments and finding a different configuration, Kawara et al. 
extended their investigation and proved that all sugar-lipid linkages in bacterial GSLs 
were of the a-configuration '6' 17 This result was further confirmed by the fact that the 
a-configurations of G1cA- and Ga1A-ceramides have recently been shown to be 
potent activators of the mammalian immune system via specific antigen receptors 
(CD 1d) on Natural Killer T-cells (NKTs). The 13-anomer present in eukaryotic GSL 
has no effect on NKT cell stimulation. This subject has been reviewed in a book 
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1.2 SERINE PALMITOYLTRANSFERASE (SPT) 
SPT catalyzes the first and rate-limiting step of the sphingolipid biosynthetic 
pathway in all organisms studied to date 20 . The reaction is a pyridoxal-5'-phosphate 
(PLP)-dependent, decarboxylative, Claisen condensation of the amino acid L-senne 
and the long chain (Cl 6) fatty acid palmitoyl-CoA, which produces the sphingolipid 
precursor, 3-ketodihydrosphingosine (KDS, Figure 1-2). 
1.2.1 PLP-dependent Enzymes 
1.2.1.1 Chemistry 
PLP is the biologically active form of vitamin B6 and it is a cofactor in 
numerous enzymatic reactions involving various amino acid and amine substrates 21 . 
PLP-depedent enzymes are found to play important roles in all species of life and are 
involved in essential biochemical pathways. In spite of this diversity, the 
mechanisms of PLP-dependent enzymes share several common steps, the first one 
involving the initial Schiff s base exchange: the transimination step. The cofactor 
PLP is covalently bound in the catalytic site by formation of a Schiff s base (imine) 
with the amino group of a lysine residue, named the internal aldimine (Figure 1-4). 
The next common step consists of the binding of the amino acid substrate and 
displacement of the lysine residue to form the external aldimine (transaldimination 
reaction, Figure 1-4). 





° c Irydroxymethyt ' transferases 
The variation in PLP-dependent enzymatic reactions arises from this common 
external aldimine intermediate and by the reaction at one of the amino acid carbons 
(a. 0 or y). The PLP enzymes can be divided into three major families depending of 
which carbon modification they catalyse (Figure 1-5). 
I) u-carbon reactions: transamination, racemisation and decarboxylation (in 
green), elimination (aldol cleavage). 
13-carbon reactions: elimination and replacement (in blue). 
y-carbon reactions: elimination and replacement (in pink). 
All of these reactions have as a starting point the breakage of one three bonds the 
attached to Cu of the PLP:amino acid external aldimine and are described below 
(Figure 1-5). The diversity of PLP-catalysed reactions has been extensively 
reviewed - 
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Figure 1-5 The diversity of reactions catalysed by PLP dependent enzymes. 0 indicates a 
quinonoid intermediate. Adapted from reference 24. 
The reaction specificity is determined by the position of the three possible "leaving 
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conjugate. In 1966 Dunathan 
25  proposed that the transition state of the reaction must 
place the bond to be broken in a plane perpendicular to the pyridoxal imine it-system 
(Figure 1-6A), whereby its p orbital is aligned with those of the conjugated Schiff 
base/pyridine ring it-system. The bond so oriented would be selectively labilized. 
The three conformations described below (Figure I-6B) will yield different types of 
reactions and reaction products. Conformation (1) activates the Cu-H bond and leads 
to transamination. u,13-elimination. 13.y-elimination and 3-decarboxylation. The 













Figure 1-6 Illustration of Dunathan hypothesis (A) Stereoelectronic control of reaction 
specificity in PLP-catalyzed reactions (B) The 3 possible conformations of the external 
aldimine Ca (C) Principal resonance forms obtained after external aldimine deprotonation 
(carbanion and quinonoid). Adapted from references 25 and 26. 
The bond breaking steps are facilitated by the formation of a carbanion that is 
stabilised by the electron sink property of the pyridine ring of the PLP cofactor. The 
stabilised carbanion intermediate is named a quinonoid in that particular resonance 
form (Figure I-6C). The exact roles played by the protonated/deprotonated states of 
the Schiff s base and the pyridine nitrogen on the carbanion stabilisation process has 
been discussed recently by Toney26 ' 27 and Bach28 . 
Each PLP-dependent enzyme works using this common mechanism. The only 
exceptions are the PLP-dependent phosphorylases. The chemistry of these enzymes 
is completely different and the phosphate group of the PLP is used in catalysis but at 
the present its role is unclear 29 
1.2.1.2 Classification 
Due to the large number of PLP-dependent enzymes and the vast chemical 
diversity they exhibit, a classification was proposed by Christen et al.30 based on the 
chemical characteristics of the catalysed reactions. This classification divides the 
PLP-enzymes into three classes: a, 13,  y depending on the carbon atom of the 
substrate involved in the chemistry. Later, another classification was proposed by 
Goldsmith et al.3 ' that further separated this superfamily into five different structural 
fold types. These five classes are discussed in two reviews by Jansonius 23 and 
Schneider24 . Enzymes were classified according to their amino acid sequences, 
secondary structure predictions and available three-dimensional structures. The five 
classes are often named by the first enzyme characterised for the group. This 
classification includes; the aspartate aminotransferase family (fold type I), the 
tryptophan synthase 13 family (fold type II), the alanine racemase family (fold type 
III), the D-amino acid aminotransferase family (fold type IV) and the glycogen 
phosphorylase family (fold type V). This last family is sometimes considered as 
separate from the others due to its utilisation of PLP-phosphate group in the catalysis 
of its reactions. 
The Fold type I or aspartate aminotransferase family 
Of the five fold type families, the Fold-type I family of enzymes has been the best 
characterised and it is further divided into six subclasses. Aminotransferases catalyse 
the amino group transfer between an amino acid and an oxoacid. The three-
dimensional structures of this group reveal them to be homodimers containing two 
actives sites. Each subunit of this dimer contains a large and a small domain. The 
small domain contains the C and N termini. The PLP is attached to the large domain 
by a covalent bond with a conserved lysine residue and residues from both subunits 
are necessary for the formation of an active catalytic site. 
The Fold type II or tryptophan synthase /3 family 
This family is characterised by three different three-dimensional structures. The first 
is represented by the tryptophan synthase 13 from Salmonella typhimurium and forms 
a a2132 tetramer where 13  is the PLP catalytic subunit and a the regulatory subunit. 
Threonine deaminase is an a 4 tetramer which is a dimer of a "catalytic" dimer. Each 
monomer consists of a PLP-binding site in the N-terminal domain, which form the 
catalytic part, and a regulatory domain situated at the C-terminus. Finally, 0-
acetylserine suithydrylase is an active a 2 dimer. Each subunit contains a PLP-binding 
domain but lacks a regulatory domain. 
The Fold type III or alanine racemase family 
Enzymes of this group are homodimers. Each monomer contains two domains, an 
a113 barrel and a domain mainly comprising 13  strands. These enzymes contain only 
one molecule of PLP which is bound at the mouth of the barrel between the two 
subunits. The active-site lysine is situated at the C-terminal end of the first strand. 
The Fold type IV or D-amino acid aminotransferase family 
Here, the enzyme is homodimeric and contains a unique active site at the interface of 
the two subunits. The monomers are composed of a large C-terminal domain and a 
small N-terminal domain. The PLP binds to a lysine residue situated on the C-
terminus but residues of both subunits contribute to the catalytic site. The active sites 
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of D-amino acid transferases are virtually mirror images of the active site of the fold 
type I aminotransferase. 
The Fold type V or glycogen phosphorylase family 
These enzymes are multidomain proteins and contain three distinctive domains, the 
C- and N-terminal domains and a glycogen-binding domain. The C-terminal domain 
binds the PLP and also contains a dinucleotide-binding fold. The action of PLP in 
this family is totally different from those mentioned above and instead of playing a 
role as electrophilic catalyst; the phosphate group is used for proton transfer. 
1.2.2 PLP-dependent a-oxoamines Synthase Family (AOS) 
SPT belongs to the a-oxoamine synthase (AOS) subfamily of PLP-dependent 
enzymes, which contains three other well characterized members: 8-amino-7-
oxononanoate synthase (AONS) 32 ' 5-aminolevulinate synthase (ALAS) 3436, and 2-
amino-3-ketobutyrate-00A ligase (KBL) 37 . These enzymes catalyze the Claisen-like 
condensation between a specific pair of amino acid and an acyl-coenzyme A 
thioester2 ' substrates to produce a-oxoamines (Figure 1-7). Three of the four enzymes 
catalyze decarboxylation of the amino acid (SPT, AONS and ALAS) but KBL is 
unusual as it produces a carboxylated product, 2-aminoketobutyric acid. Each 










Figure 1-7 The decarboxylative Claisen-like condensation between an amino acid and 
thioester substrates catalysed by enzymes in the AOS family. 
Structural studies have shown AONS, ALAS, and KBL isoforms from various 
species to be homodimers32' 36, 11 . In marked contrast, eukaryotic SPTs are 
heterodimeric, membrane-bound proteins consisting of two subunits, SPT1 and SPT2 
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(encoded by the lcbl and lcb2 genes, respectively) 38 . However, a water soluble 
homodimeric enzyme has been isolated from the cytoplasm of the bacterium 
Sphingomonas paucimobilis" and sequence alignment data has shown it displays 
—30% sequence homology with the other members of a-oxoamine synthase family. 
The first high-resolution x-ray crystal structure of the S. paucimobilis holo-SPT was 
recently solved 39  in our group in collaboration with Prof. Jim Naismith (Figure I-81)). 
The four AOS structures closely resemble each other and they are all intimate, 
interlocked dimers with each subunit comprising three domains (N-terminal, central 
catalytic and C-terminal, see Figure I-813). The two PLP-containing active sites are 
situated at the dimer interface. Key residues (Lys, His, Asp) are responsible for the 
stabilisation of the cofactor and are highly conserved throughout the family (Figure 
I-8E). 
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Table I-I Members of the PLP-dependent o-oxoamines synthase family (AOS) 
Amino acid Thioester Enzyme Product Pathway PDB files 
L-Alanine Pimeloyl-CoA 8-amino-7-oxononanoate synthase 8-amino-7-oxononanoate Biotin E. co/i apo AONS 1BSO 
(AONS) (AON) E. co/i AONS complexed 
with PLP and 8-amino-7- 
oxononanoate 1DJ9 
Glycine Acetyl-CoA 2-amino-3-ketobutyrate-00A ligase 2-amino-3-ketobutyrate Threonine E. co/i holo-KBL 1 FC4 
(KBL) (AKB) degradation 
salvage  
Glycine Succinyl-CoA 5-aminolevulinate acid synthase 5-aminolevulinate (ALA) Tetrapyrrole R. capsulatus holo-ALAS 
(ALAS) 2BWN 
R. capsu/atus ALAS 
complexed with glycine 
2BWP 
capsu/atus ALAS 
complexed with succinyl- 
CoA 
2BWO 
L-Serine Palmitoyl-CoA Serine palmitoyltransferase (SPT) 3-ketodihydrosphingosine Sphingolipids paucimobi/is apo-SPT 
(KDS) 2JGT 






Figure 1-8 Overall 
structure of the AOS 
family homodimers. In 
each enzyme, the two 
PLP molecules are 
drawn in spheres and 
coloured green. (A) 
AONS monomer A is 
shown in dark green 
and monomer B in 
orange (B) KBL 
monomer A is shown in 
purple and monomer B 
in yellow (C) ALAS 
monomer A is shown in 
dark blue and 
monomer B in red (D) 
SPT monomer A is 
coloured with the N-
terminal domain shown 
in red, the central 
catalytic domain in 
dark green, and the C-
terminal domain in 
yellow. The second 
subunit is shown in 
cyan. (E) Overlay of 
key conserved 
residues involved in 
cofactor 	binding: 
His234, His159, 
Asp231 Lys265 (SPT 
numbering). AONS 
shown in orange, KBL 
in magenta, ALAS in 
green and SPT in 
cyan. 
Since all four of the AOS enzymes catalyse similar type of condensation reaction, 
structural and functional studies have led to the proposition of a common 
mechanism 20, comprising the following steps: formation of an external 
aldimine via displacement of the lysine-PLP internal aldimine (holo-SPT) by the 
incoming amino acid substrate; formation of a quinonoid intermediate by abstraction 
of the a-proton from the PLP-amino acid external aldimine; a Claisen-like 
condensation with the fatty acid-CoA thioester substrate, followed by displacement 
of the CoASH to form a a-ketoacid intermediate; decarboxylation of this species to 
form a product quinonoid; protonation of this quinonoid to form the product external 
aldimine; and finally release of the a-oxoamine product and regeneration of the 
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Figure 1-9 Proposed 
catalytic mechanism of 
SPT and AOS family. (a) 
the internal aldimine 
(holo-form) is displaced 
by L-serine to form the 
external aldimine; (b), 
binding of second 
substrate palmitoyl-CoA 
causes conformational 
change to give the 
Dunathan intermediate; 
(c) formation of the 
quinonoid by 
deprotonation of Co 
hydrogen; (d) thioester 
bond hydrolysis and 
release of CoASH to 
give 3-keto acid 
intermediate; (e) 
decarboxylation to form 
KIDS product quinonoid; 
(f) reprotonation to form 
KIDS product external 
aldimine; (g) KIDS 
product release and 
reformation of the holo-
form. The dotted line 
shows that steps e and f 
may be bypassed by an 
alternative mechanism 
that does not proceed 
via a product quinonoid. 
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Although PLP-dependent AOS enzymes have been extensively studied periodically 
newly characterized enzymes appear in the literature that display interesting twists 
and surprises. The AOS family has recently expanded with the characterisation of 
four new members (CqsA, LqsA, Fum8 and SerT). CqsA45' 
46  catalyses the 
condensation between L-threonine and/or L-2-aminobutyric acid and decanoyl-CoA 
and is involved in the biosynthesis of the cholerae autoinducer- I (CAI-1) or its 
intermediate amino-(CAI-l)(Figure I-1OA 1 and 2). LqsA 47 is part of the gene cluster 
producing the Legionella autoinducer-1 (LAI-1) (Figure MOB) and its substrates 
remain undetermined at the moment. CqsA and Lqsa are involved in quorum sensing 
by production of the volatile auto-inducers which are able to "escape" their original 
cell to go on to activate receptors of neighbouring cells. The structure of CqsA has 
been recently solved by two independent research groups 45, 46 and both these 
structures revealed that CqsA displayed the same characteristics as the others 
members of the AOS family. CqsA is a homodimeric enzyme with two active sites 
and both monomers are needed to form an active enzyme. The structure of the 
decanoyl-CoA complex revealed a hydrophobic tunnel to which this substrate binds. 
Fum8p48  is involved in chain release in the biosynthesis of the fungal natural product 
fumonisin and catalyses the condensation between L-alanine and steroyl-ACP to 
produce the corresponding sphingosine (Figure 1-1C). Finally, SerT 49, subunit of a 
multidomain NRPS-PKS protein, catalyses the condensation between L-serine and 
pyrrolyl-3-ketoacyl-S-ACP to form 4-hydroxy-2,2'-bipyrrole-5-methanol (HBM) 
(Figure MOD) and is involved in prodigiosin biosynthesis. 
A 
	 B 
0 	 0 
OH 	 OH 
0 
OH 
C 	 NH2 
0 	 OH 
NH 
NH 
Figure 1-10 Condensation products of (A) CqsA (B) LqsA (C) Fum8 (D) SerT. 
17 
1.2.3 Serine palmitoylransferase isozymes 
1.2.3.1 Eukaryotic SPTs 
SPT was first isolated from S. cerevisiae by Pinto et al. in their work on 
mutant strains which required an external supply of phytosphingosine for growth50' 
5I 
Subsequently, mammalian homologs were identified in mice 52 , hamster CHO cells 53 
and humans 54. Sequence alignment of these proteins has shown that there is 40% 
amino acid sequence identity between mammalian and yeast and 95% homology 
between mammalians types. It was shown 51, 53 that mammalian and yeast SPTs 
comprise two non-identical subunits each encoded by two different genes LCB1 and 
LC132. In the human genome, the LCB1 gene is located in the chromosome 9q21-q22 
region. It comprises 15 exons and contains around 85kbp. The second gene, LC132, is 
located in the chromosome 14q24.3-q31 region and is formed by 12 exons and its 
size is llOkbp. Weiss et al.54 and Hanada et al.55 have both successfully purified the 
two protein subunits and characterised the isolated SPT enzyme but only in 
microgram amounts. Based on their encoded gene sequences the hSPTI and hSPT2 
monomers are proteins of 53kDa and 63kDa respectively and sequencing alignment 
shows 20% identity between the two subunits. The recent identification of a 
hLCB3 gene expressed mainly in placenta (with homology to hLCB2) suggests 
greater complexity of the enzyme than previously thought. 56  A highly hydrophobic 
domain situated at the N-terminus of hSPT1 is thought to play the role of a 
membrane anchor. 52, 54 Studies by Mandon et al. 57 showed that SPT is localised in 
the ER with membrane spanning domains in both the C- and N-termini. The major 
part of the enzyme faces the cytosol allowing the substrates free access to their active 
sites. 
In yeast SPT1, three other hydrophobic domains have been identified. 58 The first 
domain is located between residues 50-84. It is not required for stability, membrane 
association, interaction with ySPT2 protein or enzyme activity. The two other 
domains are situated between 342-371 and 425-457 and are required for protein 
stability. Another subunit of -iOkDa encoded by the Tsc3 gene has been identified 
by Teresa Dunn and her colleagues 59 This protein is associated with the yeast 
SPTI/SPT2 heterodimer but is not essential for SPT activity. 
60  It appears to play a 
role in regulation and is required for optimum activity of SPT. The same research 
group very recently identified small subunits (ssSPTa and ssSPTb) of mammalian 
SPT that increase SPT activity over 10 fold and confer distinct acyl-CoA substrate 
specificities .6 1  These two small subunits possess a central hydrophobic domain 
predicted to reside in the membrane. Each small subunit interacts with both hSPTI 
and hSPT2. 
For both human and yeast SPT, residues constituting the catalytic site are highly 
conserved (Figure I-I 1). These residues are situated on the SPT2 subunit around the 
catalytic lysine residue involved in the PLP binding. Although SPT2 is considered as 
the -catalytic" unit and SPTI the "regulatory" one both of the subunits are required 
to obtain an active enzyme. 
Figure I—lI The catalytic site, a highly conserved domain with the active site lysine 
highlighted (h, human; y, yeast; b, bacterial; v, viral). 
More recent studies showed that eukaryotic SPTs are even more complex proteins. 
Two research groups 62' 63 identified the conserved endoplamic reticulum (ER) 
membranes proteins Ormi and Orm2 as negative regulators of sphingolipids 
biosynthesis. Breslow et al. 62 showed that Orm proteins and yeast SPT formed a high 
molecular weight complex (the SPOTS complex) constituted of Orin I, Orm2, SPT1, 
SPT2, Tsc3 and the phosphatase Sac 1. The exact role of these other subunits in the 
regulation of SPT activity awaits further analysis. 
1.2.3.2 Viral SPT 
Recently, a novel single chain SPT has been identified in Coccolithovirus.M 
This enzyme contains two different domains comparable to the eukaryotic SPT but 
these are linked together, in a head-to-tail fashion (Figure 1-12). The N-terminal 
domain is related to the SPT2 subunit and the C-terminus to the SPTI and both 
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display high overall amino acid sequence homology to other members of the family. 
The catalytic site is also highly conserved (Figure I-lI). However, the viral SPT 
lacks the N-terminal membrane binding region that exists in the mammalian and 
yeast enzymes. It is noteworthy that this hydrophobic domain is not present in other 
AOS enzymes and is not essential for enzymatic activity. Substrate specificity has 
been observed for this enzyme which has a preferred affinity for myristoyl-CoA 




hLCBI 53 kDa 473 AA 	 hLCB2 63 kDa 562 AA 	
K379 
Yeast Saccharomyces Cerevisae 	 \ 
62 kDa 558 AA 	 yLCB2 	 561AA  
Bacteria Sphingomonas Paucimobilis 
/ 
X265 
bSPT 45kDa 420 AA 
Coccolithovirus 	 ... 
/1 
111+1' I UUIIIlI 
vSPT 96kDa 870 AA 
Figure 1-12 Subunit composition of SPT isozymes. Green bars represent hydrophobic 
transmernbrane domains. 
1.2.3.3 Bacterial SPTs 
A water soluble homodimeric SPT was isolated from S. paucimobilis by 
Ikushiro etal. 1 ' in 2001. This homodimer is composed of two monomers of 45kDa 
and contains two active sites (Figure 1-12). Each monomer is able to bind a molecule 
of PLP but the two subunits are required to obtain the active enzyme. Recently, three 
novel bacterial SPTs from Sphingobucterium multivorum, Sphingohacteriurn 
spiritivoruin and Bdellovibrio stolpii, have been isolated and purified by Ikushiro and 
colleagues. 12  Each enzyme is a water-soluble active homodimer that displays —30% 
homology with the two human subunits. Interestingly the S. inultivorurn and 
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Bdeliovibrio stolpii enzymes are bound to the inner membrane of cells which 
suggests that these enzymes could be a prokaryotic model of the membrane bound 
eukaryotic SPT. 
1.3 HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY TYPE 1 
(HSAN 1) 
HSAN I is the most common inherited disorder of peripheral sensory neurons 
and involves an autosomal dominant progressive degeneration of dorsal root ganglia 
and motor neurons. 7 In the early stages of disease a symmetric sensory loss is 
observed, whereafter symptoms progress slowly and affect the lower limbs 
disproportionately. This loss of sensation leads to painless injuries, predisposition to 
tissue/bone infections and mutilation of the feet. Deafness has been reported in some 
families. 65  As the disease progresses, there is also degeneration of motor neurons 
with secondary denervation atrophy and weakness of distal limb muscles. 66, 67 The 
first symptoms start to appear between 20 and 30 years old and the expression of the 
disease is different by gender within the same family. 68  Symptoms start later in 
women and they are, in general, less severe than in men. It is interesting to note that 
HSAN1 specifically affects the peripheral neurons; no adverse effect on the function 
of other neuronal tissues such as the CNS was reported. HSAN1 is a genetically 
heterogeneous disease for which 4 variants genes have been reported . 697 ' The 
HSAN1 locus was initially mapped to chromosome 9q22.1-22.3 72 , then more 
specifically by Dawkins et al.69 who assigned it to the SPTLC1 gene, lcbl, encoding 
the SPTI subunit. Three missense mutations concerning two amino acids have been 
identified . 69 Two of these are located in exon 5 and result in the replacement of a 
cysteine residue by a tryptophan or a tyrosine (C133W or C133Y, Figure 1-13). The 
third mutation is that of a valine residue to an aspartate (V144D, Figure 1-13). These 
three mutations are located within a twelve amino acid segment encoded by exons 5 
and 6. In initial studies 69 , it was believed that these mutations lead to an increase of 
SPT enzymatic activity that resulted in high levels of ceramides and their metabolites 
present in organisms carrying this mutation. However in 2002, Bejaoui et al. 70 
showed that HSAN1 leads to a decrease of SPT activity and that mutations confer 
dominant negative effects on the SPT enzyme. A fourth mutation linked to HSAN1 
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has been identified by Verhoeven et al. 7 ' This mutation is located in exon 13 and 
concerns a missense mutation of a glycine residue to an alanine (G387A, Figure I-
13). Unlike the two other amino acids, this glycine is not involved in the same amino 
acid segment. Although patients had a typical HSAN1 phenotype, it has been 
recently shown that the G387A mutation is not disease associated. 73 It is possible that 
G387A has a bystander effect by increasing the risk to develop a HSAN phenotype 
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Figure 1-13 HSAN1 mutations on SPT1. 
More recently, two new mutations that cause HSAN1 (S331F and A352V, Figure I-
14) have been identified downstream of the previously characterised HSAN1 
mutations 74 . The S33 IF mutation changes a senne residue that is highly conserved in 
eukaryotic SPTs (Figure 1-14). Interestingly this mutation was not carried by the 
parents of the patient and must have arisen by spontaneous mutation. The resulting 
phenotype is very severe and is characterised by a congenital onset and mental 
retardation. In an independent study Dunn and colleagues found several LCB I 
mutants that complemented mammalian cells lacking the small subunits (ssSPTa and 
ssSPTb); incredibly, the LCB1 mutant S331F was the best at complementing the 
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cells and also at increasing basal SPT activity in the absence of small subunits. This 
mutant was not activated by ssSPTa but was activated by ssSPTh. According to the 
most recent topological study of LCB 158,  the S3 311 F mutation is predicted to be 
located on a loop between TM2 and TM3 in the lumen of the ER membrane. In 
contrast, the most common HSAN1 mutations C133Y, CI33W and VI44D are all 
located between TM 1 and TM2 of LCB 1; this section of the protein is predicted to 
face the cytosol and contains the residues that interface with LCB2 at the enzyme 
active site. Therefore it is likely that S33 1 F affects interaction between LCB 1 and 
ssSPTa and results in a highly compromised enzyme function causing symptoms 
more severe than those associated with the most common HSANI mutations. The 
pathology of the second mutation A352V could not be confirmed and the affected 
amino acid is not well-conserved among the species. Furthermore the amino acid 
change is mild considering the chemical properties of alanine and valine. 
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Figure 1-14 SPT1 alignment-HSAN 1 mutations. Identic amino acids are highlighted in black. 
Chemically similar amino acids are highlighted in grey. Amino acid involved in HSAN 1 
mutations are highlighted in magenta. 
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The changes created in SPT and their effect on the enzyme are not well understood 
but the mutated cysteine residue involved in both C 133W and C1 33Y mutants is 
thought to lie in close proximity to the PLP binding site. Therefore, it has been 
postulated that the mutation affects PLP binding and catalysis 70,  Hornemann et 
al.7678 propose that HSANI mutations alter the amino acid specificity of the mutant 
SPT enzyme leading to the formation of two toxic side-products, 1-
deoxysphinganine (DoxSA) and 1 -amino-2-deoxy-n-heptadecane (ADHD) (Figure I-
15), formed by the condensation of palmitoyl-CoA with L-alanine and glycine. The 
hypothesis is that these lipids are not metabolised through normal SL catabolism and 
build up slowly over time to a toxic level. Support for this comes from the fact the 




Figure 1-15 Deoxysphingosine bases formed by condensation of palmitoyl-CoA and (A) L-
alanine, (B) glycine. 
As the human SPT is a membrane bound enzyme, mechanistic and structural studies 
of both wild type and mutants SPTs would be extremely difficult (less than 1% of 
available structures in the PDB are membrane proteins) . 79 To gain insight into the 
nature of these mutations, Yard et al. 39 used bioinformatic analysis to map the 
cysteine residue (C133) of the human SPT onto the asparagine (NiOO) on S. 
paucimobilis SPT. Analysis of the tertiary structure of the wild type SPT showed that 
the side-chain of this asparagine residue is located near to the catalytic site and is 
involved in a hydrogen-bond with the backbone chain supporting the lysine residue 
(Lys 267) binding the PLP (Figure 1-16). The impact of HSAN1-like mutations at 
this Ni 00 residue on the structure, function and enzymatic activity of the bacterial 
SPT is the focus of part of this thesis. 
25 
1 
Figure 1-16 Location of AsnlOO in the active site of S. paucimobiis SPT. Structure of the 
SPT-L-serine external aldimine complex. Catalytic site of SPT dimer showing one monomer 
in teal and the other in purple. The internal aldimine and the residues His234, Hisi 59, Asp23 
from the teal monomer are shown in stick form and are coloured yellow. The residues N100 
from the purple monomer is coloured green. This clearly shows that the AsnlOO from one 
monomer interacts with the active site of the other monomer. 
1.4 ACYL CARRIER PROTEIN (ACP) 
Acyl earner proteins (ACPs) are highly conserved small acidic proteins made 
up of approximately 70-80 amino acids. ACPs require post-translational activation 
by addition of a 4-phosphopanthetheinyl (4-PP) group from coenzyme A onto a 
specific serine residue; this modification is carried out by phosphopantheinyl 
transferase enzymes (PPTase). ACPs are multifunctional and have been shown to be 
used in several essential primary metabolic pathways. For example, they are an 
indispensable component of the fatty acid synthases (FAS), where they are part of a 
multi-domain protein (type I) or are an independent subunit (type II). In bacteria, 
ACPs or PCPs (peptide earner proteins) are involved in polyketide synthase (PKS) 
and non-ribosomal peptide synthase (NRPS) which produce a large diversity of 
natural products such as polyketides and peptide antibiotics. 80 
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1.4.1 Fatty Acid Synthase (FAS) 
1.4.1.1 Type I FAS 
Eukaryotic ACPs are small components of large multifunctional proteins 
called fatty acid synthases (FAS). Mammalian FAS is an homodimeric enzyme of 
—250 kDa81 82  Each subunit comprises three N-terminal domains separated from 
four C-terminal domains by a central core domain devoid of any catalytic activity. 
The order of functional domains was established as [3-ketoacyl synthase (KS), 
malonyl/acetyl transferase (MAT). dehydratase (DH), enoyl reductase (ER), - 
ketoacyl reductase (KR), ACP and thioesterase (TE)(Figure 1-17A). 
A 
KS AT DH 	ER KR ACP TE 
[;i 
ACP KR KS PPT 
	
AT ER DH MPT 
70 
AT ER DH MPT ACP KR KS 
Figure 1-17 FAS type I systems (A) Mammalian FAS (B) Yeast FAS (C) Mycobacterium FAS 
KS: ketoacyl synthase, AT: acyltransferase, DH: dehydratase, ER: enoyl reductase, KR: 
ketoreductase, ACP: acyl carrier protein, TE: thioesterase, PPT: phosphopantetheine 
transferase, MPT: malonyl/palmitoyl-transacylase. 
The ACP domain has spatial access to all FAS components. Recently, the porcine 
FAS crystal structure was solved 83  and this revealed an asymmetric X-shaped 
conformation with two reaction chamber (Figure 1-18). With a structural resolution 
of 4.5 A each catalytic domain was identified in the complex apart from the ACP and 






Figure 1-18 Mammalian FAS type I (PDB: 2VZ8). Each domain is represented by a different 
color. The ketoreductase (KR) domains are coloured yellow. The enoyl reductase (ER) 
domains are represented in dark green. The dehydratase (DH) domains are drawn in pale 
green. The acyltransferase (AT) domains are red and the ketoacyl synthase (KS) domains 
are orange. 
The structure of a fungal FAS has been determined by Jenni et al.84 Like the 
mammalian FAS. the ACP domain was not visible' in this structure. In contrast to 
mammalian FAS, the fungal and yeast enzymes comprise two different polypeptides 
(-185 and 180 kDa) which aggregate into a multimeric protein (16136) resulting in the 
formation of six reaction chambers (Figure 1-19). Each a and P subunit contains four 
functional domains (Figure I-1713). Recently, two research groups85 86  crystallised 
and solved the yeast multidomain protein structure including the ACP and PPT 
domains (Figure 1-19). Interestingly, the PPT domain is situated on the outside of the 







Figure 1-19: Yeast FAS type I (PDB: 2CDH). (A) Multimer a3133 top view (B) Multimer a3 top 
view. 13 subunits are coloured in dark purple, blue and green, a subunits are coloured in pale 
purple, blue and green. ACP subunits are coloured dark grey and the PPT subunits are 
coloured orange. 
It is interesting to note that as well as higher organisms certain bacteria such as 
Mycobucteriuin tuberculosis possess a type I FAS. 57 These enzymes are u6 hexamers 
and each subunit contains seven domain, acyltransferase (AC), enoyl reductase (ER), 
dehydratase (DH), malonyl/palmitoyl-transacylase (MPT), acyl carrier protein (ACP), 
ketoacyl reductase (KR) and ketoacyl synthase (KS) (Figure l-17C). 
1.4.1.2 Type II FAS 
Type II FAS are found in bacteria, eukaryotic plastids and mitochondria 81 
Each FAS component is an individual protein encoded by a discrete gene. The 
growing acyl intermediates remain covalently bound to an independent ACP which 
shuttles them along the synthetic pathway. The FAS type II system from E. co/i has 
been extensively studied and the structures of all of the individual FAS enzymes are 
now available8 . Previous X-ray and NMR studies on bacterial and plant ACPs had 
shown that they share a high degree of structural similarity 88 . Indeed, ACPs from 
different organisms are interchangeable. 98.  The typical. highly-conserved 3-D 
structure of an ACP is characterised by 4 u-helices and a long structured loop 
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Figure 1-20 ACP type II structure from E. co/i (PDB: 1 LOH) (A) Top view (B) Side view. The 
prosthetic and C8 acyl groups are represented in stick form and coloured blue. 
High sequence conservation is observed in the second helix 90  (Figure 1-21) and it is 
thought to be a recognition' helix toward others enzymes of the FAS complex 993 . 
The unique motif DSL, situated at the end of helix 2, is present in all ACP sequences 
(Figure 1-21). The 4-PP prosthetic group derived from coenzyme A is attached to 
the serine residue of the DSL motif in the ACP holoform. The acyl chain binding site 
was determined by NMR and crystallographic characterisation of the E. co/i butyryl-
ACP intermediate revealing a hydrophobic cavity formed by helices 2 and 3 (Figure 
1-20)94  . Further X-ray studies on longer acyl chains (C6, C7 and ClO) showed that 
the hydrophobic cavity can expand in order to accommodate the growing acyl 
chain. 95  
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Figure 1-21 Sequence alignment of ACPs highlighting secondary structure elements. Identic 
amino acids are highlighted in black. Chemically similar amino acids are highlighted in grey. 
Mitochondrial FAS type II are largely present in eukaryotes and their principal 
function is to synthesise octanoyl-ACP, a precursor of lipoic acid which is a key 
cofactor for pyruvate dehydrogenase and others mitochondrial enzymes. 96 
An interesting atypical group of type II ACPs is found in Mycobacterium 
tuberculosis. 97  These proteins possess a longer C-terminus than the other ACPs and 
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are involved in the synthesis of very long chain fatty acids (C50, C60) from shorter 
acyl chains released by their FAS type I system. 
1.4.2 Polyketide synthase (PKS) and non-ribosomal peptide synthetase 
(NRPS) 
Polyketides and non-ribosomal peptides are a large class of natural products 
synthesised by bacteria using acyl-CoA and amino acids as building block. 81.98.99  
Although these two classes of compounds are chemically and functionally different, 
the enzymatic systems used for their synthesis share many similarities. Both 
molecules are synthesised via megasynthases (-.200-2000kDa) comprising repeated 
functional units named "modules'. Each module has a different enzymatic activity. 
Different types of PKS exist: type I is the multidomain protein, the type II system is 
an assembly of discrete proteins and type III uses acyl-CoA instead of acyl carrier 
protein (by analogy with FASs).'°° lOt  Only megasynthase systems are known for the 
NRPS. It is interesting to note that some ACPs have been found as free-standing 
proteins or incomplete modules.80 102  The overall structure and organisation is 
similar in PKS and NRPS. They are both made up of 3 core modules; two catalytic 
and one carrier (ACP for PKS and PCP, peptide carrier protein, for NRPS), some 
auxiliary domains (reduction, dehydratation, epimerisation) and two domains for 
initiation and termination (Figure 1-22). 
LD - AT KS ACP - KR DH - TE 
Initiation J 	 Possible 	 Termination Core domain 	auxiliary 
domain 1 domain J 	domain LD — A C PCP 	 TE 
Figure 1-22 PKS and NRPS systems. Top: PKS domains; AT: acyltransferase, KS: 
ketosynthase, ACP: acyl carrier protein, KR: ketoreduction, DH: dehydratation. Bottom: 
NRPS domains; A: adenylation, C: condensation, PCP: peptide carrier protein, NMet: N-
methylation, Cy: cyclisation. LD: loading, TE: thioesterase. 
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Despite the different chemistry, formation of C-C bond for polyketides and C-N 
bond formation for non-ribosomal peptides, the chain-elongation strategy is the same; 
the required building block (acyl- or AA) is transferred from an ACP or PCP domain 
to the growing chain by a condensation reaction (Figure 1-23). 
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Figure 1-23 Condensation reactions with (A) PKS (B) NRPS. 
1.4.3 Acyl Carrier Protein Synthase (ACPS) 
As was already mentioned, to become catalytically active, an ACP must be 
converted from the inactive apo-form to the active holo-ACP by specific PPTase 81. 
103 (Figure 1-24). These enzymes transfer the 4'-PP moiety of coenzyme A (CoA) to 
the side chain hydroxyl of a serine residue invariant in all ACPs. This post-
translational phosphopantetheinylation introduces a covalently-attached nucleophilic 
thiol on a long tether that becomes the site of all the initiation and acyl transfer 
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Figure 1 -24 Conversion of apo-ACP to holo-ACP. 
The PPTase superfamily is composed of two distinct subgroups.' °3 The first 
subgroup (Type I PPT) includes the PPTases that modify peptide carrier protein in 
NRPSs. These enzymes are generally —230 amino acids long. For example the Sf 
from B. subtilis involved in surfactin synthetase, belongs to this group. Its structure 
has been solved by Reuter et al. 104 and showed that at least two monomers were 
needed to form the active enzyme. The second subgroup (type II PPT) includes acyl 
carrier protein synthase (ACPS) involved in fatty acid synthase. They are smaller 
proteins comprising —120 residues. Three crystal structures have been obtained with 
ACPS from S. p,zeumoniae '°5 and B. suhtilis ACPS' ° in complex with coenzyme A 
and ACP. The latest structure showed that these PPTases are actually tnmenc 
enzymes which form three active sites at the subunit interfaces (Figure I-25A). These 
two subgroups share low sequence similarities although some residues are highly 
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Figure 1-25 (A) ACPS/ACP B. subtilis trimer overall structure (PDB: 1 F80). The three 
monomers of the ACIDS protein are represented in green, yellow and red. (B) Partial 
sequence alignment of 45 putative and proven phosphopantetheinyl transferases of the Sfp-
type (top) and ACPS-type (bottom). Invariant residues are shaded in pink (Sfp-type) and red 
(both types), highly conserved residues are shade in light and dark grey. Residues 
occupying conserved positions but deviating from the consensus amino acid are shaded in 
green . The three acidic residues of Sfp involved in Mg 2 complexation are marked by an 
asterisk (*)• The seeclôuence  alignment was performed using CLUSTALW (Higgins et al., 
1996) .Adapted from 1 4• 
It has been shown that the conserved residues are involved in ACP/ACPS interface, 
coenzyme A and Mg2 binding 106 . One particular residue, Lys 62 (B. subtilis ACPS 
numerotation), is believed to be involved in the mechanism by activation of the ACP 
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Figure 1-26 Mechanism of holo-ACP formation. 
It appears that each ACP has a corresponding PPT that has been optimized for 
activity. It has been shown that ACPSs from the type II PPTases family are able to 
modify 4-PP-dependent enzymes from the same class but are not able to modify 
type II 4'-PP-dependent ACPs.' °6 On the contrary, type I PPTases proteins are able 
to modify both type of carrier proteins. A logical explanation has been proposed by 
Pan-is et al. when they looked at the superposition of both protein active sites 106 . 
Type I PPTases such as Sfp have a shallow and wide active site which can easily 
accept ACPs from both large domain synthases and smaller, independent ACPs. It is 
understandable that the small, independent ACP can fit in an ACPS active site but a 
larger ACP domain cannot access it. It is interesting to note that PPTases are not only 
limited to the transfer of 4'-PP group. It has been shown in numerous studies that 
49. 107 	 48. 108 	 /09 Sfp 	or other PPTases such as Svp 	and ACPS from S. coelicolor , are able 
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to directly transfer the acyl chain in addition to the 4'-PP group from an acyl-CoA 
(Figure 1-27). This is useful since it allows the conversion of an apo-ACP into its 
acyl-ACP form in a single step rather than the two-step conversion where the holo-
form is formed first then acylated specifically on the 4'-PP afterwards. 
PPTase (:D~~oH  r_ ~ - (::r 	S) n 
AcyI-00A 3',5'-ADP 
Apo-ACP 	 AcyI-ACP 
Figure 1-27 Direct conversion of apo-ACP to acyl-ACP. 
1.4.4 Aims 
The overall goal of this work is to investigate the effect of SPT mutations that cause 
the human genetic disease HSAN1 in a bacterial mimic (SPT from Sphingomonas 
pauciniobilis). The main aims are as follows: 
Characterisation of wild-type SP SPT and development of a DTNB activity 
assay for kinetic analysis. 
• Mapping of the HSAN 1 mutations onto the bacterial enzyme and subsequent 
preparation of the mutant SPT mimic clones by site-directed mutagenesis. 
• Characterisation of HSANI mutants: activity, substrate binding, mass-
spectrometry. 
Structural biology of wild-type and mutants, co-crystallisation with 
substrates. 
The second part of the thesis investigates the possibility that a bacterial SPT from 
Sphingomonas wittichii utilises an acyl carrier protein (ACP) to deliver the acyl 
chain moiety to the enzyme instead of a palmitoyl-CoA substrate. 
Amplification of ACP and SPT genes from SW genomic DNA, followed by 
cloning into pET vectors. 
• Characterisation of SPT: activity assays, mass-spectrometry, substrate 
binding, kinetic analysis. 
• Modification of apo-ACP to holo- and acyl-ACP with several PPTase. 
Characterisation by mass spectrometry. 
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CHAPTER II: MATERIALS AND 
METHODS 
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11.1 MATERIALS AND REAGENTS 
All reagents, chemicals and media were purchased from Sigma-Aldrich, Fisher or 
Biorad unless otherwise stated. S-(2-Oxoheptadecyl) CoA was gifted from Hiroko 
Ikushiro, Department of Biochemistry, Osaka Medical College. All primers were 
purchased from Sigma Genosys. All competent cells and pET plasmids were 
purchased from Novagen and all chromatography columns were from GE Healthcare 
unless otherwise indicated. The pET28a-SPT plasmid was constructed in the lab, 
prior to this work, by Dr. Beverley Yard. The plasmids encoding the Streptomyces 
coelicolor ACPS (pET I 5b-ACPS) and Bacillus subtilis Sfp (pET28aJSfp) were 
generous gifts from Dr. Matt Crump (University of Bristol) and Prof. Jason 
Micklefield (University of Manchester) respectively. The synthetic DNA construct 
(encoding Streptomyces verticillus Svp) was purchased from Mr. Gene, Regensburg, 
Germany. 
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11.1.1 Competent E. coil Cell Lines 
Table Il-I 
Species Cell line Genotype Application 
E. coil BL21 DE3 F ompT hsdSB (rBmB) gal dcm (DE3) Transformation, 
(Novagen) expression host. 
E. coil DH5 UTM F p80dlacZAMl 5 A(lac2YA-argF) Transformation, 
(Invitrogen) U169 recAl endAl hsdRl7 (rKmK) plasmid storage. 
phoA supE44 	thi-1 gyrA96 re/Al 
E. co/i HMS 174 DE3 F recAl hsdR(rKl2 mK12) Transformation, 
(Novagen) (DE3) (Rif R) expression host. 
E. coil One Shot® Top F mcrA A(mrr-hsdRMS-mcrBC) Transformation of 
10 T80dlacZAM15 Aiacx74 recA 1 ligation, plasmid 
(Invitrogen) araAl 39 A(ara-Ieu)7697 galU ga/K storage. 
rpsL (StrR)  endAl nupG 
E. coil JMI09 endAl, recAl, gyrA96, thi, hsdRl7 Transformation of 
(Promega) (rK mK), re/Al, supE44, A(lac- ligation, plasmid 
proAB), [F' traD36, proAB, laq Iq storage. 
ZAM15]. 
11.1.2 Sphingomonas wittichil Cell stocks 
The S. wittichii RW1 strain was plated onto LB agar and grown for 2 days at 
37 °C. A single colony was used to inoculate LB (5mL) under sterile conditions. The 
inoculant was grown overnight at 37 °C with agitation. Glycerol was added to a final 
concentration of 20%. The cell stock was stored at -80 °C. 
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11.1.3 Growth Media 
All media were dissolved in distilled water and the pH adjusted to pH 7.5. All 
were autoclaved for 20 minutes at 120 °C, 15 psi before use unless otherwise stated 
and if required to be stored, were kept at 4 °C. 
2YT: Bacto- tryptone (16 gIL), bacto-yeast extract (10 gIL), sodium chloride (5 gIL) 
Luria Bertani (LB): Tryptone (10 gIL), yeast extract (5 gIL), sodium chloride (10 
gIL) 
SOC: Tryptone (20 gIL), yeast extract (5 gIL), sodium chloride (10 mM), potassium 
chloride (2.5 mM), magnesium chloride (10 mM), magnesium sulphate (10 mM), 
glucose (2 % wlv) 
11.1.4 Agar 
All agars were dissolved in distilled water and were autoclaved for 20 
minutes at 120 °C, 15 psi. Antibiotic was added on cooling (approximately 50 °C) to 
the required concentration. Plates were allowed to dry before being stored at 4 °C. 
LB: Tryptone (10 gIL), yeast extract (5 gIL), sodium chloride (5 gIL), Agar (15 gIL) 
S-GaI/Agar: Tryptone (10 gIL), yeast extract (5 gIL), sodium chloride (10 gIL), 
Agar (12 g/L), S-Gal (0.300 gIL), Ferric ammonium citrate (0.500 g/L), IPTG (0.030 
g/L) 
11.1.5 Antibiotic Stock Solutions 
All antibiotic stocks were sterile filtered (0.2 m) and stored at 4 °C. 
Ampicillin: A 100 mg/mL stock solution was made and the required volume added 
to media to give a final concentration of 100 p.g/mL. 
Kanamycin: A 30 mglmL stock solution was made and the required volume added 
to media to give a final concentration of 30 jig/mL. 
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11.1.6 Solutions and Buffers 
Each buffer was made by dissolving the components described below in 
sterile water. All buffers were 0.2 gm filtered and degassed prior to chromatography. 
All buffer stocks were stored at 4 °C. 
Stock buffer (0.5 M Potassium Phosphate, KPhos pH 7.5) : Dibasic 
potassium phosphate, K2HPO4 (0.470 moles/L), monobasic potassium phosphate, 
KH2PO4 (0.0299 moles/L). 
Buffer A: 20 mM KPhos pH 7.5, 25 tM PLP, 10 m imidazole, 150 mM NaC1 
Buffer B: 20 mM KPhos pH 7.5, 25 pM PLP, 50 mM, 150 mM NaCl 
Buffer C: 20 m KPhos pH 7.5,25 tM PLP, 100 m imidazole, 150 m NaCl 
Buffer D: 20 mM KPhos pH 7.5, 25 jiM PLP, 150 mM NaCl 
Buffer E: 20 mM KPhos pH 7.5, 150 mM NaC1 
Buffer F: 20 mM KPhos pH 7.5, 0 M KC1 
Buffer G: 20 mM KPhos pH 7.5, 1 M KC1 
Buffer H: 20 m KPhos pH 7.5, 150 mM NaCl. Addition of 10% glycerol in ACPS 
SW buffer 
Buffer I: 20 mM KPhos pH 7.9, 0.5 mM NaCl, 5 mM imidazole. Addition of 10% 
glycerol in Sfp buffer 
Buffer J: 20 mM KPhos pH 7.9, 0.5 mM NaCl, 500 mM imidazole. Addition of 
10% glycerol in Sfp and ACPS SW buffers 
Buffer K: 20 mM KPhos pH 7.5, 150 mM NaCl, 20 mM Imidazole. Addition of 
10% glycerol in ACPS SW buffer 
Buffer L: 50 mM Tns pH 7.8 
Buffer M: 75 mM MES pH 6.0 
Buffer N : 20mM KPhos pH 7.5 
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11.2 METHODS 
11.2.1 DNA Manipulation 
11.2.1.1 Cloning and Expression Plasmids 
Table 11-2 
Plasmid Cloning I Expression Application 
Provides stock of DNA available 
pGem®-T Easy 
Cloning in E. coli for manipulation into various 
(Pro mega) 
expression vector 
Expression of C-terminal His 6- 
pET-28a Expression in E. coli 
tagged protein 
Expression of C-terminal His6- 
pET-22b Expression in E. coli 
tagged protein 
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11.2.1.2 Oligonucleotide Primers 
Table 11-3 
Primer Sequence (5'-3 1 ) 
SPT Sp N 100W for GGGTCGGGCACCGGCAGCCGGATG 
SPT Sp N100W rev CATCCGGCTGCC[CCA]GGTGCCCGACCC 
SPT Sp N1 00Y for GGGTCGGGCACC[TAT]GGCAGCCGGATG 
SPT Sp N100Y rev CATCCGGCTGCC[ATA]GGTGCCCGACCC 
SPT Sp N1 00C for GGGTCGGGCACC[TGT]GGCAGCCGGATG 
SPT Sp N100C rev CATCCGGCTGCC[ACA]GGTGCCCGACCC 
SPT Sp R378A for CTCTACGTCAACATGGCG[GCC]CCGCCC 
SPT Sp R378A rev GGGCGG[GGC]CGGCATGTTGTCGTAGTG 
SPT Sp R378N for CTCTACGTCAACATGGCG[AAC]CCGCCC 
SPT Sp R378N rev GGGCGG [GTT] CGGCATGTTGTCGTAGTG 
ACP-SPT Sw BspHI for CATGTCATGAGCAGCAGAGAAGACATCTTCACC 
ACP-SPT Sw HindIll rev GGAAAAGCTTGGGGATTACTCCCGTGGCGCGCC 
SPT Sw NcoI for TGCGGCCGCAAGCTTGGGGATTAC 
SPT Sw Hind III rev AGCGGGGAACCCATATGATCATCGGCATC 
ACP Sw Hindlil rev AAGCTTGGAGAGGAGGTCGGCCACC 
ACPS Sw NdeI for AGCGGGGAACCCATATGATCATCGGCATC 
ACPS Sw XhoI rev ATCCCCCTCGAGCAGCGGGCGCGCATACA 
F2SPT BamHI for AGCCATATGGCTGGATCCGAGGCTGCCGCTCAG 
F2SPT NheI rev GCAGCCTCTGTCATGCTAGCACCAATAACCCCG 
11.2.1.3 Transformation of Competent E. coil 
Single Transformation 
Plasmid DNA (2 p.L) was added to competent E. coli cells (25 1tL) and 
incubated for 20 minutes on ice. The cells were then heat shocked for 30 seconds at 
42 °C before being incubated on ice for a further 2 minutes. Soc medium (80 jiL) 
was added and the cells were agitated (250 rpm) for 1 hour at 37 °c. Subsequently, 
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the cells (50 pL) were spread on a LB kanamycin plate (30 tgImL) and incubated 
overnight at 37 °C. 
Co-Transformation of S. wittichil ACP pET28a and ACPS pET22b 
The two plasmids DNA (2 giL) were added to competent E. coli cells (25 pL) 
and incubated for 20 minutes on ice. The cells were then heat shocked for 30 seconds 
at 42 °C before being incubated on ice for a further 2 minutes. Soc medium (80 jiL) 
was added and the cells were agitated (250 rpm) for 1 hour at 37 °c. Subsequently, 
the cells (50 j.xL) were spread on a LB Agar kanamycin (30 tg/mL) and ampicillin 
(100 1gImL) plate and incubated overnight at 37 °c. 
11.2.1.4 Polymerase Chain Reaction: QuickChange ® Site-Directed 
M utagenes"'Stratagene) 
Generally, each reaction contained forward primer (125 ng), reverse primer 
(125 ng), dNTP (1 1.tL) reaction buffer (5 pL, lOx Buffer) double stranded template 
DNA (50 ng) and PfuTurbo DNA polymerase (1 j.iL, 2.5 U). The reaction was made 
up to 50 tL with sterile water. The general thermal cycling procedure consisted of 
the following steps; step 1, initial denaturation (95 °C, 30 seconds), steps 2-19, 
denaturation (95 °c, 30 seconds), annealing (55 °c, 1 minute) and elongation (68 °C, 
I minutefkbp). Following thermal cycling, the reaction mixture was cooled to 37 °c 
before adding the restriction endonuclease DpnI (1 pL, 10 U) to remove any dam 
methylated/parental DNA. This solution was mixed using a pipette before being 
incubated for 1 hour at 37 °C. After digestion with DpnI, the DNA mixture (2 jtL) 
was used to transform TOP 10 competent cells as mentioned in section 11.2.1. 
11.2.1.5 Polymerase Chain Reaction (PCR): Taq Polymerase Beads (GE 
Healthcare) 
Generally, each PCR reaction contained; template DNA (50 ng), forward 
primer (125 ng), reverse primer (125 ng) and puRe Taq Ready-To-Go PCR beads (x2, 
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GE Healthcare). Each PCR bead was reconstituted to a final volume of 25 jiL to 
yield the following concentration of reactants; dNTPs (200 tM in 10 mM Tris-HC1, 
pH 9 at room temperature), potassium chloride (50 mM) and magnesium chloride 
(1.5 mM). The final reaction volume (50 pL) was made with sterile water. A general 
PCR reaction consisted of 30 temperature cycles; denaturation (95 °C, 1 minute), 
annealing (55 °C, 1 minute) and elongation (72 °C, 2 minutes) followed by an 
additional extension period (72 °C, 10 minutes). The reaction was terminated by the 
addition of DNA loading dye (6x, Novagen) and the mixture was separated by 
electrophoresis. The purified PCR product could then be cloned using pGEM 1-Easy 
vector (Promega) according to manufacturer's instructions. All cloned DNA was 
used to transform JM109 competent cells (50 tL) and cultures were grown on S-Gal 
agar plates containing ampicillin (100 tg/mL) thus providing blue/white screening 
for the identification of viable clone. 
11.2.1.6 Ligation Into An Expression Vector 
Ligation were carried out using the gene of interest (3 iL), the restricted 
plasmid (5 jiL), T4 Ligase (1 iL, 1x10 6 ligations /unit, New England Bio-labs), 14 
ligase buffer (1 giL, lOx, New England Bio-labs). The ligation was incubated 
overnight at room temperature and subsequently, 2 pL was used to transform JM109 
competent cells (50 j.tL) as described in section 11.2.1. 
11.2.2 DNA Purification 
11.2.2.1 Mini-prep: QiAprep® Spin Miniprep Kit (QIAGEN) 
This procedure was carried out according to the manufacturer's instructions, 
provided with the kit and is summarised below. An overnight culture (5 mL) was 
centrifuged at 3,500 rpm for 15 minutes (Denley BR 401). The supernatant was 
discarded and the pellet was resuspended in P1 buffer (250 p.L) and transferred to a 
sterile eppendorf(1.5 mL). To this, P2 buffer (250 tL) was added and the eppendorf 
was inverted 4-6 times. Subsequently, N3 buffer (350 .tL) was added and the mixture 
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inverted immediately (4-6 times). The resultant cloudy mixture was centrifuged 
(13,000 rpm, 10 minutes) after which, the supernatant was transferred to a QlAprep 
spin column and centrifuged (13,000 rpm, 1 minute). The flow through was 
discarded and the spin column washed with PE buffer (750 p.L) and centrifuged 
(13,000 rpm, 1 minute). The column was centrifuged for a further minute to remove 
any residual wash buffer before the purified DNA was eluted with sterile water (100 
tL) and stored at -20 °C until required. 
11.2.2.2 Gel Extraction-QlAquick ® Gel extraction Kit (QIAGEN) 
DNA was excised from an agarose gel (1%) and purified according to the 
manufacturer's instructions, which are summarised below. Agarose containing the 
DNA was covered in sufficient QG buffer (300 tL) and incubated at 50 °C until the 
agarose had completely dissolved. This solution was transferred to a spin column and 
centrifuged (13,000 rpm, 1 minute). The supernatant was discarded and QG buffer 
(500 1iL) was added to the column and centrifuged (13,000 rpm, 1 minute). The 
supernatant was discarded and PE buffer (750 tL) added to the column and 
centrifuged (13,000 rpm, 1 minute). The supernatant was discarded and the column 
centrifuged again to remove any residual buffer. The purified DNA was eluted with 
sterile water (10-15 pL) and stored at -20 °C until required. 
11.2.3 DNA Analysis 
11.2.3.1 Digestion by Restriction Endonuclease 
Generally, a single restriction digest contained the following; template DNA 
(8 [tL), restriction buffer (1 tL, lOx, New England Biolabs) and restriction 
endonuclease (1 p.L, lOx, New England Biolabs). This mixture was incubated at 
37 °C for 3 hours and the reaction was terminated by the addition of DNA loading 
dye (6x, Novagen). The digestion mixture was loaded onto an agarose gel (1%) and 
separated by electrophoresis. 
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11.2.3.2 Electrophoresis 
Agarose (I g) was added to TAE buffer (100 mL, Bio-Rad) and boiled until 
the agarose had completely dissolved. On cooling, to approximately 50 °C, ethidium 
bromide was added to a final concentration of 0.5 tg/mL and the solution swirled to 
ensure complete mixing. The molten agarose solution was transferred to the casting 
mould and allowed to set at room temperature. DNA loading dye (6x, Novagen) was 
added to the DNA samples (2.5 pL to small sample of approximately 10 pL and 12.5 
p.L to larger samples of approximately 50 1iL). The gel was immersed in TAE buffer 
and run at a constant voltage of 100 volts until good separation between bands was 
observed. 
11.2.3.3 Sequencing PCR 
To prepare a DNA sample for sequencing, the DNA source (3 giL) was added 
to sequencing buffer (2 tL, 5x, Applied Bioscience) containing Big Dye version 3.1 
(2 pL) and sequencing primer (1 jiL forward or reverse, 10 ItM stock). Primers 
(Table 11-4) were purchased from Sigma-Aldrich. Only one primer, forward or 
reverse was required for each sequencing reaction. The general sequencing program 
consisted of 25 cycles of the following steps; 95 °C for 30 seconds, 50 °C for 20 
seconds and 60 °C for 4 minutes. 
Table 11-4 Sequencing primers 
Primer Plasmid Sequence (5'- 3') 
pET forward pET TTAATACGACTCACTATAGGG 
pET reverse pET CTAGTTATTGCTCAGCGGT 
pGem T7 forward pGem TAATACGACTCACTATAGGG 
pGem T7 reverse pGem ATTTAGGTGACACTATAGAA 
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11.2.4 Protein Production and Isolation 
11.2.4.1 Large Scale Over-Expression in E. coil 
Single Expression 
One colony was used to inoculate 2YT or LB broth (500m1) containing the 
appropriate antibiotic and was grown overnight at 37 °C with shacking (250 rpm). 
This inoculant was sub-cultured into 2YT or LB broth (4 litres containing antibiotic) 
and grown to an OD 600  of 0.6, at 37 °C before being induced with IPTG (0.1 mM). 
Induction was carried out at 30 °C for 3 to 5 hours depending on the protein. 
Co-Expression of S. wittichil ACP and ACPS 
One colony was used to inoculate 2YT broth (500m1) containing kanamycin 
(30 tg/mL) and ampicillin (100 tg/mL) and was grown overnight at 37 °C with 
shacking (250 rpm). This inoculant was sub-cultured into 2YT broth (4 litres 
containing antibiotic) and grown to an OD 600 of 0.6, at 37 °C before being induced 
with IPTG (0.1 mM, final concentration). Induction was carried out at 30 °C for 5h. 
11.2.4.2 Cell Lysis by Sonication 
All steps were performed on ice. The cell pellet was resuspended in 
resuspension buffer (40 mL, 4:1 v/w) containing 1 protease inhibitor cocktail tablet 
(Roche) and sonicated for 15 cycles (30 seconds on, 30 second off) using a soniprep 
150. The cell debris was harvested by centrifugation (14,000 rpm, 30 minutes, 4 °C) 
and the supernatant cell free extract (CFE) retained for purification. 
11.2.5 Protein Purification 
11.2.5.1 Purification of S. wittichii and S. paucimobilis SPT wild-type and 
mutants 
Ni-NTA Agarose 
The CFE from sonication (approximately 40 mL) was incubated with pre-
equilibrated Ni-NTA agarose (2 mL, 5-10 mg protein/ml beads) at 4 °C for 1 hour 
prior to packing the beads into an empty polyprep column (5 mL, QIAGEN) by 
gentle suction. The beads were packed and washed with 20 column volumes of Ni-
NTA binding buffer (buffer A), under gentle suction, and the protein eluted with 10 
column volumes of 50 mM and 100 mM imidazole Ni-NTA elution buffer (buffer B 
and C). 
Size Exclusion Chromatography 
A HiPrepTM  26/60 Sephacryl TM S-200 High Resolution (318 mL) size 
exclusion column was pre-equilibrated with 1 column volume of buffer D. Before 
loading, the protein sample was 0.45 tIm filtered and concentrated to 3-5 % of the 
total column volume. It was eluted over I column volume and 10 mL fractions were 
collected. The approximate mass of purified protein was calculated using a 
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Figure lI-I Sephacryl TM S-200 molecular weight calibration curve. 
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11.2.5.2 Purification of S. wittichii ACP 
Anion Exchange Chromatography 
A HiLoadTM  26/10 Q SepharoseTM High Performance (53 mL) anion 
exchange column was washed with 2 column volumes of buffer F and recharged with 
1 column volume of buffer G. The column was then equilibrated with 4 column 
volumes of buffer F. The cell free extract was diluted to lOOmL with buffer F and 
0.45 .tm filtered prior being loaded onto the column. After loading, the column was 
washed with buffer F (4-6 column volumes, 4 mL/minute) and the protein eluted 
over 20 column volumes using a gradient of 0-1M KC1. 
Size Exclusion Chromatography 
A HiLoadTM  16/60 Superdex TM 75 prep grade (120 mL) size exclusion 
column was pre-equilibrated with 1 column volume of buffer H. Before loading, the 
protein sample was 0.45 p.m filtered and concentrated to 3-5 % of the total column 
volume. It was eluted over 1 column volume and 5 mL fractions were collected. The 
approximate mass of purified protein was calculated using a calibration curve (Figure 
11-2) obtained from known molecular weight standards (GE Healthcare). 
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Figure 11-2 SuperdexTM 75 molecular weight calibration curve. 
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11.2.5.3 Purification of S. coelicolor ACPS and B. subtilis Sfp 
His-trap purification 
A HisTrapTM HP (5 mL) column was washed with 10 column volumes of 
buffer I and recharged with 5 column volumes of buffer J. The column was then 
equilibrated with 10 column volumes of buffer I. The cell free extract was filtered 
(0.45 p.m filter) prior being loaded onto the column. After loading, the column was 
washed with buffer I (20-25 column volumes) and the protein eluted over 30 column 
volumes using a linear gradient of 5-500 mM imidazole. For the purification of Sf, 
all buffers contained 10% glycerol. 
11.2.5.4 Purification of S. verticillus Svp 
His trap chelating purification 
The protein in buffer K was loaded onto a HiTrap Chelating HP (1 mL) 
column was washed and pre-equilibrated as described above using buffer K and J. 
The filtered cell free extract filtered prior being loaded onto the column. After 
loading, the column was washed with buffer K (20-25 column volumes) and the 
protein eluted with a linear gradient [20 mM to 500 mM imidazole] over 10 column 
volumes. 
Size Exclusion Chromatography 
Fractions containing the protein of interest were pooled and loaded onto a 
previously calibrated HiLoadTM  16/60 SuperdexTM 75 prep grade (120 mL) size 
exclusion column. Purification was carried out as described above for ACP gel 
extraction step. 
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11.2.6 Protein Analysis 
11.2.6.1 Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
An average gel (10 mL) consisted of a 15% running gel (3.5 mL H 20, 3.75 
mL of 40 % acrylamide, 2.5 mL of 1.5 M Tris pH 8.8, 100 .tL of 10% w/v SDS, 200 
tL of 50 mg/mL ammonium peroxodisulfate and 15 p.L TEMED) and a 4% stacking 
gel (6 mL H 20, 1 mL of 40% acrylamide, 2.5 mL of 0.5 M Tris pH 6.8, 100 .tL of 
10 % w/v SDS, 200 tL of 50 mg/mL ammonium peroxodisulfate and 15 tL 
TEMED). All protein samples were denatured by the addition of SDS_loading buffer 
(1.5 M Tris pH 8.8, 5 % v/v glycerol, 10 % w/v SDS, 0.4 mL p3-mercaptoethanol and 
0.05 % wlv bromophenol blue) and boiled for 10 minutes. The mixture was 
centrifuged (13,000 rpm, 5 minutes) prior to loading the gel. The gel was run for 
approximately 50 minutes at a constant voltage of 200 volts. Subsequently it was 
immersed in Coomassie stain (11 20, 0.1 % w/v Coomassie brilliant blue R250, 
40 %v/v methanol and 10 % v/v acetic acid) and incubated for 20 minutes at 37 °C. 
The gel was destained (H 20, 40 % v/v methanol and 10 % v/v acetic acid) until all 
excess stain had been removed. An approximate molecular mass was obtained using 
pre-stained protein molecular weight markers (SeeBlue Plus 2, Invitrogen or Low 
Molecular Weight Marker, GE Healthcare). 
11.2.6.2 BCATM  Protein Assay (PIERCE) 
The BCA Protein Assay combines the reduction of CU 2+  to Cu by protein 
with the highly sensitive and selective colorimetric detection of the cuprous cation 
(Cu 4) by bicinchoninic acid (BCA)." °' The first step is the chelation of copper 
with protein in an alkaline environment containing sodium potassium tartrate to form 
a blue colored complex (X = 540 nm). The intensity of the color produced is 
proportional to the number of peptide bonds participating in the reaction. In the 
second step of the color development reaction, BCA reacts with the cuprous cation 
that was formed in step I. The purple-colored reaction product is formed by the 
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chelation of two molecule of BCA with one cuprous cation. The BCAlcopper 
complex exhibits a strong linear absorbance at 562 rim with increasing protein 
concentrations. 
lmL of working reagent (50:1, Reagent A: Reagent B) was added to a clean, dry 
eppendorf tube, containing the protein sample (50uL) and incubated for 30 minutes 
at 37 °C. A standard curve was produced from serial dilutions (Table 11-5) of a 
known stock concentration of bovine serum albumin (BSA, 2 mg/mL) and the 
concentration of protein calculated according to this standard curve. 
BCA Reagent A contains sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartarate in 0.1 M sodium hydroxide 
BCA Reagent B contains 4% cupric sulphate 













11.2.6.3 Protein and Small Molecules Mass Spectrometry Analysis 
Liquid Chromatography Electrospray lonisation Mass Spectrometry 
(LC-ESI-MS) of proteins 
Mass spectrometry was performed on a Micromass Platform II quadrupole 
mass equipped with an electrospray ion source. The spectrometer cone voltage was 
ramped from 40 to 70 volts and source temperature set to 140 °C. Protein samples 
were separated with a Waters HPLC 2690 with a Jupiter CS reverse phase column (5 
gm, 250 x 4.6 mm, Phenomenex) directly connected to the spectrophotometer. 
Proteins were eluted from the column with 5-95 % acetonitrile gradient using an 
acetonitnle/water/TFA (0.01 % v/v) solvents system (flow rate 0.4 ml/min). The total 
ion count in the range 500 to 2000 m/z was scanned at 0.1 s intervals. The scans were 
accumulated, the spectra combined and the molecular mass was determined by the 
MaxEnt and Transform algorithms of the Mass Lynx software (MicroMass). 
Electrospray lonisation Mass Spectrometry (ESI-MS) of Small Molecules 
Direct infusion mass spectrometry was performed on a Micromass ZMD mass 
spectrometer equipped with an electrospray ion source. Samples were filtered (0.22 
urn) and directly infused at a flow rate of 10 jiL/min. Source parameters were kept 
constant except for the cone voltage and desolvation temperature. Cone voltage was 
typically set at 40-60 V and desolvation temperature set at 200 °C. All electrospray 
ionization was in positive mode and data acquired in continuum mode. Scans were 
accumulated, spectra combined and molecular mass calculated using the transform 
algorithm of the Mass Lynx software (Micromass). 
Liquid Chromatography Fourier Transform Ion Cylotron Resonnance 
Mass Spectrometry (LC-FT-ICR) 
This analysis was carried out by Dr. David J. Clarke (University of 
Edinburgh). For high resolution LC-FT-ICR MS, an Ultimate 3000 HPLC system 
(Dionex Corporation, Sunnyvale, CA), equipped with a monolithic PS-DVB (500 
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tM x 5 mm) analytical column (Dionex Corporation), was used in conjunction with 
Fourier Transform-Inductively coupled mass spectrometry (FT-ICR MS). Samples 
containing l tg of ACP were centrifuged (16,100 g for 2 mm) immediately prior to 
injection onto the column. Solutions A and B were prepared comprising of 2:97.95 
and 80:19.95 actonitnle:water with 0.05 % formic acid respectively. Samples were 
injected onto the analytical column, washed with buffer A for 5 mm, followed by a 
20 min linear gradient elution (20 tl/min) into buffer B. MS data was acquired on a 
Bruker 12 Tesla Apex Qe FT-ICR (Bruker Daltonics, Billerica, MA) equipped with 
an electrospray ionization source. Desolvated ions were transmitted to a 6 cm Infinity 
cell® penning trap. Trapped ions were excited (frequency chirp 48-500 kHZ at 100 
steps of 25 ps) and detected between m/z 600 and 2000 for 0.5 s to yield a broadband 
512 K word time-domain data. Fast Fourier transforms and subsequent analyses were 
performed using DataAnalysis (Bruker Daltonics) software. 
Isotopic Fitting 
Isotope distributions of specific charge states were predicted using 
IsotopePattem software (Bruker Daltonics) from theoretical empirical formulae. 
These were overlaid upon the recorded experimental data as scatter plots, with the 
theoretical apex of each isotope peak designated by a circle. 
Top-Down Fragmentation. 
Top-down fragmentation was performed on the 12T Qh-FT-ICR. Two 
specific ions, m/z 1521 and 1304, were sequentially isolated using the mass resolving 
quadrupole, and MS/MS was performed using collision induced dissociation. For 
CID, the collision voltage was typically set between 20-3 5 V. Fragmentation data 
was the sum of 200 acquisitions and data analyses were performed using 
DataAnalysis (Bruker Daltonics). The SNAP 2.0 algorithm was used for automated 
peak picking. The resulting top-down fragment mass lists were combined and 
searched against the primary sequence of ACP using Prosight-PTM." 2 Mass error 
tolerances were set for all searches at 10 ppm. 
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11.2.7 Protein Chemistry 
All UV-visible spectra were recorded on a Varian's Cary 50 UV-Vis 
spectrophotometer and analysed using Cary WinUV software (Varian). All assays 
were carried out on a 500 jtL scale at 25 °C unless otherwise stated. 
11.2.7.1 Spectroscopic Measurements 
All UV-visible spectra were recorded on a Varian's Cary 50 UV-Vis 
spectrophotometer and analysed using Cary WinUV software (Varian). To convert 
the apo-SPT to the holo-SPT the enzyme was dialysed for lh at 4 °C against 20 mM 
potassium phosphate (pH 7.5) containing 150 mM NaCl and 25 iM PLP. Excess 
PLP was removed by passing the protein through a PD-10 (Sephadex G-25M) 
desalting column (GE Healthcare) before any spectrophotometric measurements 
were taken. The concentration of recombinant SPT was 10 tM and the 
spectrophotometer was blanked with 20 mM potassium phosphate (pH 7.5) 
containing 150 m NaCl. 
11.2.7.2 Determination of dissociation constants 
Assays were carried out in 0.5 mL quartz cuvettes (1 cm path length) and 
typically contained 10 tM SPT in 20 mM potassium phosphate (pH 7.5). Varying 
amounts of L-serine (0-80 mM) were used in each assay. After addition of substrate, 
the reactants were mixed and allowed to equilibrate for 15 mins at 25 °C. Small 
baseline changes were corrected using Sigma Plot software. Changes in absorbance 
at 425 nm (SPT WT, N100C, R378A and R378N) and 420 nm (SPT N100W and 
N  OOY) and were plotted against L-serine concentrations, and data points were fitted 




Kd + [serine] 
The AA 0bS is the observed change in absorbance at 425 nm and the AA max is the 
maximal absorbance change, [serine] is the L-serine concentration, and Kd is the 
dissociation constant. 
11.2.7.3 SPT WT, NIOOY and R378A quinonoid formation 
Assays were carried out in 0.5 mL quartz cuvettes and typically contained 5 
tM SPT in 20 mM potassium phosphate (pH 7.5). To this 45 mM of L-serine and 
1.45 mM of S-(2-oxoheptadecyl)-CoA were added in the assay. After addition of the 
substrate, the reactants were mixed and allowed to equilibrate for 20 mins at 25 °C. 
The spectroscopic data were recorded between 200 and 800 nm. Small baseline 
changes were corrected using Sigma Plot software. 
11.2.7.4 Detection of 3-ketodihydrosphingosine 
The activity of SPT was measured by monitoring the formation of 14C-KDS. 
A final enzyme concentration of 10 tM SPT in 20 mM potassium phosphate buffer, 
pH = 7.5, 150 mM NaC1) was incubated with 20 mM U-' 4C L-Serine (9250 Bq, 
0.250 tCi, GE Healthcare) and 1.6 mM palmitoyl-CoA in a final volume of 125 giL. 
The reaction was incubated at 37 °C for 20 minutes then the reaction was quenched 
by the addition of 30 tL of 2.0 M NH 40H (final concentration 0.4 M). This was then 
extracted with an equal volume of CHC1 3 :CH30H (2:1, v:v). The sample was 
centrifuged at 13,000 rpm for 5 minutes and the aqueous phase was discarded before 
the organic phase was allowed to evaporate overnight. The resulting lipid residue 
was re-suspended in 15 tL of CHC1 3 :CH 30H (2:1, v:v) and spotted onto a Silica Gel 
60 TLC plate. Separation was carried out with a mobile phase of 
CHC1 3 :CH3 0H:NH40H (40:10:1, v:v:v) using a KDS reference standard (Matreya). 
The TLC was developed with a Storage Phosphor Imager (GE Healthcare) for 4 days 
at room temperature and the Phosphor screen was visualised using Imagei software. 
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11.2.7.5 DTNB assay 
SPT activity was also measured using a continuous spectrophotometric assay 
by monitoring the release of CoASH from acyl-CoA substrates and reaction with 
5,5'-dithiobis-2-nitrobenzoic acid (DTNB)" 3 . Assays were carried out in 0.5 ml 
cuvettes in a Varian Cary-50 UV-Visible Spectrophotometer. The enzyme was 
incubated with L-serine in a buffered solution containing DTNB and the assay was 
started by addition of the second substrate palmitoyl-CoA. The CoASH thiol product 
was monitored by observation of the TNW anion at 412 flm (Amax = 14150 M'cm-
1).114 Initial rates were measured at increasing concentrations of L-senne (0.12 - 50 
mM) while maintaining palmitoyl-CoA in excess. A typical experiment to determine 
the Km value for L-serine contained 0.16 tM SPT, 0.1 - 50 mM L-serine, 250 jiM 
palmitoyl CoA and 0.2 mM DTNB in 50 mM potassium phosphate buffer pH 7.5. 
Kinetic constants (kcat and K 1 values) were calculated from Michaelis-Menten plots 
using Sigma Plot. Kinetic constant values were calculated in a similar way for CoA 
substrates (decanoyl, lauroyl, myristoyl, palmitoyl, stearoyl, arachidoyl) but by 
maintaining L-serine (100 mM) in excess. As a check, the kcat/Kin parameters for 
CoA substrates were also determined by the method of complete condensation when 
[COA]<<Km . In this case kcat/Kin is calculated at a single substrate concentration as an 
observed rate constant (kobs) by monitoring disappearance of the substrate. The data 
was fitted to the equation A = Aijm*(1 - exp (kobs*t)) where A is the absorbance at 
412 nm, is the limiting absorbance value when the substrate has completely 
disappeared, k0bs  is the observed rate constant and t is the time in seconds. 
11.2.7.6 Conversion of Apo-ACP to Holo- or AcyI-ACP 
ACP was converted into holo- or acyl- form by incubation with a specific 
PPTase (ACPS, Sfp, Svp) and free CoASH or acyl-CoA (CIO, C12, C14 and C16 
derivatives). For ease of reading, a common protocol is described using the name 
PPTase referring to ACPS S. coelicolor, Sfp, Svp or ACPS S. wittichii. 
A final enzyme concentration of 60 jiM ACP in reaction buffer was incubated with 1 
jiM PPT, 1 MM MgCl2 and 250 jiM to 1 mM CoASH/acyl-CoA in a final volume of 
250 iL. The reaction was incubated at 37 °C overnight. The reaction mixture was 
then directly injected onto a LC/MS platform for analysis. 
For each PPT, a different reaction buffer was used. Buffer L for ACPS S. coelicolor 
and Svp, buffer M for Sfp and buffer N for ACPS S. wittichii. 5 mM of DTT was 
added to the reaction mixture when use of free CoASH. 
It is important to note that a concentration greater than 1 mM of MgCl 2 could not be 
use for reaction with acyl-CoA as this would lead to precipitation of these 
compounds and the reaction would not take place. 
11.2.8 Structural Biology 
All proteins were screened for suitable crystallisation conditions at the 
Scottish Structural Proteomics Facility (SSPF) in collaboration with Prof. Jim 
Naismith. The proteins were dialysed in the presence of excess PLP to ensure 
complete reloading prior to crystallisation. Data and structures have been deposited 
in the Protein Data Bank. They have the following codes. 
2W8T: SPT WITH PLP, N100C 
2W8U: SPT WITH PLP, N100Y 
2W8V: SPT WITH PLP, N100W 
2W8W: N100Y SPT WITH PLP-SER 
2W8J: SPT WITH PLP-SER 
2X8U: SWSPT WITH PLP 
11.2.8.1 S. paucimobilis holoform SPTs NIOOY, NIOOW and NIOOC 
Crystallisation conditions that gave diffraction-quality crystals of the wild-
type/PLP protein 39  were used as a starting point to formulate stochastic optimization 
screens using software developed in-house. The screens were built on a Hamilton 
Microstar liquid handling robot controlled by the Rhombix system software 
(Thermo). Crystallisation trials were set up in hanging drop plates (EasyXtal DG-
CrystalSupport; Qiagen) using 2 - 3 p1 of the protein solution and 1 iil of well 
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solution in the hanging drop. Crystals of the mutant SPTs were obtained in the form 
of yellow plates corresponding to the high-resolution form of the holo wild-type SPT. 
The SPT N100W mutant was crystallized at 20 mg/ml in 10 mM Tris (pH 7.5), 150 
mM NaCl, 25 tM PLP using a well solution of 0.1 M MgCl2,  22% (w/v) PEG 3350, 
and 0.10 M Hepes (pH 6.5). The N100Y mutant was crystallized at 20 mg/ml in 10 
mM Tris (pH 7.5), 150 mM NaCl, 250 jiM PLP using a well solution of 0.15M 
MgC12 , 22% (w/v) PEG 3350, and 0.10 M Hepes (pH 6.5). Finally the NIOOC mutant 
was crystallized at 20 mg/ml in 10 mM Tris (pH 7.5), 150 mM NaCl, 250 PM PLP 
using a well solution of 0.1 M MgC1 2, 27% (w/v) PEG 3350, and 0.10 M Hepes (pH 
6.5). The solutions used for equilibrating harvested crystals varied slightly according 
to the crystallization conditions and consisted of 22-29 % PEG3350 (w/v), 0.1 M 
HEPES (pH6.5), 0.08 - 0.12 M MgCl2.  All crystals used for data collection were 
soaked for a few minutes in the respective equilibrating solution plus 1-2 mM PLP. 
Analysis of the density revealed that the PLP was covalently bound to Lys265 in 
every mutant, confirming we had obtained the holo-form of the proteins. The data for 
the N100C, N100Y, N100W structures were processed using XDS and scaled using 
XSCALE (http://www.mpimf-heidelberg.mpg.de/—kabsch/xds/)' 5 . All mutant 
models were refined using Refliiac5" 6 and manually adjusted including addition of 
water molecules with WinCoot" 7 . Density was clearly visible to the NIOOY 
mutation but we could not satisfactorily locate the tryptophan side chain, there is 
disordered electron density which indicates multiple conformations. 
11.2.8.2 SPT WT and NIOOY L-serine External Aldimines 
The external aldimine form of the SPT wild-type was produced by soaking a 
crystal of the holo-SPT in the equilibrating solution plus 5mM L-serine for 10 
minutes and that of the N 1 OOY mutant by soaking the crystal in the equilibrating 
solution plus 50 mM L-serine for 15 mins at room temperature. The crystals were 
mounted in a cryo-loop (Molecular Dimensions) and cryo-protected in solutions 
varying slightly for each crystal and containing the equilibrating solutions plus 15-
20 % PEG 400 (v/v). The crystals were then frozen by plunging them into liquid 
nitrogen and carried in a dry cryogenic Dewar to the European Synchrotron 
min 
Radiation Facility (ESRF, Grenoble, France) for data collection. The data sets were 
collected at 100 K to varying resolutions using 3 different beamlines. The data for 
the wild-type serine external aldimine were process with Mosfim and scaled with 
Scala from the CCP4 suite of program 118  The data for the N100Y external aldimine 
structure were processed using XDS and scaled using XSCALE (http://www.mpimf-
heidelberg.mpg.de/-kabsch1xds/) " 5 All models were refined using Refivac5" 6 and 
manually adjusted including addition of water molecules with WinCoot." 7 
11.2.8.3 S. wittichil holoform SPT 
The screens were built on a Hamilton Microstar liquid-handling robot 
controlled by Rhombix system software (Thermo). The S. wittichii SPT was 
crystallized at 20 mg/ml in 10 mM Tris (pH 7.5), 150 mM NaCl, 25 tM PLP using 
30% PEG MME 2000, 0.lM KSCN, (NEXTAL JCSG+ screen condition 81). 
Crystals used for data collection were soaked for a few minutes in a solution of 27 % 
PEGMME2k, 0.22 M K-Thiocyanate, 18 % PEG 400 plus 1-2 mM PLP. The crystal 
was mounted in a cryo-loop (Molecular Dimensions) and then frozen by plunging it 
into liquid nitrogen and carried in a dry cryogenic Dewar to the European 
Synchrotron Radiation Facility (Grenoble, France) for data collection. Multiple 
crystals were screen at beam line BM14 The data sets were collected at 100 K to 2.1 
using beam line 14 (supplementary Table I). The data for SPT S. wittichii were 
processed with Mosfim and scaled with XDS" 5 The density revealed that the PLP 
was covalently bound to Lys245 confirming that we had obtained the internal 
aldimine, holo-form of the protein. The SPT model was refined using Refmac5" 6 
and manually adjusted, including the addition of water molecules with WinCoot.' '. 
61 
CHAPTER III: RESULTS AND 
DISCUSSION 
mo 
111.1 Sphingornonaspaucitnobilis - SPT WILD TYPE AND MUTANTS 
Plasmid pET28a containing the gene for wild-type SPT was prepared previously in 
this lab. The expression and purification of the enzyme was first described by Yard et 
al. 39  
111.1.1 Wild Type SPT 
111.1.1.1 Expression, Purification and Mass Spectrometry Analysis 
The S. pauczniohths wild-type SPT gene cloned in plasmid pET28a 
(Figure Ill-I) was available at the start of this study. The pET28a plasmid contains a 
kanamycin resistance gene for selection. SPT WT gene originally cloned into NcoI 
and XhoI restriction site yields a protein with an 8 residue extension at the C-
terminus, namely LEHHHHHH, containing the 6 histidine tag which enables 
purification of the protein via Immobilised Metal Affinity Chromatography (IMAC) 
on a nickel resin. 
Xh1 (6332 
SPT 6H is 
Kan 
.\•dei 
pET28a SPT 6His 
6493 bp 
Lad -. 
Figure Ill-I pET28a/SPT WT plasmid map. 
pET28aISPT WT was used to transform HMS 174 (DE3) competent cells and 
protein expression was induced with 0.1 mM of IPTG in 2YT broth at 30 °C for five 
hours SPT. The protein of interest was isolated from the cell free extract by nickel 
affinity chromatography. Analysis of the resulting fractions under reducing 
conditions by SDS-PAGE clearly shows a band at -45 kDa due to SPT monomer 
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(Figure III-2A). The fractions containing SPT were further purified on a size 
exclusion Sephadex S-200 column (GE Healthcare). SPT eluted in a single peak 
(Figure 1II-213) with a retention time corresponding to homodimeric SPT of-92 kDa. 
From —6 grams cell pellet this two-step purification process allowed the isolation of 
—50 mg of pure and homogenous homodimeric SPT (size —92 kDa) (Figure 111-2). 
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Figure 111-2 Expression and purification of wild-type SPT (A) SDS-PAGE Lane 1: Low 
molecular weight marker, Lane 2: Non-induced cells, Lane 3: Induced cells, Lane 4: 10 mM 
imidazole imidazole wash fraction (40 ml) from [MAC, Lane 5: 50 mM imidazole elution 
fraction (20 ml) from IMAC, Lane 6:100 mM imidazole elution fraction (20 ml) from IMAC, 
Lanes 7-10: size exclusion chromatography, fractions 11-14. (B) Elution profile of size 
exclusion column (blue line A 280 nm). 
After purification, the recombinant wild-type SPT was analysed by Liquid 
Chromatography-Electrospray-Mass spectrometry (LC-ES 1-MS). The theoretical 
mass of the apo-form of SPT is 46104 Da (the reversibly-bound PLP cofactor is lost 
during analysis by mass spectrometry). The purified protein mass was 45985 Da 
which corresponds to the SPT mass minus the N-terminal methionine which is 
cleaved post-translationally (Figure III-3A). In order to capture the holo-SPT form, 
sodium borohydride was used to reduce the reversible PLP internal aldimine to form 
enzyme with PLP irreversibly bound to the sidechain of Lys. 265 A mass of 46213 Da 
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Figure 111-3 LC-ESI-MS of wild-type SPT showing the ion envelopes of (A) Apo-form (B) the 
NaBH4-reduced, holo form. Both masses were calculated by deconvolution. 
111.1.1.2 Characterisation, Activity Assay and Substrate Selectivity 
Although one of the two natural substrates for SPT is the amino acid L-serine, 
bacterial SPT has been shown to bind many L-serine analogues such as D-serine and 
L-serine methyl ester and other amino acids such as L-threonine.20' 119  Other reactive 
L-serine derivatives such as L-cycloserine and 13-chloro-L-alanine (Figure 111-4) are 
potent inhibitiors of both bacterial and mammalian SPTs and are commonly used as 
inhibitors of de novo sphingolipid biosynthesis. 20, 119 The most potent and selective 
SPT inhibitor is the fungal natural product myriocin20' 119  (Figure 111-4) which is 
thought to mimic the putative 0-keto acid intermediate during normal catalysis. The 
second of the two natural substrates for SPT is an acyl-CoA thioester. Ikushiro et 
al." have shown that the bacterial SP SPT can utilise saturated and unsturated acyl-
CoA substrates of varying carbon chain length (C12 to C20) but the best substrate is 
palmitoyl-CoA (C16). However this is not the case in all organisms, for example in a 
viral fusion SPT, the best acyl-CoA substrate is myristoyl-CoA (C14). 64 Here the 
binding affinity (UV-Vis spectrometry), the product formation (radiochemical assay) 
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Figure 111-4 Chemical structure of some SPT's inhibitors. 
Spectroscopic Properties of SPT WT - Amino acids Selectivity 
A solution of the vitamin B6 cofactor pyridoxal 5'-phosphate (PLP) is yellow 
in colour and has a characteristic UV-visible spectrum. In holo-SPT, the cofactor 
bound to Lys 265  in the active site via an internal aldimine or Schiff's base. The 
internal alimine is an equilibrium between two species, each having a specific 
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Figure 111-5 Enolimine and ketoenamine equilibrium. Conversion of apo-SPT/internal 
aldimine to holo-SPT/external aldimine. 
When L-serine binds to SPT an aldimine linkage or Schiff s base is formed between 
the cofactor and the amino group of the L-serine substrate (Figure 111-5). This is 
thought to occur via a geminal diamine intermediate 21 . In this way the PLP:Lys 265 
internal aldimine is displaced by a PLP:L-Ser external aldimine. Because the active 
form of the external aldimine is the ketoenamine species it is possible to follow 
binding of the L-serine substrate by monitoring an increase at 425 nm in the UV-vis 
spectrum (Figure III-6A). By measuring the change in absorbance at 425 nm, the 
apparent serine dissociation constant (Kd(Ls)) has been determined (Figure III-61), 
Table 111-1). The wild-type SP SPT Kd( L s) is 1.1 mM, in good agreement with the 
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Figure 111-6 UV-visible analysis of wild-type SPT. Absorbance spectra of S. paucimobilis SPT 
wild-type in presence of (A) L-serine (C) L-threonine and (E) L-cysteine. The structures of 
the enolirnine (335 nm) and ketoenamine (420 nm) forms of the external aldimine are drawn 
in spectrum A. The solid line in each spectrum is the holo-form of the enzyme (10 pM SPT, 
20mM potassium phosphate buffer (pH 7.5), 150mM NaCl, 25 °C). Increasing concentrations 
of L-amino acids were added (0, 0.1, 0.5, 1, 2, 5, 10, 20, and 40 mM; dotted and dashed 
lines), and the spectrum was recorded after 15 mm. Dissociation constants were measured 











Table Ill-I SP wild-type SPT dissociation constants and kinetics table. 




k ca /K m  
(MM) 
L-serine 1150.0±30.0 1.4±0.1 1.1±0.1 821.4 
L-threonine ND ND 3.6± 0.9 ND 
L-cysteine ND ND 5.0± 1.7 ND 
The amino acid specificity of SPT can be explored by its ability to form 
external aldimines. By monitoring changes in the 425 nm absorbance maximum, due 
to formation of the ketoenamine external aldimine, binding of two amino acids, L-
threonine and L-cysteine, was investigated. The amino acids were added to holo-SPT 
at increasing concentrations (0 and 40 mM) (Figure III-6C and 6E, respectively). L-
threonine, which contains an extra methyl group on C, formed a stable external 
aldimine and like L-serine the absorbance maximum at 420 nm increased in the 
presence of increasing concentrations of amino acid (Figure III-6C). The calculated 
dissociation constant (Kd = 3.6 ± 0.9 mM, Figure III-6D) was comparable to that 
previously determined by Ikushiro et al."9 (Lj = 3.8 mM). When L-cysteine was 
added to SPT the absorption maximum due to the external aldimine was at 412 nm 
and not 425 nm (Figure III-6E). In contrast to L-senne and L-threonine the 412 nm 
peak decreased upon addition of increasing concentrations of the amino acid and, 
interestingly, there was concomitant growth of a new peak at 330 nm. It is likely that 
the external aldimine formed with L-cysteine is not stable and reacts quickly to form 
another species. The "dissociation constant" of L-cysteine was evaluated by 
measuring the decrease in absorbance at 412 nm (Kd = 5 ± 1.7 mM, Figure I11-6F,). 
Terzuoli et al. studied the condensation of aminothiols, in particular L- and D-
cysteine with PLP, and showed that these reactions yield thiazolidine compounds. 120 
This study suggests that the unknown compound observed at 330 nm could be a 
thiazolidine ring formed by nucleophilic attack of the external aldimine Schiff base 










Figure 111-7 Formation of thiazolidone. 
3-Ketodihydrosphingosine (KDS) Formation 
A radiochemical assay of SPT activity, based on the method previously 
reported by Ikushiro and colleagues' 1,  allows measurement of the 3-
ketodihydrosphingosine (KDS) product formed. Recombinant holo-SPT was 
incubated with U_[14C]  -labelled L-serine and palmitoyl-CoA for 20 min at 37 °C. 
The assay was stopped by the addition of 30 iL of 2.0 M NH 40H (final 
concentration 0.4 M) and the product extracted with an equal volume of 
chloroform/methanol (2:1, v/v). Organic phases were removed, dried, separated by 
thin-layer chromatography (TLC), and subsequently developed on an autoradiograph 
using a Storage Phosphor Imager. A commercial KDS standard was used as a marker 
to help identify the enzymatically-produced KIDS (Figure III-8A). In this case KDS 
was identified in the organic phase after extraction of the SPT reaction mixture by 
direct injection into ESI-MS. The resulting mass spectrum showed a large peak at 
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Figure 111-8 Formation of 3-ketodihydrosphingosine (KIDS) (A) TLC of radiolabeled products 
obtained by SPT-catalyzed conversion of of [14C]L-serine L-serine and palmitoyl-CoA to 
[14C]KDS. The black lines mark the positions of the origin, commercial standard KDS and the 
solvent front. (B) Mass spectrum of SPT-produced KDS. 
Since L-threonine can form an external aldimine with SPT (Figure III-6C) samples 
were analysed for product formation when L-threonine was used as substrate instead 
of L-serine. Because [' 4C]-L-threonine is not commercially available, it was not 
possible to utilise a labelled substrate and subsequently develop TLC plates by 
phosphor-imaging. Instead unlabelled L-threonine was used as substrate and 
ninhydrin, a reagent that forms a purple colour upon reaction with free amines, was 
used to develop TLC plates. Colour development was observed for both commercial 
and SPT-produced KDS but the corresponding ketohydrosphingosine product 
derived from an L-threonine substrate was not observed (data not shown). Since SPT 
can form an external aldimine with L-threonine, but cannot form product upon 
addition of the second substrate palmitoyl-CoA, this suggests that the reaction 
pathway may be blocked at one of the intermediates between the external aldimine 
and the final product. Intermediates in the catalytic cycle of several a-oxoamine 
synthases have been observed spectrophotometri call y33' 43, 46, 119, """(Figure 111-9). 
To investigate whether an intermediate accumulates when L-threonine is the 
substrate, the reaction was followed spectrophotometrically but no further changes 
occurred to the UV-visible spectrum (not shown) when palmitoyl CoA was added to 
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the SPT:L-Thr external aldimine (425 nm peak). It is possible that the SPT:L-Thr 
external aldimine cannot deprotonate to form the next quinonoid intermediate that 
reacts with the palmitoyl CoA thioester (Figure 111-9) and therefore remains 
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Figure 111-9 SPT mechanism, highlight on UV-Vis absorbing intermediates. 
SPT Activity - Kinetic Analysis and Acyl-CoA Selectivity 
Although the autoradiography-based SPT assay is useful for checking SPT 
activity by identification of the KDS product, it is not a good method for determining 
catalytic constants. Quantitation of KDS is crude and error-prone since it relies on 
the measurement of the intensity of developed spots on the TLC plate. Also, the 
method is time-consuming as it can take up to several days to develop the TLC plate. 
To overcome these disadvantages a continuous and stoichiometric 
spectrophotometric SPT activity assay was developed whereby the release of free 
CoASH from acyl-CoA substrates was monitored by reaction with 5,5'-dithiobis-2-
nitrobenzoic acid Free thiols react with DTNB to form a mixed 
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disulphide and a 2-nitro-5-thiobenzoate (NTW) anion that has an extinction 
coefficient of 14150 M' cm' at 412 nm 114 . Initial rates of CoASH release were 
measured spectrophotometrically at 412 nm and at increasing concentrations of L-
serine in presence of recombinant SPT, palmitoyl-CoA, and DTNB. Kinetics values 
for SPT were determined using this method providing the substrates affinities (Km(L 
s )1.4 mM and Km (pCoA) 35.4 jiM, Table 111-1 and 2), as well as turnover and catalytic 
efficiency of the enzyme (kcat = 1.150 ± 0.030 s1 and kcat/ Km(Lser) = 821.4 M-  
Table 111-1). In the same way, the SPT affinity for diverse acyl-chains was 
investigated. As expected, palmitoyl-CoA (C16:0) had the fastest turnover (kcat = 
1.150 s) of all of the acyl-thioesters (Table 111-2). Although, when looking at the 
efficiency of the substrates, the longer chain stearoyl-CoA (C 18:0) was the most 
efficient substrate (kcat/ Km 65,547 M' Accurate rates could not be determined 
for longer substrates such as arachidoyl-CoA (C20:0) due to the limit of detection 
with the DTNB reagent. For example, release of I jiM CoASH will result in an 
absorbance change at 412 nm of only 0.014 units. It was clear enough that substrates 
with a chain length shorter than 16 carbons were poor substrate in terms of binding 
and turnover. A similar trend was observed by Ikushiro et al. 11 in a previous 
specificity study of SF SPT. 
Table 111-2 AcyI-00A chain length specificity of SP SPT. 
Enzyme k 	x 103(s-') cat 
Km 
(MM) 
k cat 1K m 
(MM) 
Decanoyl (10: 0) 0.045±0.002 2324.9± 175.1 19.4 
Lauroyl (12:0) 0.262 ± 0.006 822.2 ± 32.6 318.7 
Myristoyl (14: 0) 0.601±0.012 97.1±5.1 6189.5 
Palmitoyl (16:0) 1.150±0.030 35.4 ± 2.0 32485.9 
Stearoyl (18:0) 0.898 ± 0.012 13.7 ± 0.8 65547.4 
Arachidoyl 
0.327±0.014 <10 >32700 
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111.1.1.3 Structural biology 
Structure of the SPT:PLP:L-Ser external aldimine complex 
The optimisation of growth of diffraction-quality crystals, the building of 
structural models and the solution of x-ray structures of wild-type SP SPT:L-Ser 
external aldimine complexes were the result of collaborative work between myself, 
Berverley Yard, Ken Johnson and Lester Carter. 
The L-Ser external aldimine SPT complex (1.50A) was trapped by soaking SPT 
crystals with 5 mM of L-serine (Figure 111-1A). In the external aldimine form, the 
bond between Lys265 and the co-factor has been broken (Figure 111-1 1) and a new 
Schiff base between L-senne and PLP is clearly observed (Figure 111-10B). The 
structure of holo-SPT shows that the PLP binding site lies at the interface between 
the two SPT monomers and is composed of residues from both subunits. An overlay 
of the structures of the internal aldimine (holo-form) and SPT:L-Ser external 
aldimine complex reveals that the overall shape of the enzyme (not shown) and the 
relative orientation of the two monomers does not change upon formation of this first 




Figure 111-10 Structure of the SPT:L-Ser external aldimine complex. (A) Structure of the 
entire SPT dimer showing one monomer in teal and the other monomer in purple. The 
residues Lys 265 and Asn 100 from the teal monomer are shown in stick form and are coloured 
yellow. The equivalent residues from the purple monomer are coloured green. This clearly 
shows that the Asn 100 from one monomer interacts with the active site of the other monomer. 
The PLP:L-Ser external aldimine is also shown in stick form. (B) A stereo image of an Fo - 
Fc electron density map contoured at 3 o around the PLP:L-Ser external aldimine bound at 
the active site of SPT. The phases were calculated from a model that did not include 
included the PLP or aldimine. 
The main interactions between the enzyme and the PLP cofactor that were observed 
previously in the holo-SPT internal aldimine are conserved in the SPT:L-Ser external 
aldirnine complex. In both structures the PLP cofactor makes polar contacts with the 
138 	'31 	'14 	'6' 	 134 	135 side-chains of Asn , Asp , His and Thr -, with the main chain of Gly , Tyr 
and it-stacks with His' 59.  In the wild-type SPT external aldimine complex, others 
interactions appear to help stabilise the L-serine moiety. The L-serine hydroxyl group 
is within H-bonding distance of the amino side-chain of Lys 265  (2.78 A). The 
carboxylate is involved in two interactions; with the NE atom of His' 59  and an 
electrostatic interaction with guanidinium group of Arg 378 . The Arg378 residue has 
undergone a large and striking conformational change (Figure Ill-bA). In the holo-
form this residue is situated outwith of the catalytic site where it interacts with Gin 357 
(at a distance of 2.42 A) which is on helix 13 (Figure Ill- lOB). This Arg 378 residue 
undergoes a large swing to bring it into contact with the L-serine carboxylate, an 
overall movement of —14 A (measured between the guanidinium -Nw- of the Arg 
residue and the oxygen atom of the PLP:L-Ser carboxylate). Immediately following 
Arg378 are the residues PPATP (numbered 379-383). These residues form a 
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conserved loop (the PPATP' loop) which has significantly altered its conformation 
and position in the external aldimine structure compared to the internal aldimine 
structure (e.g. the C atom of Pro 379  has moved over 10 A). The reordering of the 
structure around Arg 378 seems to be linked to other movements at Phe 47 (1.2-A C 
shift). These residues are contained within the same monomer. The phosphate of PLP 
binds to the side chain of Thr 294 from one subunit and to the main chain of Ala 
294 
from the other subunit. The hydroxyl of L-Ser makes a polar contact to the main 
chain of Ala294 . In the other monomer, the side chain Met' °4 adjusts its conformation, 
and there is a slight rigid body shift of Leu' °5 to Asn' 06 . The side chain of Asn' °° 
from the other subunit has altered its position, but the hydrogen bond to Lys 265  is 
maintained. 
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Figure 111-10 Comparison of (A) internal and (B) external aldimine forms of wild-type SPT S. 
paucimobilis. In both images, one monomer is coloured in teal and the other in purple. All 
residues from the teal monomer are shown in stick form and are coloured yellow. The 
residue Asn 100 from the purple monomer is coloured green. Black dashed lines represent the 
interactions existing between the internal/external aldimines complexes with active site 
residues. In A and B, the top right corner box shows the different locations of GIn 357 and 
Arg378 when the external aldimine forms. 
Shortly after the publication of the SP SPT external aldimine structure by Raman ci 
a1.(see appendices section), Ikushiro ci al.'24 published another SPT:L-Ser external 
aldirnine structure of the protein from the bacterium Sphingobacterium multivoruin 
(SM). While the overall protein structures are fairly similar to each other, sequence 
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alignment reveals some interesting differences. For example, Arg 378 of SP SPT is not 
conserved in SM SPT indicating that there are differences in how the PLP:L-Ser 
complex is bound by each enzyme. Indeed, analysis of the SM SPT external aldimine 
structure reveals that the carboxylate of the bound L-serine interacts only with His 138 
(His 159  in SP SPT numbering) and further stabilisation of the carboxylate is assured 
by H-bonding with two water molecules. Another obvious difference between the 
two SPTs is the UV-visible spectrum of SM SPT lacking the enolimine form (X=336 
nm) of the internal and external aldimines. 
Substrate selection 
The structure of the SPT:L-Ser external aldimine was used to investigate why 
an SPT:L-Thr complex could not proceed past the external aldimine intermediate 
(see Section 111.1.1.2 ). There are no residues in the active site of the SPT:L-Ser 
external aldimine that indicate an L-threonine substrate cannot bind, and this is 
keeping with the observed SPT:L-Thr external aldimine by UV-visible spectroscopy 
(Figure III-6C). To form the putative quinonoid intermediate there must first be 
rotation around C a to bring the proton into the correct orientation for deprotonation 
by Lys.265 A model of the putative SPT:L-Ser quinonoid intermediate was made by 
mimicking the C rotation on the structure of the external aldimine. In this model it 
was found that Ser' °2 (Figure III-12A) could spatially restrain C rotation of other 
amino acid external aldimines (Figure III-12B). Rotation around C a in the L-serine 
external aldimine reduced the distance betweenCp of the L-serine substrate and Cp of 
the Ser 102 sidechain reduced from 4.78 A to 3.68 A (Figure III-12A and B). While 
this rotation is tolerated in a SPT:L-Ser complex it is likely that the presence of a 
bulky methyl group in a SPT:L-Thr external aldimine would cause a steric clash with 
SPT residues. Future experiments are required to investigate whether a Ser' °2 mutant 
of bacterial SPT could turnover an L-threonine substrate. This "selective" function 
appears to be conserved throughout the AOS members. Sequence alignment shows 
that Ser' 02 is conserved in AONS, while a threonine and a valine are present in 
ALAS and KBL respectively. It is possible that ALAS and KBL, which both utilise 
glycine as a substrate, require a larger side-chain to prevent condensation of other 
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amino acids. In the bacterial SPT. Ser' of monomer A controls the selectivity in the 
active site of monomer B, affirming that the active site is comprised of residues from 
both subunits. Sequence alignment of bacterial SPT with LCB1 of human SPT 
reveals a proline residue (Pro ' 35) at the equivalent position in the LCBI subunit. It is 
possible that the bulky proline residue could carry out the same function as bacterial 
Ser' °2 by causing a steric 'block' on amino acids other than the L-serine substrate. 
However the cyclic structure of proline means that it is often found in distinctive 
secondary structural elements such as 'turns'. It is possible that could have an 
effect on substrate specificity in human SPT. Recently a study on substrate 
specificity of human SPT in the presence of the activity-enhancing small subunits 
(ssSPTa and ssSPTb) revealed that, in contrast to bacterial SPT, L-alanine is a good 
substrate for wild-type human SPT. 125 Future experiments are required to investigate 
whether Pro 135  at this position is the cause of a relaxed substrate specificity in human 
SPT. There is increasing evidence that the HSANI disorder is caused by a 'gain of 
function' in SPT resulting from a change in substrate specificity. Since mutation of 
Cys' 33  is the most prevalent mutation found in HSANI patients, it is interesting to 
note that Pro' 35  is situated so close to this residue. 
Ser 102 
Ser 102 
Figure 111-12 Amino acid selectivity in wild-type SPT S. paucimobiis. (A) External aldimine. 
(B) Model of the putative SPT:L-Ser quinonoid intermediate. In both images, one monomer is 
coloured in teal and the other in purple. All residues from the teal monomer are shown in 
stick form and are coloured yellow. Residues from the purple monomer are coloured green. 
Black dashed lines represent the distance between CB  of the L-Serine substrate and the C 
of Ser102. 
111.1.2 Hereditary Sensory and Autonomic Neuropathy Type I SPT 
mutants 
Genetic studies have shown that the human neurological disease HSAN1 is caused 
by several single point mutations on the LCB1 gene of SPT69'72 126  (see Chapter 1). 
The most common mutation results in replacement of Cys' 33 by a tryptophan (Trp) or 
a tyrosine (Tyr). These two mutations have been previously studied and 
contradictory results were observed by studies in different laboratories. While 
Dawkins et al. 69 reported that the mutations lead to an increase in SPT activity, 
several other groups reported the opposite effect 70,75, 127 and it is generally accepted 
that HSANI mutations have a dominant negative effect on SPT activity in vivo. 
Interestingly the total sphingolipid composition in HSAN1 patients carrying these 
mutations did not change 127 . Yard et al. 39 used the sequence of human LCB1 and 
LCB2 along with the solved structure of bacterial SPT to generate a heterodimeric 
SPTI/SPT2 model of the human enzyme. They showed that Cys' 33 on human SPTI 
mapped onto Asn' 0° of the bacterial SPT. In the current study two bacterial SPT 
mutants NIOOW and N100Y were prepared. These are both "bacterial mimic 
models" of the C 133W and C133Y human mutations that occur in HSAN1 patients. 
It was hoped that a spectroscopic, kinetic and structural analysis of these bacterial 
mimics would shed light on the effect of HSAN1 mutations in human SPT. A third 
N100C mutant was constructed as a control, since cysteine occurs at this position in 
wild-type human SPT. 
111.1.2.1 Cloning of pET-28a/SPT NIOOW, NIOOY and NIOOC plasmids 
The three HSANI mutations were introduced into SPT gene by site-directed 
mutagenesis (Stratagene) using the plasmid pET-28aJSPT WT as template. 
After transformation in TOP 10 cells and purification of DNA samples, each mutant 
plasmid was analysed by enzymatic restriction (Figure 111-13) and Big Dye 
sequencing. 
79 













Figure 111-13 Restriction enzyme analysis of pET28a/N100W, pET28a/N100Y and 
pET28a/N100C. Lane 1: Hyperladder I, Lanes 2-4: pET28a/N100W, Lanes 5-7: 
pET28a/N100Y, Lanes 8-10: pET28a/N100C. Lanes 2, 5 and 8: plasm id digested with NdeI, 
Lanes 3, 6 and 9: plasmid digested with XhoI, Lanes 4, 7 and 10: plasmid digested with NdeI 
and XhoI. 
111.1.2.2 Expression, Purification and Mass Spectrometry Analysis 
Several induction conditions were tested for each mutant and different 
parameters such as the cell type, temperature, time and concentration of IPTG 
inducer were varied. For all mutants the optimised conditions for expression of large 
soluble quantities of protein were found to be: transformation into BL21 (DE3) and 
induction at 30 °C, for 5h with 0.1 mM of IPTG. Because SPT N 100W, NI OOY and 
NI OOC were all cloned in the pET28a vector the resulting protein of each construct 
contained a LEHHHHHH C-terminus extension. Each SPT mutant was purified 
following the same procedure as wild-type SPT. All four proteins were 
indistinguishable when analysed under reducing conditions by SDS-PAGE giving 
rise to a band at —45 kDa and identical elution profiles were observed for each 
protein when purified by gel filtration on a Sephacryl S-200 column (data not shown). 
Protein identity and integrity were confirmed by LC-ESI-MS. The experimentally 
determined masses of recombinant SP SPT mutants were all within 0.1% of the 
theoretical masses, which includes the C-terminal LEHHHHHH fusion affinity tag 
with the enzyme lacking the N-terminal methionine. 
111.1.2.3 Characterisation and Activity of HSANI Mutants 
Spectroscopic Properties of SPT mutants 
In the reported structure of bacterial SPT Yard et al. 39 showed that residue 
N100 lies close to the catalytic site (Figure 1-14), where it forms a contact with 
Lys 265  on the opposite monomer. Because the sidechain of Lys 265  forms a Schiff s 
base with the PLP cofactor it is possible that a mutation at position N100 may 
influence binding of cofactor and/or substrates. Here, binding of both PLP and L-
serine were investigated for each of the mutants. The UV-visible spectra of the SPT 
N 100W and NI 00Y mutants have maximum absorbance values at 340 and 415 nm 
(Figure 11-14, A and B) confirming their ability to bind PLP. However both peaks 
have shifted and the ketoenamine become the dominant form in the spectrum of each 
of these enzymes. These differences suggest a common perturbation in the PLP 
binding site of the mutants compared with the wild type (Figure 111-14, A and B, 
solid lines). The SPT N100C mutant has absorbance maxima at 335 and 425 nm 
which are comparable to the wild-type SPT values of 335 and 425 nm (Figure 111-14, 
C and D). In both native and N100C, the enolimine peak at 335 nm is dominant, 
indicating that the PLP cofactor is in a very similar chemical environment in both 
proteins. To investigate the ability of the mutant SPT's to bind L-serine and form a 
stabilised external aldimine, L-serine was added to each enzyme at increasing 
concentrations. This resulted in an increase of the absorbance at 425nm for the 
NIOOC mutant which is similar to wild-type enzyme (Figure 111-14, C and D, broken 
lines). Addition of L-serine to SPT N100W and N100Y also resulted in an increase 
of the ketoenamine peak but there was a wavelength shift to -425 nm upon substrate 
saturation. Also, the overall AAbs was less for N 100W and NI OOY compared to the 
wild-type enzyme. Taken together these results suggest that the SPT:L-Ser external 
aldimine could be bound differently in the bacterial mimics due to perturbation of the 
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Figure 111-14 UV-visible analysis of SPT wild-type and mutants. Absorbance spectra of S. 
paucimobilis (A) SPT N100W, (B) N100Y, (C) wild type and (D) N100C. The solid line in 
each spectrum is the holo-form of the enzyme (10 pM SPT, 20mM potassium phosphate 
buffer (pH 7.5), 150mM NaCl, 25 °C). Increasing concentrations of L-serine were added (0, 
0.1, 0.5, 1, 2, 5, 10, 20, and 40 mM; dotted and dashed lines), and the spectrum was 
recorded after 15 mm. For the SPT N100C, N100W, and N100Y spectra the final 
concentrations of L-serine were 0, 0.1, 0.5, 1, 2, 5, 10, 20, 40, 60, and 80 mM. AU, 
absorbance units. 
The apparent serine dissociation constants (Kd(LSer)) were determined for all 
three mutants (Table 111-3). A Kd(LSer) similar to the wild-type enzyme was obtained 
for the NIOOC "control" mutant (2.7 mM). Higher Kd(LSer) values were obtained for 
the two HSAN1 mutants (N100W, 16.2 mM, a 15-fold increase, and N100Y, 7.5 
mM, a 7-fold increase, compared with the wild-type SPT) which reinforce the 
hypothesis of active site/substrates binding perturbations created by HSAN1 
mutations. 
Table 111-3 Wild-type and SPT mutants kinetic analysis table. 






k 	/ K Ser cat rn 
(M's') 




SPTWT 1150.0± 30.0 1.4± 0.1 35.4± 2.0 821.4 32486 1.1 ±0.1 
SPTN100C 250.0±4.0 7.0±0.4 60.0±9.8 35.7 4167 2.7±0.2 
SPTN100W 9.0±0.4 1.6±0.4 19.3±2.2 5.6 466.3 16.2±3.1 
SPTNIOOY 5.0±0.1 2.5±0.4 31.4±3.3 2.0 159.2 7.5±0.5 
SPTR378A 78.3±3.2 3.8± 1.0 39.2±3.1 20.5 1997 1.1 ±0.1 
SPTR378N 33.0± 1.0 2.4± 0.2 31.0± 6.0 13.8 1571 3.1 ±0.2 
3-Ketodihydrosphingosine (KDS) Formation 
The ability of the mutant SPTs to form the KDS product was investigated 
using the radioactivity assay whereby incorporation of [ 14C]-1--serine into product 
was measured by autoradiography (see Section 111.1.1.2). The SPT N100C, N 100W 
and N 1 OOY were all able to form KDS but the total amount of radioactive products 
was -84% lower for the HSAN1 mimics compared to wild-type and N100C control 
enzymes (Figure 111-15). This indicates that activity of the HSAN1 mutant mimics is 
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Figure 111-15 Formation of 3-ketodihydrosphingosine (KIDS) - TLC plate showing radiolabeled 
products obtained by SPT-catalyzed conversion of [14C]-L-Ser and palmitoyl-CoA to 
[14 C]KDS. The arrow marks the position of the standard KDS. Lane 1: SPT N100C, Lane 2: 
SPT N100W, Lane 3: SPT N100Y, Lane 4: Wild-type SPT. 
SPT Activity - Kinetic Analysis 
To confirm the loss in activity of the HSAN 1 mimics a more thorough kinetic 
analysis of these mutants was carried out using the spectrophotometric DTNB assay 
described earlier (see Section 111.1.1.2). The kcat/Km values for the N100W and 
N100Y mutants (5.6, and 2.0 M' s', respectively) were 147- and 410-fold lower, 
respectively, compared to wild-type enzyme (kcat/Km = 821.4 Ms) (Table 11-2). 
This confirmed that the HSAN1 mimics were catalytically much poorer enzymes. 
Surprisingly the kcatlKm value for the N100C mutant was -23-fold lower than wild-
type but can be explained by the reactivity of the Cys' °° thiol with the DTNB 
reagent. Formation of a mixed disulfide with the reactive thiol group at the active site 
could potentially hinder binding of the L-serine substrate. An increased Km value (Km  
= 7.0 ± 0.4 mM) for L-serine binding but a kcat value (kcaj = 250.0 ± 4.0) similar to 
wild-type is in keeping with this explanation. In addition the N100C mutant could 
form KDS to the same extent as wild-type under saturating conditions (Figure III-
15). The K1 values for palmitoyl-CoA were comparable for mutant and wild-type 
enzymes suggesting that acyl-CoA affinity is not affected in the HSANI mimics. 
However a full investigation into acyl-CoA specificity for the HSAN1 mimics was 
not carried out because their extremely low enzyme activity would have made it 
difficult to measure rates for shorter acyl-CoA substrates. In addition, commercial 
acyl-CoA substrates are expensive. 
111.1.2.4 Structural biology 
Structure of NIOOC, NIOOW and NIOOY holo-forms 
High resolution structural studies of the S. paucimobilis SPT N  OOC, N 100W 
and Nl OOY internal aldimines were the result of collaborative work between Ken 
Johnson and myself. 
The three SPT mutants were crystallised as large yellow crystals (Figure II-
16A). Four high-resolution structures were solved: three holo-form structures 
(N100C: 1.25A, N100W: 1.43A and NiOOY: 1.5A) as well as the structure of the 
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SPT:L-Ser external aldimine for the N100Y HSAN1 mimic (2.15A). The 
enzyme: substrate complex was trapped by soaking the fully formed crystal in a 
solution containing 50mM of L-serine. An overlay of the wild-type holo-SPT 
structure with N  OOC, N 100W and N  OOY reveals that N  OOC is quasi identical to 
the wild-type with a r.m.s deviation of 0.2 A along the 396 residues. N100W and 
N100Y are very similar to each other (0.1 A r.m.s. deviation) but display noticeable 
differences with both wild-type and NIOOC (r.m.s. deviation of 0.6 A). For clarity, 
only the differences between N100Y and the wild-type enzyme are discussed here. 
Certain parts of the SPT structure do not fully align, perceived as small shifts, when 
the SPT HSANI mutant structures are overlaid with the structure of the wild-type 
enzyme. These shifts are largely conserved regardless of the combination of 
structures aligned (N100W versus native, NIOOW versus N100C, NIOOY versus 
N100C, and N100Y versus native), suggesting that they are real and not simply a 
crystallographic artefact. The largest of these 'shifts' (1.7A at C level) occurs at the 
N-terminal helix (Asp 23—G1y42), which forms an important part of the dimeric 
interface of SPT 39 . 
It might be expected that mutation of Asn' 00 to an aromatic Tyr residue could cause 
structural perturbations (Figure 111-i 613). Closer examination of the N  OOY structure 
shows that the tyrosine side chain has "flipped" out leading to a main chain 
displacement of 3.4 A of and a 180° rotation of the Ramachandran angle of the 
neighbouring Thr99 residue. As a result, the hydrogen bond observed in wild-type 
enzyme between the side chain of Asn' °° and the carbonyl of Lys 
265  is not present in 
the mutant enzyme. Rotation of the Ca atom at position 100 has a ripple effect on 
close residues and large positional movements are undergone by Leu' °5—Gly' °7 (over 
4 A for the Ca positions of Gly' °7). The Tyr' °° now occupies a new pocket at the 
dimer interface formed by hydrophobic residues from both monomers (Phe' °9 from 
the same monomer; Met", Thr 72, and 11e69 from the other monomer) (Figure III-
16B). The movement of Y 10 to a new location leads to further modification of the 
protein structure and in particular results in the perturbation of several residues of a-
helix 339  Further shifts are observed with residues His 
234  and Asp 231  which directly 
interact with the cofactor. Indeed, in the native holo-SPT both His 
234  and Asp23 ' 
stabilises PLP 39 (Figure Ill-i OB). Measurements of specific distances in the N  OOY 
EN 
mutant showed that distances between the pyridine ring and theses two residues are 
now too long to form hydrogen bonds (3.44 A and 3.64 A. Figure III-16B). 
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Figure 111-16 SPT mutant internal aldimine (A) SPTs crystals (B) N100Y active site. One 
monomer is coloured in teal and the other in purple. All residues from the teal monomer are 
shown in stick form and are coloured yellow. Residues from the purple monomer are 
coloured green. Black dashed lines shows the distances between the internal aldimine, 
His234 and Asp"'. In B, the top left corner box shows the hydrophobic pocked occupied by 
Tyr100 . 
Structural Biology of Wild Type and NIOOY L-Ser External Aldimines 
Crystallisation and solution of the S. paucimohilis NIOOY SPT:L-ser external 
aldimine structure was the result of collaborative work between myself and Ken 
Johnson. 
An overlay of external aldimine structures, wild-type and NI OOY SPT give a smaller 
r.m.s deviation (0.4 A) than the value obtained for the internal aldimine structures 
(0.6 A). Thus, it appears that formation of the external aldimine drives N100Y 
toward a more "native" conformation. The most striking difference between the two 
external aldimine structures is that in the NI00Y structure, the 'PPATP loop" 
remains in its internal aldimine conformation, and consequently Arg 378 does not enter 
the active site and does not make a salt link with the carboxylate of L-serine (Figure 
111-17). It is interesting to note that in the wild-type holo-SPT structure the side- 
M. 
chains of Arg378 and Gin 3" interact directly and this interaction is broken when the 
external aldimine is formed. In contrast, in the NIOOY holo-form these two residues 
are too far apart to interact (distance 4.77A). However, in the N100Y L-Ser:external 
aldimine form the Arg 378/Gln37 interaction is clearly observed with a shorter 
distance between the two residues (2.92A). 











Figure 111-17 Comparison of wild-type (A) and N100Y (B) SPT external aldimine. One 
monomer is coloured in teal and the other in purple. All residues from the teal monomer are 
shown in stick form and are coloured yellow. Residues from the purple monomer are 
coloured green. 
UV and kinetics analysis suggest changes in PLP environment and in the active site 
in general. These results are confirmed by the several perturbations observed in the 
crystal structures and principally at the dimer interface. The most interesting change 
concerns the non-movement of Arg 378 in NIOOY external aldimine. These 
observations combined with high Kd(L.&)  values for both HSANI mutants suggest a 
role for the arginine residue in amino acid binding/recognition. In order to investigate 
further the role of this residue, two new mutants (R378A and R378N) were made and 
studied. 
111.1.3 R378 a singular residue - SPT R378A and R378N mutants 
111.1.3.1 Cloning 
The two arginine mutations were introduced into plasmid pET-28aISPT by 
the same method used with HSANI mutant. 
After transformation of TOP 10 cells with the mutagenesis mixture and purification 
of DNA samples, each mutant plasmid was analysed by restriction enzyme digest 












Figure 111-18 Restriction enzyme analysis of pET28a/R378A, pET28a/R378N. Lane 1: 
Hyperladder I, Lanes 2-4: pET28a/R378A, Lanes 5-7: pET28a/R378N. Lanes 2 and 5: 
plasmid digested with NdeI, Lanes 3 and 6: plasmid digested with XhoI, Lanes 4 and 7: 
plasm Id digested with Ndel and XhoI. 
111.1 .3.2 Expression, Purification and Mass Spectrometry Analysis 
After SPT induction trials it was found that the optimal conditions for 
expression of SPT R378A and R378N were obtained with BL21 (DE3) competent 
cells at 30 °C for 5h with 0.1 mM IPTG. The protein of interest was isolated from the 
cell free extract by nickel affinity chromatography and the fractions containing SPT 






















allowed the isolation of —50mg of pure and homogenous homodimeric SPT mutants 
(size —92 kDa). Protein identity and integrity were confirmed by LC-MS. 
111.1.3.3 Characterisation and Activity of R378 Mutants 
Spectroscopic Properties 
As seen in the previous chapter, structural analysis of wild-type and N 1 OOY 
SPT reveals a specific role for R378 in external aldimine formationlstabilisation. In 
order to confirm and/or understand the role of this residue, binding of PLP and L-
serine was analysed. UV-analysis was carried out as described with wild-type SPT 
(see Section 111.1.1.2). SPT R378A and R378N bound PLP in a manner similar to 
wild-type with absorbance maxima at 335 and 425 nm (Figure 111-19). The 
dissociation constants obtained with L-serine were similar to that of the wild-type 
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Figure 111-19 UV-visible analysis of SP SPT R378A (A) and R378N (C). The solid line in 
each spectrum is the holo-form of the enzyme (10 pM SPT, 20mM potassium phosphate 
buffer (pH 7.5), 150mM NaCl, 25 °C). Increasing concentrations of L-serine were added (0, 
0.1, 0.5, 1, 2, 5, 10, 20, and 40 mM; dotted and dashed lines), and the spectrum was 
recorded after 15 mm. Dissociation constants for SPT R378A (B) and R378N (D) were 
measured at 425 nm. AU, absorbance units. 
3-Ketodihydrosphingosine (KDS) Formation 
The ability of each enzyme to convert [ 14C]L-senne and palmitoyl-CoA to the 
product [ 14C]KDS was examined. Only 50 and 40% of KDS was formed by R378N 
and R378A respectively when compared with the wild-type enzyme (at saturating 
substrate concentrations, Figure 111-20). 
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Figure 111-20 Formation of 3-ketodihydrosphingosine (KDS) - TLC of radiolabeled products 
obtained by SPT-catalyzed conversion of 14C]L-serine and palmitoyl-CoA to [14C]KDS. The 
arrow marks the position of the standard KDS. Lane 1: Wild type SPT, Lane 2: SPT R378A, 
Lane 3: SPT R378N. 
Kinetic Analysis 
Using the DTNB spectrophotometnc assay, Km values for L-serine and 
palmitoyl-CoA with both mutants were determined (Table 111-3). The Km(PCOA) values 
determined were very similar to the wild-type value (39.2 j.tM, 31 MM and 35.4 MM 
for R378A, R378N and WT respectively). Slightly higher KJ,I(LSeT) values were 
calculated as 3.8 mM (R378A) and 2.4 mM (R378N) compare to 1.1 mM for wild-
type SPT. The overall catalytic efficiency (A catIKn) of the R378A and R378N mutants 
were 60- and 40-fold lower compared to wild-type (Table 111-3). 
The fact that the KJ(lS er) values are similar for the R378 mutants and wild-type 
enzymes suggest that R378 is not important in binding the L-serine substrate. If this 
is the case, then the interaction observed between R378 guanidinium and the L-seflne 
carboxylate does not contribute hugely to stabilisation of the external aldimine 
complex. Another possibility is that another residue(s) can help stabilise the external 
aldimine in the absence of R378. However, it can be concluded that R378 is 
necessary for a fully functioning SPT since an increase in Km(LSer) and large decrease 
in SPT activity (kcat) indicates that this residue must play a role in one of the 
mechanistic steps. These data suggest that mutation of the R378 residue slows 
catalysis possibly by preventing an intermediate, probably formed after CoA binding, 
from achieving its optimal orientation within the active site. The step after external 
aldimine formation is deprotonation but this cannot occur until the second substrate 
binds. Binding of palmitoyl-CoA triggers rotation around the external aldimine C. 
Deprotonation of the resulting Dunathan intermediate gives rise to a quinonoid 
intermediate (Figure 111-9 and 21). This intermediate can instantaneously react with 
palmitoyl-CoA to form a 13-ketoacid (Figure 111-9). Because of its high reactivity, the 
transient quinonoid intermediate cannot be observed during normal catalysis.To 
overcome this problem, Ikushiro et al.'2 ' synthesised an analogue of palmitoyl-CoA 
(S-(2-oxoheptadecyl)-CoA) where the reactive thioester bond is replaced by a 
keto/thioether group yielding an unreactive molecule (Figure III-21A). This 
palmitoyl-CoA mimic can bind to the enzyme and the deprotonation at C can occur. 
The resulting quinonoid cannot condensate with the analogue and its accumulation 
can be observed spectroscopically at 495 nm. To investigate whether R378 plays a 
role in quinonoid formation, stabilisation of this intermediate was monitored 
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Figure 111-21 (A) Chemical structure of palmitoyl-00A analogue. Schematic representation of 
the control of the external aldimine conformation in (B) Wild type SPT and (C) R378A. 
Quinonoid formation 
The thioether analogue was added to a fully formed SPT:L-Ser external 
aldimine in wild-type enzyme, as well as the external aldimines of the N100Y and 
R378A mutants, and quinonoid formation was monitored spectroscopically. For the 
wild-type enzyme, a clear peak at 495 nm was observed corresponding to the 
formation of the quinonoid intermediate (maximal absorbance 0.06) (Figure III-
22A). In contrast, the SPT N 1 OOY mutant, under the same conditions, produced a 
small, broad shouldered 490-500 nm peak (maximal absorbance 0.01 absorbance 
units: Figure I1I-22B). Interestingly, no formation of quinonoid species was observed 
with the R378A mutant (Figure III-22C). 
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Figure 111-22 Quinonoid formation in the wild-type SPT, N100Y, and R378A mutants. UV-
visible spectra of the SPT wild type (A), N100Y (B), and R378A (C) external aldimine forms 
after titration palm itoyl-CoA thioether analog, (S-(2-oxoheptadecyl )-00A). Incubations were 
carried out with 5 pM enzyme, 45 MM L-serine, 1.4 mM analog, 20 mM potassium phosphate 
buffer (pH 7.5), 150 mM NaCl for 15 min at 25°C. The solid line in each spectrum represents 
the holo-form; the dotted line is the external aldimine form after the addition of L-serine; and 
the dashed line is after the addition of the analogue. An absorbance maximum at 495 nm 
(marked with an arrow), attributed to quinonoid species 121 , is clearly observed in the wild 
type enzyme, but only a broad shoulder is produced in the N100Y mutant, and no peak is 
observed for the R378A mutant. AU, absorbance units. 
111.1.4 Conclusion 
111.1 .4.1 Role of R378 and Mechanistic Implications 
In view of the fact that in the external aldimine structure Arg 378 undergoes a 
large swing into the active site to make a salt link with the carboxylate of the bound 
L-senne, it was surprising that the R378 mutants easily formed an external aldimine 
with L-serine when analysed by UV-visible spectroscopy. In addition, the 
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dissociation constant for L-serine was almost identical for the R378 mutants and 
wild-type enzyme indicating that binding of L-serine is not hindered in the absence 
of R378. It was interesting then that the R378 mutant enzymes were not able to form 
the subsequent quinonoid intermediate upon titration with a palmitoyl CoA thioether 
analogue. This suggests that the Arg 378 may play a role in either formation or 
stabilisation of the quinonoid intermediate. 
Analysis of the wild-type SPT external aldimine structure shows sp3 -
hybridization at C of the PLP:L-Ser complex (the angles are 111.5, 106.4, and 
109.6°, which are close to the theoretical values for a tetrahedral carbon). The angles 
between each functional group and the N-imine (which is co-planar with the PLP 
ring) were measured as follows: H-C,,-N, 107.7°; CO2-C-N, 108.4°; CH 2-C-N, 
113.3°. None of these are perpendicular to the plane of the PLP ring and as expected 
the external aldimine is not in the optimal "Dunathan conformation" suitable for 
deprotonation. As well as the salt link with Arg 378, other interactions occur from the 
bound PLP:L-Ser complex to His' 59  and Lys265 that prevent rotation to the Dunathan 
in the absence of palmitoyl-CoA (Figure III-21B). When palmitoyl-CoA enters the 
active site, the hydrogen bond between the external aldimine carboxylate and His 159 
is broken 121  and leads to rotation of the Cu. Arg 378 is still present and escort the CO 2 
to its new position. At this stage it is possible that another arginine (possibly the 
highly-conserved R390) make contacts with the external aldimine carboxylate to 
tighten/ fix the new conformation (Figure III-21B). In a final step, Lys 265  now facing 
the proton, deprotonates it and the quinonoid is formed. A double C-C bond is 
created and flattens the Ca conformation (Figure III-21B). In the R378A mutant the 
guanidium side chain is absent and cannot interact with the carboxylate in the 
external aldimine. However, the UV absorbance maxima of the enolimine and 
ketoenamine forms and dissociation constant of L-senne, the formation, 
conformation and general environment of the external aldimine does not seem to 
suffer due to the absence of this residue. However, when the second substrate is 
added the enzyme is not able to form or stabilise a quinonoid (Figure III-22C) but 
deprotonation is still possible as SPT is active and able to form the product KDS 
(Figure 111-20). This confirms the role of R378 in the control of conformation and 
suggests that it also plays an important role in quinonoid stabilisation. The passage 
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between external aldimine and quinonoid intermediates is an equilibrium controlled 
by R378 which when present will favours formation and stabilisation of the 
quinonoid intermediate (Figure 111-21 B) and when absent will favour stabilisation of 
the external aldimine and this leads to reduced SPT turnover (Figure 111-21C). The 
role of R390 still needs to be confirmed and outstanding questions about the role of 
this residue arise. Does R390 assists R378 in the stabilisation of quinonoid 1, formed 
after deprotonation (Figure 111-9) or is it involved in the stabilsation of quinonoid 2, 
formed after decarboxylation of the 13-ketoacid (Figure 111-9)? 
Another possible explanation of the non-formation of the quinoinoid 
intermediate in the R378 mutant is that in the absence of R378, it is R390 itself that 
forms the —CO, - salt link in the external aldirnine. Because of this, there is no transfer 
of the CO2 when palmitoylCoA binds, and the external aldimine remains stuck. It 
follows C rotation and subsequent deprotonation cannot occur, resulting in 
substantially decreased enzyme activity (Figure 111-23). In support of this, R390 is 
highly conserved among AOS members and forms a salt link with external aldimines 





Figure 111-23 Schematic representation of the possible control of the external aldimine by 
Arg390 in SPT R378A mutant. 
111.1.4.2 Mimics of the HSANI Disease Causing Mutations 
While the SPT NIOOC control' mutant had similar characteristics (UV-
visible spectroscopic, kinetic, and high resolution structural analyses) to the wild-
type bacterial enzyme, the HSAN I mutants showed perturbations in the cofactor 
environment. Noticeable changes were observed in the UV spectra (Figure 111-14, A- 
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D) caused by slight shifts in the PLP-stabilising residues. In the wild-type SPT (and 
NI0OC), the side chains of N100 and C 10 in one monomer make a direct contact 
with the amide backbone of the conserved PLP Schiff base Lys 265  of the other 
monomer. The NI OOW/Y structures reveal that this hydrogen bond is broken (Figure 
111-17) creating a more mobile lysine residue and consequently more mobile internal 
and external aldimines. Secondly, the "swung-out" position of R378 in the NIOOY:L-
Ser structure means that a key interaction is missing in its external aldimine form that 
could also prevents formation of the quinonoid intermediate (Figure I11-22B). 
Radioactivity assays along with kinetic analysis confirm that HSAN1 mutants can 
form the final KDS product but activity of the enzyme is severely compromised. It 
appears that local perturbations caused by a single mutation (Ni OOY or N 100W) can 
'ripple' across the interface to affect the chemical environment of the PLP cofactor. 
This in turn impacts upon catalysis. The fact that N100Y could not form a quinonoid 
upon titration with the thioether analogue suggests that the HSAN1 mimics are 
unable to form or stabilise essential intermediates on the catalytic pathway. 
The structures of the HSAN I mimics presented here allow an insight for the first 
time as to how HSAN1 mutations can result in compromised SPT activity, 
previously observed by Bejaoui et al., Gable et al. 75 and McCampbell et al. ' 27 
However many questions remain unanswered. Do the other disease-causing 
mutations (V144D, A352V, S331F) also cause deleterious structural changes that 
result in compromised activity? The recently identified HSAN1-causing mutation 
S331F seems to affect SPT in a different way to C133W and C133Y since it can 
increase basal activity in the absence of the small subunits. In addition the most 
recent topology studies place S331 in a different region of SPT to the other affected 
residues so it is intriguing to think how its mutation results in a similar phenotype. 
More and more evidence suggests that HSAN1 is caused by a build-up of 'deoxy'
metabolites arising from an SPT 'gain of function' due to a change in amino acid 
specificity 7678 . The studies presented here do not shed light on this hypothesis since 
the HSAN1 bacterial mimics did not have an altered substrate specificity but rather 
severely compromised catalytic activity. Perhaps this is not surprising since alanine 
and glycine are relatively good substrates for wild-type human SPT (Km(LA/a)  10 
mM, Km(G/y) -20 mM 125 but very poor substrates for bacterial SPT (Km (L AIa) 1 M, 
Km(Gly) -2 M, data not shown). Although the SPT crystal structure was useful in 
identifying Ser' 02 as a possible residue that confers specificity on SPT for an L-serine 
substrate rather than L-threonine, there is little to indicate why L-alanine and glycine 
are such poor substrates compared to L-serine. Therefore it is difficult to speculate 
how HSAN1 mutations can change SPT specificity to an enzyme with preference for 
these substrates. 
111.1.5 Construction of a bacterial fusion as an improved HSANI human 
SPT mimic 
There is an obvious disadvantage when using a homodimeric bacterial SPT as 
a mimic for the heterodimeric human SPT since mutations generated on the bacterial 
SPT gene give rise to mutations on both subunits. In the case of HSAN 1, mutations 
on human SPT occur only on the LCB1 subunit. One way around this, is to create a 
bacterial fusion protein comprising two identical subunits fused together by a small 
amino acid linker. Taking advantage of the degenerate genetic code the 
oligonucleotide encoding the "SPT-SPT fusion" comprises two distinct genes each 
coding for an identical SPT subunit. In this way it is possible to create mutations on 
one subunit while preserving wild-type character in the other. Successive mutations 
and/or insertions on one gene could give rise to a subunit that more closely resembles 
the inactive LCB 1 subunit of human SPT. Therefore a SPT 'fusion' gene is a useful 
tool for creating a bacterial heterodimeric enzyme that more closely resembles 
human SPT. 
A fusion SPT clone comprising two codon-optimised sequences was previously 
prepared by Teresa Dunn research group (pET28/TDF-SPT, TDF-SPT for Teresa 
Dunn Fusion-SPT, Figure 111-24 (1)). Even though it gave rise to an active fusion 
SPT homodimer, it was not possible to make mutations specific to an individual 
subunit since the clone consisted of identical genes. However the codon-optimised 
sequence is distinct from the native DNA sequence in the SPT clone used by our 
group (pET28a/SPT229, Figure 111-24 (2)). In fact there is only 37% identity 
between them. Therefore a hybrid fusion clone comprising one codon-optimised 
gene from TDFSPT and one native gene from SPT229 was prepared. First, a BamHI 
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restriction site was cloned by site-directed mutagenesis at the C-terminus end of the 
pET28aITDFSPT clone so that the first gene of this fusion could be extracted (Figure 
111-24 (3)). Next, a small chemically-synthesised DNA fragment comprising BamHI 
and NheI restriction sites, as well as the DNA sequence coding for a TEV protease 
site (synSPT. Figure 111-24 (4)), was ligated at the C-terminus of the SPT gene in 
pET28aI229SPT (Figure 111-24 (5)). Finally, the codon-optimised gene was ligated 
between these BamHI and Mel sites to give rise to the required hybrid SPT fusion 
clone pET28a/F2SPT (Figure 111-24 (6)). Further studies on this fusion have been 
done by a member of the group. Dr. Jonathan Lowther has subsequently expressed 
and purified the SPT-SPT fusion and found that it is soluble and active (personnal 
communication). 
Figure 11-24 Construction of F2SPT clone. (1) Map of the pET28aITDFSPT clone, (2) Map of 
the pET28a/229SPT clone, (3) PCR product after insertion of BamHl into clone 
pET28a/TDFSPT/(1), (4) DNA fragment chemically synthesised containing two new 
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restriction sites BamHI and NheI, and the DNA sequence for a TEV protease cleavage site, 
(5) Clone obtained by ligation of synSPT/(3) into pET28a/229SPT/(2), (6) Final 
pET28a/F2SPT clone resulting from ligation of BamHl-Nhel DNA fragment from (4) into 
plamid (5). 
111.2 SPHINGOLIPIDS BIOSYNTHESIS IN Sphiiigoinonas wittichii - A 
MODEL SL-PRODUCING BACTERIUM. 
Sphingomonas wittichii is a non-pathogenic bacteria (Figure III-25A) isolated 
from water of the river Elbe by RM Wittich' 2 . This bacterium has stimulated much 
interest because of its environmental action on organic compounds' 29. Indeed, S. 
wittichii is known to metabolise dibenzo-p-dioxin (Figure III-2513) and its derivatives 
which are highly toxic compounds and persistent organic pollutants. 
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Figure 111-25 (A) Sphingomonas wit(ichii strain. Credit: David Colquhoun, white scale = 1 
micron from website http://qenome.igi-psf.org/sphwi/sphwi.home.htmI  (B) Chemical 
structure of Dibenzo-p-dioxin. 
The entire genome of Sphingonionas ii'ittichii has been sequenced by the USA 
Department of Energy (http://www.jgi.doe.gov ). Like all sphingomonas strains, the 
cell wall of S. it'ittichii comprises glycosphingolipids (GSL, see Section 1.1.2 )16• 
Since the GSL de noi'o biosynthetic pathway begins with condensation of palmitoyl-
CoA and L-serine catalysed by SPT, it follows that the genome of S. it'ittichii should 
contain a gene encoding an SPT homologue. Indeed, a putative SPT was annotated 
on the genorne. Interestingly a small gene encoding an 80 amino acid protein is 
located immediately upstream of SPT and has been annotated as an acyl carrier 
protein (ACP) (Figure 111-26). Some SPT homologues are expressed with an 
accompanying ACP that brings the acyl chain to the enzyme. Examples include a 
seryl transferase (SerT) that along with an ACP didomain make up the PigH gene 
involved in prodigiosin biosynthesis 49 . On the biosynthetic pathway of the fungal 
natural product fumonisin, Fum8p catalyses the condensation between L-alanine and 
steroyl-ACP48 . Taking these examples into consideration a possible hypothesis for 
SW SPT is that instead of using palmitoyl-CoA as a substrate it uses palmitoyl-ACP. 
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Figure 111-26 ACP and SPT gene cluster. 
111.2.1 Cloning of Sphingomonas wittichii ACP and SPT 
The S. vt'ittichil RW1 strain was a kind gift from Dr. Rolf Halden, John 
Hopkins University, USA. The SPT and ACP genes were amplified from the S. 
wittic/zii genornic DNA by PCR and expressing plasmids were engineered. ACP and 
SPT were cloned separately and a third clone was engineered co-expressing both 
proteins (Figure 111-27). Three DNA sequences encoding for ACP-SPT, ACP and 
SPT were amplified from S. wittichii strain RWI genomic DNA and introduce with 
the appropriate restriction sites into pET28a (ACP and ACP-SPT) and pET30c (SPT) 
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Figure 111-27 Plasmid maps of S. wittichii expressing clones (A) ACP (B) SPT (C) ACP-SPT. 
Note: After purification and characterisation of SPT from pET28a ACP-SPT plasmid 
(see section 111.2.2 below), it was discovered that the bioinformatics 
analysis/annotated gene in the genome (http://img.jgi.doe.gov ) contains an N-
terminal extension not present in the isolated protein (at the time of the experiment). 
After further analysis of the SPT genomic sequence, it has been deduced that the 
original chosen start codon was wrong and that the correct one was located 10 amino 
acids further down stream. Since this observation, the genome database has been 
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updated and the SPT sequence contains now 400 amino acids instead of the 410 
annotated previously. The correct SPT sequence was amplified form the previous 
ACP-SPT pET28a plasmid and cloned back into pET28a. 
The SPT start codon was a valine (GTG) and has been changed to a methionine 
(ATG) in the new clone. 
111.2.2 Expression and purification of S. wittichii ACP and SPT 
Expression of the three plasmids described above was investigated and 
optimised by small-scale induction. It is interesting to note that the ACP protein 
could not express by itself but required co-expression of the SPT gene. The 
expression of SPT alone, as well as the co-expression of ACP-SPT in pET28a, was 
carried out in BL21 (DE3) at 30°C for 5h with 0.1 mM of IPTG. SPT was purified 
by nickel affinity using its C-terminal His 6 Tag. Similar one-step purification on Ni-
NTA agarose was earned out to investigate whether the untagged ACP co-purified 
with SPT in an ACP/SPT complex. All buffers were prepared without salt to prevent 
potential disruption of ionic interactions between the two enzymes. Unfortunately 
only SPT bound to the resin while ACP remained in the cell free extract indicating 
that only weak interactions, if any, form between the two proteins (Figure 111-28). 
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Figure 111-28 SDS-PAGE S. wittichii SPT and ACP cell free extract and IMAC purification. 
Lane 1: cell free extract, lane 2: flow-trough, lane 3: 10 mM imidazole, lane 4: 50 mM 
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The SW SPT was then further purified to homogeneity by gel filtration. The 
experimentally determined mass of recombinant SW SPT was within 0.1% of the 
theoretical mass, which includes the C-terminal KLAAALEHHHHHH fusion affinity 
tag but lacks the N-terminal methionine. The ACP containing cell free extract was 
loaded on an anion exchange column and the fractions containing the protein of 
interest were pooled, concentrated and re-loaded on a size exclusion column. This 
two-step purification process allowed the isolation of —30mg of pure and 
homogenous monomeric ACP from 5L culture (Figure 111-29). 
Figure 111-29 Expression and purification of S.wittichii ACP (A) Anion exchange purification 
step, lane 1: See-blue marker, Lane 2-6: Q-sepharose fractions (B) Size exclusion 
purification step, lane 1: See-blue marker, Lane 2-4: Superdex 75 fractions (C) Elution profile 
of size exclusion column (blue line A280 nm). 
111.2.3 Characterisation of SWSPT 
Spectroscopic Properties 
Using the same method as previously described for SP SPT the ability of SW 
SPT to bind PLP and L-senne was investigated. The UV-visible spectrum ofSWSPT 
was very similar to SP SPT. The internal aldimine had maxima at 340 and 425 nm. 
Addition of increasing concentrations of L-serine gave rise to formation of the 
external aldirnine (X= 425 nm) and allowed measurement of the L-serine dissociation 
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Figure 111-30 UV-visible spectroscopic analysis of S. wittichii SPT (A) in presence of L-serine. 
The solid line in the spectrum is the holo-form of the enzyme (10 liM SPT, 20 mM potassium 
phosphate buffer (pH 7.5), 150 mM NaCl, 25 °C). Increasing concentrations of L-serine were 
added (0, 0.1, 0.5, 1,2,5, 10, 20, and 40 mM; dotted and dashed lines), and the spectrum 
was recorded after 15 mm. (B) The L-serine dissociation constant was extracted from 
changes in absorbance at 425 nm. AU, absorbance units. 
Table 111-4 Kinetic parameters for the purified SP and SW SPTs. 





kcat l K 
(M's) 






68.7+/-1.5 0.78 +1- 0.10 23.4+/-4.5 88.1 2936 0.80 +1- 0.1 
S. wittichii 
sPT 
1150.0+!- 30.0 1.40+/-0.10 35.4± 2.0 821.4 32486 1.1 +/-0.1 
S.paucirnobilis 
KDS Formation - Acyl-00A selectivity 
The ability of SW SPT to convert L-serine and palmitoyl-CoA to the product 
KDS was examined by the radiochemical method and also by mass spectrometry 
(Figure 111-31 A, B and Q. Furthermore, the ability of SPT to use other substrates 
than palmitoyl-CoA was investigated. It was shown that SW SPT was active and able 
to form KDS and can also use several acyl-CoA substrates from C12 to C20. The 
mass of each KDS derivatives was measured by mass spectrometry (C14-KDS 
M+H= 244 Da, C16-KDS M+H 272 Da, C18-KDS M+H= 300 Da, C20-KDS 
M+H= 328 Da). The C22-KDS compound could not be observed, probably due to 
ionisation problems. 
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Figure 111-31 Formation KDS and different acyl length derivatives (A) TLC of radiolabeled 
products obtained by SPT-catalyzed conversion of [ 14C]L-serine and acyl-CoA to [14C]KDS. 
Lane 1: 1 -hydroxy-2-aminotetradecan-3-one(C1 4KDS), Lane 2: 1 -hydroxy-2-aminohexan-3-
one (C16KDS), Lane 3: 3-ketodihydrosphingosine (KIDS), lane 4: 1-hydroxy-2-
am i note icosan-3-one (C20KDS), Lane 5: 1 -hydroxy-2-aminodocosan-3-one (C22KDS). ESI-
MS of (B) 1-hydroxy-2-aminotetradecan-3-one (C14KDS) (C) 1-hydroxy-2-aminohexan-3-
one (Cl 6KDS) (D) 1 -hydroxy-2-aminoteicosan-3-one (C20KDS). 
Kinetic analysis 
SW SPT bound L-serine and palrnitoyl-CoA with K, values of 0.78 mM and 
23.4 1iM. respectively (Table I11-4).The enzyme turned over with a kcat of 0.069 51 
and an efficiency (kcat/Km) of 87.7 M' s for L-serine. The comparison of these 
values with those of SP SPT, show that SW SPT have similar binding affinities for its 
substrates but has a much lower turnover and efficiency (-16 fold and 10 fold 
respectively). This could indicate that instead of using palmitoyl-CoA. SW SPT 
utilises palmitoyl-ACP. The acyl-CoA chain length specificity was investigated. 
Steroyl-CoA (C18:0) displayed the fastest turnover (kcat = 0.083 s') of all of the 
MI 
acyl-thioesters and a Km of 12.92 p.M (Table 111-5). When comparing the kat/Kin 
values, stearoyl-CoA (C18:0) was also the most efficient substrate (6,416 M- I 1) • 
The shorter substrates, decanoyl-CoA (Cl0:0) and lauroyl-CoA (C12:0), were the 
poorest substrates. Their binding constants and turnover could not been measured 
due to limit of detection of the DTNB assay. 
Table 111-5 Acyl-CoA chain length specificity of SW SPT. 
Acyl CoA k 1 	(s-1) KOA 	(PM) I KOA  (M1s1) 
Decanoyl(10:0) ND ND ND 
Lau royl (12:0) ND ND ND 
Mynstoyl(14:0) 0.0077±0.0005 39.0± 7.7 198 
Pal mitoyl (16:0) 0.0687±0.0037 23.4± 4.5 2938 
Stearoyl (18:0) 0.0829± 0.0015 12.9 ± 0.9 6416 
Arachidoyl (20:0) 0.0530± 0.0019 <10 >5300 
111.2.4 Structure biology 
The growth of SW SPT crystals and the solution of the crystal structure were carried 
out in collaboration with Dr. Ken Johnson and Prof. Jim Naismith. 
Structure of SW holo-SPT 
SW SPT crystallised is a dimer in the asymmetric unit (Figure 111-32), in contrast to 
the SP SPT where the dimer is generated by crystal symmetry. 19,44, 124 There was no 
density for the disordered C-terminal histidine tag on each monomer and therefore 
our model contains 399 of the 413 amino acids from A1a2 to Pro399 inclusive. A 
PLP cofactor is bound at the active site of each monomer and at the interface with 






Figure 111-32 Structure of SW SPT (A) Crystals (B) Overall structure of the SPT dimer 
showing one monomer in blue and the other in olive. The cofactor PLP bound to the residue 
Lys265 the blue monomer is shown in stick form and is colored green. The equivalent 
residue from the olive monomer is colored magenta SW SPT. 
Several interactions occur between active site residues and the PLP cofactor that are 
present in both active sites. There are hydrogen bonds to the side chains of Asn 118 , 
Thr242 . Thr274 and to main chains of GIyH4,  Tyr 11
5,  Ala 275  (Figure 11I-33A). In 
addition His' 39  n-stacks with the pyridine ring of PLP (Figure 1II-33A). Two 
important interactions that occur in the internal aldimine of SP SPT and other 
members of the AOS family seem not to be formed or weakened in this structure. 
Both Asp2 " and His214 appear to be too far away (3.2 and 3.1 A respectively) to form 
the hydrogen bonds to the PLP that were observed in other structures (Figure III-
33B). These two residues are absolutely conserved amongst all SPTs and AOS 
family members and are known to stabilise and anchor the PLP in the active site. 
Although these residues seem too far to interact with PLP in the internal aldimine, 
they must be involved in solution during stabilisation of other intermediates (eg the 
external aldimine). The conserved Arg 358 , equivalent to Arg378 in SP SPT, is in the 
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Figure 111-33 (A) SWSPT active site. View showing the cofactor PLP of monomer A and the 
residues H139, H214 and Ni 18 involved in its stabilisation. Monomer A is drawn in blue and 
monomer B is drawn in olive. The black dashed line represents the H-bond usually present 
between PLP and equivalent residues of H214 in others AOS enzyme structures. The red 
dashed line represents the "new" H-bond between PLP and Ni 18. (B) Active sites overlay of 
SW and SP SPT. The black dashed line represents the H-bond between PLP and D231 of 
SP SPT. The red dashed line represents the H-bond between PLP and Ni 18 of SWSPT. 
The entrance to the active site situated at the top' of the protein surface is much 
wider than observed in SP SPT, which could indicate the binding of a much wider 
substrate (ACP) instead of palmitoyl-CoA (Figure 111-34). The entrance to the active 
site is delimited by four conserved residues. Vertically we can measure the distance 
between SWDI36/SPDI56 and SWL1O/SPL30 (distance at the 2 C) and 
horizontally between SWP360/SPP380 and SWF273/SPF290 (distance at ProCh  and 
PheC). The vertical distances in SW SPT are longer of 0.8 A vertically and 1.4 A 
horizontally. Both the dimer and monomer structures are similar (with a few 
differences) between the proteins of the Sphingomonas strains: the root mean square 
B 
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(rms) deviation for the dirner is 0.65 A (796 C alpha backbone) and 0.61 A for the 
monomer (398 C alpha backbone). 
Figure 111-34 Surface structures of SPTs showing their active site entrances. (A) SW SPT. 
Monomer A is show in blue and monomer B in olive. The four residue delimiting the active 
site entrance: D136, L10, P360, F273 are coloured green. (B) SP SPT. Monomer A is show 
in steal blue and monomer B in purple. The four residue delimiting the active site entrance: 
D156, L30, P380, F290 are coloured green. 
Palmitoyl-00A hydrophobic channel 
The structure of the bob-form of CqsA, another PLP-dependent AOS 
family member, has recently been solved along with structures of the enzyme co-
crystallised with various substrates. 45  Of particular interest, the product external 
aldimine from the condensation of L-threonine and decanoyl-CoA was trapped in the 
active site. A clear channel or groove was delineated where the C 1() acyl chain binds. 
To define a potential channel in SPT for binding of the acyl chain of palmitoyl-CoA, 
the SW SPT and CqsA structures (PDB: 2WKA) were overlaid (Figure 111-35 A and 
B). The protein backbone of CqsA was hidden and only the substrate decanoyl was 
kept into SW SPT structure to identify the potential residues creating the hydrophobic 
channel. The channel is formed at the interface of the two monomers (Figure 111-35 
A and B) and comprises side-chains or backbone-chains of the following residues: 
Monomer A (Lb. R15, 17-ALL-19, 21-TGVRDPY-27, V341, 358-RPP-361), 
Monomer B (84-VL-85, L266, V272). The side chains from two valines (V23 and 
V341 from the same monomer) appear to delimit the end of the channel. 
Figure 111-35 Surface structure of SW SPT showing palmitoyl-CoA binding cavity. (A) View 
from the top. (B) Top view zoom. Monomer A is show in blue and monomer B in olive. The 
two hydrophobic cavities are coloured in red. Decanoyl-00A is drawn in green stick form. 
111.2.5 Characterisation of SW acyl carrier protein 
Acyl carrier proteins (ACP) require post-translational modification to be 
active 81 (see section 1.4). The apo-protein is converted to the holo-form by addition 
of a 4-PP arm from coenzyme A' °3 . As discussed in the introduction (section 1.4) 
ACP is used in fatty acid and complex natural compound biosyntheses. Varying fatty 
acid synthase (FAS) and polyketide synthases (PKS) systems exists in mammalian, 
plants and bacteria but some elements of a similar system like ACP or ACPS issued 
from different organisms can be interchangeable. Indeed, the high degree of 
structural similarity within the ACP family means that ACPs from other bacteria, 
plants and mammals can function as an acyl group carrier with the enzymes of E. 
coil FAS and can be subsequently modified in their holo- and acyl-forms when over- 
109 
expressed in E.coli.88'89' 130  After expression and purification of SW ACP, the protein 
was analysed by LC-ESI-MS to determine the post-translational status of the protein. 
A mass of 8781 Da was measured, corresponding to the apo-form theoretical mass 
(M+H) lacking the N-terminal methionine (Figure 111-36). This result suggests that 
SW ACP must not be recognised by E. coli ACPS enzymes and therefore not 
converted into the active holo-form required for activity. To this end, PPTases more 
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Figure 111-36 ESI-MS of SW apo-ACP. Values A8, A7, A6 and A5 represent the different 
protonation states of the protein. 
111.2.6 Modification of SWACP by PPTases 
In general, ACPs are modified by PPTases by addidtion of the 4'-PP group 
and subsequently the fatty acid chain is built up step-by-step by a fatty acid synthase. 
However, some PPTases are able to catalyse the direct transfer of an acyl group to 
ACP from an acyl-CoA.48'49' 107-109  In this study, three PPTases were investigated: S. 
coelicolor ACPS, B. Subtilis Sfp and S. verticillus Svp. These were expressed, 
purified and incubated with ACP, coenzyme A and several acyl-CoA in an attempt to 
transfer the corresponding group to ACP. Furthermore, an ACPS gene was identified 
in the S. wittichii genome and the corresponding DNA sequence was amplified and 
cloned in order to investigate the function and activity of the protein. 
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111.2.6.1 Cloning of SWACPS and Streptomyces verticillus Svp 
The ACPS DNA sequence was amplified from S. wittichii strain RW1 
genomic DNA and was introduced using appropriate restriction sites into pET22b 
and to add a His 6 Tag at the C-terminal. SW ACPS original start codon was Val 
(GTG). This has been changed to Met (ATG). The Streptomyces verticillus (SP) Svp 
gene has been chemically synthesised from the sequence described in Sanchez et 
al. 108  The synthetic gene contained the restriction site NcoI and XhoI to ligate the 
gene into pET22b and to obtain a His6 Tag at the C-terminal. 
111.2.6.2 Expression, Purification and Characterisation 
BL21 (DE3) competent cells transformed with the relevant plasmid were 
induced with 0.1 mM IPTG and incubated at 30 °C for five hours. These were the 
optimised conditions for the over-expression of soluble SC ACPS, SW ACPS and B. 
subtilis (B5) Sfp. Under these conditions, expression of Svp was too high leading to 
protein aggregation. To solve this problem, Svp expression was slowed-
down/reduced by using HMS 174 (DE3) competent cells and stopping the induction 
after three hours. Co-expression of SW ACP and ACPS was performed in BL21 
(DE3) competent cells with 0.1 mM IPTG at 30 °C for four hours (Figure 111-37). 
111 







Figure 111-37 SIDS-PAGE of the induction trial of S. wittichii ACPS and ACP co-expression. 
Induction tested in BL21 (DE3) competent cells at 30 °C. Lane 1: Low molecular weight 
protein marker, lane 2: induction with 0.1 mM IPTG for 3h, lane 3: induction with 0.25 mM 
IPTG for 3h, lane 4: induction with 0.5 mM IPTG for 3h, lane 5: induction with 1 mM IPTG for 
3h, lane 6: induction with 0.1 mM IPTG for 4h, lane 7: induction with 0.25 mM IPTG for 4h, 
lane 8: induction with 0.5 mM IPTG for 4h, lane 9: induction with 1 mM IPTG for 4h, lane 10: 
non-induced cells. 
All proteins were purified by nickel affinity chromatography (Figure I1I-38A to D). 1 2 1 	 2 1 2 1 2 97000 A 	 B 	 D 66000 ________________ 
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Figure 111-38 SIDS page of purified PPTases. (A) S.coelicolorACPS (Mw = 14729 Da) (B) BS 
Sfp (Mw = 28373 Da)(C) SWACPS (Mw = 15548 Da)(D) SVSvp (Mw = 26682 Da). 
A second purification step by gel filtration was performed in some cases (Figure III-
39A, B and Q. SC ACPS was obtained in the tnmeric form and Svp as a mixture of 
dimeric and hexameric forms (Figure III-39A and B). Svp expression and isolation 
were not easily reproducible and each purification gave different results and a 
different ratio of dimer versus hexamer (Figure III-39B). 
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Figure 111-39 PPTase size exclusion elution profiles (blue line A280 nm) (A) SC ACPS (B) SV 
Svp (C) SWACPS. 
111.2.6.3 Modification of ACP 
The protocol used to modify the SW apo-ACP with the different PPTases 
was modified from previously described methods '()'-'09 . For brevity, the protocol is 
described using the generic name PPTase that refers to each of the recombinant 
ACPS enzymes used; SC ACPS, BS Sfp, SV Svp and SW ACPS. ACP in reaction 
buffer was incubated with PPTases, MgCl, and CoASH/acyl-CoA at 37 °C overnight. 
The reaction mixture was then injected directly onto an LC-ESI-MS platform for 
analysis. For each PPTase a different reaction buffer was used. For SC ACPS and S V 
Svp, 50 mM Tris buffer, pH 7.8 was used. For BS Sfp the reaction was performed in 
75 mM MES buffer at pH 6.0 and for SW ACPS this was carried out in 20 mM 
potassium phosphate buffer (pH 7.5). DTT (5 mM) was added to the reaction mixture 
when using free CoASH as a substrate. It is important to note that a concentration 
greater than 1 MM  of MgC12 could not be used for reaction with acyl-CoA as this 
lead to precipitation of these compounds and the reaction did not take place. 
Concentrations of enzymes and reactants were varied until optimal conversion 
conditions were achieved. 
Several lengths of fatty acid chain (decanoyl CIO, lauroyl C12, myristoyl 
CM, palmitoyl C16 and steroyl C18) CoA derivatives were tested as substrates that 
could modify the ACP. The first attempt to modify SW ACP with SC ACPS was 
unsuccessful. SC ACPS is well characterised and was previoulsy used to modified 
several ACPs with a large diversity of substrates'09 131  This negative result suggests 
113 
that SC ACPS does not recognise SW ACP. Sfp successfully modified ACP into the 
bob-form (Figure 111-40) and the CIO (Figure III-40B), C12 (Figure III-40C) and 
C14 (Figure III-4013) acyl-forms. However, Sfp failed to transfer a palmitoyl (C16) 
or a steroyl (C18) chain onto the ACP. Palmitoyl chain transfer by Sfp was further 
explored by testing several reaction conditions (enzymes, substrate, co-factor 
concentrations, temperature, time) without success. In the literature Sfp has been 
successfully used to modify a large number of ACP and PCP with various substrates 
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apo-forms of ACP 
are shown in blue. 
Halo and acyl-
ACP forms are 
shown in magenta. 
Another interesting PPTase, Svp, with similar characteristics to Sf, has been shown 
to have a preference for longer carbon chains 48 . Incubation of Svp with ACP 
successfully produced the bob-form of ACP but failed to transfer any acyl groups. 
Hence Svp can accept SW ACP as a substrate (producing the holo-form) but is 
unable to tranfer an acyl group onto it. The problem with the long chain transfer must 
come from the ACP itself. 
SW ACPS was successfully expressed and purified and used to obtain the 
bob-form of the SWACP. Furthermore, SWACP and ACPS have been co-expressed 
in E. co/i to see if, after modification in vivo by SW ACPS the holo-ACP would be 
recognised by the FAS enzyme of E. cvii and build a long chain fatty acid on SW 
ACP. After co-expression, ACP was isolated from the cell free extract, purified and 
analysed by high resolution Fourier transform ion cyclotron resonance mass 
spectrometry (FT-ICR-MS). The ACP fraction analysed reveals a mixture of several 
compounds (Figure 111-41), including the apo and the holo-forms of ACP. The most 
abundant compound corresponds to ACP modified with phosphopantetheine and 
acetyl group (+ 381.2 Da). Another pair of peaks was also observed, the first 
corresponding to an unidentified modification of apo-ACP (apo-ACP + X) and the 
second corresponding to further addition of phosphopantetheine and acetyl again (+ 
381.2 Da). It appears that the fatty acid chain cannot extend past the acetyl-form and 
this further confirms that SWACP is not recognised by E. co/i. 
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Figure 111-41 High-resolution FT-ICR MS analysis of SWACP co-expressed with SWACPS. 
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High resolution mass spectrometry coupled with fragmentation techniques were used 
on both apo- and holo-ACP samples (Figure III-42A, B and C) to confirm that the 
sidechain of Ser39 (within the conserved DSL motif residue, Figure 111-43) is the site 
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Figure 111-42 (A) FT-ICR mass spectrum of apo-ACP. 4 charge states were observed 
corresponding to [M+4H]4 to [M+7H]7 forms of apo-ACP. Insert, the isotopic distribution of 
the [M+6H]6 is consistent with that predicted for ACP (red circles, [C387 H617 N97 0129 
S3]6 ; error 2ppm). (B) FT-ICR mass spectrum of apo-ACP and holo-ACP. A second 
species is observed with charge states were corresponding to the [M+4H] 4 to [M+7H]7 
forms of apo-ACP (nominal mass +339 Da). Insert, the isotopic distribution of the [M+6H] 6 
species is consistent with that predicted for holo-ACP (green circles, [C398 H638 N99 0135 
S4 P1]6 ; error 2ppm). (C) Top-down fragmentation map of holo-ACP. A single m/z species 
was isolated and subject to CID. The resulting b and y ion fragments, shown in blue, were 
mapped onto the primary sequence of ACP using Prosight-PTM. Fragmentation allowed the 
assignment of the phosphopantetheinylation to a 10 amino acid section of the protein 
containing Ser39 which is within the DSLT motif. Raw data in appendice. 
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111.2.6.4 ACP structural model 
Although protein sequence alignment revealed that SW ACP resembles FAS 
II ACPs (Figure 111-43), there are some differences that could be responsible for non-
recognition by E. co/i ACPS and also the inability of Sfp to transfer the 4-PP arm 
and acyl chain of palmitoyl-CoA to the ACP. Of the six ACPs aligned in Figure III-
42 only SW ACP contains a tryptophan residue positioned immediately before the 
DSL catalytic sequence motif. The bulky sidechain of tryptophan (Trp 37 ) is likely to 
have structural consequences that would be characteristic ofSWACP (Figure 111-43), 
perhaps indicating a specific role for this residue. 
M.tuberculosis FAS II PE • DBP 	I 1K 
E.coli FAS II NN I C 	ii 	I TE 
B.subtilis FAS II LE I ii 	I 
S.wittichii ET I' II 
S.coelicolor PKS LDLR ii 	7 	= - 	JS 
IPM human FAS I NLD 7 LIV 
Figure 111-43 ACPs alignment. Zoom on recognition residues: D38, D44, E50 and D51 (SW 
numbering). 
Numerous ACP structures are available and despite the diversity of ACP in nature, 
their secondary structure and overall folding are very similar 88.  Using 3D-JIGSAW 
server 133-135  and Swiss-model ' 338 , 3D-models of SW ACP have been generated in 
order to understand the function of the Trp 37 residue (Figure III-44A). Superposition 
of these models shows two possible conformations for the Trp 37 residue. With the 
residue positioned on a flexible loop, it is plausible to imagine the Trp side-chain 
moving between open and closed conformations thereby selecting the entrance of 
different substrates. Superposition of the 3D-JIGSAW model with the ACP E. co/i 
structure (Figure I1I-44B) shows the tryptophan residue blocking the entrance to the 
active site and this supports the idea that this tiyptophan could control binding and/or 
release of phosphopantetheinyl or acyl groups. A possible explanation for the non-
modification of our ACP with Cl 6- or C  8-CoA esters is that the tryptophan acts as 






Figure 111-44 3D-models of SWACP (A) Superposition of Swiss and JIGSAW ACID 3D-model. 
The ACP Swiss-model is coloured cyan and the JIGSAW-model is coloured green. In each 
model, Trp37 is shown in stick form. (B) Superposition of JIGSAW model and E.coli ACP 
structure (PDB: 1LOH). JIGSAW-model is coloured green and E. co/i structure in magenta 
with the acyl group shown in stick form and coloured in dark blue. 
111.2.7 Conclusion 
SW SPT was expressed, purified and characterised using a number of 
techniques which showed that the enzyme binds its co-factor PLP and its substrate L-
serine. SW SPT was enzymatically active but kinetic analysis revealed that the 
enzyme was ten-fold slower than its homologue SP SPT. One explanation for such a 
large discrepancy is that SWSPT utilises an acyl-ACP instead of acyl-CoA substrates. 
This hypothesis is tempting given that the sequenced S. ii'ittichii genome reveals a 
gene encoding an ACP lying immediately prior to the SPT gene. In order to 
investigate this relationship, a recombinant form of the ACP was expressed and 
subsequently purified. ACP was not modified to the acylated active form by the FAS 
system in E. co/i and was isolated in its inactive apo-form. Four phosphopantetheinyl 
tranferase (SW ACPS, SC ACPS, BS Sfp and SV Svp) were expressed, purified, 
characterised and subsequently used to modify the ACP to its holo- and acyl-forms. 
Three of these enzymes successfully placed a 4-PP arm on ACP. Only Sfp managed 
to transfer acyl-groups. Transfer of a palmitoyl group (C16) on SW ACP was 
unsuccessful and is possibly due to a recognition problem between SW ACP and the 
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PPTases used. Arthur et al. 139  recently described the different interactions created 
between SC ACP and two PPTases from FAS or PKS systems. ACP interacts with 
FAS PPTs by ionic interaction while the recognition between PKS PPTases and ACP 
is made via a hydrophobic interface. SWACP is closely related to other FAS II ACPs 
and despite possessing the four necessary residues for recognition by ACPS (D38, 
D44, E50 and D5 1, Figure 111-43), was not always recognised as a substrate by the 
ACP synthases used in this study. Modelling studies reveal that these problems could 
be caused by an uncharacteristic tryptophan positioned at the beginning of helix II. 
Further investigation by site-directed mutagenesis is required to confirm whether 
removal of the sidechain from this Trp could improve modification to the acylated 
active form by ACPS. If the tryptophan is effectively involved in the recognition of 
phosphopanthetenyl transferase and/or regulation of acyl-goup length/entrance, the 
corresponding mutant should be recognised by a larger number of PPTases and/or 
accept longer substrates. Design, expression, isolation and characterisation of this 
mutant are the aim of a new project. Another solution would be to chemically modify 
the ACP using N-acylimidazole chemistry. 140 
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111.3 GENERAL CONCLUSIONS AND FUTURE WORK 
The PLP-dependent enzyme serine palmitoyltransferase (SPT) is a fascinating 
enzyme to study for many reasons. Firstly, it catalyses the first and rate-limiting step 
in de novo biosynthesis of sphingolipids, a family of natural products fundamental to 
membrane composition in mammals that have gained increased importance as potent 
signalling molecules in numerous cellular processes. Secondly, eukaryotic SPT is 
unusual among the AOS family (which together catalyse similar chemical reactions) 
because it is a heterodimer. While all other members of the AOS family reported to 
date are homodimers, with each subunit binding a PLP cofactor and being 
catalytically competent, human SPT comprises only one catalytic monomer (lcb2 
encoding SPT2) and an other which lacks the necessary residues to bind PLP or carry 
out catalysis (lcbl encoding SPT1). The discovery of small regulatory subunits 
(ssSPTs) in various eukaryotes as well as novel phosphorylating Orm proteins, 
reported during the course of this work, have added to the elaborate organisation of 
an increasingly large membrane-bound human SPT complex. Uncovering how all 
these components come together to regulate SPT activity is an exciting prospect. 
Lastly, puzzling questions remain regarding why single point mutations in human 
SPT specifically on the "inactive" SPTI subunit that appears not to bind PLP leads to 
the neurological disorder HSAN 1. Structural information on the human enzyme 
remains elusive so that at the moment we have to rely on models from soluble 
cytosolic bacterial SPT's. At the start of the project the first crystal structures of an 
apo-SPT and a holo-SPT (PLP-bound form) from Spingomonas paucimobilis had 
been reported by this laboratory. 
The work presented here encompasses structural, spectroscopic and kinetic 
analyses of recombinant forms of SPT from two bacterial strains of Sphingomonas. 
The crystal structure of SPT from S. paucimobilis with its amino acid substrate L-
serine bound at the active site is presented here and has provided the next step. 
Capturing this enzyme-bound PLP:L-Ser external aldimine intermediate by x-ray 
crystallography along with the identification of quinonoid intermediates by UV-vis 
spectroscopy for wild-type and mutant SPT enzymes has provided an insight into 
how bacterial SPT catalysis of the Claisen-like condensation between L- 
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serine and palmitoyl CoA. An unexpected finding was the importance of an arginine 
residue (R378) located on a mobile loop that swings into the active site to form a 
contact with the carboxylate of the PLP:L-Ser complex. This residue is necessary for 
a fully functioning enzyme and R378A and R378N mutants had severely reduced 
activity. Interestingly, this residue is not conserved among the AOS family indicating 
that although all members of the family catalyse the condensation of amino acid and 
acyl-CoA substrates, the way that each particular enzyme controls this reaction is 
specific to that AOS member. A second arginine residue (R390) conserved in all 
other SPT homologues, also points into the active site of the external aldimine 
structure but does not make any contacts. Future studies utilising an R390 mutant 
will be useful to investigate whether this residue is necessary to stabilise quinonoid 
intermediates subsequent to the external aldimine. The co-crystallisation of SPT with 
various substrates, inhibitors and analogues would shed further light on how SPT 
binds its intermediates during normal catalysis. For instance, the first structure of a 
quinonoid intermediate is attainable by capturing SPT in complex with the palmitoyl 
CoA thioether analogue. This structure would also identify the binding site of the 
acyl chain moiety of the palmitoyl-CoA substrate. The determination of SPT 
structures in complex with other ligands such as D-serine, L-threonine, and the 
product KDS, could give valuable information on what active site residues confer 
specificity on SPT for its amino acid substrate and product binding. The inhibitor 
myriocin is also a valuable ligand since it mimics the 13-keto acid intermediate 
formed during normal catalysis. One other feature that has not been probed in any 
AOS enzyme is the nature of the decarboxylation step. What triggers loss of CO 2 
from the 3-keto acid intermediate and by what route does this product leave the 
active site? It may be that the conserved R390 residue is the last SPT side-chain to 
make contact with the carboxylate before it is expelled from the intermediate. 
A characterisation of bacterial mutant SPT's that mimic mutations found in 
human SPT of HSAN1 patients is presented here. These mimics have helped our 
understanding of how a single point mutation can cause such a debilitating disease. 
Structural analysis of these mimics demonstrates how a mutation on one monomer 
can ripple across the protein interface to cause structural changes on the opposite 
monomer. Although these structural changes were subtle, binding of the essential 
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PLP cofactor was perturbed, catalytic efficiency was decreased, and an overall more 
rigid structure did not allow the L-serine substrate to be bound in the same way as in 
wild-type enzyme. There is growing evidence in other laboratories that HSAN1 
mutations result in a 'gain of function' that could arise from relaxed specificity for 
the amino acid substrate in the mutated SPT. These promiscuous mutants generate 
deoxysphingolipids that are thought to build up over time to a toxic level that 
damages tissues in HSAN1 patients. Until the structure of the human SPT is 
available it will be difficult to answer why five different single point mutations all 
result in a HSANI phenotype. Although study of membrane proteins is still 
challenging, methods and techniques in this area are improving. Future studies could 
first be directed towards preparing an improved bacterial SPT mimic. Successive 
mutations on the 'fusion' SPT presented here may result in a soluble SPT mimic that 
more closely resembles the heterodimeric human homologue. Excitingly, Teresa 
Dunn and colleagues have constructed a clone which enables them to express a 
recombinant, soluble and active "triple" fusion (lcb2/ssSPTa/lcbl) of human SPT. 
Whilst great progress has been made on delineating the genes, enzymes and 
intermediates involved in sphingolipid biosynthesis in plants, yeast, fungi and 
mammals our knowledge of bacterial synthesis has surprisingly lagged behind. Since 
Shingomonas paucimobilis is a pathogenic organism we used a safer strain whose 
complete genome sequence was recently completed by the US DoE. This work 
reports the structure and characterisation of holo-SPT from Sphingomonas wittichii. 
It also describes the isolation, characterisation and modification of an unusual ACP 
and proposes a link between fatty acid biosynthesis and sphingolipid biosynthesis. 
While it was difficult to prepare the C16 holo-ACP, this problem could possibly be 
overcome by mutation of an unusual tryptophan residue (W37) which is predicted to 
block the active site. A second alternative is to prepare the holo-ACP by chemical 
acylation. Only when the acyl-ACP is prepared will it be possible to show whether 
the acyl-ACP is a substrate for SPT. A kinetic analysis to compare the efficiency of 
acyl-ACPs with acyl-CoA substrates will be interesting to investigate whether the 
specificity trend remains the same. 
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GENE AND PROTEIN SEQUENCES 
Sphingomonas paucimobilis 
Gene sequence pET28a/SPT WT 
1 ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA CATCGCGCCG 
61 GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG AGCGGCAGAA GCTGCTCGAC 
121 TCCGGCGTCA CCGATCCCTT CGCGATCGTG ATGGAACAGG TGAGTCGCC GACCGAGGCC 
181 GTGATCCGTG GCAAGGACAC GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC 
241 GATCCGGACG TGATCGCAGC GGGCAAGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCAAT 
301 GGCAGCCGGA TGCTCAACGG CACCTTCCAC GACCATATGG AAGTCGAACA GGCGCTGCGC 
361 GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG GTTACATGGC CAATCTCGGC 
421 ATCATCTCAA CGCTGGCGGG CAAGGGTGAG TATGTCATCC TCGACGCCGA CAGCCATGCG 
481 TCGATCTATG ACGGCTGCCA GCAGGGCAAT GCCGAGATCG TCCGCTTCCG CCACAATTCG 
541 GTCGAGGATC TCGACAAGCG GCTGGGCCGT CTGCCCAGG AACCTGCCAA GCTGGTCGTG 
601 CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT GGTCGCGGTC 
661 GCCAAGAAGC ATGGCGCAAT GGTCTTGGTC GACGAAGCGC ATTCGATGGG CTTTTTCGGC 
721 CCCAACGGGC GCGGCGTGTA CGAGGCGCAA GGGTTGGA1G GCCAGATCGA TTTCGTCGTC 
781 GGCACCTTCT CCAPATCGGT CGGCACAGTC GGCGGCTTCG TCGTGTCCAA TCATCCGAAG 
841 TTCGAGGCGG TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT GCCGCCCTCG 
901 GTGGTAGCGA CCGCGACGAC GTCGATCCGC APGCTGATGA CCGCGCATGA AAAGCGTGAG 
961 CGGCTGTGGT CGAATGCCCG CGCGTTGCAT GGCGGGCTGA AGGCGATGGG CTTCAGGCTC 
1021 GGCACCGAGA CCTGCGACAG CGCGATCGTC GCGGTCATGC TGGAGGATCA GGAACAGGCC 
1081 GCGATGATGT GGCAGGCGCT GCTCGACGGC GGGCTCTACG TCAACATGGC GCGCCCGCCC 
1141 GCGACCCCGG CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201 CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG CGTCATCGGC 
1261 CTCGAGCACC ACCACCACCA CCACTGA 
SF SPT wild-type protein sequence (translated from the sequence above) 
1 MTEAAAQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
51 MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTN 
101 GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMANLG IISTLAGKGE 
151 YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201 LEGVYSMLGD IAPLKEMVAV AKKHGAJVIVLV DEAHSMGFFG PNGRGVYEAQ 
251 GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301 VVATATTSIR KLMTAHEKRE RLWSNARALH GGLKAIVIGFRL GTETCDSAIV 
351 AVMLEDQEQA AMMWQALLDG GLYVNMARPP ATPAGTFLLR CSICAEHTPA 
401 QIQTVLGMFQ AAGRAVGVIG LEHHHHHH 
134 
Gene sequence pET28a/SPT N100W 
1ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA CATCGCGCCG 
61 GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG AGCGGCAGAA GCTGCTCGAC 
121 TCCGGCGTCA CCGATCCCTT CGCGATCGTG ATGGAACAGG TGAAGTCGCC GACCGAGGCC 
181 GTGATCCGTG GCAGGACAC GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC 
241 GATCCGGACG TGATCGCAGC GGGCAAGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCTGG 
301 GGCAGCCGGA TGCTCACGG CACCTTCCAC GACCATATGG AAGTCGAACA GGCGCTGCGC 
361 GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG GTTACATGGC CAPTCTCGGC 
421 ATCATCTCAA CGCTGGCGGG CAAGGGTGAG TATGTCATCC TCGACGCCGA CAGCCATGCG 
481 TCGATCTATG ACGGCTGCCA GCAGGGCAAT GCCGAGATCG TCCGCTTCCG CCACAATTCG 
541 GTCGAGGATC TCGACA1GCG GCTGGGCCGT CTGCCCAAGG AACCTGCCAA GCTGGTCGTG 
601 CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT GGTCGCGGTC 
661 GCCAAGAAGC ATGGCGCAT GGTCTTGGTC GACGAAGCGC ATTCGATGGG CTTTTTCGGC 
721 CCCAACGGGC GCGGCGTGTA CGAGGCGCAA GGGTTGGAAG GCCAGATCGA TTTCGTCGTC 
781 GGCACCTTCT CCAAATCGGT CGGCACAGTC GGCGGCTTCG TCGTGTCCAA TCATCCGAAG 
841 TTCGAGGCGG TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT GCCGCCCTCG 
901 GTGGTAGCGA CCGCGACGAC GTCGATCCGC AAGCTGATGA CCGCGCATGA AAAGCGTGAG 
961 CGGCTGTGGT CGAATGCCCG CGCGTTGCAT GGCGGGCTGA AGGCGATGGG CTTCAGGCTC 
1021 GGCACCGAGA CCTGCGACAG CGCGATCGTC GCGGTCATGC TGGAGGATCA GGAACAGGCC 
1081 GCGATGATGT GGCAGGCGCT GCTCGACGGC GGGCTCTACG TCAACATGGC GCGCCCGCCC 
1141 GCGACCCCGG CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201 CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG CGTCATCGGC 
1261 CTCGAGCACC ACCACCACCA CCACTGA 
SF SPT NIOOW protein sequence (translated from the sequence above) 
1 MTEAAAQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
51 MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTW 
101 GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMPNLG IISTLAGKGE 
151 YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201 LEGVYSMLGD IAPLKEMVAV AKKHGAMVLV DEAHSMGFFG PNGRGVYEAQ 
251 GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301 VVATATTSIR KLMTAHEKRE RLWSNARALH GGLKAIGFRL GTETCDSAIV 
351 AVNLEDQEQA ANMWQALLDG GLYVNMARPP ATPAGTFLLR CSICAEHTPA 
401 QIQTVLGMFQ AAGRAVGVIG LEHHHHHH 
135 
Gene sequence pET28a/SPT N100Y 
1 ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA CATCGCGCCG 
61 GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG AGCGGCAGAA GCTGCTCGAC 
121 TCCGGCGTCA CCGATCCCTT CGCGATCGTG ATGGAACAGG TGAAGTCGCC GACCGAGGCC 
181 GTGATCCGTG GCAAGGACAC GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC 
241 GATCCGGACG TGATCGCAGC GGGCAPGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCTAT 
301 GGCAGCCGGA TGCTCAACGG CACCTTCCAC GACCATATGG AAGTCGAFCA GGCGCTGCGC 
361 GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG GTTACATGGC CAATCTCGGC 
421 ATCATCTCAA CGCTGGCGGG CAAGGGTGAG TATGTCATCC TCGACGCCGA CAGCCATGCG 
481 TCGATCTATG ACGGCTGCCA GCAGGGCAAT GCCGAGATCG TCCGCTTCCG CCACAATTCG 
541 GTCGAGGATC TCGACAAGCG GCTGGGCCGT CTGCCCAAGG AACCTGCCAA GCTGGTCGTG 
601 CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT GGTCGCGGTC 
661 GCCAAGAAGC ATGGCGCAAT GGTCTTGGTC GACGAGCGC ATTCGATGGG CTTTTTCGGC 
721 CCCAACGGGC GCGGCGTGTA CGAGGCGCAA GGGTTGGAAG GCCAGATCGA TTTCGTCGTC 
781 GGCACCTTCT CCAAATCGGT CGGCACAGTC GGCGGCTTCG TCGTGTCCAA TCATCCGAAG 
841 TTCGAGGCGG TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT GCCGCCCTCG 
901 GTGGTAGCGA CCGCGACGAC GTCGATCCGC APGCTGATGA CCGCGCATGA AAAGCGTGAG 
961 CGGCTGTGGT CGAATGCCCG CGCGTTGCAT GGCGGGCTGA AGGCGATGGG CTTCAGGCTC 
1021 GGCACCGAGA CCTGCGACAG CGCGATCGTC GCGGTCATGC TGGAGGATCA GGAACAGGCC 
1081 GCGATGATGT GGCAGGCGCT GCTCGACGGC GGGCTCTACG TCAACATGGC GCGCCCGCCC 
1141 GCGACCCCGG CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201 CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG CGTCATCGGC 
1261 CTCGAGCACC ACCACCACCA CCACTGA 
SP SPT N100Y protein sequence (translated from the sequence above) 
1 MTEAPAQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
51 MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTY 
101 GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMANLG IISTLAGKGE 
151 YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201 LEGVYSMLGD IAPLKEMVAV AKKHGAIVIVLV DEAI-iSMGFFG PNGRGVYEAQ 
251 GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301 VVATATTSIR KLMTAHEKRE RLWSNARALH GGLKAIVIGFRL GTETCDSAIV 
351 AVMLEDQEQA ANIVIWQALLDG GLYVNMARPP ATPAGTFLLR CSICAEHTPA 
401 QIQTVLGMFQ APGRAVGVIG LEHHHHHH 
136 
Gene sequence pET28a/SPT R378A 
1 ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA CATCGCGCCG 
61 GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG AGCGGCAGAA GCTGCTCGAC 
121 TCCGGCGTCA CCGATCCCTT CGCGATCGTG ATGGAPCAGG TGAAGTCGCC GACCGAGGCC 
181 GTGATCCGTG GCAAGGACAC GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC 
241 GATCCGGACG TGATCGCAGC GGGCAAGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCAAT 
301 GGCAGCCGGA TGCTCAACGG CACCTTCCAC GACCATATGG AAGTCGAACA GGCGCTGCGC 
361 GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG GTTACATGGC CAATCTCGGC 
421 ATCATCTCAA CGCTGGCGGG CAAGGGTGAG TATGTCATCC TCGACGCCGA CAGCCATGCG 
481 TCGATCTATG ACGGCTGCCA GCAGGGCAAT GCCGAGATCG TCCGCTTCCG CCACAATTCG 
541 GTCGAGGATC TCGACAAGCG GCTGGGCCGT CTGCCCAAGG AACCTGCCAA GCTGGTCGTG 
601 CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT GGTCGCGGTC 
661 GCCAAGAAGC ATGGCGCAAT GGTCTTGGTC GACGAAGCGC ATTCGATGGG CTTTTTCGGC 
721 CCCAACGGGC GCGGCGTGTA CGAGGCGCAA GGGTTGGAAG GCCAGATCGA TTTCGTCGTC 
781 GGCACCTTCT CCAPATCGGT CGGCACAGTC GGCGGCTTCG TCGTGTCCA1 TCATCCGAAG 
841 TTCGAGGCGG TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT GCCGCCCTCG 
901 GTGGTAGCGA CCGCGACGAC GTCGATCCGC AGCTGATGA CCGCGCATGA AAPGCGTGAG 
961 CGGCTGTGGT CGAATGCCCG CGCGTTGCAT GGCGGGCTGA AGGCGATGGG CTTCAGGCTC 
1021 GGCACCGAGA CCTGCGACAG CGCGATCGTC GCGGTCATGC TGGAGGATCA GGAPCAGGCC 
1081 GCGATGATGT GGCAGGCGCT GCTCGACGGC GGGCTCTACG TCACATGGC GGCCCCGCCC 
1141 GCGACCCCGG CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201 CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG CGTCATCGGC 
1261 CTCGAGCACC ACCACCACCA CCACTGA 
SF SPT R378A protein sequence (translated from the sequence above) 
1 MTEAAAQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
51 MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTW 
101 GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMANLG IISTLAGKGE 
151 YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201 LEGVYSMLGD IAPLKEMVAV AKKHGAMVLV DEAHSMGFFG PNGRGVYEAQ 
251 GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301 VVATATTSIR KLMTAHEKRE RLWSNARALH GGLKPJ4GFRL GTETCDSAIV 
351 AVMLEDQEQA AI'4MWQALLDG GLYVNMAAPP ATPAGTFLLR CSICAEHTPA 
401 QIQTVLGMFQ AAGRAVGVIG LEHHHHHH 
137 
Gene sequence pET28a/SPT R378N 
1 ATGACCGAAG CCGCCGCTCA GCCCCACGCC CTCCCCGCCG ACGCGCCCGA CATCGCGCCG 
61 GAACGCGACC TGCTCTCCAA GTTCGACGGC CTGATCGCCG AGCGGCAGAA GCTGCTCGAC 
121 TCCGGCGTCA CCGATCCCTT CGCGATCGTG ATGGAACAGG TGAAGTCGCC GACCGAGGCC 
181 GTGATCCGTG GCAPGGACAC GATCCTGCTC GGCACGTACA ACTATATGGG CATGACCTTC 
241 GATCCGGACG TGATCGCAGC GGGCAAGGAA GCGCTGGAGA AGTTCGGGTC GGGCACCAAT 
301 GGCAGCCGGA TGCTCAACGG CACCTTCCAC GACCATATGG A1GTCGAACA GGCGCTGCGC 
361 GATTTCTACG GCACGACCGG CGCGATCGTC TTTTCGACCG GTTACATGGC CAATCTCGGC 
421 ATCATCTCAA CGCTGGCGGG CAAGGGTGAG TATGTCATCC TCGACGCCGA CAGCCATGCG 
481 TCGATCTATG ACGGCTGCCA GCAGGGCAPT GCCGAGATCG TCCGCTTCCG CCACAATTCG 
541 GTCGAGGATC TCGACAAGCG GCTGGGCCGT CTGCCCAAGG ACCTGCCAA GCTGGTCGTG 
601 CTGGAGGGCG TCTATTCGAT GCTCGGCGAC ATCGCTCCGC TGAAGGAGAT GGTCGCGGTC 
661 GCCAAGAAGC ATGGCGCAAT GGTCTTGGTC GACGAAGCGC ATTCGATGGG CTTTTTCGGC 
721 CCCAACGGGC GCGGCGTGTA CGAGGCGCAA GGGTTGGA1.G GCCAGATCGA TTTCGTCGTC 
781 GGCACCTTCT CCAAATCGGT CGGCACAGTC GGCGGCTTCG TCGTGTCCAA TCATCCGAAG 
841 TTCGAGGCGG TCCGCCTCGC CTGCCGTCCG TACATCTTCA CCGCCTCGCT CCCGCCCTCG 
901 GTGGTAGCGA CCGCGACGAC GTCGATCCGC AAGCTGATGA CCGCGCATGA AAAGCGTCAG 
961 CGGCTGTGGT CGATGCCCG CGCGTTGCAT GGCGGGCTGA AGGCGATGGG CTTCAGGCTC 
1021 GGCACCGAGA CCTGCGACAG CGCGATCGTC GCGGTCATGC TGGAGGATCA GGAACAGGCC 
1081 GCGATGATGT GGCAGGCGCT GCTCGACGGC GGGCTCTACG TCAACATGGC GAACCCGCCC 
1141 GCGACCCCGG CCGGCACCTT CCTGCTGCGC TGCTCCATCT GTGCCGAGCA CACGCCGGCG 
1201 CAGATCCAGA CCGTGCTGGG CATGTTCCAG GCCGCGGGCC GCGCGGTCGG CGTCATCGGC 
1261 CTCGAGCACC ACCACCACCA CCACTGA 
SF SPT R378N protein sequence (translated from the sequence above) 
1 MTEAPQPHA LPADAPDIAP ERDLLSKFDG LIAERQKLLD SGVTDPFAIV 
51 MEQVKSPTEA VIRGKDTILL GTYNYMGMTF DPDVIAAGKE ALEKFGSGTW 
101 GSRMLNGTFH DHMEVEQALR DFYGTTGAIV FSTGYMANLG IISTLAGKGE 
151 YVILDADSHA SIYDGCQQGN AEIVRFRHNS VEDLDKRLGR LPKEPAKLVV 
201 LEGVYSMLGD IAPLKEMVAV AKKHGANVLV DEAHSMGFFG PNGRGVYEAQ 
251 GLEGQIDFVV GTFSKSVGTV GGFVVSNHPK FEAVRLACRP YIFTASLPPS 
301 VVATATTSIR KLMTAHEKRE RLWSNARALH GGLKAI'4GFRL GTETCDSAIV 
351 AVMLEDQEQA AMMWQALLDG GLYVNMANPP ATPAGTFLLR CSICAEHTPA 













































GAGAAGACAT CTTCACCCGC GTCGCCGAGC AGATCGAGCC GTTCAACAAG 
ACCTGGCTGA GACGACGAGC TTCGCCGGCG ACCTCGAATG GGACAGCCTG 
ATTTCGTCGC GGCGGTGGAG GATGAGTTCG ACATCATCAT CACGATGAAC 
AGATCGAGAC CGTCGGCCAG CTCGTCGATG CCGTCGCCAA GCTGCGGGGC 
GCCGACCTCC TCTCCA1GTT CGACCCGCTG ATCGCCGAGC GCGAGGCGCT 
GGCGTGCGCG ATCCCTACGC GATCGTCATG GACAAGGTGC TGTCGCCGAC 
ATCAACGGCA GGAAGACGAT CCTGCTCGGC ACCTATAATT ACATGGGCAT 
CCGGACGTCA TCGCCGCCGG CAAGCAGGCG CTCGACGAAT TCGGCTCGGG 
AGCCGGGTGC TCAACGGCAC CTATCAGGGT CACAAGGCGT GCGAGGACGC 
TTCTACGGGA CCGAGCACGC CATCGTCTTC TCGACCGGCT ACCAGGCCA 
ATCTCCACCC TGGCTGGCAA GGGCGACTAC ATCATCCTCG ACGCCGACAG 
ATCTATGACG GCTGCTGGCT CGGCGACGCG GAGATCGTCC GCTTCCGCCA 
GAGGACCTCG ACAAGCGGCT CGGCCGCCTG CCGGCCGAGG CGGGCAAGCT 
GAAGGCGTCT ATTCGATGAT GGGCGACATC GCCCCGCTCC AGGAGATGGT 
AAGAAGCACG GCGCGATGAT CCTCGTCGAC GAGGCGCACG GCATGGGCTT 
CATGGCCGCG GCGTGTTCGA GGAGGCCGGG GTGGAGGCCG ACGTCGACTT 
ACCTTCTCCA AGTCGGTCGG CACGGTCGGT GGCTTCTGCG TCTCCAACCA 
GAGGTGCTGC GCCTCGTCTG CCGGCCCTAT GTCTTCACCG CCTCGCTGCC 
GTCGCGACCG CCGCGACCTC GATCCGCAG CTGATGCATG CGGGCGACAA 
CTCTGGAAGA ATTCGCGCCG CCTGCACCAG GGCCTGCGCG ACATGGGCTA 
ACCGAGACCG CCCAGTCGGC GATCATCGCG GTGATCCTGA CCGACATGGC 
GCGCTGTGGC AGGGCCTGCT CGAGGCGGGG CTCTATGTGA ACACCGCCCG 
ACGCCGGCCG GCATGTTCCT GCTGCGCTGC TCGCTGTGCG CCGAACATAG 
GTCGAGCAGA TCCTGGGCAT GTTCGAGAGC GCGGGGCGCG CCACGGGAGT 
CTTGCGGCCG CACTCGAGCA CCACCACCAC CACCACTGA 
SW ACP protein sequence (translated from the sequence above) 
1 MSSREDIFTR VAEQIEPFNK KGIDLAETTS FAGDLEWDSL TVMDFVAAVE 
51 DEFDIIITM1I MQAEIETVGQ LVDAVAKLRG 
SW SPT protein sequence (translated from the sequence above) 
1 VADLLSKFDP LIAEREALLA TGVRDPYAIV 
51 GTYNYMGMTF DPDVIAAGKQ ALDEFGSGTT 
101 EFYGTEHAIV FSTGYQNLG MISTLAGKGD 
151 AEIVRFRHNS VEDLDKRL,GR LPAEAGKLVV 
201 SKKHGAMILV DEAHGMGFFG EHGRGVFEEA 
251 GGFCVSNHPK FEVLRLVCRP YVFTASLPPS 
301 HLWKNSRRLH QGLRDMGYKL GTETAQSAII 
351 GLYVNTARPP ATPAGMFLLR CSLCAEHSDE 
401 KLAAALE}iHH HHH 
139 
Gene sequence pET28a/ SPT SW 
1 ATGGCCGACC TCCTCTCCAA GTTCGACCCG CTGATCGCCG AGCGCGAGGC GCTGCTCGCC 
61 ACCGGCGTGC GCGATCCCTA CGCGATCGTC ATGGACAAGG TGCTGTCGCC GACCGAGGCG 
121 ATGATCAACG GCAGGA1GAC GATCCTGCTC GGCACCTATA ATTACATGGG CATGACCTTC 
181 GACCCGGACG TCATCGCCGC CGGCAAGCAG GCGCTCGACG AATTCGGCTC GGGCACCACC 
241 GGCAGCCGGG TGCTCAACGG CACCTATCAG GGTCACAAGG CGTGCGAGGA CGCGCTCAAG 
301 GAATTCTACG GGACCGAGCA CGCCATCGTC TTCTCGACCG GCTACCAGGC CAATCTCGGG 
361 ATGATCTCCA CCCTGGCTGG CAAGGGCGAC TACATCATCC TCGACGCCGA CAGCCACGCC 
421 TCGATCTATG ACGGCTGCTG GCTCGGCGAC GCGGAGATCG TCCGCTTCCG CCACAATTCG 
481 GTCGAGGACC TCGACAAGCG GCTCGGCCGC CTGCCGGCCG AGGCGGGCAA GCTCGTCGTC 
541 CTCGAAGGCG TCTATTCGAT GATGGGCGAC ATCGCCCCGC TCCAGGAGAT GGTCGCCGTC 
601 TCGAAGAAGC ACGGCGCGAT GATCCTCGTC GACGAGGCGC ACGGCATGGG CTTCTTCGGC 
661 GAGCATGGCC GCGGCGTGTT CGAGGAGGCC GGGGTGGAGG CCGACGTCGA CTTCGTCGTC 
721 GGCACCTTCT CCAAGTCGGT CGGCACGGTC GGTGGCTTCT GCGTCTCCAA CCATCCGAAG 
781 TTCGAGGTGC TGCGCCTCGT CTGCCGGCCC TATGTCTTCA CCGCCTCGCT GCCGCCGTCG 
841 GTGGTCGCGA CCGCCGCGAC CTCGATCCGC AAGCTGATGC ATGCGGGCGA CAAGCGCGCG 
901 CACCTCTGGA AGAATTCGCG CCGCCTGCAC CAGGGCCTGC GCGACATGGG CTACAAGCTC 
961 GGCACCGAGA CCGCCCAGTC GGCGATCATC GCGGTGATCC TGACCGACAT GGCCCAGGCG 
1021 GTCGCGCTGT GGCAGGGCCT GCTCGAGGCG GGGCTCTATG TGAACACCGC CCGTCCGCCC 
1081 GCGACGCCGG CCGGCATGTT CCTGCTGCGC TGCTCGCTGT GCGCCGACA TAGCGACGAA 
1141 CAGGTCGAGC AGATCCTGGG CATGTTCGAG AGCGCGGGGC GCGCCACGGG AGTAATCCCC 
1201 AAGCTTGCGG CCGCACTCGA GCACCACCAC CACCACCACT GA 
SW SPT protein sequence (translated from the sequence above) 
1 MADLLSKFDP LIAEREALLA TGVRDPYAIV MDKVLSPTEA MINGRKTILL 
51 GTYNYMGMTF DPDVIAAGKQ AL]JEFGSGTT GSRVLNGTYQ GHKACEDALK 
101 EFYGTEHAIV FSTGYQANLG MISTLAGKGD YIILDADSHA SIYDGCWLGD 
151 AEIVRFRHNS VEDLDKRLGR LPAEAGKLVV LEGVYSMMGD IAPLQEMVAV 
201 SKKHGANILV DEAHGMGFFG E}IGRGVFEEA GVEADVDFVV GTFSKSVGTV 
251 GGFCVSNHPK FEVLRLVCRP YVFTASLPPS VVATATSIR KLMHAGDKRA 
301 HLWKNSRRLH QGLRDMGYKL GTETAQSAII AVILTDMAQA VALWQGLLEA 
351 GLYVNTARPP ATPAGMFLLR CSLCAEHSDE QVEQILGMFE SAGRATGVIP 
401 KLAAALEHI-iH HHH 
140 
Gene sequence pET22a/ ACPS SW 
1 ATGATCATCG GCATCGGCTC CGACCTCTGC AACATCGAGC GAATCCAGAA GTCGCTCGAC 
61 CGCTTCGGCG AGCGCTTCGT CGTCCGGGTG TTCACCGATG TCGAGCGCGC CAGGCGGAG 
121 CGCCGGGTGC TGACCCGCGC CGCCACCTAT GCGAAGCGAT TCGCGGCGAA GGAGGCCTTC 
181 TCCAAGGCGG TGGGCACCGG CTTCAGGGCC GGCGTGTTCA TGAAGGACAT CGGCGTCGCC 
241 AACCTGCCGA GCGGCGCCCC TACCCTGGTT TTGACCGGCG GGGCCAAGGC AAGGCTTGAC 
301 GCGCTCACGC CGCCGGGCCA CGCGGTGGAT GTACATTTGA CGATGACGGA CGATCATCCC 
361 TGGGCGCAGG CGTTCGTGAT CCTGTATGCG CGCCCGCTGC TCGAGCACCA CCACCACCAC 
421 CACTGA 
SW ACPS protein sequence (translated from the sequence above) 
	
1 	MIIGIGSDLC NIERIQKSLD RFGERFVVRV FTDVERAKAE RRVLTRA?TY 
51 AKRFAAKEAF SKAVGTGFRA GVFMKDIGVA NLPSGAPTLV LTGGAKARLD 
101 	ALTPPGHAVD VHLTMTDDHP WAQAFVILYA RPLLEHHHHH H 
141 
TOP-DOWN FT-ICR MASS SPECTROMETRY DATA 
Method 
Protein samples were buffer exchanged into 100 mM ammonium acetate, acidified 
with 2-fold H20:MeOH:HCOOH (v/v/v 50:48:2), and analysed by FT-ICR-MS at a 
final concentration of 5 jiM. Mass spectrometry data was acquired on an Apex Ultra 
Qh-FT-ICR mass spectrometer equipped with a 12 Tesla superconducting magnet 
and an electrospray ion source (Bruker Daltonics, Billerica, MA). Nano-ESI was 
performed using a Tn Versa Nanomate (Advion BioSciences, Ithaca, NY) running in 
infusion mode. Broadband data was typically acquired between m/z 600 and 4000 for 
0.5 s and each spectrum was the sum of 32 scans. The mass spectra were externally 
calibrated using ES tuning mix (Agilent) and analysed using DataAnalysis software 
(Bruker Daltonics). 
Top-down fragmentation was performed on the 12T Qh-FT-ICR. First, a specific ion 
species was isolated with the instrument's mass resolving quadrupole and MS/MS 
was performed using collision-induced dissociation (CID) The collision voltage was 
typically set between 20-35V. Fragmentation data was the sum of 200 scans and 
data analyses were performed using DataAnalysis (Bruker Daltonics). The SNAP 2.0 
algorithm was used for automated peak picking and the resulting top-down fragment 
mass lists were searched against the primary sequence of ACP using Prosight-PTM 
12, 141 Phosphopantetheinylation modification was calculated to produce a 
Amass modification of 340.086 Da (C 11 H21 N206P 1 S 1 ). 
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# 	mlz 	I 
1 	714.483 	347666 
2 816.9463 99934 
3 835.0118 	77043 
4 881.4701 203778 
5 899.5476 353492 
6 935.4276 	563818 
7 990.0848 158575 
8 999.0892 1027422 
9 1064.613 1431996 
10 1113.124 	691282 
11 1121.639 6478008 
12 1178.648 	666168 
13 1187.163 8192392 
14 1218.654 	100166 
15 1229.175 335044 
16 	1237.69 4825131 
17 1285.721 	239197 
18 1294.236 3426285 
19 1350.782 1650130 
20 1399.746 	277234 
21 1407.329 171918 
22 1426.264 	772760 
23 1463.798 85037 
24 1464.845 	214471 
25 1470.289 522825 
26 1474.119 	70355 
27 1476.616 425445 
28 1480.279 	122757 
29 1483.109 577091 
30 1486.605 	154363 
31 1489.268 414497 
32 1493.261 	62910 
33 1495.762 304327 
34 1499.258 	197199 
35 1502.088 580975 
36 1505.751 	108159 
37 1508.415 356655 
38 1514.741 	215184 
39 	1514.81 151297 
40 1515.518 	762845 
41 151 7.811 1683973 
42 1520.445 	187816 
43 1520.648 3397564 
44 1522.916 	603275 
45 1522.978 153854 
46 1524.311 	493807 
47 1526.807 1959378 
48 1533.133 	111449 
49 1548.548 115662 
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# 	mlz 	I 
1 714.4831 	680304 
2 816.9468 204695 
3 	881.471 	497034 
4 899.5482 233021 
5 935.4277 	484370 
6 990.0846 145466 
7 990.5747 	122301 
8 999.0893 677807 
9 	1040.22 	330432 
10 1064.614 1180994 
11 1113.124 	560208 
12 1121.639 5221105 
13 1161.303 	149317 
14 1178.649 638422 
15 1187.163 	6666894 
16 1218.655 253705 
17 1226.771 	147424 
18 1229.176 389841 
19 	1237.69 	4997191 
20 1256.352 107293 
21 1265.952 	323188 
22 1268.947 244639 
23 1271.231 	1600710 
24 1274.371 301378 
25 1276.653 	885493 
26 1279.793 180736 
27 1282.219 	395519 
28 1285.216 333222 
29 1286.222 	204428 
30 1287.642 850680 
31 1290.638 	183172 
32 1292.921 392798 
33 1294.236 	4004073 
34 1298.487 277748 
35 1298.519 	192249 
36 1299.371 262266 
37 1300.128 	530756 
38 1301.817 131061 
39 1302.769 	944566 
40 1307.106 10875908 
41 1331.241 	85184 
42 1342.267 159797 
43 1350.782 	1983837 
44 1393.475 100771 
45 1399.746 	481149 
46 1407.329 310243 
47 1407.412 	166154 
48 1418.494 150444 
49 1440.436 	79899 
50 1460.453 196862 
51 1464.847 	373917 
52 1467.122 101902 
53 1470.289 	188772 
54 1471.453 114809 
55 1474.287 	963061 
56 1476.616 663874 
57 1480.786 	369587 



















































































































































































































































Prosight PTM Output 
Observed Theoretical Mass Error Mass Error 
Ion 
Mass (Da) Mass (Da) (Da) (PPM) 
Y32 3546.9903 3546.7968 0.1935 54.54 
Y31 3447.9127 3447.7284 0.1843 53.44 
Y30 3318.8703 3318.6858 0.1845 55.58 
Y29 3203.8206 3203.6589 0.1617 50.47 
Y28 3074.7673 3074.6163 0.151 49.11 
Y27 2927.683 2927.5479 0.1351 46.15 
2927.6865 2927.5479 0.1386 47.34 
Y26 2812.6508 2812.521 0.1298 46.16 
2812.6504 2812.521 0.1294 46.02 
Y25 2699.5557 2699.4369 0.1188 44.01 
2699.5561 2699.4369 0.1192 44.16 
Y24 2586.4649 2586.3528 0.1121 43.33 
2586.4655 2586.3528 0.1127 43.56 
Y23 2473.3719 2473.2688 0.1031 41.69 
2473.3727 2473.2688 0.1039 42.02 
Y22 2372.3178 2372.2211 0.0967 40.76 
2372.3183 2372.2211 0.0972 40.97 
Y21 2241.2696 2241.1806 0.089 39.71 
2241.2701 2241.1806 0.0895 39.93 
Y20 2127.2194 2127.1377 0.0817 38.42 
2127.2197 2127.1377 0.082 38.56 
Y19 1996.171 1996.0972 0.0738 36.98 
1996.1714 1996.0972 0.0742 37.18 
Y17 1797.0879 1797.0015 0.0864 48.08 
1797.0891 1797.0015 0.0876 48.75 
Y16 1668.0163 1667.9589 0.0574 34.41 
Y12 1225.7706 1225.7162 0.0544 44.4 
Y7 713.483 713.4567 0.0263 36.83 
713.4831 713.4567 0.0264 36.97 
B62 7320.8214 7320.4257 0.3957 54.05 
B61 7249.7777 7249.3886 0.3891 53.67 
B60 7121.7084 7121.3301 0.3783 53.13 
B59 6990.6538 6990.2896 0.3642 52.1 
B58 6876.605 6876.2466 0.3584 52.11 
B57 6745.555 6745.2061 0.3489 51.72 
B55 6531 .4441 6531 .0744 0.3697 56.6 
B54 6418.306 6417.9903 0.3157 49.18 
B53 6305.2101 6304.9063 0.3038 48.19 
B52 6190.1693 6189.8793 0.29 46.84 
B48 5669.9543 5669.6988 0.2555 45.06 
B37 4196.2229 4196.0338 0.1891 45.08 
4196.2234 4196.0338 0.1896 45.2 
B35 3895.0977 3894.9275 0.1702 43.7 
B34 3766.0423 3765.8849 0.1574 41.79 
B33 3652.9468 3652.8009 0.1459 39.95 
3652.9517 3652.8009 0.1508 41.3 
B31 3480.8945 3480.7525 0.142 40.81 
B27 3074.7673 3074.5672 0.2001 65.07 
B23 2660.4736 2660.3558 0.1178 44.29 
B15 1760.933 1760.8693 0.0637 36.17 
1760.9346 1760.8693 0.0653 37.08 
B14 1631.8853 1631.8267 0.0586 35.9 






Natural and Synthetic Stimulators of the Immune Response 
Marine C. Raman and DominicJ. Cam popiano 
6.1 
Introduction 
Mammals have evolved sophisticated early-warning, self-defense systems to be 
ready to defend themselves against incoming pathogenic organisms. Once a 
pathogen has been detected, a vast battery of weaponry can be sent out to tackle 
the invader. This natural innate immunity is required to sense a range of patho-
gen-specific signals and set off an immunological response cascade that will lead 
to controlled killing and mediated cell death. Controlled inflammation is required 
and delicate balances must be maintained, since unnecessary stimulation and 
inflammation is highly dangerous and detrimental to the mammalian host. A 
range of stimuli are recognized by the innate immune system and in this chapter 
we concentrate on two that provide fascinating fields of study for microbiologists, 
immunologists, clinicians and chemists alike. Detailed molecular knowledge of 
"natural" stimulators and their protein receptors has begun to impact on the syn-
thesis of chemical tools with highly desirable ixnmunomodulatory properties 
which could have great clinical use. 
6.2 
El Lipopolysaccharide Endotoxin—A Potent Immunostimulatory Molecule 
Bacterial membranes are composed of lipids and proteins. The selective recogni-
tion of bacterial versus mammalian membrane components (nonself and self) is 
an important function of the immune system. Specific bacterial components can 
induce acute inflammatory responses via a number of sensitive cascades. One 
important molecule that has fascinated scientists for many years is lipopolysac-
charide (LPS), also known as "endotoxin". An excellent review of the story of the 
discovery, characterization and biological analysis of this molecule can be found 
in [1]. Endotoxin is a highly abundant proportion of the outer membrane of the 
Gram-negative bacterial cell wall and can also be shed by growing as well as dying 
Cellular and Biomolecular Recognition: Synthetic and Non-Biological Molecules. Edited by Raz Jelinek 
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cells. The discovery and characterization of endotoxin dates back over 100 years. 
At the end of the 1800s, Richard Pfeiffer showed that cholera bacteria that had 
been killed by heat retained their toxic potential. This experiment proved that the 
poison was not a classical protein toxin and led him to conceive the idea that Vibrio 
cholerae harbored a heat-stable toxic substance that was associated with the insol-
uble part of the bacterial cell. The active substance was named endotoxin (taken 
from the Greek endo meaning "within"). Pfeiffer postulated that these endotoxins 
were fundamental constituents of bacterial species. Chemical characterization of 
the endotoxins involved contributions from many researchers who devised 
methods to extract, purify and analyze this complex natural product (Osborn, 
Nikaido, Luderitz, Westphal, Boivin and Rietschel). 
Detailed chemical analysis ultimately revealed LPS to be organized into three 
parts—lipid A, core and 0-antigen. There are around 106  lipid A residues and iø 
glycerophospholipids per Escherichia coli cell [2]. The LPS from E. coli has been 
studied extensively to provide a model endotoxin architecture for comparative 
studies with those from other species. The lipid A (Kdo 2-lipid A) from a deep rough 
E. coli strain is shown in Figure 6.1 (compound 1). 
The lipid A is an usual glucosamine-based 31,6-linked disaccharide with long-
chain fatty acids attached to the 2 and 2' positions via amides. The 3 and 3' posi-
tions are also derivatized as fatty acid esters. Monophosphate esters are found at 
liii the 1 and 4' positions, and can be the site for further functionalization (see below). 
The 6' position links the glucosamine disaccharide to an unusual 3-deoxy-o-
manno-octulosonic acid (Kdo) disaccharide. To this Kdo is the site of attachment 
of heptose sugars that form part of the core region. Finally, the characteristic, 
bacterial-specific oligosaccharide 0-specific chain ("0-antigen") is attached to this 
core. 
A seminal breakthrough in the field of endotoxin research came in the 1980s 
when Kusumoto and Shiba synthesized E. coli lipid A, thereby confirming the 
structure of the isolated natural product. More importantly, this synthetic lipid A 
had identical endotoxic activity against mammalian cells as its bacterial counter-
part [3]. Thereafter began a series of structure—functional relationships to explore 
the nature of the inflammatory potential of this important bacterial toxin [4]. 
A large number of synthetic lipid A derivatives were prepared, but none were 
as active as the parent molecule. 
6.3 
LPS Recognition 
Various proteins have been sequentially discovered that generate a circuit that 
connects LPS recognition through cell surface receptor binding and intracellular 
signaling [5]. LPS-binding protein (LBP) is an approximately 60-kDa serum binding 
protein that belongs to the lipid transfer family. It is the LBP that binds the LPS 
in the blood and delivers it to the CD14 receptor that is present on many cell types, 
including macrophages and dendritic cells [6]. CD14 is a glycosyl phosphatidylino-
sitol-anchored, high-affinity membrane protein that can also circulate in a soluble 
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Figure 6.1 Chemical structures of lipid As. (1) Kdo 2 -lipid A, 
from a deep rough Strain of E. coli. (2) Lipid A from F. 
novicida U112. (3) Lipid A core from B. cepacia (dashed line 
represents non-stoichiometric substitution). 
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16 	 18 
2 
14 	 16 
3 
14 	
12 	14 	14 
1 
140 I 6 Natural and Synthetic Stimulators of the Immune Response 
form. Another protein involved in passing this signal onto cell-surface receptors 
Eli is myeloid differentiation-2 (MD-2) (see below). It is thought that CD14 concen-
trates LPS for binding to a Toll-like receptor (TLR) TLR4—MD-2 complex. How this 
complex recognizes lipid A and signals across the plasma membrane is still not 
completely understood [7]. Toll is a Drosophila fruit-fly receptor essential for the 
production of antimicrobial peptides in response to fungal pathogens that is also 
essential for fly development. This link in flies led to the isolation of a human 
homolog then the discovery of a family of mammalian transmembrane, Toll-like 
pattern recognition receptors. The Toll receptor has the characteristic modular 
structure of a type I transmembrane receptor: an ectodomain containing blocks 
of leucine-rich repeats (LRRs) and a conserved intracellular region, the 
Toll/interleukin (IL)-1 receptor domain, that is required for downstream signal 
transduction. In 1998, the direct link between LPS and the TLR4 receptor was 
made by Beutler et al. [who had previously isolated tumor necrosis factor (TNF)-(X] 
[8] and the expanding TLR family has been intensively studied over the past decade 
[7-12]. Specific TLRs have been shown to interact with RNA, DNA and many other 
ligands. The TLR4 pathway activates the key transcriptional regulator NF-iB, 
resulting in the production of proinflammatory cytokines and the progression to 
adaptive immunity. A complicated series of intracellular proteins are then 
expressed including MyD88, although a MyD88-independent pathway has also 
been discovered. The complex gene expression networks are highly regulated, and 
are now the target of various anti-inflammatory and autoimmune disease drugs. 
The details of LPS binding and signaling, and discussions of the TLR family have 
been the subject of a number of recent excellent reviews [5, 9, 12-151. 
6.4 
Septic Shock 
Sepsis is a systemic inflammatory response syndrome triggered by an infection 
and is the major cause of death in patients in intensive care units [16]. In severe 
cases it can lead to organ failure or dysfunction, and severe sepsis with hypoten-
sion unresponsive to fluid resuscitation defines septic shock. Sepsis syndrome 
results from the body's systemic inflammatory response to any of several infec-
tious stimuli. Endotoxins, such as LPS from Gram-negative bacteria and other 
antigens from infectious agents (e.g., DNA, peptidoglycan and flagellan, lipote-
choic acid, niannan) stimulate macrophages and monocytes to release TNF-a, 
resulting in a cascade of cytokine release [17]. Following the release of TNF-x, 
other proinflammatory cytokines, including IL-1 and IL-6, are released into the 
circulation that, in turn, trigger numerous additional proinflammatory events 
within endothelial cells and leukocytes. Although these proinflammatory responses 
are vital to the host defense against infection, TNF-ct acts in conjunction with IL-1 
to produce the clinical signs of the systemic inflammatory response syndrome, 
and their synergistic effects are probably responsible for the hypotension and 
resultant organ dysfunction seen early in the course of severe sepsis. Sepsis 
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syndrome afflicts almost 750 000 patients in the United States each year, costing 
almost $17 billion and causing 210000 deaths annually. Despite increasing 
research and accrued knowledge about the pathophysiological pathways and pro-
cesses involved in sepsis, morbidity and mortality remain unacceptably high. A 
large number of natural and synthetic immunomodulatory agents have been 
studied in experimental and clinical settings in an attempt to find an efficacious 
Eli anti-inflammatory drug that reduces mortality (see below [18]). 
6.5 
LPS Biosynthesis 
The efforts of Raetz et at. have delineated the biosynthetic steps involved in the 
synthesis of the lipid A core using E. coli as a model (see excellent reviews 
[19, 20]). There are nine enzymes required to convert the UDP-Glc-NAc sugar 
nucleotide precursor into Kd0 2-lipid A. Each enzyme has been named, the gene 
cloned and characterized to some extent at a biochemical or genetic level: LpxA, 
LpxC, LpxD, LpxH, LpxB, LpxK, WaaA, LpxL and LpxM. In the first step, the UDP-
Glc-NAc building block is acylated with an acyl-carrier protein substrate in 
a thermodynamically reversible step. Thereafter, an N-acyl deactylase irreversibly 
removes the acetate group which commits the UDP-sugar to the pathway. The 
N-acetyl glucosamine disaccharide is generated by cleavage of the UDP-
pyrophosphate of 1 mol of bis-acylated UDP-2,3-diacylglucosamine to give 2,3-
diacylglucosamine-1-phosphate (lipid X). Then another mole of bis-acylated 
UDP-2,3-diacylglucosamine is condensed with lipid X to give the disaccharide. 
Phosphorylation of the 4' position is then followed by the addition of the Kdo 
residue(s). This step is bacteria-specific and Kdo-transferase isozymes can add one, 
two or three Kdo residues. The product in E. coli, Kd0 2-IVa, with four fatty acids 
is then converted to the hexa-acylated Kdo 2-lipid A by two acyl-transferases. Since 
the early genes in the pathway are essential they have been identified as good 
targets for the development of new lipid A-specific antibiotics. One such antibiotic, 
CHI R-90, has been shown to be active against Pseudomonas aerugiwsa and F. coli. 
This is specific for the second enzyme, the deacetylase LpxC, and a recent structure 
of the LpxC/CHIR-90 complex has revealed the molecular details of the mechanism 
of inhibition thus paving the way for development of more potent agents [21]. 
6.6 
Minimal, Modified Lipid A 
Until recently, it was thought that the minimal LPS required for the growth of E. 
coti consisted of the lipid A core and disaccharide made up of two Kdo sugars (e.g., 
JI1 Figure 6.1a). However, recent work by Woodard et at. has challenged this 
dogma. Meredith et at. revealed that an E. coli K-12 nonconditional suppressor 
strain, KPM22, disrupted in D-arabinose-5-phosphate isomerase activity (through 
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manipulation of kdsD and gutQ) could not produce a LPS containing Kdo and thus 
generated the endotoxically inactive LPS precursor lipid IVa [22]. These cells grew 
and were viable, albeit that they were hypersensitive to large, hydrophobic antibiot-
ics (e.g., rifampin, fusidic acid, novobiocin and erythromycin) and sodium dodecyl 
sulfate. The cell wall of the mutant strain also showed unusual altered morphology 
in the inner and outer membrane cell walls. Interestingly, inclusion of the inner 
membrane LPS transporter MsbA on a multicopy plasmid partially suppressed the 
lethal Kdo knockout phenotype directly in the auxotrophic parent strain, suggest-
ing increased rates of nonglycosylated lipid A transport can, in part, compensate 
for Kdo depletion. 
It appears that bacterial species use a range of biosynthetic strategies to build 
lipid A derivatives that allows them to escape detection by the mammalian innate 
immunity surveillance system. This is exemplified by a recent study that revealed 
Frctncisellci tulcirensis, the causative agent of tularemia —a highly contagious disease 
of animals and humans, and the related mouse pathogen Frcincisellci novicida 
synthesize unusual lipid A molecules lacking the 4'-monophosphate group typi-
cally found in the lipid A of Gram-negative bacteria (Figure 6.1, compound 2). 
During lipid A biosynthesis LpxF, a selective phosphatase located on the periplas-
mic surface of the inner membrane, removes the 4'-phosphate moiety in the late 
stages of F. novicida lipid A assembly. To evaluate the relevance of the LpxF 
4'-phosphatase to pathogenesis, Raetz et al. constructed a IpxF deletion mutant 
and compared its virulence with the wild-type organism [23]. Intradermal injection 
of 1 x 106  wild-type F. novicida cells is lethal to mice, but 100-fold (1 x 10) mutant 
is not. The rapid clearance of the !pxF mutant was associated with a stronger local 
cytokine response and a greater influx of neutrophils compared with wild-type. 
Furthermore, the IpxF mutant was highly susceptible to the cationic antimicrobial 
peptide polymyxin. The authors conclude that LpxF represents a kind of virulence 
factor that confers a distinct lipid A phenotype, preventing Francise flu from activat-
ing the host innate immune response and preventing the bactericidal actions of 
host cationic peptides. Here, the loss of a simple phosphate moiety allows the 
bacterial pathogen to survive. This emphasizes how chemically sensitive the mam-
malian LPS detection is, but also suggests it can be "blindfolded" by a small 
modification [24]. 
It is now apparent that there is an increasingly diverse range of covalent modi-
fications that various bacteria use to decorate their lipid A core. This allows them 
to escape the mammalian immune system but also protects them from killing by 
lethal agents such as cationic antimicrobial peptide antibiotics (cAMPs) including 
mammalian defensins and bacterial polymyxins [polymixin B (PM B)] [25]. More-
over, bacteria can rapidly react to changes in their external environment (e.g., pH, 
NaCl concentration, as well as Mg 2 , Ca", Fe") and alter their metabolism to 
express lipid A-modifying enzymes. These enzymes have been shown to catalyze 
the transfer of, among other things, phosphoethanolamine (e.g., EptA and EptB) 
and the unusual sugar 4-amino-4-deoxy-L-arabinose (L-Ara4N; catalyzed by ArnT) 
onto the lipid A phosphate residues. Alteration of the fatty acid content of 
lipid A can also be achieved using acyl-transferases (e.g., PagP uses palmitate). 
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An excellent, in-depth review of this field has recently been published [26]. The 
sensing of environmental change that controls expression of the modification 
genes is complex, involving the interesting a two-component PhoP/PhoQ system. 
Detailed molecular, genetic and immunological analyses of this system and its 
role in Salmonella pathogenesis have been carried by out Miller et cii. over a number 
of years [27]. Unusual anomalies in lipid A biosynthesis continue to spring up—we, 
in collaboration with others, have studied the pathogen Burkholderia cepacici and 
related species, and their unusually high resistance to cAMPs and other clinically 
useful antibiotics. These organisms cause a range of clinical problems, especially 
to Cystic Fibrosis sufferers, and infection with certain strains leads to chronic lung 
inflammation and increased mortality. Burkholderici LPS is also highly inflamma-
tory and has unusual fatty acid and sugar content including L-Ara4N modification 
on the Ko octulosonic acid sugar (Figure 6.1, compound 3) [28, 291. Burkho!deria 
are able to modify both their lipid A core sugar phosphates and their inner core 
sugars by Ara4N presumably with two different transferases. It is interesting to 
also note that Burkholderia LPS cannot be neutralized by polymyxin and indeed 
the LPS/PMB complex has unusual properties [30]. Covalent L-Ara4N modification 
of LPS has been linked to increased cAMP resistance in F. coli and Pseudomortas 
aeruginosa, but the L-Ara4N biosynthetic pathway in these bacteria is not essential 
since deletion causes an increased cAMP sensitivity. In contrast, we found that 
the operon encoding the Ara4N biosynthetic genes in B. cepacia is constitutively 
expressed and that deletion of the L-Ara4N biosynthetic genes in strain K56-2 was 
lethal, suggesting that this pathogen has evolved to have an intrinsic requirement 
for this sugar [31]. We could not isolate sufficient quantities of LPS from the 
mutant strains to characterize the L-Ara4N content, but there appears to be no 
logical biochemical explanation as to why Burkholderia should need its lipid A to 
be covalently modified. It could be that L-Ara4N plays roles in other, as yet undis-
covered, metabolic pathways in this highly resistant pathogen. 
6.7 
Isolation of "Natural" Kdo 2-Lipid A 
Such is the importance of LPS in human biology that the National Institutes of 
Health and National Institute of General Medical Sciences awarded a 5-year, $35 
million grant in 2003 to fund a Lipid Metabolites And Pathways Strategy (LIPID 
MAPS) consortium led by Edward A. Dennis which included 18 universities, 
medical research institutes and companies across the United States [32]. They have 
worked together in a detailed analysis of the structure and function of lipids, and 
their work is published in major journals and online (see www.lipidmaps.org  and 
www.sphingomap.org). Their goal is to provide comprehensive procedures to the 
community for identifying all lipids produced by mammalian cells. They have 
begun with the macrophage, following activation by endotoxin, aiming to quantify 
temporal and spatial changes in lipids that occur with cellular metabolism, as well 
as to develop bioinformatic approaches that establish dynamic lipid networks. To 
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achieve these aims, a natural endotoxin of the highest possible analytical specifica-
tion was crucial. The LPS used by researchers in the immunology field are typically 
chemically heterogeneous mixtures obtained from bacterial strains such as E. coli 
or Salmonella typhimurhtm. These preparations have high inflammatory proper -
ties, but display batch-to-batch variability. An extremely useful tool has recently 
become available from the LIPID MAPS consortium. They recently reported the 
[II] isolation of Kdo z-lipid A, a nearly homogeneous Re LPS substructure with endo-
toxin activity equal to LPS [33]. The LPS was extracted from 2kg cell paste of a 
heptose-deficient E. coli mutant WBB06. This material is composed of six lipid A 
molecules with Kd02-lipid A present in 91% abundance (compound 1, Figure 6.1). 
The structure and purity were evaluated by electrospray ionization mass spectros-
copy, liquid chromatography mass spectroscopy and 1 H-nuclear magnetic reso-
nance (NMR), and its activity was compared with LPS in RAW 264.7 cells and 
bone marrow macrophages from wild-type and TLR4-deficient mice. Cytokine and 
eicosanoid production (e.g., TNF-(x), in conjunction with gene expression profiling 
were employed as readouts, and it was found that this material was as potent as 
LPS. The possibility of generating pure ' 3C-labeled Kd0 2-Lipid A should greatly 
facilitate NMR solution studies of complexes with MD-2 or CD14. This material 
is commercially available through Avanti Polar Lipids. 
6.8 
Synthetic LPS, Lipid A and Their Uses 
As knowledge of the molecular details of the host/pathogen interaction is increased, 
it is hoped that this could be transferred into useful clinical applications. One such 
expanding area is the adjuvant field. An effective adjuvant should help modulate 
or enhance the effects of an antigen (vaccine) and promote an immune response, 
but have no toxic side-effects itself. A recent reviews of this area was recently 
published [34]. These adjuvants could act upon a number of cells and receptors to 
illicit a range of responses, and have taken the form of TLR agonists. Others such 
as liposomes and mineral salts (e.g., aluminum hydroxide, alum) have been used 
extensively where their exact mode of action is still unclear. Again, an understand-
ing of what makes a pathogen able to escape detection as well as those with potent 
inflammatory properties could aid in adjuvant design. 
Since natural preparations are inherently heterogeneous (even the E. coli Kd0 2 -
lipid A has five other lipid A derivatives), synthetic preparations of single com-
pounds have proven useful tools to tease out the details of LP S recognition. A 
number of groups have developed synthetic routes to various lipid A derivatives 
and tested their activity against a range of cell types. It is around 20 years since 
Shiba et al. made synthetic lipid A derivatives and tested their activity [3]. A non-
toxic lipid A derivative from Salmonella Minnesota R595 lacking the 1-phosphate 
and fatty acid esters on the first glucosamine was chemically synthesized and this 
monophosphoryl lipid A (MPL) was shown to have low cytokine stimulation activ-
ity (Figure 6.2, compound 4). This further emphasized that hexa-acylation is a 
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Figure 6.2 Various synthetic lipid A analogs. (4) MPL (R = H 
or Cl 6). (5) Generic ACPs (R 1 , R2 , R3 , R4 range in change 
length, n = 1-7). In adjuvant RC529 R 1 = R2 = R3 = 
n-C13 H 27CO 3 R4 = H, n = 1. (6) Synthetic lipid [Va. 
prerequisite for endotoxin activity and that underacylated lipid As tend to be less 
immunologically active. The authors also probed fatty acid chain length, and used 
their strategy to prepare the MPL containing the all C14 hexa-acyl lipid A which 
had "intermediate" activity and toxicity. Stöver et at. used transcriptional profiling 
of human monocytes and responses of TLR4 transfectants to demonstrate a clear 
dependence of the length of the secondary acyl chain on receptor activation [35]. 
Also of interest is a MPL derivative with seven fatty acids that is being used as an 
adjuvant in therapeutic cancer vaccine trials [36]. 
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A range of monosaccharide lipid A derivatives have also been prepared and 
tested for biological activity (reviewed in [18].). In some cases the glucosamine 
saccharide core has been retained, whereas in others it has been replaced alto-
gether by an acylic derivative. Although penta-acylated monosaccharides tend to 
be inactive, some containing three acyl residues on a nonreducing monosaccha-
ride are endotoxic, but still 100 times less active than F. coli lipid A in TNF-a 
production, possibly due to its biophysical properties. To overcome these prob-
lems, a series of synthetic aminoalkyl glucosaminide 4-phosphonates (AGP5) has 
been investigated (Figure 6.2, compound 5). These glycolipid/LPS "hybrids" are 
based on a serine scaffold and it appears that the carboxyl group is a good isostere 
for the 1-phosphate of lipid A. A number of academic and industrial groups have 
explored the structure—activity relationships of these AGPs by changing esters for 
ethers, moderating chain length and optimization of the distances between func-
tional groups. This has led to the clinical use of RC-529 as a safe and effective 
adjuvant in a hepatitis B vaccine. 
Boons et at. have also developed elegant, highly convergent synthetic strategies 
to generate a range of useful lipid A analogs. They generate a "prototypical" lipid 
A from E. coli that is hexa-substituted in an asymmetrical fashion, as well as a 
derivative with several of its acyl groups having been shortened. They also synthe-
sized hepta-acylated lipid As derived from S. typhimurium LPS that differ in lipid 
length and phosphorylation pattern. Their strategy employed an advanced disac-
charide intermediate building block that could then be selectively modified with 
any lipid at the desired position [37]. The authors then exposed mouse macro-
phages to their synthetic lipid As and E. coli 055:B5 LPS, and the resulting super-
natants were examined for mouse TNF-a, interferon (IFN)-, IL-6, lP-10, RANTES 
(Regulated upon Activation, Normal T cell Expressed and Secreted) and IL-101. 
They found that particular modifications had different effects on the potencies and 
efficacies of induction of the various cytokines. However, no bias toward a MyD88-
or TRIF (Toll/IL-1 receptor domain-containing adaptor)-dependent response was 
observed, which emphasizes the fact that lipid A derivatives modulate innate 
immune responses in a highly complex manner. 
As well as tackling lipid A targets, Boons et at. have also examined the role of 
the Kdo moieties in enhancing the biological activities of LPS. They have also 
optimized the synthesis of a lipid A derivative containing Kdo and the strategy was 
employed for the synthesis of Neisseria. nseningitidis lipid A containing Kdo on the 
nonreducing sugar [38]. Mouse macrophages were exposed to the synthetic com-
pound and E. coli lipid A and a hybrid derivative that has the asymmetrical acyla-
tion pattern of F. coli lipid A, but the shorter lipids of meningococcal lipid A. The 
resulting supernatants were examined for TNF-a and 1FN43 production. The lipid 
A derivative containing Kdo was much more active than lipid A alone and just 
slightly less active than its parent LPS, indicating that one Kdo moiety is sufficient 
for full activity of TN F-a and IFN-P induction. The lipid A of N. rneningitidis was 
a significantly more potent inducer ofTNF-a and IFN-P than E. coti lipid A, which 
is due to a number of shorter fatty acids. The compounds did not demonstrate a 
bias towards a MyD88- or TRI F-dependent response. 
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A number of Japanese groups have also contributed greatly to the development 
of synthetic tools for studying lipid A activity [4, 39]. Various lipid A analogs, as 
well as their radiolabeled derivatives and more complex partial structures of LPS 
have also synthesized. For example, a Kd0 2-lipid A tetrasaccharide (Re LPS) has 
been synthesized and its IL-6-inducing activity tested. The synthetic Kd0 2-lipid A 
clearly showed that the addition of the Kdo residues enhances the potency of lipid 
A to activate the innate immune system. Their strategy also allowed the synthesis 
of 3 H-labeled LPS to study the stoichiometry of binding to various receptors (e.g., 
MD-2, TLR4). These synthetic LPS derivatives including molecules such as lipid 
IVa have also been used in high resolution structural studies (Figure 6.2, 	 - 
compound 6, and below) [40]. 
The neutralization of LP S to prevent toxic shock has also been a goal of synthetic 
chemists. There is growing literature in this field but, a recent example took a lead 
from the fact that the bacterial peptide natural product PMB binds and neutralizes 
LPS toxicity and is commonly used by immunologists. PMB is too toxic to be used 
clinically; however, based on the NMR-derived model of a PMB—LPS complex the 
authors designed a small molecule (a linked mono-alkyl spermine derivative) that 
binds LPS and neutralizes its toxicity with a potency indistinguishable from that 
of PMB in a wide range of in vitro assays. It also affords complete protection in a 
murine model of LPS-induced lethality and is apparently nontoxic in vertebrate 
animal models [41, 42]. 
Finally, LPS has been an attractive target for synthetic chemists to target sensi-
tive sensors to detect the presence of contaminating endotoxin in water and other 
fluids. For example, one group have prepared fluorescently labeled analogs of two 
peptide variants derived from the putative ligand-binding domain of the LBP CD14 
that detect and discriminate LPS and lipids down to the submicromolar concentra-
tion range [43]. In a different sensor approach fluorescent quantum dots coated 
with a zinc complex can selectively stain a rough LPS E. coli mutant and permit 




LBP, CD14 and FhuA 
It is hoped that knowledge of the high-resolution three-dimensional structures of 
various LBPs (e.g., MD-2, CD14 and TLR4) in complex with synthetic LPSflipid A 
ligands and their natural product ancestors will further guide the design of more 
specific, clinically useful molecules [45]. Furthermore, the structures of protein 
complexes will shed light on how these proteins signal to each other and generate 
the interlinked networks. A number of structural studies have been carried; these 
are too extensive to cover in this chapter, but we aim to pick out personal high-
lights. Efforts to reveal the molecular structures of LPSs from various organisms 
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and their interaction with bacterial and mammalian protein targets are time con-
suming due to the inherent heterogeneity of natural LPS and the fact that many 
of the protein receptors are membrane bound. 
The importance of LBP as the initial LPS binder has meant it has undergone a 
range of structural studies, but a high-resolution LBP/LPS structure has not been 
realized to date. However, the structure of a related human bactericidal/permea-
bility-increasing protein has been determined and has been used as a model for 
LBP [46]. A group of cationic residues at the N-terminus of LBP have been shown 
to be essential for LPS binding. Synthetic fragments of LBP (14 amino acids) have 
been used in NMR studies with LPS to reveal the LPS-binding epitope and aid 
design inhibitors [47]. 
The first structure of mouse CD14 (residues 5-313) was also recently published, 
albeit without a bound ligand (PDB code: 1WWL) [48]. The monomeric subunit 
of CD14 contains 13 n-strands and 11 of them overlap with conserved LRRs. The 
concave surface of the horseshoe-shaped structure consists of a large n-sheet of 
11 parallel and two antiparallel p-strands. The binding sites for LPS in CD14 have 
been intensively studied by mutagenesis and by epitope mapping of antibodies 
that block LPS binding, and four regions have been identified within the N-termi-
nal 65 residues of CD14. The most striking feature of the structure of CD14 is the 
N-terminal pocket that is located on the side of the horseshoe near the N-terminus 
and it is entirely hydrophobic except for the rim. The main pocket is both wide 
and deep with dimensions 8A wide x 13A long x bA deep; thus, overall, the 
pocket has a total volume of around 820A' and is thus large enough to accom-
modate at least part of the lipid chains of LPS. The authors propose that LPS would 
induce only small changes to the CD14 structure and we await the structure of 
such a complex. 
It was thought that the inherent conformational flexibility (and heterogeneity) 
would prevent crystallization of LPS, but over 10 years ago a breakthrough was 
made due to the serendipitous cocrystallization of LPS with a protein, FhuA, which 
is the receptor for ferrichrome-iron (Figure 6.3) [49]. FhuA is found in the outer 
membrane of E. coli, where, in addition to its crucial role in iron metabolism, it 
also functions as the primary receptor for the structurally related antibiotic albo-
mycin and for several bacteriophages. The authors were primarily interested in 
the structure and mechanism of action of FhuA, and to facilitate this they overex-
pressed the FhuA gene in E. coli with a surfaced-exposed six His-tag and extracted 
the protein from the outer membrane C12-DAO as a solubilizing agent. It turned 
out that crystallization of FhuA is dependent on the presence of stoichiometric 
amounts of LPS. In fact, if LPS is completely removed from FhuA protein prepara-
tions or if an excess of LPS is present in such preparations, the growth of FhuA 
crystals is inhibited. They propose that LPS remained bound to FhuA throughout 
the process of purification and crystallization, and that it did not adsorb to FhuA 
during isolation. Since it is known that LPS is localized to the outer leaflet of the 
outer membrane, the location of bound LPS marks its position relative to the upper 
aromatic girdle of FhuA and to the outer membrane. The single LPS molecule 
that is noncovalently associated with the membrane-embedded outer surface of 
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Figure 6.3 (a) Side view of FhuA with bound LPS. (b) Top view of same complex. 
FhuA exhibits the expected chemical structure for F. coil K-12 LPS (PDB code: 
1FCP, Figure 6.3). 
6.9.2 
MD-2/Lipid IVa Complex 
Recent structural analyses by Ohto et al. have begun to reveal the key features of 
LIPS recognition by essential components of the mammalian innate system. They 
presented crystal structures of human MD-2 alone and its complex with F. coil 
lipid IVa [401. Lipid IVa inhibits the effects of bacterial LIPS since it is similar in 
structure to lipid A (it is a lipid A precursor), but lacks two of the six fatty acids 
present on lipid A that is found in the LPS of E. coil or S. typhinis.rium. LPS is 
recognized by the receptor complex of MD-2 and T1R4. MD-2 is a 160-amino-acid 
glycoprotein and member of the MD-2-related lipid recognition family that forms 
a complex with TLR4 on the cell surface 15 01• It has been shown that MD-2 and 
the MD-2/TLR4 complex can bind LIPS with nanomolar affinity although LPS can 
bind to TLR4 alone. The recombinant human MD-2 used in the study was isolated 
from Pichia pcxstoris and treated with a glycosidase to produce a homogenous, 
monomeric protein. The structure of MD-2 alone and in complex with lipid IVa 
revealed that MD-2 displays a deep hydrophobic cavity sandwiched by two n-sheets, 
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(a) 	 (b) 	 (c) 
Figure 6.4 (a) Structure of ligand-free MD-2 rendered as a 
molecular surface showing cavity. (b) Structure of MD-2 with 
lipid IVa bound with MD-2 displaying il-sheet fold and lipid in 
chemical structure format. This shows penetration of fatty 
acids into cavity. (c) Structure of this complex rendered in 
molecular surface. 
The phosphorylated glucosamine disaccharide parts are located at the entrance 
to the cavity. MD-2 is folded into a single domain consisting of two sets of )3-sheets 
in a common immunoglobulin fold. The structures suggest that MD-2 plays a 
principal role in LPS recognition. These two sheets (made up of a three and six 
antiparallel strands) generate a large and deep hydrophobic cavity with a volume 
El big enough to accommodate the LPS molecule (dimensions of 15 x 8 x 10 A giving 
a volume of around 1710k). The ligand-free MD-2 cocrystallized with bound lipid 
molecules (which were presumed to be 3 x C14 myristic acids). In the MD-2/lipid 
IVa complex electron densities bound in the cavity were assigned to glucosamine 
disaccharide, 1- and 4'.phosphates, and four fatty acid chains. Comparison of the 
complex structure with the "unbound" (remembering that it has myristic acid 
bound) revealed very little conformational change upon LPS binding apart from a 
lysine residue at the cavity entrance. Overall, the MD-2 is cationic (p1 8.7) and two 
positively charged residues are at the entrance where they interact with hydrophilic 
parts of the lipid IVa. This positively charged entrance leads to the hydrophobic 
cavity (Figure 6.4c) that accommodates the four fatty acid chains. The 1- and 
4'-phosphates do not directly interact with MD-2 residues, which is a surprise since 
these ligands are essential for the inflammatory properties of LPS. MD-2 residues 
that are essential to the interaction with the TLR4 receptor are located at the cavity 
entrance. The lipid IVa-binding cavity of MD-2 shows some similarity to the larger 
hydrophobic cavity of CD14 [48], the protein that transfers LPS to MD-2. Of inter-
est, it appears that CDI4 can accommodate lipid A (with six fatty acid chains) due 
to this expanded cavity, whereas MD-2 cannot. Although lipid IVa is not a potent 
immunostimulatory molecule since it lacks the six fatty acids of lipid A, the MD-2/ 
lipid IVa complex provides a useful insight into the molecular details of the 
immune response and begin to answer the question "How does the mammalian 
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immune response recognize such diverse LPSs from the thousands of bacterial 
species?". 
In a complementary paper in the same issue of Science, Mata-Haro et at. also 
investigate the molecular basis of the interactions between LPS and its receptors 
[51). The exact molecular details are not yet known as to why certain lipid mole-
cules trigger an inflammatory response as opposed to others that do not. They 
report that, in mice, MPL interacts with the TLR4—MD-2 complex differently from 
LPS—they suggest that it is likely caused by the active suppression, rather than 
passive loss, of proinflammatory activity of this LPS derivative; it is thought that 
it only activates one part of the inflammatory signal cascade [TRIF and TRAM 
(TRIF-related adaptor molecule)] and results in T cell activation. They also suggest 
that MPL could be used as an adjuvant to stimulate the immune response but not 
cause adverse inflammation. 
6.9.3 
TLR4—MD-2 Complex 
Another recent breakthrough in the understanding of the molecular interactions 
between the partners involved in LPS detection has recently been published. En-
toran is a synthetic lipid A analog based on the LPS analog from Rhodobacter 
sphaerodies. It is a strong antagonist of the TLR4—MD-2 complex and is currently 
in phase III clinical trails for severe septic shock. The structure of the full-length 
ectodomain of the mouse TLR4 alone and in complex with MD-2 was determined 
using protein expressed in insect cells [52]. The TLR4—MD-2 form a 1: 1 complex 
in solution and in the crystals. The crystal structure shows that TLR4 is an unusual 
member of the "typical" subfamily of the LRR superfamily with a characteristic 
horseshoe-like structure whose concave surface is formed by parallel 3-strands and 
whose convex surface is formed by loops and 3 10 helices. Unlike other typical 
family members, analysis of the 3-sheet conformation of TLR4 demonstrates that 
it can be divided into N-, central and C-terminal domains and undergoes sharp 
structural transitions at the domain boundaries. The MD-2 adopts a n-cup fold 
with two antiparallel [i-sheets that contain three and six n-strands, respectively, 
similar to that found for the human MD-2. In comparison to the human protein 
the mouse MD-2 pocket is narrow and deep with a total surface area of around 
1000 A2 that could accommodate LPS. The structure of the complex provided 
insight into the surface of TLR4 that interacts with MD-2—it has along and narrow 
shape with dimensions 40 x 20A. It can be divided into two chemically and evo-
lutionarily distinct areas—the A and B patches. The A patch is negatively charged 
and evolutionarily conserved across other species, whereas the B patch is positively 
charged and located in a less-conserved area, although the residues directly inter-
acting with MD-2 are strictly conserved. The A and B patches of TLR4 are com-
posed of the residues in the concave surface derived from the "LxLxxN" part of the 
LRR modules in the N-terminal domain and of the central domain, respectively 
The interaction between TLR4 and MD-2 is also mediated by an extensive network 
of charge-enhanced hydrogen bonds. 
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Figure 6.5 The TLR4—MD-2—Eritoran complex. The TLR4 is in 
red, the MD-2 in green, and Eritoran in ball and stick. The 
TLR4 contains a TV3 hybrid domain at the C-terminus. 
To facilitate soluble expression and crystallization of the TLR4—MD-2 complex 
with bound ligands, the authors also developed a novel technique that they termed 
the "hybrid LRR technique". They produced fusion proteins—the variable lympho-
cyte receptor (VLR) proteins of hagfish were chosen as fusion partners because all 
VLR proteins have canonical LRR structures with sequence diversity in their vari-
able regions maximized. Among the hybrids, MD-2-bound TV3 was successfully 
crystallized with Fritoran and their complex structure was solved. They found that 
Eritoran binds to the hydrophobic pocket in human MD-2, and that there is no 
direct interaction between Eritoran and TLR4. The structure formed by the four 
acyl chains of Eritoran complements the shape of the hydrophobic pocket and is 
a very good fit since it occupies almost 90 0% of the solvent-accessible volume of 
the pocket, leaving only a narrow groove near its opening (PDB codes: 2Z65 and 
2Z64) (Figure 6.5). They used their fusion structures to also assemble a model of 
the human TLR4 protein and also used biochemical studies to study cross-linking 
of the complexes. This allowed them to propose three models for LPS-induced 
dimerization of the TLR4—MD-2 complex and favor one that fits with the biochemi-
cal data. Although Eritoran has a clear structural resemblance to LPS, it is an 
antagonist, whereas LPS is an agonist. Therefore, there must be significant differ-
ences in their modes of interaction. The molecular details of these differences 
await further structural analysis. 
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6.10 
Bacterial LPS.Binding Proteins 
As well as components of mammalian LPS detection and signaling, another area 
of intensive research is to understand the molecular details of processing of the 
lipid A and LPS intermediates during the bacterial biosynthetic pathway described 
by Raetz. Recent breakthroughs have come in the understanding how the lipid A 
is transported from where it is synthesized in the cytoplasm through the inner to 
the outer membrane in bacteria. MsbA is a member of the ABC transporter super-
family and is a lipid flippase that transports lipid A and LPS from the cytoplasmic 
leaflet (inward-facing) to the periplasmic leaflet (outward-facing) of the inner 
membrane. The structures of the MsbA from three different bacteria (E. coil, V. 
cholercie and S. typhimurium) in four various open and closed conformational states 
has begun to reveal the how bacteria process the LPS intermediates [53]. More 
recently the structure of a bacterial periplasinic transporter LptA has been 
determined-this protein is believed to act as a LPS shuttle (with MsbA, LptB and 
Imp/RlpB) between the inner and outer membranes [54]. 
6.11 
Sphingolipids- Essential Membrane Components of Mammals, Plants, Fungi, 
Yeast and Bacteria 
The sphingolipids were discovered over 100 years ago by Johann Thudichum who 
described an enigmatic "Sphinx-like" molecule, and since then numerous studies 
of their structure, function and metabolism have been described in the literature 
It was not until the middle of the last century that the chemical structure of 
the family of sphingolipids was determined by Carter et cii. [56]. They represent a 
large family of bioactive molecules, and are ubiquitous constituents of all eukary-
otic and some prokaryotic membranes. In association with cholesterol, they form 
lipid rafts that are implicated in signal transduction and membrane trafficking  
[57]. Their metabolites (such as ceramides) are also known to be involved in several 
cellular events such as proliferation, differentiation and apoptosis [58, 59]. Fur-
thermore, sphingolipid metabolites play a crucial action in various pathological 
processes including tumor cell angiogenesis (60]. For example, sphingosine-1-
phosphate (SIP) is a potent signaling molecule in eukaryotic cells and a focus of 
intense research since it has have been linked to various human diseases [61, 62]. 
The sphingolipids consists of a long-chain base (LCB), fatty acid and a polar head 
group. This amino alcohol core is decorated with a large variety of functionality 
and hundreds of sphingolipids are now known. 
Sphingolipids are found in several species and so assume that all of these 
species possess their own sphingolipid biosynthetic pathway (Figure 6.6). Mam-
malian, plant, yeast, fruit-fly, parasite and fungal sphingolipid pathways are well 
described, and many of the intermediates, genes and encoded enzymes have been 
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Figure 6.6 Abbreviated sphingolipid biosynthetic pathway 
showing the early steps and key molecules such as S1 P. 
identified. Comprehensive reviews of the yeast and plant pathways were recently 
published [63, 64]. Thematic reviews have recently been published in the Journal 
of Lipid Research (from May 2008 onwards) in honor of Professor Carter and also 
in Nature Reviews Molecular Cell Biology (February 2008). 
In summary, the early steps of sphingolipid biosynthesis appear to be highly 
conserved and the species-specific features occur after attachment of various N- 
acyl chains, hydroxylation at specific carbons and addition of complex sugars. Of 
intense recent interest has been the characterization of an unusual, growing 
family of Gram-negative bacteria that have an unusual membrane composi- 
tion-it was discovered that instead of the LPS described above for F. coli, their 
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Figure 6.7 Abbreviated reaction mechanism of SPT. 
The "Sphingomonads" include organisms such as Sphingomonas paucimobilis, 
Sphingobactcrium multivorum and Sphingobium yanoikuyae [66]. Since bacterial 
GSLs have similar core structures to their eukaryotic homologs it was assumed 
that the pathway would begin with the production of the common intermediate, 
3-ketodihydrosphingosine (KDS) from L-serine and palmitoyl-CoA. This reaction 
is catalyzed by the enzyme serine palmitoyltransferase (S PT; EC 2.3.1.50). Indeed, 
a bacterial SPT was isolated from S. paucimobilis by Ikushiro et al. in 2001 [67]. 
SPT catalyses the first and rate-limiting step of the sphingolipid biosynthetic 
pathway in all organisms studied to date [68]. The reaction is a pyridoxal-5'-
phosphate (PLP).dependent, decarboxylative, Claisen condensation of the amino 
acid L-serine and the long chain (C16) fatty acid palmitoyl-CoA, which produces 
KDS. SPT is a member of the cx-oxoamine synthase subfamily of PLP-dependent 
enzymes, which contains three other enzymes: 8-amino-7-oxononanoate synthase, 
5-aminolevulinate synthase and 2-amino-3-ketobutyrate-CoA ligase [69-74]. These 
enzymes generally catalyze the Claisen-like condensation between an amino acid 
and a CoA-thioester [75]. A common mechanism has been suggested [68, 74, 
76-79] comprising the following steps (Figure 6.7): (a) formation of an external 
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aldimine (H) via displacement of the lysine-PLP internal aldimine (I, holo-SPT) 
by the incoming amino acid substrate; (b) formation of a quinonoid intermediate 
(III) by abstraction of a-proton from the PLP-amino acid external aldimine; (c) a 
Claisen condensation with the fatty acid-CoA substrate followed by displacement 
of the CoA to form a -ketoacid (IV); (d) decarboxylation of this species to form a 
product quinonoid (V); (e) protonation of this quinonoid to form the product 
external aldimine (VI); and, finally (1) release of the u-oxoamine product and 
regeneration of the enzyme PLP-internal aldimine. The enzyme is assumed to go 
through a number of conformational changes as it proceeds through the reaction 
cycle of C—C formation, C—S bond cleavage and decarboxylation. More recent 
evidence for the reaction sequence shown was obtained using the elegant use of 
a CoA thioether analog, S-(2-oxoheptadecyl)-CoA. L-Serine deprotonation was 
accelerated more than 100-fold when this CoA substrate was added, suggesting 
remarkable substrate synergism [80]. 
SPT isozymes have been discovered in numerous organisms, such as mammals, 
fungi, yeast, bacteria and viruses, and sequence analysis of the encoded SPTs from 
various organisms suggests structural diversity across different isozymes [68]. For 
example, in humans and the yeast Sacchcromyces cerevisiae the SPT is formed by 
two different subunits (SPT1 and SPT2, encoded by the genes tcbl and lcb2, 
respectively), both of which are required for a functionally active enzyme. These 
two eukaryotic SPTs are predicted to contain large hydrophobic domains at their 
N- and C-termini, and are membrane-bound proteins, which has made their isola-
tion in high yield and purity particularly difficult. Sequence analysis revealed the 
SPT1 subunit to be devoid of active site residues, suggesting the SPT1/SPT2 dimer IM 
has only one active site, with the SPT1 subunit playing a regulatory role. The recent 
identification of a LCB3 gene expressed mainly in placenta (with homology to 
LCB2) suggests greater complexity to this important first enzyme in the pathway 
[81]. A viral SPT was also recently discovered where it appears that the LCB2 and 
LCB1 genes are fused head-to-tail to give a large SPT enzyme [82, 83]. 
Fortunately, a soluble homodimenc enzyme was isolated from S. paucimobilis 
—the structure of this enzyme was determined in our group (the first high-resolu-
tion structure of an enzyme from the sphingolipid biosynthetic pathway) and 
provides a useful tool for structural and mechanistic studies of the SPTs [67, 84]. 
The bacterial SPT consists of two monomers of45kDa and possesses two active 
sites at the subunit interface (Figure 6.8a).The cofactor PLP is bound into the active 
site through the formation of a Schiff base with a specific lysine residue (Lys265). 
The internal aldimine and other intermediates are stabilized by a group of specific 
catalytic residues. These residues (His159, Asp231 and His234) interact with PLP 
via it-7c stacking, hydrogen bonding or salt bridge (Figure 6.8b). Each monomer 
is able to bind a molecule of PLP, but the two subunits are required to obtain the 
active enzyme. 
The structure of the bacterial enzyme allowed a model of the human SPT1/SPT2 
heterodimer to be built using powerful bioinformatics methods. This model gave 
molecular insight into the cause of heredity sensory and autonomic neuropathy 
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Figure 6.8 Structure of S. paucimobilis SPT. (a) Overall 
dimeric structure. (b) Catalytic residues at the 
PLP-binding site. 
type I, a rare genetic disease that leads to progressive loss of peripheral nerve 
function. Mutations causing this disease are clustered on the Ichi gene and 
encoded S PT1 subunit, which is surprising since this subunit lacks catalytic resi-
dues [85, 86]. Studies of how these mutations impact SPT activity and sphingolipid 
metabolism are underway in a number of laboratories. 
Sphingolipid biosynthesis is a multistep pathway, with many species-specific 
branch points catalyzed by specific enzymes, so inhibitors of each step have the 
potential to be powerful drugs. A range of natural product inhibitors are known 
to inhibit the sphingolipid biosynthetic pathway. Myriocin inhibits directly SPT 
since it is thought to perfectly mimic the intermediate in the catalytic reaction 
between L-serine and palmitoyl.CoA. L-Cycloserine has also been shown to 
inhibit SPTs prokaryotes and eukaryotes. Other enzymes in the pathway from 
other organisms are also inhibited by interesting natural products -for example F 
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fumonisins inhibit ceramide synthase and inositol phosphorylceramide synthase 
(AUR1) is a target for the peptide aureobasidin in fungal cells. In fact, this 
pathway is a good antifungal target in general [87]. The regulation of SiP metabo-
lism in mammals is also a target for a number of potential therapies. 
6.12 
Natural Killer I Cells and GSLs 
As well as playing roles as membrane building blocks and signaling molecules, 
GSLs have recently been shown to be potent activators of the mammalian immune 
system via specific antigen receptors. The mechanism is somewhat different to 
the TLR4—LPS interaction. Natural killer T (NKT) cells are a sublineage of natural 
memory T cells that share properties of both T lymphocytes that were discovered 
over 10 years ago. Excellent, comprehensive reviews of the NKT field have been 
published [88, 89]. GSLs are presented by CD1d molecules on antigen-presenting 
cells (e.g., dendritic cells) to NKT T cell receptors (TCRs), leading to production 
of several cytokines including IFN-y [T helper type (Thi) response] and IL-4 [T 
helper type 2 (Th2) response] (Figure 6.9). CD1d is part of the CD1 family, major 
histocompatibility complex-like molecules that evolved to capture lipid antigens 
for display at the surface of antigen presenting cells. CD1 genes encode five CD1 
molecules in human (CD1a, CD1b, CD1c, CD1d and CD1e) and two homologs in 
mice (CD1d1 and CD1d2). CD1d, involved in GSL transport, associate with con-
served semi-invariant human V24—J18/Vp8 (V = "variable" and J = "joining") or 








 helper 2 9 IL-4 APC T IL-10 
Figure 6.9 Schematic of the interaction between the Cold 
receptor found on antigen-presenting cells (APC, e.g., 
dendritic cells), with presented antigen (GSL) and the NKT 
TCR, and examples of released inflammatory cytokines. 
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6.13 
GSL Antigens 
Screening for products with antitumor activities, Kirin Pharmaceuticals identified 
the first ligand for the NKT TCR. This was a natural product (Agelasphin 9b, 
Ii] Figure 6.5a) extracted from the marine sponge Agelas mauritianu and structural 
studies of the molecule identified it as a GSL [90, 911. This compound was 
unusual due to its a-glycosidic linkage instead of the n-linkage present in mam-
malian glycolipids. In order to increase its potency, structure—activity relationship 
studies were carried out on a range of agelasphin derivatives. They simplified the - 
sphinganine chain and added two more carbons on the acyl chain. After modifi- 
cation of the saccharidic hydroxyl groups they found that the 4'-OH played a 
minor role and that the 3'-OH was necessary for optimal activity. Extension of the 
N-acyl fatty acid chain led to the final compound named KRN7000 or U-
galactosylceramide (a-GalCer) (Figure 6.10) [92]. This GSL is still one of the most 
potent agonists known for NKT TCR. A number of synthetic GSL variants were 
also made (including both mono- and disaccharides) to begin to explore the 
nature of the receptor—ligand interaction [93]. Since then extensive synthetic 
libraries have probed the molecular details to an even greater extent (see below). 
Very recently, Chung et at. explored the stereoselectivity involved by the synthesis 
of each of all eight stereoisomers of KRN7000 and presentation of their biological 
activities [94]. 
The fact that U-GalCer was extracted from a marine sponge raised doubts about 
its physiological significance and it seems illogical that the mammalian immune 
system would evolve a defense mechanism against a product from a marine 
species. It is interesting to speculate that since the sponge Algea mauritianus could 
have been contaminated by a-proteobacteria, the original glycolipid a-GalCer 
isolated could be in fact of bacterial origin from a symbiotic organism. Numerous 
studies searched for other natural product antigens for TCRs, which led to the 
.... 	2 
Figure 6.10 Structure of agelasphin 9b (7) and a-GaICer (KRN7000, 8). 
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Figure 6.11 Structures of endogenous and exogenous ligands 
9 (iGB3) and GSLs of bacterial origin (10-12). 
discovery of an endogenous ligand, isoglobotrihexosyl ceramide (iGB3), as well as 
exogenous ligands from bacteria (Figure 6.11). 
iGB3 was identified as the endogenous ligand by various studies on mutant 
mice. The first study by Stanic et al. concerned mice deficient in 13-D-
galactosylceramide (13-D-GalCer)  or -D-glucosylceramide (-D-GlcCer) [95]. Sur-
prisingly, -D-GalCer-deficient mice (produced by knocking out -D-GalCer 
synthase) developed normal NKT cells and were able to activate NKT hybridomas. 
In contrast, 3-D-GlcCer-deficient cells failed to react with the same hybridomas 
and the addition of f-D-GlcCer synthase restored the recognition. However, direct 
addition of f3-D-GlcCer to NKT TCR did not result in the activation of the receptor. 
Work by Zhou et cii. showed that mice deficient in t3-hexosaminidase B were also 
deficient in NKT cells. [3-Hexosaminidases B are responsible for degradation of 
G134 and iGB4 to GB3 and iGB3 respectively. NKT cell stimulatory properties were 
tested with the two last molecules and only iGB3 led to a positive stimulation [96]. 
These analyses of self/nonself stimulators greatly expanded using the fact that 
sphingomonad-derived GSLs and mycobacterial lipids had been shown to activate 
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the immune system via NKT cells. Lipids from various species and strains have 
been tested for example, the mycobacterial lipid phosphatidylinositol mannoside 
was reported by Fischer et al. to stimulate a modest cytokine release from NKT cells 
[97]. More efficient NKT activators isolated from Sphingomonas possesses GSLs 
with mono-, di-, tn- and tetrasaccharide units. They present an a-glycosidic linkage 
similar to the a-GalCer isolated in A. mauritianus. GSL-1 can contain galactose or a 
glucose sugar and unlike c-GalCer can also have a carboxylic acid functional group 
on the saccharidic C6 instead of a hydroxyl group. GSL-1 and GSL-4 (Figure 6.11, 
compounds 10 and 12) have shown high stimulatory activity against NKT TCR. 
6.14 
Structure—Activity Relationships 
Since it now known that natural endogenous and exogenous GSLs are able to 
activate the mammalian immune system, it makes these molecules attractive 
targets as therapy against numerous diseases. However, the caveat must be that 
care must be taken to generate a molecule having only therapeutic benefits and 
no stimulatory side-effects. NKT cells have been implicated in several immune 
responses, including pathogens, tumors, tissues grafts, allergens and autoanti-
gens. From these observations, several groups have worked on the modification 
of the a-GalCer agonist in order to increase the affinity/activity of this compound. 
Furthermore, activation of NKT cells leads to production of two types of biological 
response. When a-GalCer binds to TCR, IFN-y (Th i) and IL-4 (Th2) are released 	 iz 
in the cell. Several studies have shown that specific modification of the GSL 
chemical structure can lead to specific activation of one or the other response. 
The a-GaICer structure can be separated in two parts: the sugar moiety and the 
lipid chains. Both of them contain functional groups that can be modified and play 
a role in the interaction with CD receptors and NKT TCRs. Over the years, a mul-
titude of modifications have been tested and the results obtained permit a better 
understanding of the structure—activity relationship between the G S L ligands and 
their receptor. An excellent recent review of this growing literature has recently 
appeared [98]. The a-GalCer designed by Kirin group possesses a galactose sugar 
moiety, a sphingosine chain (C 18 1-1 34) and acyl chain (C 26H 51 ) as the lipid part. The 
hydroxyl groups as well as the glycosidic linkage are numerous points of modifica-
tion for the polar head. Concerning, the lipid chains, the length, the degree of 
unsaturation, as well as the two hydroxyls carried by the sphingosine part allow 
several possibilities of modification. 
6.15 
Saccharide Modification 
A relatively simple change replaces the galactose by a glucose or a mannose [99] 
(Figure 6.12, compounds 13 and 14). The anomeric configuration was tested as 
well, by synthesis of an a-GalCer (compound 15). It was observed that the glucose 
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Figure 6.12 GSL variations (13-21). 
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analog has a weak agonist activity, and mannose and -Ga1Cer analogs have no 
activity at all. The different OH positions have been investigated and each of them 
gave rise to different results. The 2'-OH position has been substituted by a diverse 
range of functional groups (compounds 16 and 17) and in every case the activity 
toward TCRs is lost [100, 101]. 
In contrast, the 3'-OH can accommodate changes such as the sulfate (compound 
18) [101]. The 6'-OH position is quite tolerant of other functional groups (COOH) 
(Figure 6.11, bacterial GSL-1, 10), a second sugar (compound 19) or affinity probes 
(biotin, compound 20).The diverse modifications made on the sugar moiety 
described above affected the recognition with the CD1 receptor part of the complex. 
The degree of activity was measured against the u-GalCer standard". No specific-
ity toward Thi or TO release was noticed. However, Schmieg et al. and Yang et at. 
synthesized two C-glycoside analogs and observed that these compounds were able 
to stimulate specifically a TO response (compound 21) [102, 1031. Furthermore, 
this compound showed an activity 1000 times superior compared with a-GalCer 
and this increase of potency was explained by the longer stability of the compound 
in the cells. Effectively, a-GalCer and other 0-glycosides can be cleaved by 
glycosidase which is not the case for C-glycosides. 
6.16 
Ceramide Modification 
In their library of synthetic GSLs, Sidobre et at. also probed the 3- and 4-sphingo-
sine positions by substitution with H (Figure 6.13, compounds 22 and 23) [99]. 
They reported that they were both involved in CD1d interaction and their substitu-
tion leads to destabilization of the complex, with a total loss of activity concerning 
the substitution of the 3-OH group. Miyamoto et al. first examined the effect of 
lipids chain truncation and synthesized three new compounds [100]. One of them, 
OCH (compound 24), induced a Th2 bias response of NKT cells. Several other 
truncated cz-GalCer derivatives have been synthesized over the years with the addi-
tion of small modifications such as insertion of unsaturation [101, 104-1061. Two 
particular compounds (25 and 26) have shown similar behavior than OCH, leading 
to a specific Th2 response. It has been suggested that this specificity could be 
explained by the fact that IFN-y (Thi) needs longer stimulation of NKT cells than 
IL-4 (Th2) to be released [107]. Shorter chain analogs of a-GalCer or removal of 
OH groups leads to destabilization and shorter life time of the glycolipids—CD1d 
complexes, resulting in shorter stimulation of NKT cells. 
6.17 
High-Resolution Structural Analysis of Receptor—GSL Complexes 
Recent breakthroughs in the determination of the structures of the receptor- 
GSLs complexes has greatly increased our understanding of the nature of the 
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Figure 6.13 Ceramide modifications (22-26). 
immunostimulatory properties of the various antigens. Numerous structural anal-
yses have been performed on CD1d and NKT TCR. Both have been studied by 
alone, as well as with ligand-free, ligand-bound and in complex with each other. 
The different interactions and recognition systems between the CD1d—TCR and 
different glycolipids have been investigated by various groups [108-111]. Presented 
here are the structures of the human CD1d—a-GalCer complex (exogenous ligand, 
PDB code: 1ZT4) [109] and CD1d—a-GalCer—TCR [111], the mouse CD1d—iGB3 
complex (endogenous ligand, PDB code: 2Q7Y) and a model of its interactions 
with TCR [1121. 
The human CD1d protein structure was reported in 2005 by Koch et al. They 
discuss the structural changes between the ligand-free and ligand-bound protein, 
as well as the similarities existing between the mouse and the human CD1d. The 
CD1d protein consists of two large domains (a and 2M). Three helices cxl, a2 
and a3 form the heavy chain (cc) of CD1d that is responsible for GSL binding. The 
antigen-binding site is composed of a large hydrophobic groove allowing the fitting 
of a-GalCer lipid chains. The acyl chain (C26) binds into pocket A' in a counter-
clockwise circular curve, filling the whole of the pocket. A second channel C' 
(human) or F' (mouse) allows the binding of the sphinganine chain (C18) in a 
more linear conformation (Figure 6.14a). 
The galactose ring is located at the surface of the protein and stabilized by spe-
cific interactions. Three hydrogen bonds are involved in the stabilization of the 
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Figure 6.14 Human CD1d structure. (a) Binding of the GSL. 
Direct interaction of the GSL 2'-OH with AsplSl 
antigen. The 3'OH of the sphingosine chain interacts with Asp80 and the glycol 
linkage 1'-0 forms a hydrogen bond with Thr154. Finally, the galactose ring is 
correctly oriented for TCR recognition by interaction of the 2'OH with Asp151 
(Figure 6.14b). The "ligand-free" CDId is highly similar to the a-GalCer-bound 
complex. The main difference concerns the binding groove which is noticeably 
wider (1 A difference between the Ca chains) than in the lipid-bound form. It may 
be possible that CD1d adopts a unique "open" conformation to interact and load 
lipids. The comparison of human and mouse structures showed that they were 
highly similar, although some subtle differences in the mouse structure were 
observed, the ability to specifically bind a-GalCer and its recognition by TCR are 
not compromised. The ligand-binding pockets are similar in size and hydrophobic-
ity, and residues involved in galactose and alkyl chain binding are conserved. 
Recently, Rossjohn et al. successfully crystallized the human complex CD1d—cz. 
GalCer—TCR (PDB code: 2P06) giving a first insight into the GSL, TCR and CD1 
interactions [1111. The TCR is a semi-invariant protein that comprises an invariant 
a-chain and a restricted TCR 3-chain repertoire. The NKT TCR adopts an unusual 
parallel docking mode in its interactions with CDId (Figure 6.15a). Contacts 
between the two proteins are made via the V chain and the Vp chain of TCR and 
al-helix and a2-helix of CDId. More specifically, two TCR loops, CDR30C and 
CDR2, are responsible for the CD id-restricted response. A number of arginine 
residues from both partners, Arg79 (CDId), Arg103 and Arg95 (CDR3a), are 
involved in a complex hydrogen bond network permitting the specific recognition/ 
activation of NKT TCR by CD1d—a-GalCer. The strong positive charged created 
by the group of arginines is dissipated by negative residues including Asp94 
(CDR3(x) and Asp80 (CD1d). Previous mutational studies of these residues on 
mouse CD1d led to the inactivation of NKT TCR [113-115]. 
a-GalCer protrudes outside of CD1d, and interacts only with the CDR1a and 
CDR3a loops of TCR. The galactose ring is sandwiched between Trp153 of CD1d 
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Figure 6.15 (a) Structure of the human NKT TCR—a-GalCer-
CD1d complex (NKT TCR: cyan and green; CD1d: yellow, 
purple and orange; ligand: ball and stick. l21VI = 
-microglobulin. (b) Close-up view of the interface between 
the proteins and ligand [colors same as in (a)]. 
Arg95 is also involved in stabilization of the lipid part by forming a hydrogen bond 
with the 3'-OH group of the sphingosine chain. The three sugar hydroxyl groups 
are involved in specific hydrogen bonds with the a invariant achain of TCR. The 
2'-OH interacts with G1y96iz (CDR3(x), 3'-OH and 4'-OH have contact with Ser30a 
and Phe29a (CDRIa). This specific hydrogen bond system is in correlation with 
u-GalCer high affinity for TCR (Figure 6.15b). The a-glycosidic linkage allows a 
strategic orientation of the sugar head and the presence of a n-linkage would lead 
to a more perpendicular orientation creating perturbations in CDRI(X interactions. 
Curiously, a cross-reactivity between human TCR and mouse CD1d (and the 
converse) have been observed. Indeed, it was proved that mouse CD1d—a-GalCer 
were able to bind and activate human NKT TCR and human CD1d—a-GalCer 
bind to mouse TCR. This cross-reactivity is easily understandable by comparison 
of both human and mouse a-GalCer—TCR interactions. All residues and interac-
tions involved in antigen recognition are conserved. 
Comparison of the TCR structure with and without CD1d—a-GalCer reveals that 
no large conformational changes takes place. The TCR protein appears to present 
a rigid lock and key" conformation, attributable to strong intermolecular interac-
tions between the CDR loops in the ligand.free TCR. 
Most recently, Zajonc et al. have solved the structures of the mouse CD1d—iGB3 
complex and the mouse TCR (PDB codes: 2Q7Y and 2Q86 for CD1d—iGb3 and 
TCR, respectively). By analogy with the human CD1d—cx-GalCer—TCR, they pro-
posed two models to explain the interactions between the endogenous ligand and 
1CR [112]. 
The stabilization of the lipid chains in CDId—iGB3 complex is very similar to 
that observed in CDld—u-GalCer. The most differences are, as expected, located 
at the interface between CD1 and the saccharidic moiety. The polar head group is 
still solvent exposed and only the proximal glucose is well ordered. The second 
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Figure 6.16 (a) CD1d and iGB3 specific interactions. (b) 
Superposition of human CD1d—a-GaICer (green) and mouse 
CD1d—iGB3 (cyan) structures. 
glucose and the galactose are highly flexible, and do not interact with CD1d. The 
group of residues involved in the first glucose stabilization is totally different to 
those used for the galactose binding in CDId-a-GalCer complex. The two hydroxyl 
groups, 2'-OH and 3'-OH, form H-bonds with Asp153 and G1y155 (water medi-
ated), whereas the lipid chains interact with Asp80 and Met69 (Figure 6.16a). 
The TCR crystal obtained by Zajonc et al. possesses two TCR molecules in the 
asymmetric unit. Superposition of the molecules reveals a change in the confor-
mations of CDR loops, especially CDR3z and CDR30. Furthermore, by alignment 
of mouse and human TCR, the same conformational differences appear, whereas 
CDR1 loops stay very similar. As in other TCRs, CDR3 domains are known to 
interact with the ligand-this flexibility in the unbound structure may reflect their 
capacity to recognize different ligands. 
In order to understand the interaction between the CD1d-iGB3 complex and 
TCR, Zajonc et al. made a model where they positioned the TCR and CD1d in the 
exact same position as in the human structure with ci-GalCer. However, this model 
reveals serious steric clashes between iGB3 and several TCR residues. This can be 
explained by the structural differences between iGB3 and ct-GalCer (three versus 
one sugar). From these first results, they proposed two new models to obtain a 
better fit of iGB3 between the CD1d and TCR. 
In the first, they described a "cavity" model where the mouse TCR presents a 
large and deep positive binding pocket. This cavity formed by the CDR3u and 
CDR3P loops would be able to fit the two "free" sugars ofiGB3. In a second model, 
the three sugars of iGB3 are positioned between the CD1d and TCR. In this 
"squashed" model, the parallel orientation of CD1d along TCR as well as the 
interactions between CD1d and TCR described in the human structure are con-
served. Each of these models allows us to probe the different ligand-binding 
constraints existing in the human structure; however, both of them have limita-
tions. In the "cavity" model, the CDR30 flexibility permits TCR adaptability 
towards various ligands; however, it is commonly accepted that CDR30 is not 
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involved in ligand recognition. On the other hand, the "squashed" model requires 
bond breaking/reforming to orient the polar group properly, which is energetically 
unfavorable. 
Recent studies have begun to shed light on the role of the tetrasaccharide and 
sphingosine units found in many naturally occurring GSLs derived from Sphin-
gomonads. Kinjo et at. made synthetic GSL-4A derivatives varying the nature of 
the tetras accharide, as well as generating G SLs with different lipid chains [116]. 
Since the initial studies of the effect of GSLs on NKT cells used material isolated 
from bacteria (probably a heterogeneous mixture) it was therefore important to go 
back and test homogeneous, synthetic versions of these antigens. In contrast to 
earlier studies, GSL-4A showed weak activity and the GSL-4B was inactive. Long 
et at. had also used synthetic GSL-1, GSL-2, GSL-3 and GSL-4 (as well as various 
lipid hybrids) to show that only the monosaccharide GSLs are potent antigens. 
Furthermore, they probed whether these higher order GSLs could be metabolized 
by various cell types. It may be that Sphingomonads and other bacteria have 
evolved a sugar coat to avoid detection by the immune system. 
6.18 
Conclusions 
In both the LPS/endotoxin and GSL fields combinations of natural product chem-
istry, synthetic chemistry, structural biology, microbiology, immunology and 
genetics have begun to reveal the molecular interactions involved in the innate 
recognition between colonizing bacterial cells and their mammalian host. The 
exact details of what makes one microbe a beneficial symbiotic partner and another 
a life-threatening pathogen are beginning to emerge. These details are also opening 
our understanding of the nature of the inflammatory response and its links to a 
range of autoimmune diseases. 
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The External Aldimine Form of Serine Palmitoyltransferase 
STRUCTURAL, KINETIC, AND SPECTROSCOPIC ANALYSIS OF THE WILD-TYPE ENZYME AND 
HSAN1 MUTANT MIMICS* 
Received for publication, March 16,2009, and in revised form, April 15,2009 Published, JBC Papers in Press, April 17,2009, DOI 10.1 074/jbc.M109.008680 
Marine C. C. Raman*l2,  Kenneth A. Johnson 51 , Beverley A. Yard 2 '3 , Jonathan Lowther, Lester G. Carter 5 , 
James H. Naismith 54, and Dominic J. Cam popiano*2 .3 .1  
From *EaStChem,  School of Chemistry, University of Edinburgh, Edinburgh EH9 3JJ and 5EaStChem, Scottish Structural Proteomics 
Facility, and Centre for Biomolecular Science, University of St. Andrews, Edinburgh KY16 9RH, Scotland, United Kingdom 
Sphingolipid biosynthesis begins with the condensation of 
L-serine and palmitoyl-CoA catalyzed by the PLP-dependent 
enzyme serine palmitoyltransferase (SPT). Mutations in human 
SPT cause hereditary sensory autonomic neuropathy type 1, a dis-
ease characterized by loss of feeling in extremities and severe pain. 
The human enzyme is a membrane-bound hetereodimer, and the 
most common mutations are located in the enzymatically incom-
petent monomer, suggesting a "dominant" or regulatory effect. 
The molecular basis of how these mutations perturb SPT activ-
ity is subtle and is not simply loss of activity. To further explore 
the structure and mechanism of SPT, we have studied the 
homodimeric bacterial enzyme from Sphingomonaspaucimobi-
us. We have analyzed two mutants (N100Y and N100W) engi-
neered to mimic the mutations seen in hereditary sensory auto-
nomic neuropathy type 1 as well as a third mutant N100C 
designed to mimic the wild-type human SPT. The N100C 
mutant appears fully active, whereas both N100Y and NIOOW 
are significantly compromised. The structures of the holoen-
zymes reveal differences around the active site and in neighbor-
ing secondary structure that transmit across the dimeric inter-
face in both N100Y and N100W. Comparison of the L-Ser 
external aldimine structures of both native and N100Y reveals 
significant differences that hinder the movement of a catalyti-
cally important Arg378 residue into the active site. Spectroscopic 
analysis confirms that both N100Y and N100W mutants subtly 
affect the chemistry of the PLP. Furthermore, the N100Y and 
R378A mutants appear less able to stabilize a quinonoid inter-
mediate. These data provide the first experimental insight into 
how the most common disease-associated mutations of human 
SPT may lead to perturbation of enzyme activity. 
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Sphingolipids are ubiquitous constituents of eukaryotic cells, 
where they play important roles in signaling, differentiation, 
and apoptosis (1-4). Defects in sphingolipid catabolism have 
been linked to several human diseases, such as hypertension, 
cancer, and disorders of the peripheral nervous system. The 
most common inherited peripheral neuropathy is hereditary 
sensory autonomic neuropathy type 1 (HSAN1). 6 The disease 
leads to progressive loss of sensation in extremities and is often 
associated with searing pain (5— 8). Genetic studies by two inde-
pendent groups mapped the disease-associated mutations to 
the lcbl (long chain base 1) gene on chromosome 9q22, which 
encodes the SPT1 subunit of serine palmitoyltransferase (SPT; 
EC 2.3.1.50) (9-11). SPT catalyzes the first and rate-limiting 
step of the sphingolipid biosynthetic pathway in all organisms 
studied to date (12). The reaction is a pyridoxal 5'-phosphate 
(PLP)-dependent, decarboxylative, Claisen condensation of the 
amino acid L-serine and the long chain (C16) fatty acid palmi-
toyl-CoA, which produces the sphingolipid precursor, 3-ke-
todihydrosphingosine (KDS). 
SPT belongs to the a-oxoamine synthase subfamily of PLP-
dependent enzymes, which contains three other well character-
ized members: 8-amino-7-oxononanoate synthase (AONS) 
(13, 14), 5-aminolevulinate synthase (ALAS) (15-17), and 2-
amino-3-ketobutyrate-CoA ligase (KBL) (18). These enzymes 
catalyze the Claisen-like condensation between an amino acid 
and an acyl-coenzyme A thioester (19). A common mechanism 
has been proposed (12, 14, 20-23) comprising the following 
steps: formation of an external aldimine via displacement of the 
lysine-PLP internal aldimine (holo-SPT) by the incoming 
amino acid substrate; formation of a quinonoid intermediate by 
abstraction of the a-proton from the PLP-amino acid external 
aldimine; a Claisen condensation with the fatty acid-CoA thio-
ester substrate, followed by displacement of the CoASH to form 
a 13-ketoacid intermediate; decarboxylation of this species to 
form a product quinonoid; protonation of this quinonoid to 
form the product external aldimine; and finally release of the 
a-oxoamine product and regeneration of the enzyme PLP-in-
ternal aldimine (Fig. 1). Structural studies have shown AONS, 
ALAS, and KBL isoforms from various species to be 
The abbreviations used are: HSAN 1, hereditary sensory autonomic neurop-
athy type 1; SPT, serine palmitoyltransferase; PLP, pyridoxal phosphate; 
KDS. 3-ketodihydrosphingosine; DTNB, 5,5'-dithiobis-2-nitrobenzoic acid; 
r.m.s., root mean square; AONS, 8-amino-7-oxononanoate synthase; ALAS, 
5-aminolevulinate synthase; KBL, 2-amino-3-ketobutyrate-00A ligase; 
PEG, polyethylene glycol. 
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FIGURE 1. Proposed catalytic mechanism of SPT. a, the internal aldimine (holo-SPT) is displaced by L-serine to form the external adlimine; b, binding of second 
substrate palmitoyl-00A causes conformational change to give the Dunathan intermediate; c, formation of the quinonoid by deprotonation of Ca hydrogen; 
d, thioester bond hydrolysis and release of CoASH to give 13-keto acid intermediate; e, decarboxylation to form KDS product quinonoid; 1, reprotonation to form 
KIDS product external aldimine; g, KDS product release and reformation of the holo-form. The L-serine external aldimine has been trapped in the current study. 
The dotted line shows that steps e and I maybe bypassed by an alternative mechanism that does not proceed via a product quinonoid (see Ref. 21). 
homodimers (13, 17, 18). In marked contrast, eukaryotic SPTs 
are heterodimeric, membrane-bound proteins consisting of 
two subunits, SPT1 and SPT2 (encoded by the lcbl and 1cb2 
gene, respectively) (24). 
Analysis of a number of HSAN1 patients has revealed the 
four most common mutations to be C133W, C133Y, V144D, 
and G387A, with the cysteine mutations appearing to be the 
most prevalent in populations (10, 25). The impact that these 
mutations have on SPT activity and sphingolipid metabolism 
has been the focus of attention by a number of groups. Most 
surprisingly, these disease-associated mutations occur in the 
SPT1 monomer, a protein that must be inactive, since it lacks 
the key lysine, histidine, and aspartate residues necessary to 
bind and stabilize the PLP cofactor. It is the SPT2 protein that 
contains the conserved, active site lysine residue that forms a 
Schiff base internal aldimine with the PLP. However, both sub-
units are essential to produce functionally active SPT het-
erodimer (26-29), indicating that the inactive subunit has a 
crucial role in function. Dunn and co-workers (30) created sev-
eral mutations in the yeast lcbl and lcb2 genes, including those 
corresponding to the HSAN1 SPT1 mutations, and found that  
they dominantly inhibit SPT activity. A transgenic mouse 
model also revealed that the LCB1 C 133W mutation led to mice 
with decreased tissue SPT activity and HSAN1 symptoms 
despite unaltered ceramide concentrations (31). A different 
study found that SPT activity was decreased in the tissues of 
HSAN1 patients, and in a Chinese hamster ovary model, ham-
ster LCB1 C133Y and C133W mutations could not rescue cells 
lacking endogenous LCB1 (32). These combined studies 
revealed that the HSAN1 mutations act directly on the SPT 
enzyme but the pathological consequence on sphingolipid 
metabolism is unclear. Very recently, Dunn and colleagues dis-
covered a small 80-amino acid protein (TSC3p) in yeast that 
stimulated yeast SPT activity, but its role is still unclear (33). 
Recently, a third eukaryotic subunit (SPT3) has been character-
ized and appears to be required for optimum SPT activity, 
although it is expressed most highly in placental tissue and 
human trophoblasts (34). It has been suggested that these three 
subunits could form a higher order SPT complex (35). The 
instability and hydrophobic nature of eukaryotic SPTs has 
made their isolation and therefore biophysical characterization 
particularly challenging (24, 36-38). 
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We have targeted homodimeric SPT from Sphingomonas 
paucimobilis EY2395 to provide molecular insight into the 
enzymatic properties of SPT (39,40). Recently, we reported the 
first high resolution x-ray crystal structure of the S. paucimobi-
us holo-SPT (41) and showed that the active site containing the 
PLP cofactor is at the dimer interface. We used this structure to 
model the human enzyme and map the human cysteine residue 
(Cys'33) of SPT1 onto Asn' °° of the bacterial SPT (41). We 
found that Asn 10° is proximal to the PLP binding site and lies at 
the dimer interface. To explore the effects of the HSAN1 muta-
tions on human SPT activity and structure, we have studied 
mutants of the bacterial enzyme. We made the N100C mutant 
to better mimic native human SPT and N100W and N100Y to 
mimic the most common mutations in human SPT. We have 
characterized the mutations using kinetics, spectroscopy, and 
structural biology, including structures of the external L-Ser 
aldimine. These data provide molecular insights into the effects 
of HSAN1 mutations. Also, as part of these studies, we identify 
residues that play a role in the stabilization of intermediates in 
the SPT reaction and have been able to generate new insights 
into the substrate specificity and mechanism of the a-oxamine 
synthase family. 
EXPERIMENTAL PROCEDURES 
Chemicals—Plasmids and Escherichia coli competent cells 
were purchased from Novagen, and all chromatography col-
umns were from GE Healthcare. All buffers and reagents were 
from Sigma. Palmitoyl-CoA was from Fluka and Avanti Lipids, 
and [U-14C]L-serine  (specific activity 1.85 MBq/ml) was from 
GE Healthcare. The QuikChange site-directed mutagenesis kit 
was purchased from Stratagene. The decanoyl-CoA (10:0), lau-
royl-CoA (12:0), myristoyl-CoA (14:0), stearoyl-CoA (18:0), 
and arachidoyl-CoA (20:0) were from Sigma. Oligonucleotide 
primers were sourced from SigmaGenosys. PEG 3350 was from 
Fluka. S-(2-oxoheptadecyl)-CoA was a kind gift from Dr. 
Hiroko Ikushiro (Department of Biochemistry, Osaka Medical 
College, Japan). 
Cloning and Expression of S. paucimobilis SPT N100W, 
NJOOY, N100C, R378A, and R378N Mutants in E. coli—Plas-
mid pET-28a/SPT WT was used as the template for mutations 
(N100W, N100Y, N100C, R378A, and R378N) that were intro-
duced into the SPT gene by site-directed mutagenesis using the 
following mutagenic primers (the mutagenic bases are shown 
in boldface type) and confirmed by big Dye sequencing: 5'-
GGGTCGGGCACCTGGGGCAGCCGGATG-3' (SPT N100W 
forward), 5 '-CATCCGGCTGCCCCAGGTGCCCGACCC-3' 
(SPT N100W reverse), 5'-GGGTCGGGCACCTATGGCAG-
CCGGATG-3' (SPT N100Y forward), 5'-CATCCGGCTGCC-
ATAGGTGCCCGACCC-3' (SPT N100Y reverse), 5'-GGG-
TCGGGCACCTGTGGCAGCCGGATG-3' (SPT N100C 
forward), 5 '-CATCCGGCTGCCACAGGTGCCCGACCC-3' 
(SPT N100C reverse), 5'-CTCTACGTCAACATGGCGGCC-
CCGCCC-3' (SPT R378A forward), 5'-GGGCGGGGCCGCC-
ATGTTGACGTAGAG-3' (SPT R378A reverse), 5'-CTCTA-
CGTCAACATGGCGAACCCGCCC-3' (SPT R378N for-
ward), and 5'-GGGCGGGTTCGCCATGTTGACGTAGAG-
3' (SPT R378N reverse). 
The recombinant plasmids were used to transform E. coli 
BL21 (DE3) competent cells, and selection was carried out on 
LB agar containing 30 gg/ml kanamycin. For each mutant (and 
native), a single colony was used to inoculate 500 ml of 2YT 
broth (16 g/liter Bacto-tryptone, 10 g/liter Bacto-yeast extract, 
5 g/liter sodium chloride (pH 7.5)), which was shaken at 250 
rpm overnight at 37°C. The overnight culture was added to 4 
liters of 2YT broth supplemented with kanamycin and grown at 
37 °C to an A 600 of 0.6. Protein expression was induced by the 
addition of isopropyl 1-thio--o-galactopyranoside to give a 
final concentration of 0.1 mm, and growth was continued for 5 h 
at 30°C. Cells were harvested (Sorvall RC5B centrifuge) by cen-
trifugation at 3500 rpm for 20 min at 4°C. 
Purfl cation of SPT WT, Ni 00 W, N100Y, N1 00C, R3 78A, and 
R378N—The proteins were purified essentially according to 
the previously described method, which is based polyhistidine-
tagged protein binding to Ni 2 -nitrilotriacetic acid-agarose 
(Qiagen) (41). After elution, fractions were pooled and desalted 
by dialysis against 20 mrvt potassium phosphate (pH 75), 150 
mm NaCl, and 25 ium PLP. A gel filtration step (Sephacryl S200 
26/60 HR; GE Healthcare) was carried out in the same buffer. 
For enzymatic assays and UV-visible spectroscopy, this buffer is 
also used. For x-ray crystal trials, the protein was exchanged 
into 10 mm Tris (pH 7.5), 150 mm NaCl, and 25 pM or 250 p.M 
PLP. For storage, the enzymes were transferred to the same 
buffer containing 20% glycerol (vlv) and stored at —80°C until 
use. Protein identity and integrity were confirmed by high pres-
sure liquid chromatography electrospray mass spectrometry on 
a MicroMass Platform II quadrupole mass spectrometer 
equipped with an electrospray ion source. The experimentally 
determined masses of recombinant S. paucimobilis SPT WT 
and each of the mutants were within 0.1% of the theoretical 
mass, which includes the C-terminal LEI-IHHHHH fusion 
affinity tag with the enzyme lacking the N-terminal methionine 
(41). 
Spectroscopic Measurements—All UV-visible spectra were 
recorded on a Cary 50 UV-visible spectrophotometer (Varian) 
and analyzed using Cary W1nUV software (Varian). Prior to 
enzymatic assays, SPT was converted to the holo-form by dial-
ysis against freshly prepared 20 mm potassium phosphate (pH 
7.5) containing 150 mm NaCl and 25 p.M PLP for 1 h at 4°C. 
Excess PLP was removed by passing the protein through a 
PD-10 (Sephadex G-25M) desalting column (GE Healthcare) 
before concentration to 10-20 mg/ml using a VivaSpin 30 kDa 
cut-off concentration filter. For UV-visible assays, the concen-
tration of recombinant SPT was 10 p.M, and the spectropho-
tometer was blanked with 20 mtui potassium phosphate (pH 7.5) 
containing 150 mm NaCl. 
Determination of Dissociation Constants—Assays were car-
ried out in 0.5-ml quartz cuvettes (1-cm path length) and typi-
cally contained 10 p.M SPT in 20 mm potassium phosphate (pH 
7.5). Varying amounts of L-serine (0-80 mm) were used in each 
assay. After the addition of substrate, the reactants were mixed 
and allowed to equilibrate for 15 min at 25 °C. Small base-line 
changes were corrected using Sigma Plot software. Changes in 
absorbance at 425 nm (SPT WT, N100C, R378A, and R378N) 
and 420 nm (SPT N100W and N100Y) were plotted against 
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L-serine concentrations, and data points were fitted to a hyper - 
bolic saturation curve (Equation 1) using Sigma Plot software, 
4max[serite] 
iA0b, 
= Kd + [serine] 	
(Eq. 1) 
where 1tobs  represents the observed change in absorbance at 
422 nm, and AA is the maximal absorbance change, [serine] 
is the L-serine concentration, and Kd  is the dissociation con-
stant (Table 1). The errors are asymptotic S.E. values of each 
parameter derived from the curve fitting procedure within 
Sigma Plot, and values were reproducible across a number of 
enzyme preparations. 
SPT W7 Ni 00 Y, and R378A Quinonoid Formation—Assays 
were carried out in 0.5-ml quartz cuvettes and typically con-
tained 5 gm SPT in 20 mm potassium phosphate (pH 7.5). To 
this 45 mvi L-serine and 1.45 mm S-(2-oxoheptadecyl)-CoA 
were added in the assay. After the addition of the substrate, the 
reactants were mixed and allowed to equilibrate for 20 min at 
25 C. The spectroscopic data were recorded between 200 and 
800 nm. Small base-line changes were corrected using Sigma 
Plot software. 
Assay ofRecombinant SPTActivity—The activity of SPT was 
measured by monitoring the formation of ['4C]KDS.  A final 
enzyme concentration of 10 gm SPT in 20 mm potassium phos-
phate buffer, pH 7.5, 150 ma't NaCl) was incubated with 20 mm 
[U- 14C]L-serine (9250 Bq, 0.250 MCi; GE Healthcare) and 1.6 
mm palmitoyl-CoA in a final volume of 125 1.d. The reaction was 
incubated at 37 °C for 20 mm, and then the reaction was 
quenched by the addition of 30 1.d of 2.0 M NH4OH (final con-
centration 0.4 M). This was then extracted with an equal volume 
of CHC1 3/Cl-130H (2:1, v/v). The sample was centrifuged at 
13,000 rpm for 5 mm, and the aqueous phase was discarded 
before the organic phase was allowed to evaporate overnight. 
The resulting lipid residue was resuspended in 15 Ll of CHC13/ 
CH30I-1 (2:1, v/v) and spotted onto a silica gel 60 TLC plate. 
Separation was carried out with a mobile phase of CHCI3I 
CH3OH/NH4OH (40:10:1, v/v/v), using a KDS reference stand-
ard (Matreya). The TLC was developed with a Storage Phos-
phorimager (GE Healthcare) for 4 days at room temperature, 
and the phosphor screen was visualized using ImageJ software. 
SPT activity was also measured using a continuous spectro-
photometric assay by monitoring the release of CoASH from 
acyi-CoA substrates and reaction with 5,5'-dithiobis-2-nitro-
benzoic acid (DTNB) (42). Assays were carried out in 0.5-ml 
cuvettes in a Varian Cary-50 UV-visible spectrophotometer. 
The enzyme was incubated with L-serine in a buffered solution 
containing DTNB, and the assay was started by the addition of 
the second substrate, palmitoyl-CoA. The CoASH thiol prod-
uct was monitored by observation of the TNB anion at 412 nm 
= 14,150 m -1 cm-1 (43). Initial rates were measured at 
increasing concentrations of L-serine (0.12-50 mm) while 
maintaining palmitoyl-00A in excess. A typical experiment to 
determine the Km  value for L-serine contained 0.16 gm SPT, 
0.1-50mM L-serine, 250 Am palmitoyl-CoA, and 0.2 mMDTNB 
in 50 mm potassium phosphate buffer, pH 7.5. Kinetic constants 
(k at  and  Km  values; Table 1) were calculated from Michaelis-
Menten plots using Sigma Plot. Kinetic constant values were  
calculated in a similar way for CoA substrates (decanoyl, lau-
royl, myristoyl, palmitoyl, stearoyl, and arachidoyl) but by 
maintaining L-serine (100 mm) in excess (Table 2). As a check, 
the kcatlKm parameters for CoA substrates were also deter-
mined by the method of complete condensation when [CoA] 
was <<Km . In this case, kcat/Km is calculated at a single sub-
strate concentration as an observed rate constant (kObS) by 
monitoring disappearance of the substrate. The data were fitted 
to the equation,A = A iim  X (1 - exp(—kOb$ X t)), where  is the 
absorbance at 412 nm, A iim  is the limiting absorbance value 
when the substrate has completely disappeared, kOb is the 
observed rate constant, and t is the time in seconds. The errors 
are asymptotic S.E. values of each parameter derived from 
the curve fitting procedure within Sigma Plot. The values 
obtained were reproducible over a number of enzyme prep-
arations, and the errors can be used as a gauge of the fitted 
curve's accuracy and were generally less than 5% of the value 
of the parameter. 
Structural Biology—The three mutant proteins were 
screened for suitable crystallization conditions at the Scottish 
Structural Proteomics Facility. The proteins were dialyzed in 
the presence of excess PLP to ensure complete reloading prior 
to crystallization. Conditions used to obtain crystals of the wild-
type/PLP protein (41) were used as a starting point to formulate 
stochastic optimization screens using software developed in 
house. The screens were built on a Hamilton Microstar liquid-
handling robot controlled by Rhombix system software 
(Thermo). Crystallization trials were set up in hanging drop 
plates (EasyXtal DG-CrystalSupport; Qiagen) using 2-3 Al of 
the protein solution and 1 Al of well solution in the hanging 
drop. 
Crystals of the mutant SPTs were obtained in the form of 
yellow plates corresponding to the high resolution form of the 
holo wild-type SPT. The SPT N100W mutant was crystallized 
at 20 mg/ml in 10 mm Tris (pH 7.5), 150 mm NaCl, 25 .LM PLP 
using a well solution of 0.1 M MgCl2, 22% (w/v) PEG 3350, and 
0.10 M Hepes (pH 6.5). The N100Y mutant was crystallized at 20 
mg/ml in 10 mm Tris (pH 7.5), 150 m'vi NaCl, 250 j.LM PLP, using 
a well solution of 0.15 M MgC12, 22% (w/v) PEG 3350, and 0.10 M 
Hepes (pH 6.5). Finally, the N100C mutant was crystallized at 
20 mg/ml in 10 mrvt Tris (pH 7.5), 150 mm NaCl, 250 jim PLP, 
using a well solution of 0.1 M MgCl 2, 27% (w/v) PEG 3350, and 
0.10 M Hepes (pH 6.5). 
The solutions used for equilibrating harvested crystals 
varied slightly according to the crystallization conditions 
and consisted of 22-29% PEG 3350 (w/v), 0.1 M HEPES (pH 
6.5), 0.08-0.12 M MgCl2 . All crystals used for data collection 
were soaked for a few minutes in the respective equilibrating 
solution plus 1-2 mm PLP. Additionally, the external aldi-
mine form of the SPT wild-type was produced by soaking the 
crystal in the equilibrating solution plus 5 MM L-serine for 10 
mm, and that of the N100Y mutant was produced by soaking 
the crystal in the equilibrating solution plus 50 miss L-serine 
for 15 min at room temperature. The crystals were mounted 
in a cryo-loop (Molecular Dimensions) and cryo-protected 
in solutions varying slightly for each crystal and containing 
the equilibrating solutions plus 15-20% PEG 400 (v/v). The 
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FIGURE 2. UV-visible analysis of SPTwild-type and mutants. Absorbance spectra of S. paucimobilis SPTwild-type (A) and mutants Ni OOC (B), N1 00W (C), and 
NI OOY  (D). In spectrum A the enolimine (335 nm) and ketoenamine (420 nm) forms of the external aldimine are drawn. The solid line in each spectrum is the 
halo-form of the enzyme (10 pum SPT, 20 mm potassium phosphate buffer (pH 7.5),150 mm NaCl, 25 °C). Increasing concentrations of L-serine were added (0, 0.1, 
0.5, 1, 2, 5, 10, 20, and 40 mm; dotted and dashed lines), and the spectrum was recorded after 15 mm. For the SPT Ni OOC, N 100W, and N1 00Y spectra the final 
concentrations of L-serine were 0,0.1,0.5, 1,2, 5, 10, 20,40,60, and 80 mm. AU, absorbance units. 
gen and carried in a dry cryogenic Dewar to the European 
Synchrotron Radiation Facility (Grenoble, France) for data 
collection. The data sets were collected at 100 K to varying 
resolutions using three different beam lines (supplemental 
Table 1). The data for the wild-type serine external aldimine 
were processed with Mosfim and scaled with Scala from the 
CCP4 suite of programs (44). The data for the N100C, 
N100Y, N100W, and N100Y serine external aldimine struc-
tures were processed using XDS and scaled using XSCALE 
(available on the World Wide Web) (45). 
Analysis of the density revealed that the PLP was covalently 
bound to Lys265 in every mutant, confirming that we had 
obtained the holo-form of the proteins. All mutant models were 
refined using Refmac5 (46) and manually adjusted, including 
the addition of water molecules with WinCoot (47). Data and 
structures have been deposited in the Protein Data Bank. 
Density was clearly visible to the N100W mutation, but we 
could not satisfactorily locate the tryptophan side chain; 
there is disordered electron density, which indicates multi-
ple conformations. 
RESULTS 
Spectroscopic Properties of SPT N100 Mutants-The three 
mutants were obtained in milligram quantities as the internal 
aldmine, holo-form, confirming their capacity to bind the PLP 
cofactor (Fig. 2). The SPT N100C mutant has absorbance max-
ima at 335 and 425 rim, akin to the wild-type SPT values of 340 
and 425 nm (Fig. 2, A and B). In both native and N100C, the 
enolimine peak at 335 nm is dominant, indicating that the PLP 
cofactor is in a very similar chemical environment in both pro-
teins. In contrast, the U\'-visible spectra of the SPT N100W and 
N100Y mutants have maximum absorbance values at 340 and 
415 rim. (Fig. 2, C and D). We noted that the ketoenamine peak 
(415 nm) had not only blue-shifted; it had also become the 
dominant form in the spectrum in these enzymes. These differ-
ences suggest a common perturbation in the PLP binding site of 
the mutants compared with the wild type (Fig. 2, C and D, solid 
lines). The ability of the mutants to form the external aldimine 
form by binding L-serine was measured by the addition of 
increasing concentrations of the amino acid (ranging between 0 
and 100 mm). This addition resulted in an increase of the 
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FIGURE 3. Assay of SPT activity. A and B, TLC of radiolabeled products obtaine 
Of L-serine and palmitoyl-00A to E'4C]KDS. Recombinant holo-SPT was incubati 
and palmitoyl-00A for 20 mm at 37 'C.The assay was stopped by the addition of 
equal volume of chloroform/methanol (2:1, v/v). Organic phases were removed 
analyzed by a Phosphorlmager. The arrow marks the position of the standard KI 
reaction of the SPT N100C (lane 1), SPT N100W (lane 2), SPT NIOOY (lone 3), an 
observed after reaction of the SPT WF (lane 1), SPT R3 78A (lane 2), and SPT R378 
wild-type SPT using a spectrophotometric assay. i, initial rates of C0ASH releaset 
cally at 412 nm and at several final concentrations of L-serine: 6.25 m (a), 1.56 n 
and 0.12 mm (e). Each assay contained 0.16 LM enzyme, 250 M palmitoyl-00A, 
rates were converted to kg," values and plotted against L-serine concentration 
parameters. iii, complete condensation of SMM palmitoyl-00A by 0.57 gm wild-t' 
MM n.,,rin k 1K for nslmitovl-CnA was rairtilateil Liv dividinci k. by the en 
absorbance at 425 rim for the wild-type and the N100C enzyme. 
Titration of i -serine into the SPT N100W and N100Y mutants 
led to a small shift of a few nm to a longer wavelength. Although 
all mutants form the external aldimine, the N100W and N100Y 
mutants have clear differences (Fig. 2, A-D). By measuring the 
change in absorbance at ketoenamine-specific wavelengths 
that are specific to the external aldimine, the apparent serine 
dissociation constants (K") have been determined for the wild 
type SPT and each of the mutants (Table 1). The wild-type SPT 
jer is 1.1 mm, in good agreement with the found by 
Ikushiro etal. (40) (1.4 mm). A similar KY,  was obtained for the 
N100C mutant (2.7 mm; -2.5-fold higher). Higher i<er  values 
were obtained for two SPT mutants: N100W, 16.2 mm, a -15-
fold increase, and NIOOY, 7.5 mm, a -7-fold increase, com-
pared with the wild-type SPT. 
TABLE 1 
Kinetic parameters for the purified SPT wild-type and mutant 
enzymes 
Enzyme k s ,,, X 10' K' KIW,A  
fllM 1AM fliM 
SPT WT 1150.0.t 300 1.4 1-0.1 35.4 ± 2.0 821.4 I.! ± 0.1 
SPT IJ100C 250.0 ± 4.0 7.0 -0.4 60.0 -9.8 35.7 2.7 ± 0.2 
SPT NIOOW 9.0 ± 0.4 1.6 1-0.4 19.3 -2.2 5.6 16.2 ± 3.1 
SPTNIOOY 5.0± 0.1 2.5 1-0.4 31.4±3.3 2.0 75±0.5 
SPI R378A 78.3 ± 3.2 3.8 1-1.0 39.2 ± 3.1 20.5 1.1 1 0.1 






KDS Formation by SPT WT and Mutants-The ability of 
each enzyme to convert [' 4C]L-serine and palmitoyl-CoA to the 
product ['4C]KDS was examined (Fig. 3A), using the method 
previously described (48). The N100C mutant showed an activ-
ity similar to the wild-type SPT; however, both the N 100W and 
N100Y mutants showed a large decrease in activity (-84%) 
compared with the wild-type enzyme (with saturating substrate 
concentrations) (41). The R378N and R378A produced 50 and 
40% KDS, respectively, in comparison with the wild-type 
enzyme (Fig. 3B). 
Kinetic Analyses of Wild-type, HSAN1 Mimics, and Arg 378 
Mutants-The raw data for wild-type SPT are shown in Fig. 3C. 
The SPT WT bound 1-serine and palmitoyl-CoA with K,,, val-
ues of 1.4 m and 35.4 .LM, respectively (Table 1). The enzyme 
turned over with a of 1.150 s_ i and an efficiency (kcat/K,,,)  of 
821.4 M s - 1 for L-sertne. We observed k,,1/K,,,  values of 35.7, 
5.6, and 2.0 M 1 s - ' for  the mutant SPTs N100C, N 100W, and 
N100Y, respectively. The lower values observed for the HSANI 
mimics N100W and NIOOY (147- and 410-fold respectively) 
confirm that the mutations have had an impact on catalysis. We 
attribute the lower value for the N100C mutant (23-fold lower) 
to reactivity of the Cys' °° thiol with the DTNB reagent (data not 
shown), since this mutant showed comparable KDS formation 
in the radioactive assay. The coupled assay was used to investi-
gate the chain length specificity of wild-type SPT with various 
acyl-CoA substrates. We found palmitoyl-CoA (C16:0) to have 
the fastest turnover (kcat = 1.150 
s) of all of the acyl-thioesters, 
(a) (b 	 with a K,,, of 35.4 MM (Table 2). 
(c When comparing the kcat/Kn,  val- 
(d 	ues, stearoyl-CoA (C18:0) was the 
e most efficient substrate (65,547 M 
S'). The thioester with the longest 
0 1 	2 3 4 5 	chain, arachidoyl-CoA (C20:0) was 
Time (mine) 
a good substrate, with a K,,, of <10 
MM, but below this concentration, 
accurate rates could not be deter-
mined due to the limit of detection 
with the DTNB reagent. In contrast, 
o 	o o 	the shortest substrate, decanoyl- 
L-Serine (mM) CoA (C10:0), was the poorest sub-
strate in terms of binding and turn-
over. In the first study of S. 
paucimobilis SPT carried out by 
Ikushiro et al. (39), they found a 
similar trend, with palmitoyl-CoA 
(C16) being the best substrate 
matching the human SPT. The 
recently discovered, unusual fused, 
viral SPT displayed highest activity 
with myristoyl-CoA (C14) (12, 49). 
Similar analysis was also carried 
out on the SPT R378A and R378N 
mutants. These bound PLP in a 
manner similar to wild-type with 
absorbance maxima at 335 and 425 
nm (data not shown). The values 
obtained were similar to that of the 
Solvent 
trOflt 
• - KDS 
øf 
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i by SPT-catalyzed conversion 
sd with U- 14C-labeled L-serine 
NH40H and extracted with an 
I, dried, separated by TLC, and 
DS. A, products observed after 
d SPT WT (lane 4). B, products 
N (lane 3). C, kinetic analysis of 
measured spectrophotometri-
iM (b) 0.78 mm (c) 0.39 mm (d), 
and 0.2 mm OTNB. ii, the initial 
to determine the Kr,, and krat 






JUNE 19, 2009•VOLUME 284 NUMBER 25 	790@01 	 JOURNAL OF BIOLOGICAL CHEMISTRY 17333 
Supplemental Matenal can be found at- 
http I/www jbcorg/content/suppl/2009106/1 7/Ml 09 008680, DC 1 html 
External Aldimine Form of Serine Palmitoyltransferase 
wild-type SPT (K values of 1.1 and 3.1 mm for the R378A and 
R378N, respectively). Using the coupled spectrophotometric 
assay, we measured 60- and 40-fold decreases in kcat IJ< r for 
each mutant (R378A and R378N, respectively; Table 1). 
SPT W1 N100Y, and R378A Quinonoid Formation-The 
ability of the wild-type enzyme and both the N100Y and R378A 
mutants to form a quinonoid intermediate was tested by the 
addition of a thioether analogue of palmitoyl-CoA reported by 
Ikushiro etal. (50). The addition of the analogue to the L-serine 
external aldimine form of the wild-type enzyme led to the 
appearance of a clear peak at 495 nm due to the quinonoid 
TABLE 2 
Chain length specificity of wild-type SPT 
AcyI-CoA 	 k,/K"  
LM Al , 
Decanoyl (10:0) 0.045 ± 0.002 2324.9 ± 175.1 19.4 
Lauroyl (12:0) 0.262 ± 0.006 8212 ± 32.6 318.7 
Myristoyl (14:0) 0.601 ± 0.012 97.1 ± 5.1 6189.5 
Palmitoyl (16:0) 1.150 ± 0.030 35.4 ± 2.0 32,485.9 
Stearoyl (18:0) 0.898 ± 0.012 13.7 ± 0.8 65547.4 
Arachidoyl (20-{)) 0327 ± 0.014 10 >32,7(() 
(increase in absorbance --0.06), in agreement with that found 
previously (Fig. 4A). In contrast, the SPT N100Y mutant, under 
the same conditions, produced a small, broad shoulder 490-
500 nm (increase in absorbance -0.01 absorbance units; Fig. 
4B). We could not observe the formation of a quinonoid species 
at all in the R378A mutant (Fig. 4C). 
The Structure of the Wild-type SPTL-Ser External Aldimine 
Complex-The dimeric form of the L-Ser external aldimine SPT 
complex is shown in Fig. 5A. Of course, the major difference 
between the internal (holo-) and external aldimine forms is that 
in the internal adimine, the Schiff base is between Lys 265  of the 
protein and the PI.P co-factor, whereas in the i.-Ser external 
aldimine, this C-N bond has broken. The PLP-L-ser external 
aidmine is clearly observed in the electron density (Fig. 5B). An 
overlay of the structures of the internal (41) and external aldi-
mine shows an r.m.s. deviation of 0.3 A and reveals that most of 
the interactions between the enzyme and the PLP cofactor are 
unchanged. In both structures, the PLP hydrogen-bonds to the 
side chains of Asp"', His 2 , Thr262, and Ser 2 , the main chain 
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FIGURE 4. Quinonoid formation in the wild-type SPT, N1 00Y, and R378A mutants. UV-visible spectra of the SPT wild type (A), N100Y(B), and R378A (C) 
external aldimine forms after titration of the thioether analog (S.(2-oxoheptadecyl)-00A) of palmitoyl-00A. Incubations were carried out with 5 iM enzyme, 45 
MM L-serine, 1.4 mm analog, 20 mm potassium phosphate buffer (pH 7.5), 150 mtvi NaCl for 15 min at 25 'C. The solid line in each spectrum represents the 
holo-form; the dotted line is the external aldimine form after the addition of L-ser; and the dashed line is after the addition of the analogue. An absorbance 
maximum at 495 nm (marked with an arrow), attributed to a quinonoid species (50), is clearly observed in the wild-type enzyme, but only a broad shoulder is 
produced in the NIOOY mutant, and no peak is observed for the R378A mutant. AU, absorbance units. 
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B 
served throughout all of the members of the a-oxoamine syn-
thase family (41). As a result of external aldimine formation, the 
PLP has shifted, essentially rotating around the phosphate, with 
the Schiff base nitrogen moving over 1.5 A. Lys2"5 adopts a 
different conformation as a result of breaking its link to PLP and 
now makes a hydrogen bond with the hydroxyl of the L-ser 
component of the external aldimine (Fig. 6A). Accompanying 
the change in Lys 265 conformation, Tyr 71  substantially alters its 
position. The carboxylate group of i.-Ser hydrogen-bonds to the 
conserved His"' and makes a salt link with Arg 378 , which has 
"swung" into the active site. In the native structure, this residue 
is at the end of a 13-strand and hydrogen-bonded to the side 
chain of GIn357 . In order to make the salt contact, the 13-strand 
has been disrupted, and the Ca of Arg 378 has been moved over 
5 A. The loop following Arg 378 (the "PPATP" loop) has signifi-
cantly altered its conformation and position (e.g. the Cy atom of 
Pro"' has moved over 10 A). The reordering of the structure 
around Arg378 seems to be linked to other movements at Phe 47 
(1.2-A Ca shift). These residues are contained within the one 
monomer. The phosphate of PLP binds to the side chain of 
Thr294 from one subunit and to the main chain of AJa 294 from 
the other subunit. The hydroxyl of L-Ser makes a polar contact 
to the main chain of Ala 294. In the other monomer, the side 
chain Met" adjusts its conformation, and there is a slight rigid 
body shift of Leu' °5 to Asn' The side chain of Asn' °° from the 
other subunit has altered its position, but the hydrogen bond to 
Lys265 is maintained. 
Structural Biology of the Holo-firms of the HSAN1 Mutant 
Mimics—The wild-type SPT and N100C structures superim-
pose with an r.m.s. deviation of 0.2A along the 396 Ca residues 
and are largely identical. Similarly, the N 100W and N100Y 
mutant structures superimpose with 0.1 A r.m.s. deviation for 
their Ca positions, mirroring their similar spectroscopic prop-
erties. However, both NIOOW and N100Y superimpose with 
the native structure (and N 100 with an r.m.s. deviation of 0.6 
A. For ease of discussion, only the differences between N100Y 
and the native enzyme are reported. The N100W structure is 
essentially identical to N100Y, whereas N100C is essentially 
identical to native. Reflecting the large deviation in Ca posi-
tions, there are a number of small shifts in secondary structure 
elements throughout the structure when comparing the N100Y  
mutant with the native SPT. These 
shifts are largely conserved, regard- 
less of which structures one com- 
pares (N 100W versus native, 
N100W versus N100C, N100Y ver- 
sus NIOOC, and N100Y versus 
-1 	"— 	native), suggesting that they are real 
and not simply a crystallographic 
- 	 artifact. The most obviously visible 
change is the N-terminal helix 
(Asp23–G1y42), which has under-
gone an approximately 1.7-A shift. 
This helix is an important part of 
the dimeric interface of SPT (41). At 
the site of mutation itself, the tyro-
sine side chain has "flipped" out the 
pocket occupied by Asn' °° (Fig. 6B). 
At the Ca level, this is a displacement of 3.4 A and is accom-
plished by an almost 180' rotation of the Rarnachand ran angle 
at Thr99 . As a result, the hydrogen bonds between the side chain 
of Asn' °° with the key Lys265 from the other monomer have 
been broken. Instead, the Tyr" now occupies a new pocket at 
the dimer interface formed by hydrophobic residues from both 
monomers (Phe' °9 from the same monomer; Met 51 , Thr72 , and 
11e6° from the other monomer) (Fig. 6B). These hydrophobic 
residues have adjusted their position to accommodate the bulky 
tyrosine side chain. The most pronounced of these changes 
appear to accompany the movement of Phe' °9 , which connects 
to an a-helix. Residues of the first turn of the helix, His"', 
Asp''', His' 12, Met' 13, and Glu' 14, all show disturbed side 
chain and main chain positions relative to the native structure. 
The main chain at Leu' 05 , Asn' °6, and Gly' (17  sits opposite and 
close to Asn' °° in the native structure. The movement of the Ca 
atom at position 100 by 3.4 A causes Leu' °5–Gly' °7 to undergo 
large positional movements (over 4 A for the Ca positions of 
Gly' °7) and changes in their Ramachandran angles. 
Structural Biology of Wild Type and NJOOY L-Ser External 
Aldimines—The r.m.s. deviation between the two external aldi-
mines, native SPT, and N100Y mutant at 0.4 A is less than the 
value for the internal aldimine structures (0.6 A). Thus, it 
appears that formation of the external aldimine drives N100Y 
toward a more "native" conformation. This can be seen most 
clearly in the loop between Tyr"' and Gly' °7 , which is more 
similar to the native structure in the external aldimine complex. 
The most striking difference between the two external aldinsine 
structures is that in the N100Y structure, the "PPATP loop" 
remains in its internal aldirnine conformation, and conse-
quently Arg378 does not enter the active site and does not make 
salt links with the carboxylate of i.-ser (Fig. 6C). Rather, in the 
external aldirnine of N100Y, Arg.d78  is hydrogen-bonded to 
an interaction that is absent in the N100Y internal aldi-
mine due to a small shift in structure. 
DISCUSSION 
Mechanistic implications—The seminal hypothesis, for-
warded by Dunathan (51) over 40 years ago, to explain how 
PLP-dependent enzymes can catalyze numerous chemical 
reactions is still valid. The key steps involve the deprotonation 
FIGURE 5. Structure of the SPTi-serine external aldimine complex. A, overall structure of the SPT dimer 
showing one monomer in light blue and the other in purple. The residues Lys 265 and Asn 10° from the light blue 
monomer are shown in stick form and are colored yellow. The equivalent residues from the purple monomer are 
colored green. This clearly shows that the Asn' °° from one monomer interacts with the active site of the other 
monomer. The PLPL-ser external aldniine is also shown in stick form. B, a stereo image of an F. - F, electron 
density map contoured at 3 aaround the PLPL-ser external aldimine found in the native SPT. The phases were 
calculated from a model that had never included the PLP or aldimine. 
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FIGURE 6. Structure of the SPTi.-serine external aldimine complex and 
impact of the N1 00Y HSAN1 mutation. A, a stereo image showing residues 
involved in binding the PLPL-ser external aldimine complex are shown. 
His 159, Asp251 , His 2 , Thr262 , LYSShS,  and Arg 378 are from monomer A (light 
blue) in yellow stick format. Residues Thr  21  and Asn t0° are from monomer B 
(purple), are colored green, and are annotated with an asterisk. Residues His' 59 
and Arg 378 interact with the carboxylate group of the L-serine; Lys 265 
(denoted by dashed lines) interacts with the hydroxyl group of the L-serine; 
and His234 interacts with the hydroxyl group of the PLP. Residue Asp 23 ' binds 
to the nitrogen atom of the PLP cofactor, and the side chain of Asn 10° (from 
monomer B) interacts with the backbone of Lys" of the opposite monomer A. 
B, a stereo image of an overlay of the external aldimine forms of the wild-type and 
N  COY. The wild-type structure has been rendered with monomer A colored with 
a blue backbone and yellow side chains, and monomer B is shown with a purple 
backboneand green side chains. In the N  COY mutant, the monomerA backbone 
and side chains are colored gold, and monomer B is colored with a red backbone 
and salmon pink side chains. The N100 side chain from monomer B of the wild-
type SPT (green stick, asterisk) interacts with residues from monomer A. However, 
in the SPT N100Y mutant, the Tyr' o' side chain has flipped into a pocket formed 
by displacement of Phe' °9 of the same monomer B, residue Asn 1°6 from mono-
mer B has also undergone a large shift, and residue Asn 375 from monomer A has 
also changed The backbone containing residue Tyr" has also undergone a 
large conformational change. C, a stereo image of an overlay of the external aldi-
mine forms of the wild-type and N1 00Y showing the impact of mutation on 
Arg378 and the PPATP loop. The coloring is the same as in B, In wild-type SPT, 
residue Arg 378 (side chainyellowon the blue backbone) is in the swung in position 
and interacts with the L-Ser carboxylic acid. In the SPT N  COY mutant, the "PPATP 
loop" and the Arg 378 residue (backbone and side chain colored gold) are in the 
"swung out" conformation observed in the wild-type internal aldimine form. The 
interaction between Arg 378 and Gin 351 (both in gold) and the different positions 
of the Asn t0° and Tyr" residues are shown. 
of the amino acid'PLP external aldmine to form the quinonoid 
species, which condenses with the incoming acyl-CoA thioester 
(Fig. 1). This is thought to generate a f3-keto acid intermediate 
that then decarboxylates to give a product aldimine (23). The 
first intermediate in the catalytic cycle of SP'I' is the external 
aldimine formed between L-ser and PLP. Deprotonation of the 
Ca of this external aldimine intermediate is the crucial next 
step. In studies with ALAS, this deprotonation has been 
observed to be accelerated by over 250,000-fold by the binding 
of the incoming thioester substrate (14, 52). Studies on AONS, 
which uses L-alanine and pimeloyl-CoA, suggest that this 
enzyme undergoes conformational change during intermediate 
formation. Incubation of the enzyme with palmitoyl-CoA pre-
equilibrated with i-alanine gave a 30-ms lag before quinonoid 
formation at 486 nm was observed with a rate of 45 s" (14). 
Recently, a thioether CoA substrate analogue (S-(2-oxohepta-
decyl)-CoA) was shown to increase the rate of proton abstrac-
tion from the serine external aldimine of SPT by around 100-
fold (50). 
Our new structure provides insight into the residues that 
control the i.-Ser external aldimine conformation (Fig. 7, A — C). 
How was this intermediate trapped in the crystal? The high 
resolution data confirm that the L-serine'PLP external aldimine 
is sp3-hybridized at the Ca (the angles are 111.5, 106.4, and 
109.6", which are close to the theoretical values for a tetrahedral 
carbon). In the external aldimine structure, the Nz atom of 
Lys265 contacts (3.4 A) the Ca proton of the i -Ser. This double 
role for the Schiff base forming lysine was suggested by studies 
of members of the a-oxoamine synthase family (14, 17, 18,20), 
and SPT has now been shown to use the same feature. The 
angles between each functional group and the N-imine (which 
is co-planar with the PLP ring) were measured as follows: 
H-Ca-N, 107.7; CO 2-Ca-N, 108.4°; CH 2-Ca-N, 113.3°. None 
of these have the desired perpendicular orientation to the 
plane, indicating that in the crystal structure, the external aldi-
mine is not in the optimal "Dunathan conformation" suitable 
for deprotonation. 
If, as seems likely, palmitoyl-CoA binding leads to rapid dep-
rotonation, we suggest that it does so by triggering the rotation 
of the external aldimine about the imine N—Ca bond. A small 
turn of —15-20° would bring the Ca hydrogen into the 
required perpendicular geometry (Fig. 7B). Of course this 
would cause the simultaneous movement of the -CO group 
and the -CH 20H side chain. Ikushiro proposed a role for the 
conserved residue Arg 39° in the SPT mechanism (50). The 
structural data show that Arg 9° is over 6.5 A distant from 
the carboxylate; rotating around the Ca—N bond to reach the 
likely quinonoid conformation shortens this distance to 4.6 A 
(Fig. 7, C and D). An additional rearrangement, promoted by 
palmitoyl-CoA binding, could allow Arg39° to interact with the 
carboxylate, as seen in the KBL external aldimine. We note that 
Arg ° plays an important role in stabilizing the conformation 
of Tyr  71,  which forms the active site. The rotation to form the 
quinonoid would disrupt the salt link to Arg'75 in the absence of 
any additional structural adjustment. The interplay of Arg ° 
and Arg 78 in interacting with the carboxylate group may be an 
important component in controlling the formation and depro-
tonation of the external aldimine. Together, they could act to 
pick up, ferry, then anchor the carboxylic acid group. This func-
tional group is ultimately lost from the -keto acid as CO, and 
future work will be required to understand how this important 
ext aka1ll J 
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FIGURE 7. Schematic representation of the residues involved in SPT catalysis, conformations of the external aldimines, and roles of active site arginine 
residues in controlling. A, key residues involved informing the active site are highlighted. The Arg °78 side chain is in the swung out conformation and interacts 
with Gin 351 . B, binding of L-Ser leads to PLPi-Ser external aldimine formation. The residues observed in the wild-type crystal structure are shown. The 
carboxylate of L-Ser interacts with the side chains of His' 59 and Arg 378, which is now in the swung in conformation. Rotation around the Co-No bond (arrow) 
brings the intermediate into the desired Dunathan conformation shown in C. The carboxylate is shown to possibly interact with Arg 390, and the Ca-H is now 
perpendicular to the PLP ring. This is then deprotonated by Lys"' to form the quinonoid. 0, stereo image of a model of the external aldimine Dunathan 
conformation using the external aldimine structure. 
step is controlled. Ikushiro el al. (50) also proposed a role for 
I-us 159 acting as a hydrogen donor to accommodate the devel-
oping negative charge on the C0 of the thioester. The struc-
ture shows that the NE atom of His' 59 hydrogen-bonds to the 
L-serine CO 2  group as well as maintaining a n-stacking inter-
action with the PLP ring. This is consistent with the reported 
SPT H159F mutant, which bound L-serine weakly (Kd = 11.1 
mm) and was incapable of KDS formation. Whether the residue 
also plays a role in the chemistry of the thioester activation 
remains an open question. 
That Arg378 binds to the external aldimine was unsuspected, 
since it required a very large conformational change from the 
holoenzyme structure. Mutation of this residue (R378A and 
R378N) reduces enzyme efficiency by over a factor of 10 (Table 
1). Thus, we suggest that this residue plays an important, but 
not essential, role possibly influencing the stabilization of an 
intermediate after both substrates have bound. Weight is given 
to this hypothesis by the fact that R378A cannot form a quinon-
old in the presence of the thioether analogue (Fig. 4C). The 
nonessential nature of the residue is consistent with its lack of 
sequence conservation in all SPT isoforms, and an equivalent 
residue in the human SPT1/SPT2 heterodimer awaits identifi-
cation. That there may be such a residue comes from analysis of 
enzymes in the a-oxoamine synthase family. In the two glycine- 
specific members, KBL and ALAS, residues Asn 5° and Asn54 , 
respectively, make direct contact with the -00 1 group (17, 18) 
of the amino acid. In AONS, Webster et al. (14) used the 
AONS-AON product external aldimine structure to predict 
that the L-alanine carboxylate would coordinate with residue 
Asn47 . Sequence homology lines up residue Asn 74 from S. 
paucimobilis SPT with the three Asn residues from AONS, 
ALAS, and KBL; however, analysis of the structure reveals that 
this residue in not involved in the active site. Thus, there is 
reason to suspect that some residue is required to coordinate to 
the carboxylic group of the external aldimine; however, given 
that the function is not essential, the conservation of the residue 
is not absolute. 
The organization of the active sites of AONS, KBL, and ALAS 
is different compared with the bacterial SPT; the constellation 
of residues around the PLP cofactor is conserved, but there are 
subtle differences. SPT favors L-Ser as the substrate, and in the 
SPT external aldimine structure, the side chain hydroxyl makes 
a number of hydrogen bonds, which could explain this prefer-
ence. Interestingly, although SPT can form an external aldi-
mine with t-Thr (K4 = 3.8 mm) (40), it cannot be deprotonated 
to the quinonoid in our hands (data not shown). Looking at the 
structure of the aldimine, the additional methyl group of L-Thr 
would appear to clash with Ser' °2 and Arg378 in the proposed 
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quinonoid model. In the ALAS structure, Thr 83 would seem to 
select against any substituent at the Ca position, explaining the 
preference for Gly of this enzyme. 
Mimics of the HSAN1 Disease Causing Mutations—The two 
most common mutations (C133W and C133Y) associated with 
the human disease 1-ISANI have intrigued a number of 
researchers as to how they impact on sphingolipid metabolism 
and regulation. The fact that these mutations are in the inactive 
subunit, LCBI (SPT1), has added to their scientific interest. 
Tissue from HSAN1 patients contains relatively normal levels 
of total sphingolipids (10, 31, 32). However, there are differing 
reports as to the intrinsic SPT activity of cells from HSAN1 
individuals, and questions remain as to the precise conse-
quence of the HSANI mutants on SPT turnover, stability, and 
regulation. Gable et al. (30) produced mutants of the yeast lcbl 
gene (C180Y and C180W) that mimic the HSAN1 substitutions 
(C133W and C133Y). Interestingly, these mutations domi-
nantly inactivated the SPT activity of the yeast LCB1LCB2 het-
erodimeric complex. This study proposed that the LCB1 
HSAN1 mutations perturbed the active site of the LCB1LCB2 
dimer. McCampbell et al. (31) expressed the human LCB1 
C 133W mutant in a transgenic mouse and found that the SPT 
activity was decreased in various tissues and mice developed a 
number HSAN1 symptoms. However, the levels of total cera-
mide in these mice were unchanged, as was also observed in 
human HSANI individuals. This indicates that to some extent, 
SPT activity is preserved, and the mutants have a more subtle 
effect than simple loss of activity. It would also indicate that 
there is some regulation of sphingolipid biosynthesis after KDS 
formation by SPT. 
We had previously mapped the human CystSS  residue to 
Asn t0° on the bacterial SPT (41). We first engineered an N100C 
mutation as a better mimic for the human enzyme. This mutant 
enzyme behaves within the sensitivity of our UV-visible spec-
troscopic, kinetic, and high resolution structural analyses as 
native. This gave us confidence that the other mutations at 
Asn' °° in the bacterial enzyme should provide a meaningful 
insight into human SPT. 
NIOOW and N100Y mutants displayed marked spectro-
scopic, enzymatic, and structural differences when compared 
with wild-type SPT. Although both mutants are severely com-
promised in their activity, importantly, they do retain the ability 
to make the desired KDS product. It was obvious from the dis-
tinctive IJV-visible properties of PLP-containing holo-forms of 
the enzymes that the mutants had altered the cofactor's chem-
ical environment (Fig. 2, A–D). This change in the chemical 
environment apparently disturbs catalysis. After formation of 
an external aldimine, deprotonation gives a quinonoid interme-
diate (Fig. 1), which has been detected for both AONS and 
ALAS enzymes (14, 52). In the native SPT enzyme, the quinon-
oid form can be detected by adding the palmitoyl-CoA 
thioether analog. However, in the N100Y mutant, the signal for 
the quinonoid is essentially absent, indicating that the stabili-
zation of this intermediate is significantly decreased (Fig. 4, A 
and B). In the wild-type holo-SPT (and N100C), the side chain 
of one monomer makes a direct contact with the amide back-
bone of the conserved PLP Schiff base Lys"' of the other mon-
omer. This hydrogen bond is lost by the disruption introduced  
by the mutation. We suggest that this would increase the mobil-
ity of the internal aldimine. The most striking observation is 
that the N100Y and NIOOW mutations cause, because of the 
key location of Asn' °° at the dimer interface, complex struc-
tural changes to ripple across the dimer interface (Fig. 6B). A 
striking illustration of this can be seen in the external aldimine 
of N100Y, particularly the role of Arg 58 . In the native enzyme, 
this residue plays an important role in binding to the carboxy-
late of the external aldimine, but in the N100Y mutant, Arg 378 
remains uninvolved with the intermediate (Fig. 6C). Although 
it is difficult to identify a clear cut interaction that disfavors 
Arg375 from entering the active site, this residue is in contact 
with LeutOS  from the other subunit. Leu' °5 is one of the residues 
directly affected by the mutation at Asn' °°. The change in 
Leu lOS position introduced by the mutation would increase the 
van der Waals contact between Arg 378 (in the "swung in" state) 
and LeuWS  in the mutant. It is this ability for structural changes 
to "reach across the interface" that we propose underlies the 
C133W and C133Y mutation effects in HSAN1. The perturba-
tions in the neighboring structure give rise to the changed 
chemical environment of both the internal and external aldi-
mine, altering the enzyme function. 
Combined with previous studies on AONS, ALAS, and KBL, 
the SPT data presented here shed more light on the catalytic 
mechanism employed by members of the a-oxoamine synthase 
family. The eukaryotic SPT heterodimeric isozymes appear to 
be more complex than their bacterial homologs, since a third, 
tissue-specific SPT subunit has been identified recently (34). 
Furthermore, an abnormal, "dead end" sphingolipid product, 
1-deoxysphinganine (also known as the natural product 
"spisulosine"), formed by SPT using L-Ala as a substrate, has 
been identified in mammalian cells (53, 54). Whether the 
SPT HSAN1 mutations impact directly on substrate and 
product specificity requires further detailed investigation. In 
the absence of large amounts of homogenous eukaryotic com-
plexes, the bacterial enzymes provide some insight into how the 
wild-type and mutant forms behave and aid in the design of 
isolation strategies for the more complex SPTs (55). Studies 
aimed at the capture of complexes of various SPTs with a range 
of substrates, products, and inhibitors are under way. 
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Cycloserine (CS, 4-amino-3-isoxazolidone) is a cyclic amino acid mimic that is known to inhibit 
	 15 
many essential pyridoxal 5'-phosphate (PLP)-dependent enzymes. Two CS enantiomers are 
known; D-cycloserine (DCS, also known as Seromycin) is a natural product that is used to treat 
resistant Mycobacterium tuberculosis infections as well as neurological disorders since it is a 
potent NMDA receptor agonist, and L-cycloserine (LCS) is a synthetic enantiomer whose 
usefulness as a drug has been hampered by its inherent toxicity arising through inhibition of 
	 20 
sphingolipid metabolism. Previous studies on various PLP-dependent enzymes revealed a common 
mechanism of inhibition by both enantiomers of CS; the PLP cofactor is disabled by forming a 
stable 3-hydroxyisoxazole/pyridoxamine 5'-phosphate (PMP) adduct at the active site where the 
cycloserine ring remains intact. Here we describe a novel mechanism of CS inactivation of the 	 25 
PLP-dependent enzyme serine palmitoyltransferase (SPT) from Sphingornonas paucimobilis. 
SPT catalyses the condensation of L-serine and palmitoyl-CoA, the first step in the de novo 
sphingolipid biosynthetic pathway. We have used a range of kinetic, spectroscopic and structural 
techniques to postulate that both LCS and DCS inactivate SPT by transamination to form a free 
pyridoxamine 5'-phosphate (PMP) and 3-aminooxyacetaldehyde that remain bound at the active 	 30 
site. We suggest this occurs by ring opening of the cycloserine ring followed by decarboxylation. 
Enzyme kinetics show that inhibition is reversed by incubation with excess PLP and that 
LCS is a more effective SPT inhibitor than DCS. UV-visible spectroscopic data, combined 
with site-directed mutagenesis, suggest that a mobile Arg 378 residue is involved in cycloserine 
35 inactivation of SPT. 
10 
Introduction 
Sphingolipids are a large family of bioactive molecules that are 
found in all eukaryotic and some prokaryotic membranes. 
An important example is sphingomyelin, a constituent of 
the protective myelin sheath that surrounds nerve cells.' 
Sphingolipids can associate with cholesterol to form 
'lipid rafts' or sphingolipid-based microdomains necessary 
for signal transduction and membrane trafficking. 2 
Sphingolipid metabolites such as ceramides and sphingosine-
1-phosphate play important roles in cell proliferation, 
differentiation and apoptosis 5 and it follows that pharma-
ceutical intervention that regulates the sphingolipid metabolic 
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pathway could help to combat pathological processes such as 
carcinogenesis, 6 atherosclerosis 7 and Parkinson's disease. 5 
The de novo biosynthetic pathway for sphingolipids varies 40 
from one organism to another but the first and rate-limiting 
step is common to all: condensation of L-serine with palmitoyl-
CoA to form 3-ketodihydrosphingosine. 9 This step is catalysed 
by the pyridoxal 5'-phosphate (PLP)-dependent enzyme, 
serine palmitoyltransferase (SPT), a member of the -oxo-  45 
amine synthase (AOS) subfamily. Other members of this 
subfamily that have been well characterised include 8-amino-
7-oxononanoate synthase (AONS),' °" 5-aminolevulinate 
synthase (ALAS) 12,13  and 2-amino-3-ketobutyrate-CoA 
ligase (KBL).' 4 These enzymes catalyse reactions in heme bio-  50 
synthesis, biotin biosynthesis and threonine degradation, 
respectively. Recent additions to the growing list of identified 
AOS enzymes are the bacterial quorum-sensing autoinducer 




The AOS enzymes utilise a PLP cofactor at the active site to 
catalyse the Claisen-like condensation between an amino acid 
and an acyl-CoA substrate. The first high resolution crystal 
structure of the holo-form of a bacterial, homodimeric SPT 
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from Sphingononas paucimob i/is clearly shows the cofactor 
covalently attached to the side-chain of a conserved Lys 265 
residue via a Schiff's base (also known as an internal aldimine) 
at the dimer interface. 18 Transaldimination occurs when the 
L-serine substrate binds at the active site to form an external 
aldimine that is stabilised by other conserved residues: a His 159 
that stacks above the PLP ring and His  234  that hydrogen 
bonds with the PLP-bound intermediate.  19 The crystal structure 
of the enzyme-bound PLP:L-serine external aldimine complex 
has recently been resolved for SPTs from the sphingolipid-
producing bacteria S. paucimobi/is20 and Sp/iingobacierium 
nlu/tivorurn. 21 The proposed steps subsequent to the formation 
of the external aldimine are deprotonation at C a of the 
external aldimine complex to form a quinonoid (carbanion 
equivalent) intermediate; a Claisen condensation with the 
acyl-CoA substrate and loss of free CoASH to form a 
ketoacid intermediate; decarboxylation to form a product 
quinonoid; protonation of this quinonoid to form the product 
external aldimine; release of the c-oxoamine product and 
regeneration of the enzyme PLP internal aldimine (Fig. I). 
Both enantiomers of cycloserine (Fig. 2A) can be thought of 
as cyclic analogues of serine and/or alanine and have been 
shown to be irreversible inhibitors of many PLP-dependent 
transaminases, 22 racemases 23 and decarboxylases. 24 L-Cyclo-
serine (LCS) is prepared synthetically whereas D-cycloserine  
(DCS) is a natural product isolated from Sirepiornyces 
strains  25  and is a broad spectrum antibiotic. Due to its severe 
side effects DCS is most commonly used as a second-line 
drug in combination therapy to treat tuberculosis.  26  DCS is 
also used in neurological studies since it is a potent agonist 
of IV-methyl-D-aspartic acid (NMDA) receptors that are 
involved in neurotransmission.  27  One of its main anti-
bacterial targets is the PLP-dependent alanine racemase, 28'29 
an essential enzyme that generates n-alanine for the formation 
of the D-alanyl—D-alanine dipeptide incorporated into the 10 
bacterial peptidoglycan layer. Unlike many irreversible 
inhibitors that inactivate their protein targets by covalent 
modification, CS renders its targets inactive by forming a 
stable adduct with the essential PLP cofactor. It is not 
surprising that CS has also been shown to be a potent inhibitor IS 
of bacterial SPT 3° as well as mammalian SPT in mouse brain 
microsomes. 3 1 Although LCS is commonly used as a regulator 
of lipid metabolism in biological research, its mechanism 
of inhibition is still unknown. In this paper we used a 
combination of X-ray crystallography, mass spectrometry, 20 
UV-Vis spectroscopy and enzyme kinetics to elucidate the 
mechanism of SPT inactivation by both enantiomers of 
CS. We highlight differences in the enantiospecific inhibition 
observed for both LCS and DCS and provide further insight 







Fig. I Catalytic mechanism of SPT. 
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Fig. 2 (A) Structures of SPT substrates and inhibitors. (B) Mechanism of formation of the aromatic adduct observed in each of the crystal 40 








Both LCS and DCS are irreversible inhibitors 
of serine palmitoyltransferase 
When either LCS or DCS was incubated with SPT, enzyme 
activity decreased over time. Log plots of % activity remaining 
versus time, according to the method of Kitz and Wilson, 32 
were linear for each enantiomer indicating classical time-
dependent inactivation of SPT activity (Fig. 3A and B). We 
noted that the Kitz and Wilson secondary plots (Fig. 3C) 
appeared to pass very close to the origin—there are many 
examples of this in the literature such as the inhibition of the 
thiamine-dependent enzyme benzaldehyde lyase (BAL) by 
methyl benzoylphosphonate 33 and the inhibition of the PLP-
dependent y-aminobutyric acid aminotransferase (GABA-AT) 
by (I S,35)-3-amino-4-difluoromethylene-cyclopentanecarboxylic 
acid. 34 Kitz and Wilson replots of this nature suggest that both 
DCS and LCS form very weak complexes with SPT but 45 
inactivation is fast compared with the formation of the 
CS:SPT complexes. Moreover, these prevent the estimation 
of the ki nact and K1 values directly. In comparison with LCS, 
we found that approximately 15-fold higher concentrations of 
DCS were required to inactivate SPT activity to the same 50 
extent and over a similar period of time. From the secondary 
plot of l/k 	versus l/[cycloserine] the second-order rate 
constant of inactivation kj nact/Ki was calculated as ]/slope 
for each inhibitor (Fig. 3C). LCS (k nact/Ki = 0.83 ± 0.5 M' 
S-1 ) was found to be 	14-fold more effective at inactivating 55 
SPT than DCS (k jnact/K i = 0.06 ± 0.002 M s). 
Activity of SPT, measured by monitoring formation of the 
free thiol of CoASH using a continuous DTNB assay, 20  was 
reduced to 1% and 22% after 2 hours inhibition with 5 mM 
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Fig. 3 (A) Inactivation of SPT by LCS at inhibitor concentrations of 
0, 0.625, 1.25, 2.5 and 5 mM. (B) Inactivation of SPT by DCS at 
inhibitor concentrations of 0, 10, 20, 40 and 80 mM. (C) Secondary 
plot of l/kapp  versus 1/[inhibitor] for LCS and DCS. 
LCS and DCS, respectively (Fig. 4). When these samples were 
dialysed against buffer in the absence of free PLP we noted 
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Fig. 4 Inhibition of SPT activity by LCS and DCS and regeneration of 
activity by dialysis against PLP buffer. SPT activity of the following 
samples was measured by DTNB assay: (A) 20 pM SPT, (B) 20 pM SPT 
and 5 mM LCS at 25 °C after 2 hour incubation, (C) sample B after 
dialysis against 20 mM potassium phosphate buffer, pH 7.5, (D) sample 
B after dialysis against 20 mM potassium phosphate, pH 7.5, and 
containing 25 i.tM PLP, (E) 20 pM SPT and 5 mM DCS at 25 °C after 
2 hour incubation, (F) sample E after dialysis against 20 mM potassium 
phosphate buffer, pH 7.5, and (G) sample E after dialysis against 
20 mM potassium phosphate, pH 7.5, and containing 25 pM PLP. 
returned to 83% (LCS) and 79% (DCS) of the original activity 
after dialysis against buffer containing 25 pM PLP. The fact 
that activity can be recovered upon dialysis against PLP shows 
that inactivation by both enantiomers does not occur through 
covalent modification of the protein but rather by disabling 	) 
the PLP cofactor. 
UV-visible spectroscopy analysis of LCS and DCS binding to 
holo-SPT 
10 
The UV-visible spectrum of holo-SPT displays absorbance 
maxima at 336 nm and 425 nm corresponding to the enolimine 
and ketoenamine forms of the PLP-bound enzyme, respectively 
(Fig. 5A and B, solid line). When LCS (5 mM) was added to 
the enzyme at pH 7.5 and 25 °C, notable changes in these 15 
peaks occurred suggesting that LCS interacts with 
the PLP cofactor (Fig. 5A, dashed lines). Over a period of 
30 minutes the ketoenamine peak (425 nm) was reduced to 
10% of its original value with concomitant growth of new 
peaks at 330 nm and 380 nm. No further changes in this 20 
UV-vis spectrum were observed when the sample was incu-
bated for - 8 h. This suggests that the PLP cofactor bound to 
residue Lys 265  as an internal aldimine is displaced and one or 
more new species are formed. 
A number of mechanisms have been proposed for cyclo- 25 
serine inhibition of a range of PLP-dependent enzymes and 
have been collated by Olson ci al. 35 In one mechanism 
originally proposed for the inhibition of alanine racemase, 
the authors speculate that the cycloserine ring of the inhibitor-
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Fig. 5 (A) SPT and 5 mM LCS at time 0 (solid line), 30 seconds 
(long dash), 1 minute (dotted line) and 30 minutes (dash dot). (B) SPT 
and 5 mM DCS at time 0 (solid line), 30 seconds (long dash), 2 hours 
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nucleophile on the enzyme or hydroxide ion. 36,37  In the case of 
S. pauciniobilis SPT Ikushiro el al.30 proposed that hydrolysis 
of the ring-open adduct leads to the formation of free 
pyridoxamine 5'-phosphate (PMP) and 3-aminooxypyruvate 
(Fig. 2C). They speculated that the 380 nm peak that they 
observed upon incubation of SPT with LCS could be due to 
formation of a transient oxime intermediate while the 330 nm 
peak is due to the ring-opened adduct prior to hydrolysis 
(Fig. 2C). Of interest, a similar UV-vis spectrum was obtained 
in a study of the interaction of LCS with ArnB, the 
PLP-dependent aminotransferase involved in amino arabinose 
biosynthesis. 38  X-Ray structure analysis of that inacti-
vated enzyme revealed a bound hydroxyisoxazole-PLP adduct 
at the ArnB active site. Therefore it appears that LCS 
can interact with its target enzymes in different ways with 
the cycloserine ring remaining intact or undergoing ring 
cleavage. 
Dramatic changes in the PLP absorbance spectrum of holo-
SPT were also observed within 30 seconds after addition of 
DCS (Fig. 513, dashed line) but changes thereafter were 
much slower compared to LCS, occurring over a period of 
- 10 hours (Fig. SB, dotted and dot-dash lines). These spectro-
scopic changes correlate with the observation that DCS 
inactivates SPT activity at a slower rate than LCS (see 
Fig. 3). Loss of the 425 nm peak was accompanied by 
appearance of a new peak at 380 nm. Over time (-2-10 h) 
this peak shifted to 365 nm along with the slow appearance of 
a pronounced, broad shoulder with 1max  at 330 nm. In 
contrast to the changes that occurred in the presence of LCS 
the 380 nm peak was the most dominant and not the 330 nm 
peak. Since DCS is a much slower inhibitor than LCS a 
build-up of intermediates along with slower formation 
of products might be expected and tends to agree with 
Ikushiro's proposition 30  that the LCS-derived 380 nm peak 
could be that of an oxime intermediate, while the slow 
build-up of products is represented by the slowly-formed 
330 nm shoulder. 
The UV-vis spectra of holo-SPT in the presence of LCS and 
DCS (Fig. 5A and B) are very different to each other. In 
contrast, the spectra of free PLP in the presence of both CS 
enantiomers are identical and display maxima at 360 nm 
(Fig. SIA and B, ESI). Therefore it is clear that the enzyme 
does not simply accommodate a PLP-cycloserine aldimine 
that is formed between the cofactor and inhibitor in solution. 
The new 330 nm peak observed in the spectrum of the enzyme 
in the presence of both CS enantiomers is similar to the 1max 
(320 nm) for free PMP (Fig. SIC, ESI) and could be due to 
bound PMP. 
Identification of SPT-cycloserine reaction products by LC-MS 
The reaction products after inactivation of SPT by both CS 
enantiomers were analysed by LC ESI-MS (Fig. S2, ESI). 
After 30 min inactivation, low molecular weight products were 
separated from the protein by centrifugation through a filter 
with a 3 kDa cut-off. Analysis of this sample by LC ESI-MS 
showed a peak in the single ion monitoring (SIM) at rn/z = 
248 with a total ion count (TIC) above background at 2.8 mm 
that corresponds to PMP (Fig. 5213, ESI). We were unable to 
detect an ion above background corresponding to the 
aminooxyaldehyde so the filtrate was derivatised with 
2,4-dinitrophenylhydrazine (2,4-DNP) to form the corres-
ponding hydrazone (chemical formula C 8 1­1 9N505 = 255.06, 
Fig. S2A, ESI). When the 2,4-DNP derivatised sample was 
analysed by LC-MS a clear peak eluted from the C18 column 
at 3.1 minutes that ionized very well above background 
(Fig. S2C, ES]). Electrospray MS analysis of this peak 
revealed it to have m/z = 256 (Fig. S2C, ESI) which 
corresponds to the [M + H] ion of the 2,4-DNP derivative 10 
of 3-aminooxyacetaldehyde derived from LCS. No peaks were 
observed for free PLP and a 2,4-DNP derivative of the PLP 
aldehyde. These peaks were not observed for control SPT 
samples treated in the same way but in the absence of 
cycloserine (data not shown). We carried out a similar analysis 15 
of SPT after incubation with DCS. We observed the 
same peaks as seen in the LCS analysis but the total ion 
counts were much lower overall and the UV trace was 
more complicated, unsurprising given the slower rate of 
reaction with this enantiomer (data not shown). We 20 
conclude that LCS inactivation of SPT results in the formation 
of PMP and -aminooxyacetaldehyde from the cycloserine 
ring. 
Structure of S. paucimobilis SPT after inactivation by 	
25 
L-cycloserine 
Crystals of SPT:LCS-derived complex were prepared by 
co-crystallisation in the presence of 1 mM LCS. Colourless 
crystals were obtained that diffracted to a resolution of 1.4 A. 30 
We used our previous 1.3 A resolution structure of the holo-
form of S. paucimobilis SPT with the PLP and water molecules 
to solve the structure of this new complex. 18 It was clear that in 
the SPT:LCS complex the PLP cofactor is no longer covalently 
attached to the sidechain of Lys 265  (contoured at 3a and 35 
0.2 A -3) and that the lysine side-chain adopts a conformation 
similar to that observed in the SPT:L-ser external aldimine 
complex 20  (Fig. 6A). The experimental electron density cannot 
definitively assign the co-factor as either PLP (an aldehyde) or 
PMP (amine), as the density is very weak for the terminal 40 
atom. However, in light of the mass spectrometry results we 
have modeled the co-factor as PMP. There is no additional 
density that could be modeled by either free cycloserine or an 
isoxazole ring, which have been observed in other cycloserine-
inactivated PLP dependent enzymes (Table I). Nor could such 45 
additional groups fit into the structure given the position of 
the side chains and a clearly identified water molecule 
(Fig. 613). We do note that unusually the side chain of Tyr 73 
is disordered in the structure. The aromatic ring of the 
pyridoxal co-factor essentially rotates -23° about an axis 50 
which links the C2 and C5 atoms. The phosphate group has 
not moved and the interactions with the protein are largely 
conserved, although there are some changes in water structure. 
In this new structure the side chains of Arg 378 and GIn 357 , 
which were noted to make a salt interaction in the holo-  55 
form, 18 are disordered confirming this is a flexible region of 
the protein. In contrast, in the PLP:L-ser complex the loop 
containing Arg378 moves into the active site to allow the Arg 378 
side-chain to make a salt contact with L-ser carboxylate 
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Fig. 6 (A) Fo - Fc electron density For the PMP molecule. This \%aN calculated from molecular replacement model which was refined and had 
omitted the co-factor. The map is contoured in green at 3 (0.2 A 3 ). Also shown are the side chains of Lys265, His] 59, Asp231 and His-2 34. 	.s 
Monomer A is shown in ribbon in cyan and monomer B in magenta. The additional Fo - Fe electron density "blob" is shown in blue, contoured at 
2.7 (0.2 A 3 ). A molecule of the -aminooxyacetalaldehyde identified by mass spectrometry is placed in the density. Carbons are colored yellow, 
nitrogen blue, oxygen red and phosphorous orange. (B) Overlay of SPT:L-ser (2bwj) and the LCS inactivated form. The loop containing R378 
adopts the "swung-out" conformation in the LCS form. in contrast to the "swung in" conformation in SPT:i-ser. The color scheme for the LCS 
- 	inhibited form is as (A). For the SPT:L-ser structure, monomer A is colored light blue. Carbons are colored green, and other atoms are colored the - 
same as in (A). The main chain of R378 adopts a very different conformation from the SPT:i-ser structure because the salt contact with L-ser is 
missing. A well ordered molecule (red sphere) in the LCS structure is found in the same location as the 1-ser carhoxylale. The side chain of L-ser 
points towards the unfitted blob at the active site. This figure was prepared using PyMol (http.www.pymol.orgi). 
55 (Fig. 6B). Interestingly there is an additional 'blob' of difference 
electron density lying adjacent to the PMP cofactor and 
parallel to Lys 265 . This blob sits at the interface of the two 
subunits of the functional SPT dimer. If the density is 
contoured at 0.16 e A 3 (2.7a) it has it continuous nature 
(Fig. fiB). We have not fitted this density in the final model but 55  
in light of the mass spectrometry data have rendered it as the 
-aminooxyacetaldehyde. We have been unable to grow X-ray 
diffraction quality crystals of DCS-inactivated SPT and this is 
the focus of current research. 
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Table I PDB entries for PLP-dependent enzymes inactivated by CS 
Enzyme Organism Enantiomer PDB References 
Alanine racemase Enterococcusfaecalis DCS 3E6E 60 
Alanine racemase Escherichia co/i DCS 2RJH 61 
Atanine racemase Streploinyces lavendulae LCS IVFT 62 
Alanine racemase Sireptoinyces lavendu/ae DCS IVFS 62 
Alanine racemase Bacillus s:earot/ierinophilus LCS INIU 23 
Alanine racemase Bacillus stearoihermophilus DCS I EPV 23 
Aminodeoxychorismate lyase Escherichia co/i DCS 112L 63 
ArnB aminotransferase Salmonella typ/limuriu?n LCS IMDZ 38 
Dialkylglycine decarboxylase Pseudo,nonas cepacia DCS & LCS I D7S 24 
D-Amino acid transferase Bacillus species DCS 2DAA 46 
10 
Inactivation of a SPT R378N mutant by LCS and DCS 
We recently determined the crystal structure of the 
SPT:L-serine external aldimine complex that allowed us to 
identify any changes that occur during the formation of this 
key intermediate from the internal aldimine holo-SPT form. 
o The major difference between the two forms was the move-
ment of Arg 378 from a "swung-out" position (bound to the 
side-chain of Gin 357)  to a "swung in" position allowing it to 
form a salt bridge with the -0O2 group of the L-ser 
substrate 20  (Fig. 6B). This Arg378 residue appears to be highly 
?5 mobile in S. paucirnobilis SPT and we had probed its role in 
catalysis and found that a SPT R378N mutant was still active 
albeit at -40x fold reduced rate when compared with the 
wild-type enzyme. We inhibited the SPT R378N mutant with 
LCS and DCS to investigate the mechanism of cycloserine 
30 inhibition. The UV-visible spectrum of the SPT R378N holo-
enzyme is similar to that of the wild-type SPT showing 
absorbance maxima at 336 nm and 415 nm corresponding to 
the enolimine and ketoenamine tautomers of the PLP-bound 
enzyme, respectively (Fig. 7A and B, solid line). When LCS 
35 (5 mM) was added to the mutant enzyme, a decrease in the 
415 nm peak was observed over 30 min along with the 
appearance of a new peak at 330 nm and a small shoulder at 
380 nm (Fig. 7A). Upon completion of the LCS inactivation of 
the SPT R378N mutant we noted that the 380 nm peak 
40 (Fig. 7A) is notably smaller than that observed in the 
wild-type enzyme (Fig. 5A, dashed line) suggesting that in 
the absence of Arg 378 the mutant enzyme is unable to stabilize 
the putative oxime intermediate. 
In contrast to the LCS enantiomer, when DCS was added to 
45 the SPT R378N mutant, dramatic changes in the UV-visible 
spectrum occurred within the mixing time (Fig. 7B, dashed 
line). Most noticeable was the appearance of a new peak at 
495 nm which was transient and disappeared after 30 seconds. 
This could be due to the formation of a quinonoid species- 
50 these have been observed with SPT and other members of the 
AOS family only when incubated with substrates and 
substrate analogues and products, and have characteristic 
absorbance maxima >480 nm. 11 ' 15 ' 16'3940 In the case of 
SPT, Ikushiro el al.39 used a palmitoyl-CoA thioether analo- 
55 gue to initiate deprotonation of the PLP:L-ser external 
aldimine and the resulting quinonoid was observed as a new 
peak in the UV-visible spectrum with 2max = 493 nm. In 
addition to the 495 nm peak, DCS binding to SPT R378N 
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Fig. 7 (A) R378N and 5 mM LCS at time 0 (solid line), 30 seconds 
(long dash), 4 minutes (dotted line) and 30 minutes (dot dash). (B) 40 
R378N and 5 mM DCS at time 0 (solid line), mixing time (long dash), 
30 mm (dot dash). 
340 nm to 380 nm along with a small shoulder at 425 nm 
(Fig. 713). We suggest that the broad peak is likely to be 45 
a combination of overlapping bands due to a number of 
PLP-derived species. The peak shifted only slightly over the 
following 30 minutes and was an indication that maybe a 
DCS-derived intermediate becomes 'stalled' in the SPT R378N 
mutant. LC ESI-MS analyses of the low molecular weight 50 
fraction from both the CS enantiomer-inactivated R378N 
incubations were inconclusive e.g. no ions corresponding to 
the PMP and -aminooxyacetaldehyde products could be 
detected (data not shown). This is unsurprising since the 
R378N mutant has such a slow turnover compared with the 55 
wild-type enzyme. Taken together, the analyses of the SPT 
R378N mutant with both LCS and DCS provide further 
evidence that the SPT enzyme is controlling the reaction 
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requires residues not simply involved in binding the PLP 
cofactor directly. Current efforts are focused on capturing 
CS-derived intermediates in the mutant enzyme by X-ray 
crystallography. 
Discussion 
The antibiotic DCS was first isolated from the soil bacterium 
Streptomyces and its structure and activity determined over 
50 years ago . 4 '5 Cycloserine inactivates many PLP-dependent 
enzymes by disabling the essential PLP cofactor at the active 
site and a list of the X-ray structures from the Protein Data 
Bank with cycloserine adducts bound in the active site is 
presented in Table 1. In each case inhibitor binding results 
in transaldimination of the PLP bound, holo-enzyme and 
leads to formation of a PLP:cycloserine external aldimine. 
Deprotonation of this species gives rise to a stable 3-hydroxy-
isoxazole–PMP adduct whereby the cycloserine ring remains 
intact and covalently linked to the PLP cofactor—the 
so-called "aromatisation mechanism" 35 (Fig. 2B). Olson el al. 
studied LCS inactivation of y-aminobutyric acid aminotrans-
ferase and Peisach ci al. investigated D-amino acid amino-
transferase inhibition by DCS. 46 The aromatized CS adduct 
was observed in both cases where the active site lysine residue 
was inferred as the base which removes the CS ct-proton. It is 
interesting that inhibition by both enantiomers of CS leads to 
formation of the same isoxazole–PMP adduct in the alanine 
racemase that was studied by Fenn et al.23 This could be due to 
the alternating acid/base nature of the residues (Lys 39 , that is 
also involved in formation of the initial internal aldimine with 
PLP, and the side-chain of Tyr 265)  from an enzyme that 
catalyses racemisation of both enantiomers of alanine. How -
ever, this study revealed that the kinetics of inactivation of the 
two CS enantiomers was different; DCS inactivated alanine 
racemase much faster than the LCS. This explains why DCS 
(seromycin) is the better antibiotic. We also found different 
kinetics for each CS enantiomer with SPT; the apparent 
half-life of inactivation was approximately 15 minutes 
for 1.25 mM LCS and 20 mM DCS. Kitz and Wilson 
analysis also revealed that both enantiomers inhibit via a 
bimolecular mechanism i.e. they are weak, but fast inhibitors, 
and suggests that carrying out incubations at lower tempera-
tures would provide further insight into the inhibition 
mechanism. 32 
45 	Since SPT only catalyses condensation between palmitoyl- 
CoA and L-serine (although it does bind D-serine and forms an 
external aldimine) we expected to observe differences in SPT 
inactivation by each CS enantiomer. These were manifested in 
differences in both the rates of inactivation, with LCS being 
50 14 times faster than DCS, and time-dependent changes in the 
UV-vis spectra. We could not detect an aromatised CS deri- 
vative after inactivation, but we did identify PMP and the 
derivatised form of a novel aldehyde by mass spectrometry. 
This CS-derived product was formed from both enantiomers 
55 but to a greater extent (based on LC ESI-MS profiles) from 
LCS inactivation. Moreover, we also identified a PMP form of 
the cofactor in crystals of the LCS-inactivated SPT and a low 
molecular weight species non-covalently bound at the active 
site which clearly no longer contains a cycloserine ring and 
whose size and shape are consistent with the proposed 
-aminoacetaldehyde product. 
These combined data lead us to propose a novel decarboxy-
lative, ring-opening mechanism for inactivation of SPT by 
cycloserine (Fig. 8). The first step in the normal catalytic 
cycle of SPT is a transaldimination step when the substrate 
L-ser replaces the PLP-Lys 265 internal aldimine to form 
a PLP:L-ser external aldimine (Fig. I). Deprotonation of 
this species does not occur until the second substrate 
palmitoyl-CoA binds. It is interesting to note that SPT acts 10 
upon both CS enantiomers in the absence of palmitoyl-CoA 
suggesting that the CS binds in the SPT active site and forms a 
PLP:CS external aldimine complex which then reacts readily. 
Previously, we captured the PLP:L-ser external aldimine and 
the structure revealed the Lys 265 poised below this inter- IS 
mediate at a position where it would act as the base that 
removes the Cc proton (to form a quinonoid) once binding 
of the thioester causes rotation around the Cc–N bond. 20 
Interestingly, D-ser can form an external aldimine with SPT 
but is a poor substrate presumably because the -H is not 20 
in the correct position when palmitoyl-CoA binds. 47 To 
rationalise why we did not observe aromatization of the 
LCS inhibitor (which has the same S-configuration as L.ser) 
we suggest that the Ca proton in the PLP:LCS external 
aldimine cannot be in the optimal orientation to be removed 25 
by the lysine (Fig. I and 8A). Instead we propose ring-opening 
of the LCS ring by cleavage of the amide bond. Amide bond 
hydrolysis of peptides is catalysed by various proteases which 
use a powerful nucleophile (e.g. serine or cysteine in the serine 
or cysteine proteases) to attack this bond and generate an 30 
acylated intermediate which is subsequently hydrolysed. We 
cannot identify such a residue in the active site of SPT at 
present but conformational changes upon ligand binding may 
bring such a residue into play. An acylated ring-opened adduct 
was recently captured by Macheboeuf ci al. who studied the 35 
inhibition of penicillin-binding protein (PBP) by the natural 
product lactivicin (LTV) . 48 This interesting molecule contains 
separate cycloserine and y-lactone rings and is the only known 
natural PBP inhibitor that does not contain a 13-lactam. 
Crystallographic analysis of the PBP revealed that LTV 40 
inhibition involves opening of both the cycloserine and 
y-lactone rings upon attack by the active site serine nucleo-
phile. We have accommodated this possible route (Fig. 8, 
path (a)) into the mechanism and the acylated intermediate 
formed could be hydrolysed to give the carboxylated PLP 45 
intermediate. 
We also suggest an alternative mechanism involving 
direct attack of water on the CS ring (Fig. 8, path (b)). This 
is justified when one considers the properties of cycloserine. 
During the initial characterization of the DCS natural product 50 
Kuehl ci al. and Hidy ci al. found the CS ring opened 
upon treatment with methanol and HCI to afford the 
13-amino-o-alanine methyl ester . 43 ' 	Treatment of this 
ester with alkali converted it back to DCS. Further studies 
revealed unusual chemical properties of DCS; it was found to 55 
dimerise to give a six-membered cis-3-6-bis(aminooxymethyl)-
2,5-piperazinedione adduct in acid .44.49  The proposed mecha- 
nism of adduct formation involves nucleophilic attack of one 
CS amino group at the carbonyl position of another CS 
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Fig. 8 (A) Novel ring-opening, decarboxylative mechanism for inactivation of SPT by LCS. Path (a) denotes an enzymatic, nucleophile(Nu)-
mediated mechanism with an acylated intermediate. Path (b) is the direct hydrolytic mechanism. (B) Inactivation of SPT by DCS highlighting a 35 
proposed quinonoid intermediate observed in the SPT R378N mutant. The paths are the same as in (A). 
molecule, which then ring opens at the amide bond to generate 
the aminooxy form. This reaction occurs again in an intra-
molecular fashion to generate the piperazine ring. So, in 
the context of a SPT catalysed mechanism ring-opening 
could also proceed through acid catalysis and a number 
of potential proton donors are found in the active site 
(e.g. His159). 
We predict two possible routes for the ring-opened adduct. 
Firstly, it can form an oxime intermediate, observed as a 
380 nm peak in the UV-visible spectrum (Fig. 2C and 5A). 
In the second, novel route, the ring-open adduct decarboxy-
lates, which is then followed by imine hydrolysis to form the 
products, PMP and 3-aminooxyacetaldehyde (Fig. 8). This fits 
well with the SPT mechanism since the enzyme catalyses 
decarboxylation of the putative -keto acid Claisen condensa-
tion intermediate to give a product external aldimine which is 
then hydrolysed to release KDS (Fig. 1). Since LCS effectively 
acts as an amino donor to generate PMP, the enzyme has to be 
regenerated by addition of excess PLP (Fig. 4). In contrast to 
LCS, DCS is a much slower inactivator of SPT and this 
suggests that it forms a PLP:DCS external aldimine which 
can react via a similar decarboxylative mechanism, possibly  
requiring some conformational change of the ring opened 
intermediate to promote this step (Fig. 8B). To probe the 
formation of intermediates during SPT inactivation by both 40 
enantiomers we utilised a SPT R378N mutant since this 
residue forms a salt bridge with the carboxylate of the external 
aldimine with L-ser. Again, we saw clear enantiospecific 
differences in the behaviour of this mutant with LCS and 
DCS by UV-vis spectroscopy (Fig. 7). Incubation of SPT 45 
R378N with LCS gave rise to a similar spectrum to the 
wild-type enzyme but lacked a shoulder at 380 nm (Fig. 7A). 
In contrast, we were excited to observe transient formation of 
a quinonoid species at 510 nm during DCS inactivation of the 
R378N mutant (Fig. 7B) and we suggest that this is due to the 50 
quinonoid formed by decarboxylation (Fig. 8B). Of interest in 
a previous study Fenn el al. used a Y265F mutant of alanine 
racemase to probe the different LCS and DCS inactivation 
mechanisms of this enzyme. 37  The Y265F mutant produced 
only the aromatised isoxazole PLP adduct with DCS, whereas 55 
LCS inactivation led to formation of a range of products 
including PMP and acetate. They concluded that this 
active site residue "steers" the pathway of inactivation. In 
our work, mutation of Arg 378 has revealed the presence of 
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transient species and may be useful to capture intermediates 
in future. 
LCS is commonly used in biological research to inhibit 
de novo biosynthesis of sphingolipids in mammalian cells but 
it remains debatable whether it specifically targets SPT. LCS 
was shown to be a potent inhibitor of SPT activity derived 
from mouse brain microsomes 5° and inhibited mouse brain 
SPT activity in vivo after intraperitoneal injection. 51  On the 
other hand cycloserine toxicity in Chinese hamster ovary 
cells was not attributed to SPT inhibition since exogenous 
sphingosine could not rescue cell death. 52 Further research is 
required to examine whether LCS targets SPT alone or can 
inhibit other PLP-dependent enzymes on the sphingolipid 
biosynthetic pathway such as sphingosine-l-phosphate lyase. 
With knowledge gained from our study of the bacterial, 
homodimeric SPT, it will be interesting to characterise the 
products of LCS and DCS inhibition of the heterodimeric 
human enzyme. Whether the 0-aminooxyacetaldehyde deriva-
tive is produced by the more complex mammalian isoforms 
remains to be seen. The identification of two small subunits 
(ssSPTa and ssSPTb) that stimulate human SPT activity > 100 
fold should facilitate the analysis of cycloserine inactivation 
products. 53 
Interestingly DCS is a much more potent inhibitor of 
alanine racemase compared to the synthetic LCS. 23 When 
the antibacterial effect of DCS and LCS was tested on a large 
number of bacterial strains, most had lower tolerance towards 
DCS. 54 In contrast, the sphingolipid-producing bacterium 
Bacteroides /evii was much more susceptible to LCS than 
DCS which correlated to inhibition of SPT. 5° Future investi-
gations are necessary to determine whether LCS could target 
sphingolipid-producing bacterial pathogens. 
Materials 
Plasmids and Escherichia co/i competent cells were purchased 
from Novagen, and all chromatography columns were from 
GE Healthcare. All buffers and reagents including LCS and 
DCS were from Sigma. Palmitoyl-CoA was from Avanti 
Lipids. 
Methods 
Cloning and expression of S. paucimobilis SPT wild-type and 
R378N mutant 
The SPT wild-type gene and R378N mutant were cloned in 
pET28a expression vector (Novagen) as previously described. 20 
The plasmids were transformed into E. co/i BL2I (DE3) 
competent cells and selection was carried out on LB agar 
containing 30 Vg m1' kanamycin. A single colony was used to 
inoculate an overnight culture grown at 37 °C in 500 ml 2YT 
broth (16 g L' Bacto-tryptone, 10 g l' Bacto-yeast extract, 
5 g 1' sodium chloride (pH 7.5)). This culture was added to 
4 litres of 2YT supplemented with kanamycin and grown to 
0D600 of 0.6 before addition of 0.1 mM isopropyl l-thio--D-
galactopyranoside to induce protein expression. Growth 
was continued for 5 hours at 30 °C. Cells were harvested 
(Sorvall RC513 centrifuge) by centrifugation at 3500 rpm for 
20 minutes at 4 °C. The enzyme was purified using IMAC 
on nickel resin (Invitrogen) as well as size exclusion chromato-
graphy (Sephadex S200HR, GE Healthcare). Before UV-vis 
spectroscopy and inactivation assays, the enzyme was freshly 
converted to the PLP-bound form by dialysis against buffers 
containing 25 jiM PLP. 
UV-visible spectroscopy of SPT inhibition by cycloserine 
All UV-visible spectra were recorded on a Cary 50 UV-visible 
spectrophotometer (Varian) and analysed using Cary WinUV 10 
software (Varian). Enzyme was dialysed against 20 mM 
potassium phosphate (pH 7.5) containing 150 mM NaCl 
and 25 jiM PLP for 4 hours at 4 °C. Excess PLP was 
removed on a PD-10 (Sephadex G-25M) desalting column 
15 (GE Healthcare). For UV-visible assays, the concentration of 
recombinant protein was 20 jiM. The spectrophotometer 
was blanked with 20 mM potassium phosphate (pH 7.5) 
containing 150 mM NaCl and spectra were collected from 
800 nm to 200 nm. Quartz cuvettes from NSG Precision 20 
Cells, Type 18-BM (Material quartz, Lightpath 10 mm), had 
a sample volume of 500 pl. By setting the instrument to cycle 
mode and collecting spectra at time intervals, changes in the 
UV-visible spectrum were monitored after addition of 
cycloserine. 	
25 
Rates of SPT inactivation by cycloserine using DTNB assay 
SPT activity was measured using the DTNB assay as 
previously described . 20 Assays contained enzyme, substrates 
and DTNB with final concentrations as follows: I jiM enzyme, 30 
25 MM L-serine, 250 jiM palmitoyl-CoA, 0.2 mM DTNB in 
20 mM HEPES buffer, pH 8.0. SPT was incubated with LCS 
(0 mM, 0.63 mM, 1.25 mM, 2.5 mM and 5 mM) and DCS 
(0mM, 10mM, 20mM, 40 m and 80mM). At time intervals 
an aliquot of the enzyme plus inhibitor solution was diluted 35 
into the assay buffer to record the activity. The remaining 
activity was calculated as a percentage of the total activity in 
the absence of inhibitor i.e. at time zero. Kitz and Wilson 
plots of In % remaining activity against time were linear. 32 
Graphs were plotted using WinCurveFit software, Kevin 40 
Raner, Australia. 
Isolation and derivatisation of aldehyde followed by detection by 
LC-MS 
SPT (100 jiM) was inactivated with 5 mM LCS for 2 hours 45 
followed by centrifugation at 13000 rpm for 10 minutes in a 
Vivaspin 500 concentrators (VWR) to separate the low and 
high molecular weight material. The filtrate (0.1 ml) was added 
to a 2,4-DNP solution (0.5 ml) prepared in acetonitrile and 
containing 0.5% HCI. The solution was incubated at 37 °C for 50 
30 minutes to allow derivatisation of the aldehyde. The 
hydrazone product was detected by LC-MS on a 6130 
quadrupole mass spectrometer with a 1200 Series quaternary 
LC system (Agilent Technologies). Sample volumes were 
typically 10 jil under automated injection into a LC system 55 
equipped with a C18 column followed by separation in a 
methanol : water : formic acid (80 : 19 : I) mobile phase. 
The mass spectrometer was set up in selected ion monitoring 
(SIM) mode to search for ions with masses corresponding 
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to the 3-aminoacetaldehyde and its 2,4-DNP hydrazone 	Acknowledgements 
derivative (Fig. S2, ESIfl. 
Structural biology 
Crystals of LCS-inactivated SPT were prepared by co-
crystallisation. A 10 mM stock solution of LCS was prepared 
and added to freshly prepared holo-SPT (20 iiM, in 10 mM 
Tris 7.5, 150 mM NaCl and 25 .tM PLP) to give a final LCS 
concentration of 1 mM. After overnight incubation at 4 °C, 
the protein was concentrated to 20 mg ml and this solution 
was used to set up crystal trials. Colourless SPT:LCS crystals 
grew from a 2 jil drop consisting of I tl of the SPT/LCS 
solution and I i.tl of well solution (100 mM HEPES, pH 6.5, 
110 MM  MgCl2 , 21.5% PEG 3350). A single crystal was 
mounted in a cryo-loop and cryo-protected in 22% PEG 
3350, 120 mM MgCl,, 100 mM HEPES, pH 6.5, 20% PEG 
400. The crystal was frozen and data obtained that diffracted 
to a resolution of 1.40 A on beamline 1D14-1 (wavelength = 
0.934 A) at 100 K. Data were collected on and processed to 
1.40 A using XDS. 55 The structure was solved by molecular 
replacement using the 1.3 A holo-form as the model (with co-
factor and water molecules removed). Due to an oversight a 
new Free-R set was devised for the structure, more rigorous 
would have to be use the same as the isomorphous search 
model. To overcome the bias in the Free-R set, all the ligands 
and waters were removed, the B-factors reset to a common 
value and then the structure was refined. TLS groups were 
defined using the TLS server 56  and once again the B-factors 
reset to a single value. The asymmetric unit contains a mono-
mer of protein, but as with the native contains a functional 
dimer. The structure was refined using REFMAC5, 57 
TLS groups were used and in the final steps of refinement 
anisotropic thermal factors were refined for all atoms. Inclu-
sion of anisotropic B-factors decreases R-free by 0.6% and 
was therefore judged appropriate. PMP was modelled into the 
difference electron density immediately after molecular repla-
cement, the density was unambiguous. The choice of PMP not 
PLP was made based on mass spectrometric data not the 
X-ray data themselves. Water molecules were added manually 
and checked using COOT. 58 A dictionary of the aldehyde was 
made using the PRODRG server. 59 The aldehyde was not 
included in the final model. Its inclusion did not perturb either 
the R-factor or the stereochemical quality of the model. 
The data collection and refinement statistics are given in 
Supplementary Table4 
Abbreviations 
2,4-DNP 	2,4-dinitrophenylhydrazine  
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ABSTRACT: 
Serine palm itoyltransferase (SPT) catalyses the first step 
in the de novo biosynthesis of sphingolipids (SLs). It uses 
a decarboxylative Claisen-like condensation reaction to 
couple L-serine with palm itoyl-CoA to generate a long-
chain base product, 3-ketodihydrosphingosine. SLs are 
produced by mammals, plants, yeast, and some bacteria, 
and we have exploited the complete genome sequence of 
Sphingomonas wittichii to begin a complete analysis of 
bacterial sphingolipid biosynthesis. Here, we describe the 
enzymatic characterization of the SPT from this 
organism and present its high-resolution x-ray structure. 
Moreover, we identified an open reading frame with 
high sequence homology to acyl carrier proteins (ACPs) 
that are common to fatty acid biosynthetic pathways. 
This small protein was co-expressed with the SPTand 
we isolated and characterised the apo- and holo-forms of 
the ACP. Our studies suggest a link between fatty acid 
and sphingolipid metabolism. © 2010 Wiley Periodicals, 
Inc. Biopolymers 93: 811-822, 2010. 
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phingolipids (SLs) are essential structural compo- 
nents of eukaryotic membranes and more recently 
\\ they have been found to play important roles in cell 
)
signaling, inflammation and apoptosis. They are 
also found in various microbial species such as yeast 
and fungi, as well as bacteria such as Sphingomonas. The 
early steps in SL biosynthesis appear to be conserved in all 
species studied to date; the first reaction in the pathway is 
catalysed by the pyridoxal 5'-phosphate (PLP)-dependent 
enzyme serine palmitoyltransferase (SPT). It produces 3-
ketodihydrosphingosine (KDS) by a Claisen-like condensation 
Of L-serine and palmitoyl-CoA (see Figure 1). SPT belongs to 
the c-oxoamine synthase (AOS) 5 family which contains three 
other well-characterized members: 8-amino-7-oxononanoate 
synthase (AONS), 6 ' 7 5-aminolevulinate synthase, ° and 
2-amino-3-ketobutyrate-00A ligase." 2 Together they cata-
lyse similar chemical reactions but have specificity for their 
respective amino acid and fatty acid CoA thioester substrates. 
Genes encoding SPT have been identified in numerous 
organisms but the species-specific traits of each enzyme have 
only emerged in recent years.' 3 In humans, SPT is a heterodi-
meric, membrane-bound enzyme encoded by two homolo-
gous genes making its isolation in a catalytically active form 
extremely challenging. 14  Recent evidence suggests that the 
human enzyme is even more complex with the identification 
of two small subunits that activate in vitro SPT activity '10 
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2S II 	+ HO 
ScoA 	NH3 H3F H 
Palmitoyl-00A 	
L-Senne 	CoASH + CO2 	3-Ketodihydrosphingosine 
FIGURE 1 Reaction catalysed by SPT. 
fold. 15  Insight into the structure and mechanism of SPT has 
been obtained from studies of a cytoplasmic, water-soluble, 
homodimer that was isolated from Sphingomonas paucimobi-
us. 16 The interactions between this SPT and various sub-
strates and inhibitors have also been explored.' 7 ' 9 Our 
group solved the first SPT structure, that of the PLP-bound, 
holo-form of S. paucimobilis that brought to light important 
catalytic residues and substrate specificity. 20 This also allowed 
a model of the human heterodimeric enzyme to be built to 
probe residues involved in human neurological disorders 
such as hereditary autonomic neuropathy type I (HSAN1). 
More recently, we captured the PLP:L-ser external aldimine 
complex which provided insight into how this key intermedi-
ate is stabilised. 2 ' Recently, Ikushiro et al. 22 reported the 
structure of the holo- and external aldimine forms of SPT 
from the bacterium Sphingobacterium multivorum showing 
some differences with the S. paucimobilis SPT. 
As well as detailed studies on the individual enzymes 
involved in SL and lipid synthesis and metabolism, increasing 
effort has also been placed on expanding our knowledge of 
the structures and functions of all lipids within an organism, 
the field of "lipidomics." 23 Reports of the lipid content of 
mammals, plants and microbes have begun to appear and it 
is important to investigate interesting model organisms. 
Here, we describe our work on Sphingomonas wittichii RW1, 
a strictly aerobic Gram-negative bacterium that produces 
both glucuronosyl and galacturonosyl ceramide types of 
SLs. 24 This is also an environmentally useful organism as it 
metabolises toxic pollutants such as dioxin. 25  The genome 
sequence of S. wittichii RW1 was recently completed and this 
stimulated our interest in using this organism as a good 
model for bacterial SL biosynthesis. We identified the gene 
encoding S. wittichii SPT using the amino acid sequence of 
the SPT from S. paucimobilis. Curiously, upstream from SPT, 
we found a small gene product that showed high sequence 
homology to fatty acid synthase (FAS) type II acyl carrier 
proteins (ACPs; Supporting Information Figure 1). ACPs are 
small (—'10 kDa), acidic proteins that play essential roles in 
the biosynthesis of fatty acids and other important natural 
products including polyketides. 26 ' 27 ACPs are expressed in an 
apo-form and then post-translationally modified to their 4'- 
phosphopantetheine (4'-PP), holo-form using CoASH by an 
ACP synthase (ACPS also known as a phosphopantetheinyl 
transferase, PPTase). 28 The fatty acid is built up step-by-step 
by enzymes within the multi-subunit FAS complex whilst 
attached to the ACP as a thioester. 26 ACPs have also been 
shown to be key components of polyketide synthases and 
their peptidyl carrier protein (PCP) homologs also carry out 
essential roles in nonribosomal peptide synthases. 29 The car-
rier protein must interact with each of the enzymes within 
each complex and the exact details of these protein—protein 
interactions are the subject of current research. 30 
The discovery that the S. wittichi ACP and SPT genes are 
encoded by consecutive open reading frames (ORFs) on the 
genome suggest a possible direct link between fatty acid and 
sphingolipid biosynthesis. In this study, we report the struc-
tural and functional characterization of S. wittichii SPT. We 
have also isolated and purified the linked apo-ACP and have 
successfully converted it into the holo-form. Sequence analy-
sis, coupled with chemical and molecular modeling, suggest 
that it is an unusual apo-ACP. Our work provides the plat-
form for future studies of bacterial sphingolipid biosynthesis. 
MATERIALS AND METHODS 
Strains, DNA, and Expression Plasmids 
The S. wittichii RW1 strain was a kind gift from Dr. Rolf Halden, John 
Hopkins University, USA. The complete genome sequence is available 
(http://img.jgi.doe.gov ). The plasmids encoding the Streplomyces coe-
licolor ACPS (pET15b-ACPS) and Bacillus subtilis Sfp (pET28a/Sfp) 
were generous gifts from Dr. Matt Grump (University of Bristol) and 
Prof. Jason Micklefield (University of Manchester), respectively. The 
synthetic DNA construct (encoding Strep tomyces verticillus SVP) was 
purchased from Mr. Gene, Regensburg, Germany. 
Molecular Biology Reagents, Chemicals, and 
Chromatography Media 
Plasmids (pET) and Escherichia coli chemically competent cells 
BL21 (DE3), HMSI74 (DE3) were purchased from Novagen. PCR 
products were cloned using the pGEM-T Easy cloning kit from Pro-
gema. Taq Polymerase Beads were from GE Healthcare. Plasmid and 
chromosomal DNA isolation kits were from Qiagen and used as per 
manufacturers' instructions. All buffers and chemical reagents were 
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FIGURE 2 StruLlurc o) J)/w//l c ))aS wittic/Ili SPI. (a) Overall structure of the SPI dimer show-
ing one monomer in blue and the other in olive. The cofactor PLP bound to the residue Lys245 in 
the blue monomer is shown in stick form and is colored green. The equivalent residue from the 
olive monomer is colored magenta. (b) Catalytic site view showing the cofactor PL.P of monomer A 
and the residues Hisl39, His214, and AsnI 18 involved in its stabilization. Monomer A is drawn in 
blue and monomer B is drawn in olive. (C) Overlay of SPT SW and SPT SP showing similar residues 
involved at the active sites. SP1 SW is colored blue and the PLP plus active sites residues are represented 
in green. SPI SP is colored magenta and the PLP cofactor and the active site residues are pink. 
from Sigma. Palmitoyl-CoA was from Avanti Polar Lipids and 
[U- 14C]i -serine (specific activity 1.85 MBq/mL) was from GE 
Healthcare. The decanoyl-CoA (10:0), lauroyl-CoA (12:0), myris-
toyl-CoA (14:0), stearoyl-CoA (18:0), and arachidoyl-CoA (20:0) 
were from Sigma. Oligonucleotide primers were purchased from 
SigmaGenosys. PEG 3350 was from Fluka. All chromatography col-
umns (Ni-sepharose, gel filtration) were from GE Healthcare. 
Gene Cloning 
Using the Sphingomonas gene sequence (Supporting Information 
Figure 2) four PCR products that amplified the genes encoding 
ACP-SPT together. ACP alone, SPT alone and ACPS were amplified 
using purified genomic DNA from S. wiuichii strain RWI as a tem-
plate and the following primers: 
(ACP-SPT and ACP forward BspHl) 
5'-CATGTCATGAGCAGCAGAGAAGACATCTTCACC-3' 
(ACP-SPT reverse Hindill) 
5'-GGAAAAGCTTGGGGAUACTCCCGTGGCGCGCC-3' 
(ACP reverse HindlIl) 
5'-AAGCT1-GGAGAGGAGGTCGGCCACC-3' 
(SPT forward Ncol) 
5'-GGCTGACCCCATGGCCGACCTCCT-3' 
(SPT reverse HindlIl) 
5' -TGCGGCCGCAAGCTTGGGGATTAC-3' 
(ACPS forward Ndel) 
5'-AGCGGGGAACCCATATGATCATCGGCATC-3' 
(ACPS reverse Xhol) 
5'-ATCCCCCTCGAGCAGCGGGCGCGCATACA-3' 
These primers introduce appropriate restriction enzyme sites 
(underlined) for subsequent cloning in the E. coli expression plas-
mids; pET-28a (for ACP-SPT, ACP. and SPT), pET-22b (for ACPS) 
designed to include a His 6 tag at the C-terminus of the recombinant 
SPT and ACPS proteins. 
The predicted sequences of the S. wit:ichii gene products (or 
ORFs) are annotated in the whole genome sequence (http:// 
genome.jgi-psf.org/sphwi/sphwi.annotation.html) . This suggested 
that the "Swit_3900" ORE encoded an "AONS" of 400 amino acids 
with high sequence homology to SPT from S. paucimobilis. 
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Sequence analysis also suggests that this ORF was translated from a 
GTG start codon, 10 amino acids downstream from a possible alter-
native Met start codon. Consequently, the SPT expressing clone was 
designed in order to produce the "isolated" SPT sequence and allow 
determination of the sequence of the translated protein. 
The gene encoding the promiscuous PPTase (also known as 
ACPS) from S. verticillus ATCC15003 "Svp" was generated by a 
commercial company (Mr. Gene, Germany) using the sequence 
described in Sanchez et al. 3 ' The synthetic gene contained the 
restriction site Ncol and Xhol to clone the Svp gene in pET-22b and 
obtain a His6 Tag at the C-terminus to enable purification by immo-
bilised metal affinity chromatography (IMAC) on nickel resin. 
Protein Expression and Purification 
Except where specified protein expression was carried out in E. coli 
BL2I (DE3) host cells transformed with the appropriate pET plas-
mid and grown in the appropriate selective antibiotic (ampicillin at 
100 pg/mL or kanamycin at 30 igImL). To co-express S. wittichii 
ACP and SPT, cells transformed with the appropriate plasmid (pET-
28a/ACP_SPT SW) were cultured in 2YT media 116 g/L Bacto-tryp-
tone, 10 g/L Bacto-yeast extract, 5 gIL sodium chloride (pH 7.5)1 
including the appropriate antibiotic at 30°C for 3-5 h in the pres-
ence of 0.1 mM isopropyl fl-D-1-thiogalactopyranoside (IPTG) to 
induce protein expression. To express the S. verticillus Svp protein, 
the expressing plasmid was used to transform HMS 174 (DE3) cells 
which were grown at 30°C for no longer than 3 h to avoid any mis-
folding and inactivation of the enzyme. It is important to note that 
it was not possible to express the S. wittichii ACP alone, thus we co-
expressed the ACP with SPT from the T7 promoter on the pET plas-
mid. Induced cells were harvested (Sorvall RC513 centrifuge) by cen-
trifugation at 3500 rpm for 20 min at 4°C. 
For the isolation of all recombinant proteins, the cell pellet was 
resuspended in 20 mM potassium phosphate buffer (pH 7.5) contain-
ing one EDTA-free protease tablet (Roche) before being disrupted by 
sonication (Soniprep 150) for 15 cycles (30 s on, 30 s off) on ice. The 
cell debris was removed by centrifugation at 16,000 rpm for 30 min at 
4°C and the supernatant cell-free extract was filtered (0.45 pm syringe 
filter), before being loaded onto the appropriate chromatography col-
umn. All chromatography steps were carried out at 4°C using an 
ATKA (GE Healthcare) to control flow rates and salt gradients. 
Each of the poly-histidine tagged recombinant proteins, S. witti-
chii SPT, B. subtilis Sfp, and S. coelicolor ACPS were purified accord-
ing to the previously described methods. 21 ' 32 ' 33 Cell free extracts 
containing recombinant S. wittichii ACP protein in 20 mM potas-
sium phosphate buffer (pH 7.5) were loaded onto a HiLoad 
Q-sepharose anion exchange column (50 mL, GE Healthcare) pre-
equilibrated with 20 mM potassium phosphate buffer (pH 7.5). The 
ACP protein was eluted with a linear salt gradient (0-1.OM KC1) 
over 20 column volumes (1 L). Fractions containing ACP were iden-
tified by SDS—PAGE analysis, pooled and loaded onto a calibrated 
HiLoad 16/60 Superdex 75 prep grade (120 mL) size exclusion col-
umn. Elution was carried out in 20 mM potassium phosphate buffer 
(pH 7.5), 150 mMNaCl. 
The his-tagged S. wittichii ACPS in 20 mM potassium phosphate 
buffer (pH 7.5), 150 mM NaCI, 10% glycerol (v/v), and 20 mM im-
idazole was loaded onto a HiTrap Chelating HP column pre-equili-
brated with the same buffer. The protein was eluted with a linear 
gradient (20-500 mM imidazole) over 10 column volumes. Frac- 
tions containing ACPS were pooled and loaded onto a previously 
calibrated HiLoadTSS  16/60 SuperdexTM 75 prep grade (120 mL) 
size exclusion column. The pure protein was eluted at a flow rate of 
1.2 mL/min in 20 mM potassium phosphate buffer (pH 7.5), 150 
mM NaCl, 10% Glycerol. The S. verticillus Svp protein was purified 
following the same protocol that was used for S. wittichii ACPS iso-
lation but the purification buffer did not contain any glycerol. 
For storage, the enzyme solutions were brought to a final con-
centration of 20% glycerol (v/v) (S. wittichii SPT, S. wittichii ACP, S. 
coelicolor ACPS, and B. subtilis Svp) or 40% glycerol (S. verticillus 
Svp and S. wittichui ACPS) and stored at —80°C until use. 
Protein identity and integrity were confirmed by routine high 
pressure liquid chromatography electrospray mass spectrometry 
(HPLC-ESI MS) on a MicroMass Platform II quadrupole mass 
spectrometer equipped with an electrospray ion source. The 
experimentally determined masses of each recombinant protein 
were within 0.1% of the predicted masses based on their amino 
acid sequences. 
Determination of the "Isolated" S. wittichii 
SPT N-Terminus 
The ORF annotated as "Swit3900" in the S. wittichii genome 
sequence is predicted to encode an "AONS". The translated protein 
is predicted to contain 400 amino acids and a theoretical mass of 
43,095 Da. To determine the actual size of the ORF we cloned ORFs 
"Swit_3899" and "Swit_3900" together in a pET plasmid with a sin-
gle T7 promoter and a six histidine tag at the C-terminal end of 
ORF Swit3900. Expression of both genes was induced with IPTG 
and the Swit_3900-encoded protein was purified using standard 
IMAC procedure. After liquid chromatography (LC)-ESI-MS analy-
sis, the mass of the purified recombinant protein was 44,515 Da 
which is in good agreement with a sequence containing 412 amino 
acids that has lost the N-terminal methioine residue and includes 
the C-terminal KLAAALEHHHHHH affinity fusion tag. There-
fore, the purified Swit3900 protein, hereafter named SPT SW, 
resembles a N-terminally truncated SPT SP (lacking 20 amino 
acids). 
Spectroscopic Measurements and Determination of 
Dissociation Constants 
All UV-visible spectra were recorded on a Cary 50 UV-visible 
spectrophotometer (Varian) analyzed using Cary WinUV software 
(Varian). We used the protocol previously described in Raman et 
al. 21 , to characterise the spectroscopic properties of the recombinant 
S. wittichii SPT. Briefly, the SPT was converted to its internal aldi-
mine (holo-) form by dialysis against freshly prepared buffer con-
taining 20 mM potassium phosphate buffer (pH 7.5), 150 mM 
NaCl, 25 pM PLP for 1 h at 4°C. We removed excess PLP by passage 
through a PD-10 column (GE Healthcare) eluting with the same 
buffer without PLP. The protein was concentrated to 10-20 mglmL 
using a VivaSpin 30 kDa cut-off ultrafiltration spin filter. The disso-
ciation constant for L-serine (lCd)  was determined spectroscopically 
by monitoring the changes (at 425 nm) upon incubation of the pro-
tein with increasing concentrations of L-ser (0-80 mM). Data were 
fitted to a hyperbolic saturation curve using Sigma Plot software as 
described in Raman et al. 2 ' 
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Table I Kinetic Parameters for the Purified SPT S. wittichii and S. paucimobilis 
Enzyme 	kcat X 10'(s—') 	J(Ser (mM) 	KPCOA ('UM) k/K r  (M's) 	 er k 1 /Kc0A (M's) 	x (MM) 
SPT S. wittichii 	 68.7 ± 1.5 	0.78 ± 0.10 	23.4 ± 4.5 	 88.1 	 2,936 	0.80 ± 0.1 
SPT S. paucimobillis 	1150.0±30.0 1.40 ± 0.10 35.4 ± 2.0 821.4 32,486 1.1 ± 0.1 
Assay of Recombinant SPT Activity 
We used methods previously described in Raman et al. '21  to deter-
mine the catalytic activity of S. wittichii SPT with a range of sub-
strates. Product formation was monitored by following production 
of ( 14C] KDS from [' 4C] L-serine using thin layer chromatography 
and autoradiography. SPT activity was also monitored continuously 
by measuring the release of CoASH by reaction with 5,5'-dithiobis-
2-nitrobenzoic acid (DTNB) at 412 nm. 
Structural Biology 
The SPT protein was screened for suitable crystallization conditions 
at the Scottish Structural Proteomics Facility. The proteins were dia-
lyzed in the presence of excess PLP to ensure complete reloading 
prior to crystallization. The screens were built on a Hamilton 
Microstar liquid-handling robot controlled by Rhombix system 
software (Thermo). 
The S. wittichii SPT was crystallized at 20 mg/mL in 10 mM Tris 
(pH 7.5), 150 mM NaCl, 25 pM PLP using 30% PEG monomethy-
lether (MME) 2000, 0.1M KSCN, (NEXTAL JCSG+ screen condi-
tion 81). Crystals used for data collection were soaked for a few 
minutes in a solution of 27% PEG MME 2000, 0.22M KSCN, 18% 
PEG400 plus 1-2 mM PLP. 
The crystal was mounted in a cryo-loop (Molecular Dimensions) 
and frozen by plunging it into liquid nitrogen and carried in a dry 
cryogenic Dewar to the European Synchrotron Radiation Facility 
(Grenoble, France) for data collection. Multiple crystals were 
screened at beam line BMI4.The data sets were collected at 100 K to 
2.1 A using beam line 14 (Supporting Information Table I). The 
data for S. wittichii SPT were processed with Mosfim and scaled 
with Scala from the CCP4 suite of programs. 34'35 The density 
revealed that the PLP was covalently bound to Lys245 confirming 
that we had obtained the internal aldimine, holo-form of the pro-
tein. The SPT model was refined using Refmac5 34 and manually 
adjusted, including the addition of water molecules with Win-
Coot. 36 Data and structure files have been deposited in the Protein 
Data Bank (PDB ID code 2XBU).  
mM) in a final volume of 250 ;LL. The reaction was incubated at 
37°C overnight and then analyzed by LC-ESl-MS to determine the 
extent of modification of the apo-ACP. 
For each PPTase a different reaction buffer was used. For S. coeli-
color ACPS and S. verticillus Svp, 50 mM Tris buffer, pH 7.8 was 
used. For B. subtilis Sfp we carried out the reaction in 75 mM MES 
buffer at pH 6.0 and for S. wittichii ACPS this was performed in 20 
mM potassium phosphate buffer (pH 7.5); 5 mM DTT was added to 
the reaction mixture when using free CoASH as a substrate. 
It is important to note that MgCl 2 concentrations of >1 mM 
could not be used for reactions containing acyl-CoAs as this caused 
precipitation of these substrates. 
High-resolution LC-FT-ICR Mass Spectrometry 
Analysis 
For high-resolution mass spectrometry (IC-FT-ICR MS), an Ulti-
mate 3000 HPLC system (Dionex, Sunnyvale, CA), equipped with a 
monolithic PS-DVB (500 pM X 5 mm) analytical column (Dionex), 
was used. MS data was acquired on a Bruker 12 T Apex Qe FT-ICR 
(Bruker Daltonics, Billerica, MA) equipped with an electrospray ion-
ization source. Desolvated ions were transmitted to a 6 cm Infinity 
cello penning trap. Trapped ions were excited (frequency chirp 48-
500 kHZ at 100 steps of 25 ps) and detected between m/z 600 and 
2000 for 0.5 s to yield a broadband 512 Kword time-domain data. 
Fast Fourier Transforms and subsequent analyses were performed 
using DataAnalysis (Bruker Daltonics) software. Multiple charge 
states could be observed in this way for each of the major species. 
Isotopic Fitting. Isotope distributions of specific charge states 
were predicted using IsotopePattern software (Bruker Daltonics) 
from theoretical empirical formulae. These were overlaid upon the 
recorded experimental data as scatter plots, with the theoretical 
apex of each isotope peak designated by a circle. 
Conversion of S. wittichii apo-ACP to holo-ACP and 
a_yl-ACP 
The protocol used to modify the S. wititchii apo-ACP with the differ-
ent PPTases was modified from previously described methods. 31-33  
For brevity, the protocol is described using the generic name, 
"PPTase" that refers to each of the recombinant ACPS enzymes 
used; S. coelicolor ACPS, B. subtilis Sfp, S. verticillus Svp, and S. witti-
chii ACPS. 
A final enzyme concentration of 60 pM apo-ACP in reaction 
buffer (see below) was incubated with 1 pM PPTase, 1 MM  MgCl2 
and a range of concentrations of CoASH/acyl-CoA (250 pM to 1 
Top-Down Fragmentation. Top-down fragmentation was per-
formed on the 12 T Qh-FT-ICR. Two specific ions, m/z 1521 and 
1304, were sequentially isolated using the mass resolving quadru-
pole, and MS/MS was performed using collision induced dissocia-
tion (CID). For CID, the collision voltage was typically set between 
20 and 35 V. Fragmentation data was the sum of 200 acquisitions 
and data analyses were performed using DataAnalysis (Bruker Dal-
tonics). The SNAP 2.0 algorithm was used for automated peak pick-
ing. The resulting top-down fragment mass lists were combined and 
searched against the primary sequence of ACP using Prosight-PTM 
software. 37  Mass error tolerances were set for all searches at 10 ppm. 
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RESULTS AND DIISCUSSIION 
Purification and Characterization of S. wittichii SPT 
Using BLAST analysis we searched the annotated genome of 
the sphingolipid-producing organism S. wittichii RW1 for 
the gene encoding a homologue of S. pauciinobilis SPT. We 
identified a hit ORF with 70% sequence identity that was 
annotated as "Swit_3900". It had been labeled as an AONS 
catalysing the first step in biotin biosynthesis (condensation 
Of L-alanine and pimeloyl-CoA to generate 8-amino-7-oxo-
nonanoate, AON 6) as there is highly conserved sequence 
homology between members of the AOS family. We also 
noted that just upstream of "Swit_3900" another small gene, 
"Swit_3899" had been annotated with "unknown function." 
Upon sequence analysis of this translated 80 aa protein we 
found a conserved phosphopantetheinylation sequence motif 
(DSLT) characteristic of ACPs (Supporting Information Fig-
ures 1 and 2).29.38  The conserved serine residue is post-trans-
lationally modified using CoASH as a substrate to convert 
the apo-ACP into the holo-ACP form containing a 4'-PP 
prosthetic arm. 28 Further sequence analysis of the two genes 
suggested the presence of a typical bacterial promoter 
upstream of the predicted ACP gene and ribosome binding 
sites (RBSs) before the putative ACP gene (Supporting Infor-
mation Figure 2). A consensus RBS could not be detected for 
the SPT gene. 
To explore the structure and function of this pair of pro-
teins we cloned both genes into a pET expression plasmid to 
determine if both genes could be transcribed from the strong 
plasmid-encoded T7 promoter. We also fused a six-histidine 
tag at the C-terminal end of the putative SPT to enable facile 
purification by IMAC as this tagging strategy worked well 
with our previous S. paucimobilis SPT. We induced transcrip-
tion from the T7 promoter of the expression plasmid pET-
28a/ACP...SPT SW using IPTG and we analyzed the expressed 
protein products by SDS-PAGE (Supporting Information 
Figure ib). Two clearly overexpressed bands were observed at 
10 kDa and '-'45 kDa corresponding to the ACP and SPT 
gene products, respectively. This result confirmed that both 
genes could be expressed from a single external promoter 
and suggested that the SPT product was translated from a 
RBS on the RNA transcript. 
A large-scale culture was carried out with these expressing 
cells, a cell-free extract was prepared in the presence of PLP 
(25 ,uM) and then subjected to IMAC to isolate the His-
tagged putative SPT SW. Upon elution with imidazole we 
obtained fractions highly enriched in a single 42 kDa protein 
which was further purified using size exclusion chromatogra-
phy. The protein eluted as a dimer and its UV-vis spectrum 
showed characteristic absorbance maxima at 340 and 425 nm  
which correspond to the enolimine and ketoenamine forms 
of the PLP-bound enzyme (Supporting Information Figure 
3). By measuring the change in absorbance at the ketoen-
amine-specific wavelength at 425 nm, the dissociation con-
stant for L-Serine (Kd L-Ser) was found to be 0.8 mM which is 
in the same range as the value (1.1 mM) obtained for the S. 
paucimobilis SPT (Table I). 1821 
We noted that during isolation of the His-tagged SPT SW 
by IMAC, the putative ACP protein did not bind to the col-
umn, so this unbound fraction was used for the isolation of 
the ACP by ion-exchange chromatography (see below). 
SPT Activity and Kinetics 
We measured KIDS production catalysed by the SPT SW with 
[ 14C] L-serine and palmitoyl-CoA using the method 
described previously (Supporting Information Figure 3b). 39 
We also used a continuous, spectroscopic DTNB-linked assay 
that detects formation of CoASH to determine kinetic pa-
rameters of the enzyme. The SPT SW bound L-serifle and 
palmitoyl-CoA with Km values of 0.78 mM and 23.4 pM, 
respectively (Table I). The enzyme turned over with a 'at  of 
0.069 s and a catalytic efficiency (kcatIKr) of 88.1 M' 
for L-serine. A comparison of the kinetics of the SPTs 
from S. wittichii and S. paucimobilis revealed that both 
enzymes display similar binding affinities for both substrates 
but that the SPT SW had a much lower turn over and effi-
ciency ('-'17 fold for kcal;  and 9 and 11 fold for k, 1,,/Km for 
L-ser and palmitoyl-CoA, respectively) compared with the 
SPT SR 
The acyl-CoA chain length specificity of the SPT SW was 
also investigated. We found stearoyl-CoA (C18:0) to have the 
fastest turnover (kcat = 0.083 s') of all of the acyl-thioesters 
tested and a Km of 12.9 pM (Supporting Information Table 
II). When comparing the kcattKm values, stearoyl-CoA 
(C18:0) was also the most efficient substrate (6416 A4 s'). 
In contrast, the decanoyl-CoA (C10:0) and lauroyl-CoA 
(C12:0), were the poorest substrates and accurate kinetic 
constants could not be determined. 
These combined results suggested that although the SPTs 
from these different strains displayed high sequence identity 
and similar substrate binding specificities there could be 
subtle differences that would lead to differences in turnover 
rates. It appeared that the SPT from both Sphingomonas 
strains bound L-serine with the same affinity (similar 1d  val-
ues) and similar Km values for CoASH ester substrates but 
there were large differences in catalytic rates. The presence of 
a putative ACP that co-expressed with the SPT suggested that 
instead of using palmitoyl-CoA as a thioester substrate, the 
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FIGURE 3 Surface structure of SPT showing potential palmitoyl-CoA binding cavity. (a) View 
from the top. (b) lop/side view. Monomer A is show in blue and monomer B in olive. The two 
hydrophobic cavities are colored cyan and green. The end of each channel is delimited by two valine 
residues Va123 and Va1341 shown in magenta. 
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High-resolution Crystal Structure of S. wittichii SPT 
S. wittichii SPT crystallised as a dinner in the asymmetric 
unit, in contrast to the S. paucimobilis SPT where the dimer 
is generated by crystal symmetry (Figure 2a). 2022 However, 
both the dirner and monomer structures are similar (with a 
few differences) between the Sphingomonas strains, root 
mean square deviation for the dimer is 0.65 A (796 C alpha 
backbone) and 0.61 for the monomer (398 C alpha back-
bone). In our previous SPT SP structure, it was not possible 
to model the N-terminal 22 amino acids and in both SPTs 
the C-terminal hexa-histidine affinity tags were not visible. 
The SPT SW is shorter at the N-terminus compared to the 
SPT SP and therefore the SPT SW model contains 398 of the 
412 amino acids from Ala2 to Pro400 inclusive. The PLP 
cofactor is bound in both monomers in a similar way. All 
SPT:PLP interactions observed with the cofactor in one 
active site are also present in the second PLP-binding site 
within the dimer. The PLP cofactor forms hydrogen bonds to 
the side chains of AsnlI8, Thr242, Thr274, the main chains 
of Glyl 14, Tyr l 15, A1a275, and it-stacks with His 139 (Figure 
2b). Overall the SPT SW and SPT SP active sites bear very 
close resemblance to each other (Figure 2c). 
Two important interactions present in S. paucirnobilis SPT 
and also found in other members of the AOS family appear 
to be absent in the SPT SW structure. Both Asp2 II and 
His214 appear to be too far away to form interactions to the 
PLP pyridine nitrogen and PLP oxygen atoms, respectively 
that have been observed in other structures. Both these resi-
dues are absolutely conserved among all SPTs and AOS fani-
ily members and are known to stabilise and anchor the PLP 
in the active site. Even if these residues are too far away to 
interact with PLP in this crystal structure, they may be 
involved during catalysis in solution possibly by stabilization 
of other intermediates (e.g., formation of the PLP:i-Ser 
external aldimine). We do note that a possible compensatory 
interaction involves the side chain of Asn 118 which is closer 
to the pyridine nitrogen of the PLP ring than the equivalent 
residue (Asn 138) in the SPT SP structure. In the S. paucimo-
bilis SPT structure we found that an arginine residue, 
Arg378, played a role in anchoring the carboxylate residue of 
t-Ser in the PLP:L-Ser external aldimine form of the enzyme. 
In SPT SP the side chain of Arg378 undergoes a large confor-
mational change from the holo-"swung-out" form to the 
external aldimine "swung-in" form. 21  We note that in SPT 
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FIGURE 4 Mass spectrometry of ACP. ion envelopes of (a) apo-ACP, (b) holo-ACP, (C) lauroyl-
ACP, and (d) myristoyl-ACP. Apo-forms of ACP are shown in blue. Holo- and acyl-forms are 
shown in red. The decorivoluted experimental masses based on the ion envelope are shown. 
SW residue Arg358 is suggested to play this role and is in the 
"swung-out" position characteristic of the holo-form of the 
enzyme. 
Other small differences can be observed between the two 
bacterial SPTs. In our previous study of S. paucirnobilis SPT 
we used the bacterial, homodimeric enzyme to generate a 
model of the heterodimeric (SPT1/2) human SPT. 20 We used 
this model to predict the site of mutation in the human 
SPT1 subunit (Cys133, which is mutated to Tyr and Trp) 
that causes the sphingolipid metabolic disease HSAN1. Our 
model suggested S. paucimobilis SPT residue Asn 100 mapped 
to human SPTI residue Cys133 and this side chain plays a 
role in contacting the backbone amide of the PLP-binding 
residue Lys265. In a recent study we probed its structural and 
functional role by making AsnlOOTyr and AsnlOOTrp mutant 
forms of SPT SP. 21 This revealed that mutations on one SPT 
monomer do indeed impact on the other. In S. wittichii SPT 
the Asn 100 residue is replaced by Thr80, other sequence 
changes place it in a hydrogen bonding environment at the  
interface between the two subunits. In contrast to Asn 100 of 
SPT SP, the side chain of Thr8O does not make a direct 
hydrogen bond contact with the other subunit but is imme-
diately adjacent to PLP binding Lys245 of the neighboring 
subunit (Figure 2c). 
We also observed other small differences between the SPT 
structures from both Sphingomonas strains. The entrance to 
the active site that is situated at the "top" of the SPT SW pro-
tein surface is wider than that observed in S. paucitnobilis 
SPT, possibly indicating the binding of a larger long-chain 
fatty acid substrate (e.g., acyl-ACP) instead of an acyl-CoA 
thioester (Supporting Information Figure 4). This results 
from a rigid movement of the loop Pro360-Pro363 of about 
2 A. The residues within this loop are conserved between 
SPT SP and SPT SW, however Met366 is found in SPT SW 
and is replaced with Thr386 in SPT SP; whilst residue 
Thr356 in SPT SW is replaced by Met376 in SPT SP. As a 
result the methionine side chain sits in different hydrophobic 
pockets in both enzymes and this may be responsible for the 
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different loop positions. These comparisons suggest that 
there are subtle structural differences between the bacterial 
SPT isoforms that could explain observed differences in their 
catalytic activities. 
To further probe the Nature of the acyl-CoA binding site 
we used the structure of the recently solved enzyme CqsA 
from Vibrio cholerae, a recent addition to PLP-dependent, 
AOS family, which resembles SPT and AONS. 4° CqsA is 
involved in the biosynthesis of cholerae autoinducer- 1 (CAI-
1) from (S)-2-aminobutyrate and decanoyl-CoA. 4 ' Of partic-
ular interest, the external aldimine of the final product from 
the condensation of L-threonine and decanoyl-CoA has been 
trapped in the active site (PDB ID code: 2WKA). Superposi-
tion of the SPT SW and V cholerae CqsA structures places 
the acyl-CoA binding site in a long hydrophobic channel at 
the interface of the two monomers of SPT SW (Figures 3a 
and 3b). The channel is lined by residues LeulO, Arg15, 
Ala! 7-Leu 19, Thr2 1 -Tyr27, Va134 1, Arg358-Pro36 1 from 
monomer A and Va184-Leu85, Leu266, and Va1272 from 
Monomer B. Two valine residues (Va123 and Va1341 from 
monomer A) delimit the end of the channel. We note that 
SPT SW has a lower chain length limit with regard to its 
acyl-CoA substrates and we detected no activity with sub-
strates of C12 and below. The exact details of chain length 
specificity within the AOS family are still unknown but this 
analysis will allow us to probe the role of the residues lining 
this putative channel. 
Purification, Characterization, and Modification 
of Apo-ACP 
S. wittichii ACP was co-expressed with SPT in E. coli and a 
rapid two-step purification procedure using anion exchange 
and size-exclusion chromatography led to the isolation of 
milligram quantities of the protein. We used LC-ESI-MS to 
determine the mass of the purified protein (8784 Da) and 
this revealed that the ACP SW had been expressed in the 
apo-form (predicted mass without Met residue 8782.5 Da, 
Figure 4a). This suggests that the enzymes involved in post-
translational modification of the type II FAS machinery in E. 
coli do not recognise the S. wittichii ACP and cannot convert 
it to the 4'-PP holo-form. 
Generally, ACPs are modified by a PPTase (also known as 
ACPS) by the addition of the 4'-PP group and thereafter the 
fatty acid chain is built up step-by-step by a FAS. 26 Individ-
ual members of the PPTase superfamily tend to display high 
substrate specificity and will only recognise their cognate 
ACP.28 This has caused technical problems with regard to 
production of various natural products in recombinant hosts 
(and in vitro) where the ACP is not modified correctly. Some 
PPTases are able to catalyse the direct transfer of an acyl  
group to an apo-ACP using an acyl-CoA substrate, thus gen-
erating an acylated-ACP in a single step. Some of these 
PPTases are well known for their broad substrate recognition 
and inherent "promiscuity" and have been used to solve 
problems of production of natural products in alternative 
hosts.27 '3133 As we isolated the ACP SW in an apo-form we 
wished to convert it to the holo- and various acylated forms. 
We used CoASH to install the 4'-PP arm, as well as acyl-
CoAs of varying fatty acid chain length (decanoyl do; 
lauroyl C12; myristoyl C14; palmitoyl C16 and steroyl C18) 
in combination with a number of PPTases. 
The first attempt to modify ACP SW (with CoASH and 
acyl-CoAs) was made with the S. coelicolor ACPS since it is 
known to have broad specificity. 33 '42 Unfortunately, this did 
not give any positive results (data not shown) and this sug-
gested that S. coelicolor ACPS does not recognise ACP SW. 
We next tried the broad-range ACPS B. subtilis Sfp and found 
it did successfully convert the apo-ACP into the holo-form 
with an increase mass of 4'-PP (experimental mass 9118 Da, 
Figure 4b) as well as the CIO (data not shown), C12 (mass 
9300 Da, Figure 4c) and C14 (mass 9329, Figure 4d) acyl-
ACP derivatives. The % conversions of apo- to the C12- and 
C14-modified ACPs (based on MS peak height intensities) 
were '-'-50% and "-20%, respectively. We also used high-reso-
lution MS coupled with fragmentation techniques to identify 
the site of 4'-PP attachment on the holo-ACP SW as the 
Ser39 residue within the conserved motif (Supporting Infor-
mation Figure 5). Unfortunately, B. subtilis Sfp failed to 
transfer a palmitoyl (C16:0) or a stearoyl (C18:0) chain onto 
the apo-ACP SW. The transfer of the palmitoyl chain by B. 
subtilis Sfp was further explored by testing several reaction 
conditions (varying enzyme, substrate, and co-factor concen-
trations as well as temperature and time) without any success 
(data not shown). Previous studies reported that B. subtilis 
Sfp was successfully used to modify a large number of ACPs 
and PCPs with various substrates but never with long-chain 
fatty acids ( ~!Cl6). 32 '43 '44 
Another useful promiscuous PPTase, S. verticillus Svp, 
with similar characteristics to Sfp, has been shown to have a 
preference for longer carbon chains. 45 It was also shown to 
modify both type I and type II ACPs and PCPs from either S. 
verticillus or other Streptomyces species.  3 ' However, although 
we found that S. verticillus Svp converted apo-ACP SW to the 
holo-form it failed to transfer any acyl-thioester substrates 
(data not shown). Since the S. verticillus Svp and other 
PPTases are able to catalyse formation of holo-ACP SW but 
are not able to transfer an acyl-4'-PP group, we suggest that 
the problem with the long-chain transfer must come from 
the structure of the ACP SW itself. Finally, we used sequence 
homology to identify the PPTase (ACPS) in the S. wittichii 
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FIGURE 5 (a) Sequence alignments of E. coil and S. wittich,i ALPs. ( b ) 3D models of AC!' S. nit-
tichii showing superposition of Swiss and JIGSAW AC!' 31) models. The ACP Swiss-model is col-
ored cyan and JIGSAW-model is colored green. In each model, residue Trp37 is shown in stick 
form. (c) Superposition of the JIGSAW S. wittichii ACP model and E. cob ACP structure (PDB IL): 
I LOH). The ACP SW JIGSAW-model is colored green and E. ccii structure in magenta with the C4 
acyl group shown in stick form and colored in dark blue. 
genome (ORF code Swit_3872) that enabled us to overex-
press this PPTase in E. ccli. We were able to purify the 
recombinant S. wittichii ACPS but found that in assays with 
apo-ACP SW this enzyme catalysed only the formation of the 
holo-form and provided no acyl-ACP. Similarly, co-expres-
sion of ACP SW and ACPS SW inside the same E. coli host 
provided only holo-ACP (data not shown). 
In conclusion, we found that B. subtilis Sfp was the best 
PPTase to act upon the apo-ACP SW. Unfortunately, we were 
unable to generate sufficient quantities of long-chain acy-
lated-ACP to carry out a study of its ability to act as an acyl-
donor in the SPT reaction with 1.-serine. In a recent study on 
rat type I ACP the authors also noted the tendency of the 
C16-acylated form of this protein to precipitate over 48 h. 42 
We also realised through our acyl-CoA chain length kinetic 
analysis that SPT SW failed to accept substrates with carbon 
chain lengths of <C14 (Supporting Information Table II). To 
generate sufficient quantities of long-chain acyl-ACP SW we  
may need to turn to a chemical, nonenzymatic procedure 
using N-acylimidazole derivatives and this is a target of 
future work. 46 
ACP Structural Model 
Since we found the apo-ACP SW was so difficult to convert 
to an acylated form using promiscuous PPTases, we carried 
out sequence analysis to identify any novel characteristics 
that could explain its recalcitrant nature. Protein sequence 
alignment revealed that ACP SW is rather unusual and does 
not fit perfectly into an ACP sub-family described in the lit-
erature. Its closest homologs are proteins with no published 
experimental data associated with them. However, it does 
show 26% amino acid sequence identity to E. coli ACP which 
has been characterised extensively (Figure 5a). 47 In ACP SW 
one particular residue stands out—a highly uncommon tryp-
tophan residue (Tr-p37) positioned just before the conserved 
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(WDSLT) 4'-PP sequence motif (Figure 5a). Numerous ACP 
structures are available in the literature in both apo-, bob-, 
and acylated forms. 29,38  Despite acting in diverse biosynthetic 
pathways, interacting with many different enzymes and hav-
ing low overall sequence similarity, their secondary structures 
and overall folds are very similar. 27 For example the E. coli 
ACP is typical and displays a common fold of four z-helices. 
Thus, using the 3D-JIGSAW server 48­50  and Swiss-model' 1-53 
we were able to generate two 3D models of ACP SW to gain 
some insight into the role of this unusual tryptophan residue 
(Figures 5h and Sc). The ACP SW model was based on a best 
fit to that of the ACP from E. coii. 47 This ACP was shown to 
be able to accommodate a growing acyl chain within a hydro-
phobic cavity that could expand as fatty acid synthesis pro-
ceeded, The ACP SW models adopted the typical four z-heli-
cal bundle fold. Superposition of the two models generated 
by the different software revealed two possible positions for 
the Trp37 side chain both of which are close to the site of 4'-
PP attachment (Ser39) (Figure 5b). In both models, the resi-
due is positioned on a solvent-exposed flexible loop and so 
one could imagine that the tryptophan could adopt both 
conformations. The superposition of the 3D-JIGSAW  model 
with the C4-ACP E. coli structure (Figure 5c) lends weight to 
the attractive idea that this unusually placed tryptophan 
could control transfer of 4'-PP and/or long-chain acyl 
groups. Indeed, we found that the holo-ACP SW could be 
generated from the apo-form by incubation with various 
PPTases but these structural models also provide a possible 
explanation for the lack of modification of the ACP SW with 
longer chain acyl-CoAs (>CI6) in appreciable yields. It may 
be that the ACP SW is converted to a long-chain acyl-CoA 
form only within S. wittichii as part of fatty acid synthesis. 
Thus, this directly links fatty acid and sphingolipid biosyn-
thesis. Further work will be required to find conditions 
appropriate for its formation and the role of the Trp37 in 
this conversion will he probed by site directed mutagenesis. 
CONCLUSIONS 
To begin a study of bacterial sphingolipid biosynthesis, we 
have isolated and purified recombinant proteins from the 
bacterium S. wittichii. Using various spectroscopic, kinetic, 
and structural techniques we characterised SPT SW, and 
showed that it hinds its co-factor PLP and its substrate 1-ser-
me. We proved that SPT SW was enzymatically active with L-
serine and a range of long-chain acyl-CoA substrates. Fur-
thermore, we solved the high-resolution x-ray structure of 
the enzyme which allowed a structural comparison with the 
SPT from S. paricimobilis. We noted that despite high amino 
acid sequence identity the SPT isozymes displayed differences 
in kinetics and in structure. We found that the SPT gene 
resides alongside a putative small protein with sequence 
homology to bacterial type II ACPs and this led us to 
hypothesise that an ACP-thioester, rather than a CoA-thio-
ester may be the natural substrate for SPT. We co-expressed 
the S. wittichii ACP-SPT gene pair in E. coil, isolated the 
recombinant ACP and used mass spectrometry to show it 
was recovered in an apo-form. We investigated various 
PPTases in an effort to convert the ACP into its holo-form 
and acylated forms but succeeded in isolating only the holo-, 
CIO, C12, and C14 acyl-forms. Analysis of the ACP primary 
sequence identified an unusual tryptophan residue next to 
the conserved phosphopantetheinylation motif. Using E. co/i 
ACP as a structural homolog, models of ACP SW were gener-
ated and suggest that this residue may block the attachment 
of longer acyl chains. Probing the role of this residue will he 
the focus of future structural and functional studies as will be 
the identification and characterization of other downstream 
enzymes in the Sphingomonas sphingolioid biosynthetic 
pathway. 
We thank Dr. Jonathan Lowther (University of Edinburgh) and 
Dr. Alan Brown (University of Exeter) for helpful discussions. 
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